{"items": "676", "sentiment_score_definition": "x <= -0.35: Bearish; -0.35 < x <= -0.15: Somewhat-Bearish; -0.15 < x < 0.15: Neutral; 0.15 <= x < 0.35: Somewhat_Bullish; x >= 0.35: Bullish", "relevance_score_definition": "0 < x <= 1, with a higher score indicating higher relevance.", "feed": [{"title": "Medicare drug price negotiations hit critical phase", "url": "https://www.marketwatch.com/story/medicare-drug-price-negotiations-hit-critical-phase-1f52a7e2", "time_published": "20240118T153200", "authors": ["Eleanor Laise"], "summary": "The federal government is set to make its opening offers in Medicare drug price negotiations, as courts prepare to weigh in on the process.", "banner_image": "https://images.mktw.net/im-860220/social", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}, {"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.007182, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.071357", "ticker_sentiment_score": "0.058455", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.071357", "ticker_sentiment_score": "0.072962", "ticker_sentiment_label": "Neutral"}]}, {"title": "Is Novo Nordisk Stock a Buy Now?", "url": "https://www.fool.com/investing/2024/01/18/is-novo-nordisk-stock-a-buy-now/", "time_published": "20240118T143000", "authors": ["Prosper Junior Bakiny"], "summary": "The biotech is on a roll, and that won't end soon.", "banner_image": "https://g.foolcdn.com/editorial/images/760716/doctor-with-patient-talking.jpg", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}], "overall_sentiment_score": 0.331692, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VKTX", "relevance_score": "0.061949", "ticker_sentiment_score": "0.081064", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.061949", "ticker_sentiment_score": "0.081064", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.56296", "ticker_sentiment_score": "0.386015", "ticker_sentiment_label": "Bullish"}, {"ticker": "PFE", "relevance_score": "0.061949", "ticker_sentiment_score": "0.081064", "ticker_sentiment_label": "Neutral"}]}, {"title": "4 Fidelity Mutual Funds to Buy as the Market Ebbs and Flows", "url": "https://www.zacks.com/stock/news/2211852/4-fidelity-mutual-funds-to-buy-as-the-market-ebbs-and-flows", "time_published": "20240118T103600", "authors": ["Zacks Equity Research"], "summary": "Invest in Fidelity mutual funds like FPHAX, FCAKX, FDTIX and FDSCX for high returns alongside risk reduction in the current environment.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/3b/649.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.999897"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.311928, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MSFT", "relevance_score": "0.090645", "ticker_sentiment_score": "0.135128", "ticker_sentiment_label": "Neutral"}, {"ticker": "THNOF", "relevance_score": "0.045396", "ticker_sentiment_score": "0.247153", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVDA", "relevance_score": "0.090645", "ticker_sentiment_score": "0.135128", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.045396", "ticker_sentiment_score": "0.114293", "ticker_sentiment_label": "Neutral"}, {"ticker": "BSX", "relevance_score": "0.045396", "ticker_sentiment_score": "0.126219", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.045396", "ticker_sentiment_score": "0.114293", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMC", "relevance_score": "0.045396", "ticker_sentiment_score": "0.099407", "ticker_sentiment_label": "Neutral"}]}, {"title": "Catheter Associated Urinary Tract Infections Treatment Market Surges with a Promising CAGR of 4.0% through 2033 | Persistence Market Research", "url": "https://www.benzinga.com/pressreleases/24/01/g36673659/catheter-associated-urinary-tract-infections-treatment-market-surges-with-a-promising-cagr-of-4-0-", "time_published": "20240118T101500", "authors": ["Globe Newswire"], "summary": "New York, Jan. 18, 2024 ( GLOBE NEWSWIRE ) -- Market Size & Overview: The global market for treating catheter-associated urinary tract infections ( CAUTIs ) is projected to grow at a compound annual growth rate ( CAGR ) of 4.0%.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}], "overall_sentiment_score": 0.31153, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.044359", "ticker_sentiment_score": "0.083244", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAYZF", "relevance_score": "0.029581", "ticker_sentiment_score": "0.12093", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.029581", "ticker_sentiment_score": "0.063368", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.059121", "ticker_sentiment_score": "0.096069", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSOI", "relevance_score": "0.014793", "ticker_sentiment_score": "0.096609", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.044359", "ticker_sentiment_score": "0.123953", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.029581", "ticker_sentiment_score": "0.13709", "ticker_sentiment_label": "Neutral"}]}, {"title": "What is Disease X and how will pandemic preparations help the world?", "url": "https://www.aljazeera.com/news/2024/1/18/what-is-disease-x-and-how-will-pandemic-preparations-help-the-world", "time_published": "20240118T090649", "authors": ["Al Jazeera"], "summary": "WHO Director-General Tedros joined world leaders at the Davos summit to discuss strategies for the next potential pandemic. As the winter season brings back a surge in respiratory illness and pandemic-era practices such as mask mandates, global health experts are thinking ahead about how to ...", "banner_image": "https://www.aljazeera.com/wp-content/uploads/2024/01/AP22020481118471-1705491322.jpg?resize=770%2C513&quality=80", "source": "Al Jareeza", "category_within_source": "n/a", "source_domain": "www.aljazeera.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.072612, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.044551", "ticker_sentiment_score": "0.123013", "ticker_sentiment_label": "Neutral"}]}, {"title": "AstraZeneca, Roche, peers sign renewable power purchase deal for China plants", "url": "https://www.scmp.com/business/article/3248900/astrazeneca-novartis-rival-drug-makers-buy-renewable-energy-envision-manufacturing-plants-china", "time_published": "20240118T074256", "authors": ["Yujie Xue"], "summary": "AstraZeneca, Novartis and some their global peers have agreed to buy renewable power for their manufacturing facilities in mainland China under a three-year supply deal with Envision Energy.", "banner_image": "https://cdn.i-scmp.com/sites/default/files/styles/wide_landscape/public/d8/video/thumbnail/2023/08/15/clean_1.jpg?itok=wLzNM2TO", "source": "South China Morning Post", "category_within_source": "Business", "source_domain": "www.scmp.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.139409, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.122581", "ticker_sentiment_score": "0.106725", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.061473", "ticker_sentiment_score": "0.054001", "ticker_sentiment_label": "Neutral"}]}, {"title": "The weight loss drug market may soon get more crowded. Here are the companies trying to enter the booming space", "url": "https://www.cnbc.com/2024/01/17/weight-loss-drugs-boehringer-ingelheim-terns-viking-may-join-market.html", "time_published": "20240117T204055", "authors": ["Annika Kim Constantino"], "summary": "Wall Street has been focused on Novo Nordisk, Eli Lilly and other large drugmakers hoping to join the weight loss drug market, such as Pfizer, Roche and Amgen.", "banner_image": "https://image.cnbcfm.com/api/v1/image/107310827-1696353063160-gettyimages-1692436769-64393_48_ms_1933.jpeg?v=1705518338&w=1920&h=1080", "source": "CNBC", "category_within_source": "Business", "source_domain": "www.cnbc.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": -0.083518, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VKTX", "relevance_score": "0.125898", "ticker_sentiment_score": "-0.123814", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.042122", "ticker_sentiment_score": "-0.193871", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "JPM", "relevance_score": "0.125898", "ticker_sentiment_score": "-0.003645", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.042122", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GPCR", "relevance_score": "0.084127", "ticker_sentiment_score": "-0.169389", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "TERN", "relevance_score": "0.125898", "ticker_sentiment_score": "-0.079646", "ticker_sentiment_label": "Neutral"}, {"ticker": "AWON", "relevance_score": "0.042122", "ticker_sentiment_score": "-0.049155", "ticker_sentiment_label": "Neutral"}, {"ticker": "GS", "relevance_score": "0.042122", "ticker_sentiment_score": "0.139137", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.042122", "ticker_sentiment_score": "-0.193871", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "SNY", "relevance_score": "0.084127", "ticker_sentiment_score": "-0.004144", "ticker_sentiment_label": "Neutral"}]}, {"title": "Check Out What Whales Are Doing With AZN - AstraZeneca  ( NASDAQ:AZN ) ", "url": "https://www.benzinga.com/markets/options/24/01/36664016/check-out-what-whales-are-doing-with-azn", "time_published": "20240117T170116", "authors": ["Benzinga Insights"], "summary": "Investors with a lot of money to spend have taken a bearish stance on AstraZeneca AZN. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't know.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.127601, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "PTAIF", "relevance_score": "0.102888", "ticker_sentiment_score": "0.019792", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.699089", "ticker_sentiment_score": "0.139954", "ticker_sentiment_label": "Neutral"}]}, {"title": "Here's Why You Should Add McKesson  ( MCK )  to Your Portfolio Now", "url": "https://www.zacks.com/stock/news/2211216/heres-why-you-should-add-mckesson-mck-to-your-portfolio-now", "time_published": "20240117T113000", "authors": ["Zacks Equity Research"], "summary": "McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/6e/37920.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.928139"}], "overall_sentiment_score": 0.295745, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MMSI", "relevance_score": "0.104911", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ITGR", "relevance_score": "0.208017", "ticker_sentiment_score": "0.176718", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MCK", "relevance_score": "0.490323", "ticker_sentiment_score": "0.167619", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.05257", "ticker_sentiment_score": "0.267807", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SKXJF", "relevance_score": "0.05257", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DSGR", "relevance_score": "0.208017", "ticker_sentiment_score": "-0.017028", "ticker_sentiment_label": "Neutral"}, {"ticker": "DSKYF", "relevance_score": "0.05257", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DVA", "relevance_score": "0.104911", "ticker_sentiment_score": "0.060067", "ticker_sentiment_label": "Neutral"}, {"ticker": "HCSG", "relevance_score": "0.05257", "ticker_sentiment_score": "0.099606", "ticker_sentiment_label": "Neutral"}, {"ticker": "SWTX", "relevance_score": "0.05257", "ticker_sentiment_score": "0.267807", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "3 Healthcare Mutual Funds to Buy as the Sector Turns Around", "url": "https://www.zacks.com/stock/news/2211185/3-healthcare-mutual-funds-to-buy-as-the-sector-turns-around", "time_published": "20240117T103900", "authors": ["Zacks Equity Research"], "summary": "PHSYX, JFNAX and VGHCX are three healthcare mutual funds that can lend solidity to one's portfolio today and provide big returns in the foreseeable future.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/dc/1715.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.796627"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.209374, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "JHG", "relevance_score": "0.05749", "ticker_sentiment_score": "0.181997", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.171282", "ticker_sentiment_score": "0.091061", "ticker_sentiment_label": "Neutral"}, {"ticker": "HCSG", "relevance_score": "0.05749", "ticker_sentiment_score": "-0.014002", "ticker_sentiment_label": "Neutral"}, {"ticker": "UNH", "relevance_score": "0.171282", "ticker_sentiment_score": "0.091061", "ticker_sentiment_label": "Neutral"}]}, {"title": "What is Disease X? Know all about this 'fatal than Covid-19' crisis that global leaders are brainstorming at Davos 2024", "url": "https://www.financialexpress.com/healthcare/news-healthcare/what-is-disease-x-know-all-about-this-fatal-than-covid-19-crisis-that-global-leaders-are-brainstorming-at-davos-2024-bkg/3366961/", "time_published": "20240117T081302", "authors": ["Annu Mandal"], "summary": "The World Economic Forum that commenced its annual meeting on January 15, in Switzerland's Davos, will see a brainstorming session on novel 'Disease X'. This is going to be part of the discussion after the World Health Organization ( WHO ) initiated warning people.", "banner_image": "https://www.financialexpress.com/wp-content/uploads/2024/01/Mask-pixabay.jpg", "source": "The Financial Express", "category_within_source": "n/a", "source_domain": "www.financialexpress.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.203948, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.097062", "ticker_sentiment_score": "0.071584", "ticker_sentiment_label": "Neutral"}]}, {"title": "What is Disease X? Know all about this 'fatal than Covid-19' crisis that global leaders are brainstorming at Davos 2024", "url": "https://www.financialexpress.com/healthcare/what-is-disease-x-know-all-about-this-fatal-than-covid-19-crisis-that-global-leaders-are-brainstorming-at-davos-2024-bkg/3366961/", "time_published": "20240117T081302", "authors": ["Annu Mandal"], "summary": "The World Economic Forum that commenced its annual meeting on January 15, in Switzerland's Davos, will see a brainstorming session on novel 'Disease X'. This is going to be part of the discussion after the World Health Organization ( WHO ) initiated warning people.", "banner_image": "https://www.financialexpress.com/wp-content/uploads/2024/01/Mask-pixabay.jpg", "source": "The Financial Express", "category_within_source": "n/a", "source_domain": "www.financialexpress.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.203948, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.097062", "ticker_sentiment_score": "0.071584", "ticker_sentiment_label": "Neutral"}]}, {"title": "Davos '24: Bill Gates Joins Belgium in Showcase of Innovation and Global Partnerships", "url": "https://www.prnewswire.com/news-releases/davos-24-bill-gates-joins-belgium-in-showcase-of-innovation-and-global-partnerships-302036751.html", "time_published": "20240117T080800", "authors": ["FPS Chancellery of the Prime Minister"], "summary": "BRUSSELS, Jan. 17, 2024 /PRNewswire/ -- Belgium is opening its first ever House during the World Economic Forum's 2024 Annual Meeting, held from 15-19 January in Davos, Switzerland.", "banner_image": "https://mma.prnewswire.com/media/2320321/BELGIUM_HOUSE_IN_DAVOS.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.320342, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BUD", "relevance_score": "0.059935", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOOG", "relevance_score": "0.059935", "ticker_sentiment_score": "0.071999", "ticker_sentiment_label": "Neutral"}, {"ticker": "AVHNY", "relevance_score": "0.059935", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.059935", "ticker_sentiment_score": "0.082", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.059935", "ticker_sentiment_score": "0.082", "ticker_sentiment_label": "Neutral"}]}, {"title": "Take that, Wall Street! Pariah Capital wins again - and the picks for 2024", "url": "https://www.marketwatch.com/story/take-that-wall-street-pariah-capital-wins-again-and-the-picks-for-2024-fdfe4e31", "time_published": "20240116T175400", "authors": ["Brett Arends"], "summary": "The argument for seeing what the top money managers are buying - and running in the other direction.", "banner_image": "https://images.mktw.net/im-47866811?width=700&height=471", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.01685, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "RIO", "relevance_score": "0.027476", "ticker_sentiment_score": "0.023507", "ticker_sentiment_label": "Neutral"}, {"ticker": "GS", "relevance_score": "0.027476", "ticker_sentiment_score": "0.135773", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.027476", "ticker_sentiment_score": "0.05837", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.05492", "ticker_sentiment_score": "0.025002", "ticker_sentiment_label": "Neutral"}, {"ticker": "DSSMY", "relevance_score": "0.027476", "ticker_sentiment_score": "0.135773", "ticker_sentiment_label": "Neutral"}, {"ticker": "BRK-A", "relevance_score": "0.027476", "ticker_sentiment_score": "-0.112441", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:EUR", "relevance_score": "0.05492", "ticker_sentiment_score": "0.118828", "ticker_sentiment_label": "Neutral"}]}, {"title": "Fulcrum GT to Share Insights on Disrupters in Law and the Future of Legal Engagements at Legalweek New York 2024", "url": "https://www.benzinga.com/pressreleases/24/01/g36643243/fulcrum-gt-to-share-insights-on-disrupters-in-law-and-the-future-of-legal-engagements-at-legalweek", "time_published": "20240116T150552", "authors": ["Globe Newswire"], "summary": "CHICAGO, Jan. 16, 2024 ( GLOBE NEWSWIRE ) -- Fulcrum GT, provider of the leading digital business platform for legal and professional services firms with solutions spanning new business intake, practice management, e-billing and more, announces its participation in Legalweek New York 2024 being ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.437533, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.059785", "ticker_sentiment_score": "0.20004", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Five Major Themes From The 2024 J.P. Morgan Healthcare Conference", "url": "https://www.forbes.com/sites/juergeneckhardt/2024/01/16/five-major-themes-from-the-2024-jp-morgan-healthcare-conference/", "time_published": "20240116T145429", "authors": ["Juergen Eckhardt"], "summary": "The new year always starts off with a bang for those of us in biotech and pharma.", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/65a69835209ccd5943602ce2/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds", "source": "Forbes", "category_within_source": "n/a", "source_domain": "www.forbes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}, {"topic": "Economy - Monetary", "relevance_score": "0.451494"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.796627"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.451494"}], "overall_sentiment_score": 0.225428, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.04028", "ticker_sentiment_score": "0.147886", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.04028", "ticker_sentiment_score": "0.145416", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.080458", "ticker_sentiment_score": "0.020548", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio", "url": "https://www.zacks.com/stock/news/2210778/why-this-1-growth-stock-could-be-a-great-addition-to-your-portfolio", "time_published": "20240116T144507", "authors": ["Zacks Equity Research"], "summary": "Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default95.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.769861"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.87644"}], "overall_sentiment_score": 0.416924, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "PTAIF", "relevance_score": "0.090816", "ticker_sentiment_score": "-0.053878", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.506284", "ticker_sentiment_score": "0.259327", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Is it a Good Idea to Buy Fusion Pharmaceuticals  ( FUSN )  Stock Now?", "url": "https://www.zacks.com/stock/news/2210622/is-it-a-good-idea-to-buy-fusion-pharmaceuticals-fusn-stock-now", "time_published": "20240116T132200", "authors": ["Zacks Equity Research"], "summary": "Here, we discuss some reasons why investing in Fusion Pharmaceuticals (FUSN) stock now may turn out to be a prudent move.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/39/612.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.123707, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.186738", "ticker_sentiment_score": "0.107147", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.276909", "ticker_sentiment_score": "-0.002043", "ticker_sentiment_label": "Neutral"}, {"ticker": "FUSN", "relevance_score": "0.762438", "ticker_sentiment_score": "0.284194", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ambrx Biopharma, Inc.  ( Nasdaq - AMAM ) , Gracell Biotechnologies Inc.  ( Nasdaq - GRCL ) , Axonics, Inc.  ( Nasdaq - AXNX ) , Harpoon Therapeutics, Inc.  ( Nasdaq - HARP ) ", "url": "https://www.benzinga.com/pressreleases/24/01/g36638641/brodsky-smith-shareholder-update-notifying-investors-of-the-following-investigations-ambrx-biophar", "time_published": "20240116T130500", "authors": ["Globe Newswire"], "summary": "BALA CYNWYD, Pa., Jan. 16, 2024 ( GLOBE NEWSWIRE ) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( jbrodsky@brodskysmith.com ) or Marc Ackerman ( mackerman@brodskysmith.com ) at 855-576-4847.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.796627"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.232971, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.233556", "ticker_sentiment_score": "0.266779", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DSSMY", "relevance_score": "0.233556", "ticker_sentiment_score": "0.068874", "ticker_sentiment_label": "Neutral"}, {"ticker": "GRCL", "relevance_score": "0.07887", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMAM", "relevance_score": "0.07887", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BSX", "relevance_score": "0.233556", "ticker_sentiment_score": "0.235274", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HARP", "relevance_score": "0.07887", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.15697", "ticker_sentiment_score": "0.156505", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AXNX", "relevance_score": "0.233556", "ticker_sentiment_score": "0.216405", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "4 Pharma Stocks to Buy, According to an Analyst. Novo Nordisk Isn't One.", "url": "https://www.barrons.com/articles/pharma-stocks-novo-nordisk-astrazeneca-gsk-buy-2e92c0c0", "time_published": "20240116T124300", "authors": ["Adam Clark"], "summary": "The European pharmaceutical sector looks set for a good year on strong cash flows and attractive valuations, according to UBS analysts. They picked out four stocks that could particularly benefit but left out weight-loss drug pioneer and market darling Novo Nordisk, and struck a bearish note on ...", "banner_image": "https://images.barrons.com/im-272936/social", "source": "Barrons", "category_within_source": "n/a", "source_domain": "www.barrons.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.405553, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.622414", "ticker_sentiment_score": "0.566585", "ticker_sentiment_label": "Bullish"}, {"ticker": "NVO", "relevance_score": "0.622414", "ticker_sentiment_score": "0.566585", "ticker_sentiment_label": "Bullish"}]}, {"title": "Sell AstraZeneca, says UBS, which upgrades European rivals including GSK", "url": "https://www.marketwatch.com/story/sell-astrazeneca-says-ubs-which-upgrades-european-rivals-including-gsk-ddb55ad7", "time_published": "20240116T103400", "authors": ["Steve Goldstein"], "summary": "UBS analysts shook up their ratings of European drugmakers, including making a double-downgrade of AstraZeneca and a double-upgrade of U.K. rival GSK.", "banner_image": "https://images.mktw.net/im-254778/social", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.046178, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.740604", "ticker_sentiment_score": "-0.140164", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.501398", "ticker_sentiment_score": "0.300471", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SNY", "relevance_score": "0.348103", "ticker_sentiment_score": "0.155892", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Smart Inhalers Market Will Reach US$ 235.7 Million by 2033, By Persistence Market Research", "url": "https://www.benzinga.com/pressreleases/24/01/g36635742/smart-inhalers-market-will-reach-us-235-7-million-by-2033-by-persistence-market-research", "time_published": "20240116T101500", "authors": ["Globe Newswire"], "summary": "New York, Jan. 16, 2024 ( GLOBE NEWSWIRE ) -- Smart Inhalers Market: A Breath of Fresh Air for Healthcare Smart Inhalers are inhalation devices equipped with sensors and connectivity features to monitor and manage respiratory conditions, such as asthma and chronic obstructive pulmonary ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.503682, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "MOOIF", "relevance_score": "0.015978", "ticker_sentiment_score": "0.330119", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RMD", "relevance_score": "0.015978", "ticker_sentiment_score": "0.297061", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVS", "relevance_score": "0.015978", "ticker_sentiment_score": "0.297061", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TEVA", "relevance_score": "0.031949", "ticker_sentiment_score": "0.351639", "ticker_sentiment_label": "Bullish"}, {"ticker": "AZN", "relevance_score": "0.015978", "ticker_sentiment_score": "0.297061", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Ultimovacs Updates Timeline for Reporting on Randomized UV1 Phase II Trial INITIUM in Malignant Melanoma; Topline Results expected in March 2024", "url": "https://www.globenewswire.com/news-release/2024/01/16/2809492/0/en/Ultimovacs-Updates-Timeline-for-Reporting-on-Randomized-UV1-Phase-II-Trial-INITIUM-in-Malignant-Melanoma-Topline-Results-expected-in-March-2024.html", "time_published": "20240116T060000", "authors": ["Ultimovacs ASA"], "summary": "\u2022 Study protocol enables readout of the INITIUM trial after all patients have been followed for a minimum of 18 months, or after 70 patients have progressed or died. \u2022 As of today, the 70 events have not yet occurred, but the 18-month follow-up for the last patient has now been reached.", "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/23b62627-6dd1-416b-b614-675e9c122324", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.839681"}], "overall_sentiment_score": -0.004804, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.027134", "ticker_sentiment_score": "-0.013297", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.027134", "ticker_sentiment_score": "-0.013297", "ticker_sentiment_label": "Neutral"}]}, {"title": "Heart Failure Treatment Drug Market to Accelerate Immensely by 2032, Predicts DelveInsight", "url": "https://www.prnewswire.com/news-releases/heart-failure-treatment-drug-market-to-accelerate-immensely-by-2032-predicts-delveinsight-302034593.html", "time_published": "20240115T220500", "authors": ["DelveInsight Business Research", "LLP"], "summary": "The dynamics of the heart failure market are anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the diseases, and incremental healthcare spending across the world.", "banner_image": "https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": 0.165054, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BCDA", "relevance_score": "0.046861", "ticker_sentiment_score": "0.08891", "ticker_sentiment_label": "Neutral"}, {"ticker": "PGEN", "relevance_score": "0.023441", "ticker_sentiment_score": "0.03228", "ticker_sentiment_label": "Neutral"}, {"ticker": "TNYA", "relevance_score": "0.023441", "ticker_sentiment_score": "0.03228", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.046861", "ticker_sentiment_score": "0.08891", "ticker_sentiment_label": "Neutral"}, {"ticker": "SANA", "relevance_score": "0.023441", "ticker_sentiment_score": "0.03228", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRDL", "relevance_score": "0.023441", "ticker_sentiment_score": "0.03228", "ticker_sentiment_label": "Neutral"}, {"ticker": "IONS", "relevance_score": "0.023441", "ticker_sentiment_score": "0.03228", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.023441", "ticker_sentiment_score": "0.03228", "ticker_sentiment_label": "Neutral"}, {"ticker": "SCPH", "relevance_score": "0.046861", "ticker_sentiment_score": "0.08891", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.093561", "ticker_sentiment_score": "0.092837", "ticker_sentiment_label": "Neutral"}, {"ticker": "MESO", "relevance_score": "0.046861", "ticker_sentiment_score": "0.08891", "ticker_sentiment_label": "Neutral"}, {"ticker": "PBIGF", "relevance_score": "0.023441", "ticker_sentiment_score": "0.03228", "ticker_sentiment_label": "Neutral"}, {"ticker": "WINT", "relevance_score": "0.070242", "ticker_sentiment_score": "0.050911", "ticker_sentiment_label": "Neutral"}, {"ticker": "LXRX", "relevance_score": "0.046861", "ticker_sentiment_score": "0.08891", "ticker_sentiment_label": "Neutral"}, {"ticker": "CYTK", "relevance_score": "0.046861", "ticker_sentiment_score": "0.08891", "ticker_sentiment_label": "Neutral"}, {"ticker": "ITCI", "relevance_score": "0.046861", "ticker_sentiment_score": "0.08891", "ticker_sentiment_label": "Neutral"}, {"ticker": "ATHXQ", "relevance_score": "0.023441", "ticker_sentiment_score": "0.03228", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.046861", "ticker_sentiment_score": "0.08891", "ticker_sentiment_label": "Neutral"}, {"ticker": "EWTX", "relevance_score": "0.023441", "ticker_sentiment_score": "0.03228", "ticker_sentiment_label": "Neutral"}, {"ticker": "FUJIF", "relevance_score": "0.023441", "ticker_sentiment_score": "0.03228", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.023441", "ticker_sentiment_score": "0.03228", "ticker_sentiment_label": "Neutral"}, {"ticker": "TENX", "relevance_score": "0.023441", "ticker_sentiment_score": "0.113992", "ticker_sentiment_label": "Neutral"}, {"ticker": "EVO", "relevance_score": "0.023441", "ticker_sentiment_score": "0.03228", "ticker_sentiment_label": "Neutral"}]}, {"title": "The Zacks Analyst Blog Highlights Eli Lilly, Novo Nordisk, Amgen and AstraZeneca", "url": "https://www.zacks.com/stock/news/2209905/the-zacks-analyst-blog-highlights-eli-lilly-novo-nordisk-amgen-and-astrazeneca", "time_published": "20240115T105000", "authors": ["Zacks Investment Research"], "summary": "Eli Lilly, Novo Nordisk, Amgen and AstraZeneca are included in this Analyst Blog.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/e5/1416.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.094253, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.261117", "ticker_sentiment_score": "0.085906", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.261117", "ticker_sentiment_score": "0.040358", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.210274", "ticker_sentiment_score": "0.07059", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.053153", "ticker_sentiment_score": "0.149079", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.261117", "ticker_sentiment_score": "0.241559", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Oxford scientists launch first human vaccine trials for deadly Nipah virus", "url": "https://www.business-standard.com/world-news/oxford-scientists-launch-first-human-vaccine-trials-for-deadly-nipah-virus-124011500321_1.html", "time_published": "20240115T085738", "authors": ["Press Trust of India"], "summary": "Outbreaks have occurred in countries in Asia, including Singapore, Malaysia, Bangladesh and India, with a recent one in Kerala in September last year, they said. Scientists at the University of Oxford in the UK have launched first-in-human vaccine trials for the deadly Nipah virus which impacts ...", "banner_image": "https://bsmedia.business-standard.com/_media/bs/img/article/2018-05/25/full/1527248277-5532.jpg?im=FitAndFill=(826,465)", "source": "Business Standard", "category_within_source": "GoogleRSS", "source_domain": "www.business-standard.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.181493, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.09186", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Cytosorbents Corporation - CTSO", "url": "https://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-cytosorbents-corporation---ctso-302033883.html", "time_published": "20240114T164500", "authors": ["Pomerantz LLP"], "summary": "SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Cytosorbents Corporation ... PR ...", "banner_image": "https://mma.prnewswire.com/media/2287619/Pomerantz_V3_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.101955, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.145145", "ticker_sentiment_score": "0.126751", "ticker_sentiment_label": "Neutral"}, {"ticker": "CTSO", "relevance_score": "0.727604", "ticker_sentiment_score": "0.216506", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Biotech and pharma companies are betting on a promising class of cancer drugs to drive growth", "url": "https://www.cnbc.com/2024/01/14/cancer-drugs-renewed-interest-in-adcs-will-continue-in-2024.html", "time_published": "20240114T131240", "authors": ["Annika Kim Constantino"], "summary": "The JPMorgan Healthcare Conference was likely just the beginning of another year of heightened interest and investments in ADC cancer drugs.", "banner_image": "https://image.cnbcfm.com/api/v1/image/107238280-1683650170075-gettyimages-1238822565-20090101220228-99-316819.jpeg?v=1705225358&w=1920&h=1080", "source": "CNBC", "category_within_source": "Business", "source_domain": "www.cnbc.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.099245, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.032691", "ticker_sentiment_score": "-0.025298", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMAM", "relevance_score": "0.032691", "ticker_sentiment_score": "-0.024714", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.032691", "ticker_sentiment_score": "0.092444", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.032691", "ticker_sentiment_score": "-0.024714", "ticker_sentiment_label": "Neutral"}, {"ticker": "SKXJF", "relevance_score": "0.065327", "ticker_sentiment_score": "0.044577", "ticker_sentiment_label": "Neutral"}, {"ticker": "DSKYF", "relevance_score": "0.065327", "ticker_sentiment_score": "0.044577", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.2258", "ticker_sentiment_score": "0.05974", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.032691", "ticker_sentiment_score": "-0.166405", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Astrazeneca  ( AZN )  Laps the Stock Market: Here's Why", "url": "https://www.zacks.com/stock/news/2209770/astrazeneca-azn-laps-the-stock-market-heres-why", "time_published": "20240112T225019", "authors": ["Zacks Equity Research"], "summary": "In the latest trading session, Astrazeneca (AZN) closed at $69.42, marking a +0.35% move from the previous day.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default361.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.818451"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.23633, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.631282", "ticker_sentiment_score": "0.405833", "ticker_sentiment_label": "Bullish"}]}, {"title": "Cytokinetics  ( CYTK )  Down on Report of Novartis Not Interested", "url": "https://www.zacks.com/stock/news/2209728/cytokinetics-cytk-down-on-report-of-novartis-not-interested", "time_published": "20240112T194700", "authors": ["Zacks Equity Research"], "summary": "Cytokinetics (CYTK) slumps after a report stating Novartis not interested in acquiring the company surface.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ab/2180.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.166093, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CYTK", "relevance_score": "0.654522", "ticker_sentiment_score": "0.242155", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "REGN", "relevance_score": "0.149656", "ticker_sentiment_score": "0.058089", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.075161", "ticker_sentiment_score": "0.04437", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.075161", "ticker_sentiment_score": "0.04437", "ticker_sentiment_label": "Neutral"}, {"ticker": "KDNY", "relevance_score": "0.075161", "ticker_sentiment_score": "0.067603", "ticker_sentiment_label": "Neutral"}]}, {"title": "Cytokinetics' Heart Drug Is A Multi-Billion Dollar Opportunity By 2032 Despite Novartis Setback: Analyst - Cytokinetics  ( NASDAQ:CYTK ) ", "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/01/36616494/cytokinetics-heart-drug-is-a-multi-billion-dollar-opportunity-by-2032-despite-novar", "time_published": "20240112T193814", "authors": ["Vandana Singh"], "summary": "Thursday, Novartis AG NVS decided to step back from pursuing the Cytokinetics Inc CYTK acquisition, dealing a blow to the potential deal with the promising heart drug developer. Analysts estimated Cytokinetics' cardiomyopathy drug sales of up to $3.6 billion by 2032.", "banner_image": "https://cdn.benzinga.com/files/images/story/2024/CYTK.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.167337, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CYTK", "relevance_score": "0.779232", "ticker_sentiment_score": "0.388899", "ticker_sentiment_label": "Bullish"}, {"ticker": "NVS", "relevance_score": "0.240489", "ticker_sentiment_score": "0.282284", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.240489", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.240489", "ticker_sentiment_score": "0.24173", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Here's Why Regeneron Just Hit A Record High - Again", "url": "https://www.investors.com/news/technology/regn-stock-hits-a-record-high-again-as-it-tacks-on-new-wins/", "time_published": "20240112T182200", "authors": ["ALLISON GATLIN", "Investor's Business Daily"], "summary": "REGN Stock Hits A Record High - Again - As It Tacks On New Wins Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2020/08/Stock-regeneron-01-shutt.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.929393"}], "overall_sentiment_score": 0.259275, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ALNY", "relevance_score": "0.123844", "ticker_sentiment_score": "0.02857", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.303175", "ticker_sentiment_score": "0.346108", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.123844", "ticker_sentiment_score": "0.02857", "ticker_sentiment_label": "Neutral"}, {"ticker": "ISRG", "relevance_score": "0.06211", "ticker_sentiment_score": "0.115369", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.06211", "ticker_sentiment_score": "0.337735", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SNY", "relevance_score": "0.06211", "ticker_sentiment_score": "0.190789", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Kuehn Law Encourages PXD, IMGN, HA and ICVX Investors to Contact Law Firm", "url": "https://www.prnewswire.com/news-releases/kuehn-law-encourages-pxd-imgn-ha-and-icvx-investors-to-contact-law-firm-302033722.html", "time_published": "20240112T161000", "authors": ["PLLC", "Kuehn Law"], "summary": "NEW YORK, Jan. 12, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may seek additional disclosures or other relief on behalf of the shareholders of these companies.", "banner_image": "https://mma.prnewswire.com/media/2309909/Kuehn_Law_PLLC.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.360215"}, {"topic": "Energy & Transportation", "relevance_score": "0.5"}], "overall_sentiment_score": 0.410079, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "ALK", "relevance_score": "0.136113", "ticker_sentiment_score": "0.332547", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.136113", "ticker_sentiment_score": "0.297822", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "XOM", "relevance_score": "0.136113", "ticker_sentiment_score": "0.232738", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HA", "relevance_score": "0.136113", "ticker_sentiment_score": "0.332547", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABBV", "relevance_score": "0.136113", "ticker_sentiment_score": "0.300223", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PXD", "relevance_score": "0.268294", "ticker_sentiment_score": "0.367654", "ticker_sentiment_label": "Bullish"}, {"ticker": "ICVX", "relevance_score": "0.136113", "ticker_sentiment_score": "0.297822", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "How to Find Strong Medical Stocks Slated for Positive Earnings Surprises", "url": "https://www.zacks.com/stock/news/2209409/how-to-find-strong-medical-stocks-slated-for-positive-earnings-surprises", "time_published": "20240112T135005", "authors": ["Zacks Equity Research"], "summary": "The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default44.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999937"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.353285, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.341857", "ticker_sentiment_score": "0.304664", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.404563", "ticker_sentiment_score": "0.342224", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "FDA Finds No Link Between Obesity Drugs and Suicidal Thoughts", "url": "https://www.zacks.com/stock/news/2209351/fda-finds-no-link-between-obesity-drugs-and-suicidal-thoughts", "time_published": "20240112T124700", "authors": ["Kinjel Shah"], "summary": "The GLP-1 segment is an important class of drugs for multiple cardiometabolic diseases and is gaining significant popularity.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/82/41137.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.101797, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.227007", "ticker_sentiment_score": "0.104048", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.227007", "ticker_sentiment_score": "0.056869", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.171282", "ticker_sentiment_score": "0.110461", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.05749", "ticker_sentiment_score": "0.149399", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.227007", "ticker_sentiment_score": "0.250732", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Ozempic not linked to suicidal thoughts, FDA report finds", "url": "https://www.financialexpress.com/healthcare/pharma-healthcare/ozempic-not-linked-to-suicidal-thoughts-fda-report-finds/3363168/", "time_published": "20240112T111249", "authors": ["Bloomberg"], "summary": "US regulators found no link between weight-loss drugs like Novo Nordisk A/S's Ozempic and suicidal thoughts, a positive sign for the popular medications as similar reviews in Europe remain ongoing.", "banner_image": "https://www.financialexpress.com/wp-content/uploads/2024/01/pills-384846_1280.jpg", "source": "The Financial Express", "category_within_source": "n/a", "source_domain": "www.financialexpress.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.082165, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.121037", "ticker_sentiment_score": "0.025567", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.121037", "ticker_sentiment_score": "0.025567", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.121037", "ticker_sentiment_score": "-0.009974", "ticker_sentiment_label": "Neutral"}]}, {"title": "Antibiotic Resistance Market Projected to Hit US$ 17.8 Billion by 2033 with a CAGR of 5.3% | Persistence Market Research", "url": "https://www.benzinga.com/pressreleases/24/01/g36606656/antibiotic-resistance-market-projected-to-hit-us-17-8-billion-by-2033-with-a-cagr-of-5-3-persisten", "time_published": "20240112T090835", "authors": ["Globe Newswire"], "summary": "New York, Jan. 12, 2024 ( GLOBE NEWSWIRE ) -- The growing demand for new antibiotic therapies to combat antibiotic resistance is a prominent driver in the global market. In a July 2023 Science Daily article, the World Health Organization ( WHO ) recognized antibiotic-resistant bacteria as a major ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Economy - Fiscal", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.684621"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.014889, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BIO", "relevance_score": "0.018187", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVS", "relevance_score": "0.018187", "ticker_sentiment_score": "-0.055056", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.018187", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.036365", "ticker_sentiment_score": "-0.083171", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.018187", "ticker_sentiment_score": "-0.131837", "ticker_sentiment_label": "Neutral"}, {"ticker": "TMO", "relevance_score": "0.018187", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Human trial for deadly Nipah virus vaccine begins at Oxford; Here's what you need to know", "url": "https://www.financialexpress.com/healthcare/news-healthcare/human-trial-for-deadly-nipah-virus-vaccine-begins-at-oxford-heres-what-you-need-to-know/3362833/", "time_published": "20240112T071022", "authors": ["Sushmita Panda"], "summary": "Human trial for deadly Nipah virus vaccine begins at Oxford. Here's what you need to know The Financial Express ...", "banner_image": "https://www.financialexpress.com/wp-content/uploads/2024/01/ch1159595.jpg", "source": "The Financial Express", "category_within_source": "n/a", "source_domain": "www.financialexpress.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.198526, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.063763", "ticker_sentiment_score": "-0.16721", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "AZN", "relevance_score": "0.127119", "ticker_sentiment_score": "-0.096747", "ticker_sentiment_label": "Neutral"}]}, {"title": "Here's Why Astrazeneca  ( AZN )  Fell More Than Broader Market", "url": "https://www.zacks.com/stock/news/2209187/heres-why-astrazeneca-azn-fell-more-than-broader-market", "time_published": "20240111T230020", "authors": ["Zacks Equity Research"], "summary": "Astrazeneca (AZN) closed at $69.18 in the latest trading session, marking a -0.56% move from the prior day.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default248.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.875462"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.196499, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.625937", "ticker_sentiment_score": "0.281744", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "What Is 'Disease X'? Right-Wing Circles Slam Hypothetical Pandemic", "url": "https://www.forbes.com/sites/brianbushard/2024/01/11/what-is-disease-x-right-wing-circles-slam-hypothetical-pandemic/", "time_published": "20240111T210842", "authors": ["Brian Bushard"], "summary": "With less than a week until the World Economic Forum discusses potential preparations for a hypothetical disease far deadlier than Covid-19 named \"Disease X,\" mention of the illness have sparked a firestorm on social media, with right-wing accounts slamming the plans surrounding the hypothetical ...", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/65a04fe2fe82439c4f86ca60/0x0.jpg?format=jpg&crop=3095,1740,x0,y157,safe&height=900&width=1600&fit=bounds", "source": "Forbes", "category_within_source": "n/a", "source_domain": "www.forbes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": -0.237156, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "MFCSF", "relevance_score": "0.062597", "ticker_sentiment_score": "0.04408", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.062597", "ticker_sentiment_score": "-0.092383", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.062597", "ticker_sentiment_score": "-0.092383", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOX", "relevance_score": "0.062597", "ticker_sentiment_score": "-0.092383", "ticker_sentiment_label": "Neutral"}]}, {"title": "Oxford University Kicks off Human Study for AstraZeneca's COVID-19 Vaccine Technology in Nipah Virus Defense - AstraZeneca  ( NASDAQ:AZN ) ", "url": "https://www.benzinga.com/general/biotech/24/01/36594595/oxford-university-kicks-off-human-study-for-astrazenecas-covid-19-vaccine-technology-in-nipah-vir", "time_published": "20240111T143318", "authors": ["Vandana Singh"], "summary": "Oxford Vaccine Group, part of the University's Pandemic Sciences Institute, has commenced the first-in-human trial of the ChAdOx1 NipahB vaccine, targeting the deadly Nipah virus. The trial involves 51 participants aged 18 to 55.", "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Photo-by-Paul-McManus-from-Pixabay.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": -0.346627, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.247838", "ticker_sentiment_score": "-0.096253", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.364275", "ticker_sentiment_score": "0.153943", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Focal Segmental Glomerulosclerosis Market to Observe Impressive Growth by 2032, Predicts DelveInsight | Leading Companies - ACELYRIN, Genentech, ChemoCentryx, Travere Therapeutics, Boehringer Ingelheim, Chinook Therapeutics", "url": "https://www.prnewswire.com/news-releases/focal-segmental-glomerulosclerosis-market-to-observe-impressive-growth-by-2032-predicts-delveinsight--leading-companies---acelyrin-genentech-chemocentryx-travere-therapeutics-boehringer-ingelheim-chinook-therapeutics-302030785.html", "time_published": "20240110T220100", "authors": ["DelveInsight Business Research", "LLP"], "summary": "Focal Segmental Glomerulosclerosis Market to Observe Impressive Growth by 2032, Predicts DelveInsight | Leading ... PR ...", "banner_image": "https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.106846, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ZVSA", "relevance_score": "0.028321", "ticker_sentiment_score": "0.038274", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALDX", "relevance_score": "0.028321", "ticker_sentiment_score": "0.086235", "ticker_sentiment_label": "Neutral"}, {"ticker": "TVTX", "relevance_score": "0.084821", "ticker_sentiment_score": "0.088295", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.056607", "ticker_sentiment_score": "-0.017", "ticker_sentiment_label": "Neutral"}, {"ticker": "KDNY", "relevance_score": "0.056607", "ticker_sentiment_score": "0.085954", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.028321", "ticker_sentiment_score": "0.038274", "ticker_sentiment_label": "Neutral"}, {"ticker": "DMAC", "relevance_score": "0.028321", "ticker_sentiment_score": "0.002769", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.028321", "ticker_sentiment_score": "0.038274", "ticker_sentiment_label": "Neutral"}, {"ticker": "LXRX", "relevance_score": "0.028321", "ticker_sentiment_score": "0.002769", "ticker_sentiment_label": "Neutral"}, {"ticker": "SLRN", "relevance_score": "0.028321", "ticker_sentiment_score": "0.086235", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.028321", "ticker_sentiment_score": "0.002769", "ticker_sentiment_label": "Neutral"}, {"ticker": "PROK", "relevance_score": "0.056607", "ticker_sentiment_score": "-0.017", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.028321", "ticker_sentiment_score": "0.002769", "ticker_sentiment_label": "Neutral"}]}, {"title": "SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Cytosorbents Corporation - CTSO - CytoSorbents  ( NASDAQ:CTSO ) ", "url": "https://www.benzinga.com/pressreleases/24/01/g36583095/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-cytosorbents-co", "time_published": "20240110T200813", "authors": ["Globe Newswire"], "summary": "NEW YORK, Jan. 10, 2024 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Cytosorbents Corporation ( \"Cytosorbents\" or the \"Company\" ) CTSO. Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.060686, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.132368", "ticker_sentiment_score": "0.118049", "ticker_sentiment_label": "Neutral"}, {"ticker": "CTSO", "relevance_score": "0.682689", "ticker_sentiment_score": "0.147669", "ticker_sentiment_label": "Neutral"}]}, {"title": "RS Earns a 95/100 on the Human Rights Campaign Foundation's 2023-2024 Corporate Equality Index", "url": "https://www.prnewswire.com/news-releases/rs-earns-a-95100-on-the-human-rights-campaign-foundations-20232024-corporate-equality-index-302028082.html", "time_published": "20240110T160000", "authors": ["RS"], "summary": "The HRC Foundation's annual CEI is the leading U.S. assessment of LGBTQ+ workplace equality, and as a proudly inclusive company, RS is honored to have increased its ranking by 15 points this year.", "banner_image": "https://mma.prnewswire.com/media/2164570/RS_LOGO_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Energy & Transportation", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Finance", "relevance_score": "0.166667"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "0.929393"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.309267, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DE", "relevance_score": "0.030331", "ticker_sentiment_score": "0.036848", "ticker_sentiment_label": "Neutral"}, {"ticker": "UAL", "relevance_score": "0.030331", "ticker_sentiment_score": "0.036848", "ticker_sentiment_label": "Neutral"}, {"ticker": "WEN", "relevance_score": "0.030331", "ticker_sentiment_score": "0.036848", "ticker_sentiment_label": "Neutral"}, {"ticker": "CSCO", "relevance_score": "0.030331", "ticker_sentiment_score": "0.036848", "ticker_sentiment_label": "Neutral"}, {"ticker": "PNC", "relevance_score": "0.030331", "ticker_sentiment_score": "0.036848", "ticker_sentiment_label": "Neutral"}, {"ticker": "FL", "relevance_score": "0.030331", "ticker_sentiment_score": "0.036848", "ticker_sentiment_label": "Neutral"}, {"ticker": "PTON", "relevance_score": "0.030331", "ticker_sentiment_score": "0.036848", "ticker_sentiment_label": "Neutral"}, {"ticker": "WOOF", "relevance_score": "0.030331", "ticker_sentiment_score": "0.036848", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABNB", "relevance_score": "0.030331", "ticker_sentiment_score": "0.036848", "ticker_sentiment_label": "Neutral"}, {"ticker": "LDNXF", "relevance_score": "0.030331", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSCO", "relevance_score": "0.030331", "ticker_sentiment_score": "0.036848", "ticker_sentiment_label": "Neutral"}, {"ticker": "UA", "relevance_score": "0.030331", "ticker_sentiment_score": "0.036848", "ticker_sentiment_label": "Neutral"}, {"ticker": "RYCEF", "relevance_score": "0.030331", "ticker_sentiment_score": "0.036848", "ticker_sentiment_label": "Neutral"}, {"ticker": "WFC", "relevance_score": "0.030331", "ticker_sentiment_score": "0.036848", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMD", "relevance_score": "0.030331", "ticker_sentiment_score": "0.036848", "ticker_sentiment_label": "Neutral"}, {"ticker": "DBX", "relevance_score": "0.030331", "ticker_sentiment_score": "0.036848", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALIZF", "relevance_score": "0.030331", "ticker_sentiment_score": "0.036848", "ticker_sentiment_label": "Neutral"}, {"ticker": "EENEF", "relevance_score": "0.090816", "ticker_sentiment_score": "0.09901", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALLY", "relevance_score": "0.030331", "ticker_sentiment_score": "0.036848", "ticker_sentiment_label": "Neutral"}, {"ticker": "CI", "relevance_score": "0.030331", "ticker_sentiment_score": "0.036848", "ticker_sentiment_label": "Neutral"}, {"ticker": "KSS", "relevance_score": "0.030331", "ticker_sentiment_score": "0.036848", "ticker_sentiment_label": "Neutral"}, {"ticker": "ROK", "relevance_score": "0.030331", "ticker_sentiment_score": "0.036848", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAP", "relevance_score": "0.030331", "ticker_sentiment_score": "0.036848", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNEJF", "relevance_score": "0.030331", "ticker_sentiment_score": "0.036848", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.030331", "ticker_sentiment_score": "0.036848", "ticker_sentiment_label": "Neutral"}, {"ticker": "MET", "relevance_score": "0.030331", "ticker_sentiment_score": "0.036848", "ticker_sentiment_label": "Neutral"}]}, {"title": "AIM ImmunoTech Announces Open Enrollment for Phase 1b/2 Study Evaluating Ampligen\u00ae  ( rintatolimod )  in Combination with AstraZeneca's Imfinzi\u00ae  ( durvalumab )  for the Treatment of Pancreatic Cancer", "url": "https://www.globenewswire.com/news-release/2024/01/10/2807133/29489/en/AIM-ImmunoTech-Announces-Open-Enrollment-for-Phase-1b-2-Study-Evaluating-Ampligen-rintatolimod-in-Combination-with-AstraZeneca-s-Imfinzi-durvalumab-for-the-Treatment-of-Pancreatic-.html", "time_published": "20240110T134500", "authors": ["AIM ImmunoTech Inc."], "summary": "First enrollment and first subject dosing expected soon at Erasmus Medical Center in Rotterdam, Netherlands ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/8e85b83b-047f-4f99-9c51-1aa232ffe9bb", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.310843"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Blockchain", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.185896, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.044141", "ticker_sentiment_score": "0.094527", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.044141", "ticker_sentiment_score": "0.144764", "ticker_sentiment_label": "Neutral"}]}, {"title": "Absci Appoints Professor Sir Mene Pangalos to its Board of Directors", "url": "https://www.globenewswire.com/news-release/2024/01/10/2807012/0/en/Absci-Appoints-Professor-Sir-Mene-Pangalos-to-its-Board-of-Directors.html", "time_published": "20240110T123000", "authors": ["ABSCI Corporation"], "summary": "VANCOUVER, Wash., Jan. 10, 2024 ( GLOBE NEWSWIRE ) -- Absci ( Nasdaq: ABSI ) , a generative AI drug creation company, today announced the appointment of seasoned R&D executive Professor Sir Menelas \"Mene\" Pangalos to its Board of Directors and as co-chair of Absci's Scientific Advisory Board.", "banner_image": "https://ml.globenewswire.com/Resource/Download/8a7eb744-ee7b-4c4b-89cf-387103eed7ab", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.838487"}], "overall_sentiment_score": 0.305775, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ABSI", "relevance_score": "0.27432", "ticker_sentiment_score": "0.304953", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GOOG", "relevance_score": "0.034984", "ticker_sentiment_score": "0.07597", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.139265", "ticker_sentiment_score": "0.146948", "ticker_sentiment_label": "Neutral"}, {"ticker": "LBTSF", "relevance_score": "0.034984", "ticker_sentiment_score": "0.083678", "ticker_sentiment_label": "Neutral"}]}, {"title": "SHAREHOLDER RIGHTS INVESTIGATION: Halper Sadeh LLC Investigates HA, ICVX, PGTI, GRCL - Gracell Biotechnologies  ( NASDAQ:GRCL ) , Hawaiian Holdings  ( NASDAQ:HA ) ", "url": "https://www.benzinga.com/pressreleases/24/01/g36569803/shareholder-rights-investigation-halper-sadeh-llc-investigates-ha-icvx-pgti-grcl", "time_published": "20240110T015915", "authors": ["Globe Newswire"], "summary": "NEW YORK, Jan. 09, 2024 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Hawaiian Holdings, Inc.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.181037, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ALK", "relevance_score": "0.105604", "ticker_sentiment_score": "0.084149", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.309539", "ticker_sentiment_score": "0.295576", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GRCL", "relevance_score": "0.105604", "ticker_sentiment_score": "0.134125", "ticker_sentiment_label": "Neutral"}, {"ticker": "HA", "relevance_score": "0.105604", "ticker_sentiment_score": "0.084149", "ticker_sentiment_label": "Neutral"}, {"ticker": "PGTI", "relevance_score": "0.105604", "ticker_sentiment_score": "0.150466", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DOOR", "relevance_score": "0.105604", "ticker_sentiment_score": "0.150466", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ICVX", "relevance_score": "0.209365", "ticker_sentiment_score": "0.251937", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "AstraZeneca PLC  ( AZN )  Is a Trending Stock: Facts to Know Before Betting on It", "url": "https://www.zacks.com/stock/news/2207883/astrazeneca-plc-azn-is-a-trending-stock-facts-to-know-before-betting-on-it", "time_published": "20240109T232215", "authors": ["Zacks Equity Research"], "summary": "Astrazeneca (AZN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default275.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.503496"}], "overall_sentiment_score": 0.219634, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.493128", "ticker_sentiment_score": "0.144798", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biotech ETFs Stage Solid Comeback at the Start of 2024", "url": "https://www.zacks.com/stock/news/2207551/biotech-etfs-stage-solid-comeback-at-the-start-of-2024", "time_published": "20240109T160500", "authors": ["Sweta Killa"], "summary": "The biotech space staged a strong comeback at the start of 2024, driven by multi-billion dollar deals, upbeat clinical results and cutting-edge medical advances like CRISPR gene-editing hitting prime-time.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/7b/850.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.999999"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.147642, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NVO", "relevance_score": "0.133346", "ticker_sentiment_score": "0.162037", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.089129", "ticker_sentiment_score": "0.084886", "ticker_sentiment_label": "Neutral"}, {"ticker": "KRTX", "relevance_score": "0.089129", "ticker_sentiment_score": "0.058856", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.089129", "ticker_sentiment_score": "0.084886", "ticker_sentiment_label": "Neutral"}, {"ticker": "RYZB", "relevance_score": "0.089129", "ticker_sentiment_score": "0.058856", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.089129", "ticker_sentiment_score": "0.058856", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.133346", "ticker_sentiment_score": "0.06769", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.089129", "ticker_sentiment_score": "0.058856", "ticker_sentiment_label": "Neutral"}, {"ticker": "GRCL", "relevance_score": "0.089129", "ticker_sentiment_score": "0.058856", "ticker_sentiment_label": "Neutral"}, {"ticker": "HARP", "relevance_score": "0.089129", "ticker_sentiment_score": "0.084886", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.133346", "ticker_sentiment_score": "0.162037", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.133346", "ticker_sentiment_score": "0.071668", "ticker_sentiment_label": "Neutral"}, {"ticker": "OMGA", "relevance_score": "0.089129", "ticker_sentiment_score": "0.140918", "ticker_sentiment_label": "Neutral"}]}, {"title": "Evaluating AstraZeneca Against Peers In Pharmaceuticals Industry - AstraZeneca  ( NASDAQ:AZN ) ", "url": "https://www.benzinga.com/news/24/01/36559737/evaluating-astrazeneca-against-peers-in-pharmaceuticals-industry", "time_published": "20240109T160038", "authors": ["Benzinga Insights"], "summary": "In today's rapidly evolving and fiercely competitive business landscape, it is crucial for investors and industry analysts to conduct comprehensive company evaluations. In this article, we will undertake an in-depth industry comparison, assessing AstraZeneca AZN alongside its primary competitors ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.980716"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.459462"}], "overall_sentiment_score": 0.145453, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "PTAIF", "relevance_score": "0.0699", "ticker_sentiment_score": "0.018233", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.460808", "ticker_sentiment_score": "0.266469", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Obesity drug challengers will struggle to break into plus-sized market", "url": "https://www.ft.com/content/184617f3-9a88-4d23-8e23-d1a08d5577dd", "time_published": "20240109T050017", "authors": [], "summary": "Weight loss treatments are tipped to rake in $80bn a year by 2030. Danish pioneer Novo Nordisk and rival Eli Lilly have made the running. But others are trying to find space in the field. Around a dozen companies are set to announce trial results for over 20 drugs this year.", "banner_image": "https://www.ft.com/__origami/service/image/v2/images/raw/https%3A%2F%2Fd6c748xw2pzm8.cloudfront.net%2Fprod%2F880fa250-ae40-11ee-bb0e-3537ccd787f0-standard.png?source=next-article&fit=scale-down&quality=highest&width=700&dpr=1", "source": "Financial Times", "category_within_source": "GoogleRSS", "source_domain": "www.ft.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.197503, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "C", "relevance_score": "0.07913", "ticker_sentiment_score": "0.266321", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.07913", "ticker_sentiment_score": "0.097567", "ticker_sentiment_label": "Neutral"}, {"ticker": "OMGA", "relevance_score": "0.07913", "ticker_sentiment_score": "0.211921", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVO", "relevance_score": "0.308891", "ticker_sentiment_score": "0.222308", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "CYTOSORBENTS ALERT: Bragar Eagel & Squire, P.C. is Investigating Cytosorbents Corporation on Behalf of Cytosorbents Stockholders and Encourages Investors to Contact the Firm - CytoSorbents  ( NASDAQ:CTSO ) ", "url": "https://www.benzinga.com/pressreleases/24/01/g36548622/cytosorbents-alert-bragar-eagel-squire-p-c-is-investigating-cytosorbents-corporation-on-behalf-of-", "time_published": "20240109T020000", "authors": ["Globe Newswire"], "summary": "NEW YORK, Jan. 08, 2024 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Cytosorbents Corporation ( \"Cytosorbents\" or the \"Company\" ) CTSO on behalf of Cytosorbents stockholders.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}], "overall_sentiment_score": 0.053163, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.122269", "ticker_sentiment_score": "0.113597", "ticker_sentiment_label": "Neutral"}, {"ticker": "CTSO", "relevance_score": "0.781591", "ticker_sentiment_score": "0.136969", "ticker_sentiment_label": "Neutral"}]}, {"title": "BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ambrx Biopharma, Inc.  ( Nasdaq - AMAM ) , Gracell Biotechnologies Inc.  ( Nasdaq - GRCL ) , Axonics, Inc.  ( Nasdaq - AXNX ) , Harpoon Therapeutics, Inc.  ( Nasdaq - HARP ) ", "url": "https://www.benzinga.com/pressreleases/24/01/g36547175/brodsky-smith-shareholder-update-notifying-investors-of-the-following-investigations-ambrx-biophar", "time_published": "20240108T223137", "authors": ["Globe Newswire"], "summary": "BALA CYNWYD, Pa., Jan. 08, 2024 ( GLOBE NEWSWIRE ) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( jbrodsky@brodskysmith.com ) or Marc Ackerman ( mackerman@brodskysmith.com ) at 855-576-4847.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.796627"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.232971, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.233556", "ticker_sentiment_score": "0.266779", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DSSMY", "relevance_score": "0.233556", "ticker_sentiment_score": "0.068874", "ticker_sentiment_label": "Neutral"}, {"ticker": "GRCL", "relevance_score": "0.07887", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMAM", "relevance_score": "0.07887", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BSX", "relevance_score": "0.233556", "ticker_sentiment_score": "0.235274", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HARP", "relevance_score": "0.07887", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.15697", "ticker_sentiment_score": "0.156505", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AXNX", "relevance_score": "0.233556", "ticker_sentiment_score": "0.216405", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Ionis poised for continued momentum in 2024 with product launches and key advances in robust pipeline of investigational medicines for serious diseases", "url": "https://www.prnewswire.com/news-releases/ionis-poised-for-continued-momentum-in-2024-with-product-launches-and-key-advances-in-robust-pipeline-of-investigational-medicines-for-serious-diseases-302028429.html", "time_published": "20240108T120300", "authors": ["Inc.", "Ionis Pharmaceuticals"], "summary": "Ionis poised for continued momentum in 2024 with product launches and key advances in robust pipeline of ... PR ...", "banner_image": "https://mma.prnewswire.com/media/882077/Ionis_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.1789, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.076847", "ticker_sentiment_score": "0.049882", "ticker_sentiment_label": "Neutral"}, {"ticker": "IONS", "relevance_score": "0.115048", "ticker_sentiment_score": "0.092309", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.038468", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Clarivate Identifies Thirteen Potential Blockbuster Drugs and Gamechangers in Annual Drugs to Watch Report", "url": "https://www.prnewswire.com/news-releases/clarivate-identifies-thirteen-potential-blockbuster-drugs-and-gamechangers-in-annual-drugs-to-watch-report-302027294.html", "time_published": "20240108T080000", "authors": ["Clarivate Plc"], "summary": "Therapeutic advancements for sickle cell disease, RSV, breast cancer, Crohn's and other ailments poised to advance patient health despite urgent challenges facing life science companies", "banner_image": "https://mma.prnewswire.com/media/1159266/Clarivate_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.242731, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BLUE", "relevance_score": "0.020266", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "III", "relevance_score": "0.020266", "ticker_sentiment_score": "0.240962", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.020266", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SKXJF", "relevance_score": "0.040519", "ticker_sentiment_score": "-0.030752", "ticker_sentiment_label": "Neutral"}, {"ticker": "DSKYF", "relevance_score": "0.040519", "ticker_sentiment_score": "-0.030752", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.020266", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.020266", "ticker_sentiment_score": "-0.125978", "ticker_sentiment_label": "Neutral"}, {"ticker": "CLVT", "relevance_score": "0.239502", "ticker_sentiment_score": "0.270064", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.020266", "ticker_sentiment_score": "-0.125978", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIOVF", "relevance_score": "0.020266", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.020266", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GSK", "relevance_score": "0.040519", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.020266", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Clarivate Identifies Thirteen Potential Blockbuster Drugs and Gamechangers in Annual Drugs to Watch Report", "url": "https://www.newswire.ca/news-releases/clarivate-identifies-thirteen-potential-blockbuster-drugs-and-gamechangers-in-annual-drugs-to-watch-report-802561925.html", "time_published": "20240108T080000", "authors": ["Clarivate Plc"], "summary": "Therapeutic advancements for sickle cell disease, RSV, breast cancer, Crohn's and other ailments poised to advance patient health despite urgent challenges facing life science companies", "banner_image": "https://mma.prnewswire.com/media/1159266/Clarivate_Logo.jpg?p=facebook", "source": "Canada Newswire", "category_within_source": "n/a", "source_domain": "www.newswire.ca", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.242731, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BLUE", "relevance_score": "0.020266", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "III", "relevance_score": "0.020266", "ticker_sentiment_score": "0.240962", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.020266", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SKXJF", "relevance_score": "0.040519", "ticker_sentiment_score": "-0.030752", "ticker_sentiment_label": "Neutral"}, {"ticker": "DSKYF", "relevance_score": "0.040519", "ticker_sentiment_score": "-0.030752", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.020266", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.020266", "ticker_sentiment_score": "-0.125978", "ticker_sentiment_label": "Neutral"}, {"ticker": "CLVT", "relevance_score": "0.239502", "ticker_sentiment_score": "0.270064", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.020266", "ticker_sentiment_score": "-0.125978", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIOVF", "relevance_score": "0.020266", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.020266", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GSK", "relevance_score": "0.040519", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.020266", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Cytosorbents Corporation - CTSO", "url": "https://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-cytosorbents-corporation---ctso-302027486.html", "time_published": "20240106T161500", "authors": ["Pomerantz LLP"], "summary": "SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Cytosorbents Corporation ... PR ...", "banner_image": "https://mma.prnewswire.com/media/2287619/Pomerantz_V3_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.101955, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.145145", "ticker_sentiment_score": "0.126751", "ticker_sentiment_label": "Neutral"}, {"ticker": "CTSO", "relevance_score": "0.727604", "ticker_sentiment_score": "0.216506", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "4 Superior Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip", "url": "https://www.fool.com/investing/2024/01/06/nasdaq-bear-market-4-growth-stocks-regret-not-buy/", "time_published": "20240106T100600", "authors": ["Sean Williams"], "summary": "The growth-fueled Nasdaq Composite is 9% below its record high, meaning amazing deals are still hiding in plain sight.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F760125%2Fbear-market-stocks-plunge-crash-invest-correction-getty.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.955357"}, {"topic": "Earnings", "relevance_score": "0.839681"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.218979, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BABA", "relevance_score": "0.057698", "ticker_sentiment_score": "0.095966", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.143586", "ticker_sentiment_score": "-0.001324", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIDU", "relevance_score": "0.227805", "ticker_sentiment_score": "0.193158", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PLTR", "relevance_score": "0.086452", "ticker_sentiment_score": "0.218568", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Astrazeneca  ( AZN )  Stock Falls Amid Market Uptick: What Investors Need to Know", "url": "https://www.zacks.com/stock/news/2206582/astrazeneca-azn-stock-falls-amid-market-uptick-what-investors-need-to-know", "time_published": "20240105T225018", "authors": ["Zacks Equity Research"], "summary": "The latest trading day saw Astrazeneca (AZN) settling at $68.38, representing a -0.58% change from its previous close.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default126.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.95493"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.234762, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.556576", "ticker_sentiment_score": "0.320757", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Omega  ( OMGA )  Up 95% on Obesity Drug Deal With Novo Nordisk", "url": "https://www.zacks.com/stock/news/2206517/omega-omga-up-95-on-obesity-drug-deal-with-novo-nordisk", "time_published": "20240105T175500", "authors": ["Zacks Equity Research"], "summary": "Using Omega's (OMGA) proprietary technology platform, Novo Nordisk (NVO) intends to develop a novel therapeutic for obesity, which will enhance the body's metabolism activity to burn excess fats.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/34/973.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.249163, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.171282", "ticker_sentiment_score": "0.181114", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.171282", "ticker_sentiment_score": "0.135412", "ticker_sentiment_label": "Neutral"}, {"ticker": "OMGA", "relevance_score": "0.334762", "ticker_sentiment_score": "0.156185", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVO", "relevance_score": "0.436009", "ticker_sentiment_score": "0.356733", "ticker_sentiment_label": "Bullish"}]}, {"title": "Novo Nordisk  ( NVO )  Up on $1.1B Research Deals With 2 Biotechs", "url": "https://www.zacks.com/stock/news/2206370/novo-nordisk-nvo-up-on-11b-research-deals-with-2-biotechs", "time_published": "20240105T153500", "authors": ["Zacks Equity Research"], "summary": "Novo Nordisk (NVO) gains 4% after signing $1.1 billion research collaboration agreements with two biotech companies to develop novel treatment approaches for cardiometabolic diseases.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/de/2471.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.228746, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.164749", "ticker_sentiment_score": "0.15357", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.244928", "ticker_sentiment_score": "0.091398", "ticker_sentiment_label": "Neutral"}, {"ticker": "OMGA", "relevance_score": "0.322549", "ticker_sentiment_score": "0.162148", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVO", "relevance_score": "0.467318", "ticker_sentiment_score": "0.323723", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Pharma Stock Roundup: LLY's New Digital Pharmacy, NVO & ABBV's Fresh R&D Deals", "url": "https://www.zacks.com/stock/news/2206363/pharma-stock-roundup-llys-new-digital-pharmacy-nvo-abbvs-fresh-rd-deals", "time_published": "20240105T152500", "authors": ["Kinjel Shah"], "summary": "Eli Lilly (LLY) launches a new direct-to-consumer website to provide easy access to its medicines. Novo Nordisk (NVO) announces two research collaborations to develop novel treatments for cardiometabolic diseases.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/88/898.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.143344, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.295867", "ticker_sentiment_score": "0.076649", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.295867", "ticker_sentiment_score": "0.240803", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.199859", "ticker_sentiment_score": "0.154026", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVO", "relevance_score": "0.295867", "ticker_sentiment_score": "0.125188", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.050465", "ticker_sentiment_score": "-0.119302", "ticker_sentiment_label": "Neutral"}]}, {"title": "It's Been An Abysmal Two Years. But Biotech Is Looking Up.", "url": "https://www.investors.com/news/technology/biotech-stocks-pharma-heat-up-in-2024-as-buyouts-obesity-ai-drive-excitement/", "time_published": "20240105T140000", "authors": ["Investor's Business Daily", "ALLISON GATLIN"], "summary": "Biotech Stocks, Pharma Heat Up In 2024 As Buyouts, Obesity And AI Drive Excitement Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2024/01/A1-010824-biotech-Gash.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "1.0"}], "overall_sentiment_score": 0.12567, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NVO", "relevance_score": "0.035679", "ticker_sentiment_score": "0.069333", "ticker_sentiment_label": "Neutral"}, {"ticker": "NBIX", "relevance_score": "0.02379", "ticker_sentiment_score": "0.14181", "ticker_sentiment_label": "Neutral"}, {"ticker": "KRTX", "relevance_score": "0.035679", "ticker_sentiment_score": "0.037838", "ticker_sentiment_label": "Neutral"}, {"ticker": "IONS", "relevance_score": "0.02379", "ticker_sentiment_score": "0.084592", "ticker_sentiment_label": "Neutral"}, {"ticker": "RYZB", "relevance_score": "0.02379", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.02379", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ARWR", "relevance_score": "0.02379", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALEC", "relevance_score": "0.09495", "ticker_sentiment_score": "0.150269", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "LLY", "relevance_score": "0.153696", "ticker_sentiment_score": "0.053027", "ticker_sentiment_label": "Neutral"}, {"ticker": "VERV", "relevance_score": "0.02379", "ticker_sentiment_score": "0.006781", "ticker_sentiment_label": "Neutral"}, {"ticker": "OMGA", "relevance_score": "0.02379", "ticker_sentiment_score": "0.079056", "ticker_sentiment_label": "Neutral"}, {"ticker": "NTLA", "relevance_score": "0.02379", "ticker_sentiment_score": "-0.008781", "ticker_sentiment_label": "Neutral"}, {"ticker": "BHVN", "relevance_score": "0.02379", "ticker_sentiment_score": "-0.001871", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.02379", "ticker_sentiment_score": "0.067127", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.035679", "ticker_sentiment_score": "0.017905", "ticker_sentiment_label": "Neutral"}, {"ticker": "CPRX", "relevance_score": "0.02379", "ticker_sentiment_score": "0.14181", "ticker_sentiment_label": "Neutral"}, {"ticker": "BEAM", "relevance_score": "0.02379", "ticker_sentiment_score": "0.057997", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.02379", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GRCL", "relevance_score": "0.02379", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CLNN", "relevance_score": "0.02379", "ticker_sentiment_score": "-0.020246", "ticker_sentiment_label": "Neutral"}, {"ticker": "GPCR", "relevance_score": "0.035679", "ticker_sentiment_score": "0.08972", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMPH", "relevance_score": "0.02379", "ticker_sentiment_score": "0.14181", "ticker_sentiment_label": "Neutral"}, {"ticker": "ARGX", "relevance_score": "0.011896", "ticker_sentiment_score": "-0.115274", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.02379", "ticker_sentiment_score": "0.067127", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.02379", "ticker_sentiment_score": "-0.042606", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.035679", "ticker_sentiment_score": "0.064761", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.059429", "ticker_sentiment_score": "0.106048", "ticker_sentiment_label": "Neutral"}]}, {"title": "Insmed Provides Business Update at 42nd Annual J.P. Morgan Healthcare Conference", "url": "https://www.prnewswire.com/news-releases/insmed-provides-business-update-at-42nd-annual-jp-morgan-healthcare-conference-302026833.html", "time_published": "20240105T130000", "authors": ["Insmed Incorporated"], "summary": "-ARIKAYCE\u00ae ( amikacin liposome inhalation suspension ) Delivers Full-Year 2023 Revenues Exceeding the Upper End of Guidance Range with Unaudited Global Net Product Sales of Approximately $305.2 Million-", "banner_image": "https://mma.prnewswire.com/media/801462/Insmed_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.77141"}], "overall_sentiment_score": -0.031528, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.01089", "ticker_sentiment_score": "0.013351", "ticker_sentiment_label": "Neutral"}, {"ticker": "INSM", "relevance_score": "0.1301", "ticker_sentiment_score": "-0.01699", "ticker_sentiment_label": "Neutral"}]}, {"title": "SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ICVX, RYZB, CVLY, KRTX - Icosavax  ( NASDAQ:ICVX ) , Codorus Valley Bancorp  ( NASDAQ:CVLY ) ", "url": "https://www.benzinga.com/pressreleases/24/01/g36507799/shareholder-investigation-halper-sadeh-llc-investigates-icvx-ryzb-cvly-krtx", "time_published": "20240105T122746", "authors": ["Globe Newswire"], "summary": "NEW YORK, Jan. 05, 2024 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Icosavax, Inc.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.77141"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.130236, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ORRF", "relevance_score": "0.118064", "ticker_sentiment_score": "0.087614", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.118064", "ticker_sentiment_score": "0.178266", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "KRTX", "relevance_score": "0.118064", "ticker_sentiment_score": "0.087614", "ticker_sentiment_label": "Neutral"}, {"ticker": "RYZB", "relevance_score": "0.233556", "ticker_sentiment_score": "0.136118", "ticker_sentiment_label": "Neutral"}, {"ticker": "ICVX", "relevance_score": "0.233556", "ticker_sentiment_score": "0.273638", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BMY", "relevance_score": "0.233556", "ticker_sentiment_score": "0.136118", "ticker_sentiment_label": "Neutral"}, {"ticker": "CVLY", "relevance_score": "0.118064", "ticker_sentiment_score": "0.087614", "ticker_sentiment_label": "Neutral"}]}, {"title": "Cancer Antibodies Combination Therapies Clinical Research Market Size Insight", "url": "https://www.benzinga.com/pressreleases/24/01/g36507666/cancer-antibodies-combination-therapies-clinical-research-market-size-insight", "time_published": "20240105T120951", "authors": ["Globe Newswire"], "summary": "Delhi, Jan. 05, 2024 ( GLOBE NEWSWIRE ) -- Global Cancer Antibody Combinations Market Opportunity & Clinical Trials Insight 2028 Report Findings & Highlights: Global Cancer Antibody Combinations Market Opportunity: > USD 40 Billion By 2028", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}], "overall_sentiment_score": 0.0, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.042048", "ticker_sentiment_score": "0.061243", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.042048", "ticker_sentiment_score": "0.061243", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.042048", "ticker_sentiment_score": "0.061243", "ticker_sentiment_label": "Neutral"}]}, {"title": "Lupin hit 52-week high on tentative USFDA nod to diabetes drug", "url": "https://www.moneycontrol.com/news/business/stocks/lupin-hit-52-week-high-on-tentative-usfda-nod-to-diabetes-drug-12000441.html", "time_published": "20240105T042225", "authors": [], "summary": "Dapagliflozin and saxagliptin tablets are prescribed in addition to diet and exercise to improve glycemic control in adults with type 2 diabetes ...", "banner_image": "https://images.moneycontrol.com/static-mcnews/2023/11/japan-solar-bbo.jpg?impolicy=website&width=168&height=118", "source": "Money Control", "category_within_source": "Buzzing Stocks", "source_domain": "www.moneycontrol.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}, {"topic": "Earnings", "relevance_score": "0.360215"}], "overall_sentiment_score": 0.132404, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.156461", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.156461", "ticker_sentiment_score": "0.131534", "ticker_sentiment_label": "Neutral"}]}, {"title": "Buzzing Stocks: L&T Finance, RBL Bank, Lupin, Grasim, Dabur, Utkarsh SFB, others in news", "url": "https://www.moneycontrol.com/news/photos/business/stocks/buzzing-stocks-lt-finance-rbl-bank-lupin-grasim-dabur-utkarsh-sfb-others-in-news-12001211.html", "time_published": "20240105T011122", "authors": [], "summary": "Stocks to watch: Check out the companies making headlines before the opening bell today, on January 5, 2024.", "banner_image": "https://images.moneycontrol.com/static-mcnews/2024/01/Nifty_sensex_marketup-770x433.jpg", "source": "Money Control", "category_within_source": "Buzzing Stocks", "source_domain": "www.moneycontrol.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.999701"}], "overall_sentiment_score": 0.203, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.039289", "ticker_sentiment_score": "0.114308", "ticker_sentiment_label": "Neutral"}, {"ticker": "QUBHF", "relevance_score": "0.039289", "ticker_sentiment_score": "0.118026", "ticker_sentiment_label": "Neutral"}, {"ticker": "GRSXY", "relevance_score": "0.039289", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why the Market Dipped But Astrazeneca  ( AZN )  Gained Today", "url": "https://www.zacks.com/stock/news/2205954/why-the-market-dipped-but-astrazeneca-azn-gained-today", "time_published": "20240104T230018", "authors": ["Zacks Equity Research"], "summary": "Astrazeneca (AZN) reachead $68.78 at the closing of the latest trading day, reflecting a +0.67% change compared to its last close.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default216.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.891286"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.193405, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.577173", "ticker_sentiment_score": "0.259503", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Fusion Pharmaceuticals Announces Clinical Program and Manufacturing Updates", "url": "https://www.newswire.ca/news-releases/fusion-pharmaceuticals-announces-clinical-program-and-manufacturing-updates-886037450.html", "time_published": "20240104T210500", "authors": ["Fusion Pharmaceuticals"], "summary": "HAMILTON, ON and BOSTON, Jan. 4, 2024 /CNW/ -- Fusion Pharmaceuticals Inc. ( Nasdaq: FUSN ) , a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced significant progress with its FPI-2265 development program, an update ...", "banner_image": "https://mma.prnewswire.com/media/1196797/Fusion_Logo.jpg?p=facebook", "source": "Canada Newswire", "category_within_source": "n/a", "source_domain": "www.newswire.ca", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Blockchain", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.77141"}], "overall_sentiment_score": 0.155089, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.019715", "ticker_sentiment_score": "0.063063", "ticker_sentiment_label": "Neutral"}, {"ticker": "FUSN", "relevance_score": "0.07874", "ticker_sentiment_score": "0.035908", "ticker_sentiment_label": "Neutral"}]}, {"title": "Fusion Pharmaceuticals Announces Clinical Program and Manufacturing Updates", "url": "https://www.prnewswire.com/news-releases/fusion-pharmaceuticals-announces-clinical-program-and-manufacturing-updates-302026567.html", "time_published": "20240104T210500", "authors": ["Fusion Pharmaceuticals"], "summary": "HAMILTON, ON and BOSTON, Jan. 4, 2024 /PRNewswire/ -- Fusion Pharmaceuticals Inc. ( Nasdaq: FUSN ) , a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced significant progress with its FPI-2265 development program, an ...", "banner_image": "https://mma.prnewswire.com/media/1196797/Fusion_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.77141"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Blockchain", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.157352, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.01924", "ticker_sentiment_score": "0.062878", "ticker_sentiment_label": "Neutral"}, {"ticker": "BWXT", "relevance_score": "0.076847", "ticker_sentiment_score": "0.067325", "ticker_sentiment_label": "Neutral"}, {"ticker": "FUSN", "relevance_score": "0.152983", "ticker_sentiment_score": "0.050357", "ticker_sentiment_label": "Neutral"}]}, {"title": "BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Icosavax, Inc.  ( Nasdaq - ICVX ) , Rain Oncology, Inc.  ( Nasdaq - RAIN ) , Consolidated Communications Holdings, Inc.  ( Nasdaq - CNSL ) , Cerevel Therapeutics Holdings, Inc.  ( Nasdaq - CERE ) ", "url": "https://www.benzinga.com/pressreleases/24/01/g36493927/brodsky-smith-shareholder-update-notifying-investors-of-the-following-investigations-icosavax-inc-", "time_published": "20240104T162228", "authors": ["Globe Newswire"], "summary": "BALA CYNWYD, Pa., Jan. 04, 2024 ( GLOBE NEWSWIRE ) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( jbrodsky@brodskysmith.com ) or Marc Ackerman ( mackerman@brodskysmith.com ) at 855-576-4847.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.87644"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.858979"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.228424, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "RAIN", "relevance_score": "0.284696", "ticker_sentiment_score": "0.284328", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.215574", "ticker_sentiment_score": "0.234287", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DSSMY", "relevance_score": "0.215574", "ticker_sentiment_score": "0.064631", "ticker_sentiment_label": "Neutral"}, {"ticker": "CERE", "relevance_score": "0.072655", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.215574", "ticker_sentiment_score": "0.237772", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CNSL", "relevance_score": "0.215574", "ticker_sentiment_score": "0.131303", "ticker_sentiment_label": "Neutral"}, {"ticker": "ICVX", "relevance_score": "0.215574", "ticker_sentiment_score": "0.21893", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: RayzeBio, Inc.  ( Nasdaq - RYZB ) , Gracell Biotechnologies Inc.  ( Nasdaq - GRCL ) , Daseke, Inc.  ( Nasdaq - DSKE ) , Karuna Therapeutics, Inc.  ( Nasdaq - KRTX )  - Bristol-Myers Squibb  ( NYSE:BMY ) ", "url": "https://www.benzinga.com/pressreleases/24/01/g36493511/brodsky-smith-shareholder-update-notifying-investors-of-the-following-investigations-rayzebio-inc-", "time_published": "20240104T160508", "authors": ["Globe Newswire"], "summary": "BALA CYNWYD, Pa., Jan. 04, 2024 ( GLOBE NEWSWIRE ) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( jbrodsky@brodskysmith.com ) or Marc Ackerman ( mackerman@brodskysmith.com ) at 855-576-4847.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.796627"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.253359, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.219477", "ticker_sentiment_score": "0.254532", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DSSMY", "relevance_score": "0.219477", "ticker_sentiment_score": "0.065552", "ticker_sentiment_label": "Neutral"}, {"ticker": "GRCL", "relevance_score": "0.074001", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TFII", "relevance_score": "0.289748", "ticker_sentiment_score": "0.312329", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "KRTX", "relevance_score": "0.289748", "ticker_sentiment_score": "0.239609", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DSKE", "relevance_score": "0.289748", "ticker_sentiment_score": "0.289118", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RYZB", "relevance_score": "0.289748", "ticker_sentiment_score": "0.288414", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BMY", "relevance_score": "0.422661", "ticker_sentiment_score": "0.372368", "ticker_sentiment_label": "Bullish"}]}, {"title": "Lupin gets USFDA approval to market generic medication to treat diabetes", "url": "https://www.business-standard.com/companies/news/lupin-gets-usfda-approval-to-market-generic-medication-to-treat-diabetes-124010400969_1.html", "time_published": "20240104T143250", "authors": ["Press Trust of India"], "summary": "Drug firm Lupin on Thursday said it has received approval from the US health regulator to market a generic medication to treat diabetes.", "banner_image": "https://bsmedia.business-standard.com/_media/bs/img/article/2023-03/30/full/1680174430-106.png?im=FitAndFill=(826,465)", "source": "Business Standard", "category_within_source": "GoogleRSS", "source_domain": "www.business-standard.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.201554, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.295867", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Antibody Therapeutics Market is Expected to Reach $479.0 Billion | MarketsandMarkets.", "url": "https://www.benzinga.com/pressreleases/24/01/g36487416/antibody-therapeutics-market-is-expected-to-reach-479-0-billion-marketsandmarkets", "time_published": "20240104T123000", "authors": ["Globe Newswire"], "summary": "Chicago, Jan. 04, 2024 ( GLOBE NEWSWIRE ) -- Antibody Therapeutics market in terms of revenue was estimated to be worth $247.3 Billion in 2023 and is poised to reach $479.0 billion by 2028, growing at a CAGR of 14.1% from 2023 to 2028 according to a latest report published by MarketsandMarkets\u2122.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.287429, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "IMNM", "relevance_score": "0.039745", "ticker_sentiment_score": "0.095935", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.079392", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.079392", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVS", "relevance_score": "0.079392", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.158", "ticker_sentiment_score": "0.04959", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.079392", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.079392", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.079392", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.079392", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.079392", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Moon landing apart, Indian science punches far below its weight", "url": "https://www.economist.com/science-and-technology/2024/01/03/moon-landing-apart-indian-science-punches-far-below-its-weight", "time_published": "20240103T183445", "authors": ["The Economist"], "summary": "S to get his head examined. Not that his behaviour had been odd of late. The 61-year-old civil contractor was on a routine visit to the Indian Institute of Science ( c ) in Bangalore, the country's leading research institution and one of his clients, when he heard about a study into the human ...", "banner_image": "https://www.economist.com/cdn-cgi/image/width=1424,quality=80,format=auto/content-assets/images/20240106_STC761.png", "source": "The Economist", "category_within_source": "BusinessGoogleRSS", "source_domain": "www.economist.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.13552, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "INFY", "relevance_score": "0.013151", "ticker_sentiment_score": "0.140859", "ticker_sentiment_label": "Neutral"}, {"ticker": "TWOH", "relevance_score": "0.013151", "ticker_sentiment_score": "0.102977", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.013151", "ticker_sentiment_score": "0.073389", "ticker_sentiment_label": "Neutral"}, {"ticker": "NRC", "relevance_score": "0.013151", "ticker_sentiment_score": "0.107671", "ticker_sentiment_label": "Neutral"}]}, {"title": "Tech stocks lead European bourses lower following Apple downgrade", "url": "https://www.marketwatch.com/story/tech-stocks-lead-european-bourses-lower-following-apple-downgrade-9678ce9b", "time_published": "20240103T124500", "authors": ["Jamie Chisholm"], "summary": "European bourses faltered Wednesday in the wake of Wall Street's new-year sell-off with the region's technology plays under notable pressure after a downgrade for Apple led the sector lower.", "banner_image": "https://images.mktw.net/im-408638/social", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": -0.097262, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "EADSF", "relevance_score": "0.113062", "ticker_sentiment_score": "-0.017569", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.330286", "ticker_sentiment_score": "-0.060919", "ticker_sentiment_label": "Neutral"}, {"ticker": "ASMXF", "relevance_score": "0.223866", "ticker_sentiment_score": "0.04426", "ticker_sentiment_label": "Neutral"}, {"ticker": "BCS", "relevance_score": "0.223866", "ticker_sentiment_score": "-0.068362", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.223866", "ticker_sentiment_score": "0.217071", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AOMFF", "relevance_score": "0.113062", "ticker_sentiment_score": "-0.230081", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "STM", "relevance_score": "0.113062", "ticker_sentiment_score": "-0.125072", "ticker_sentiment_label": "Neutral"}]}, {"title": "SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Cytosorbents Corporation - CTSO - CytoSorbents  ( NASDAQ:CTSO ) ", "url": "https://www.benzinga.com/pressreleases/24/01/g36458577/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-cytosorbents-co", "time_published": "20240102T201748", "authors": ["Globe Newswire"], "summary": "NEW YORK, Jan. 02, 2024 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Cytosorbents Corporation ( \"Cytosorbents\" or the \"Company\" ) CTSO. Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.060686, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.132368", "ticker_sentiment_score": "0.118049", "ticker_sentiment_label": "Neutral"}, {"ticker": "CTSO", "relevance_score": "0.682689", "ticker_sentiment_score": "0.147669", "ticker_sentiment_label": "Neutral"}]}, {"title": "Travel Updates: Gatwick Hikes Drop-Off Fee", "url": "https://www.forbes.com/uk/advisor/travel-insurance/2024/01/02/travel-latest-news/", "time_published": "20240102T180148", "authors": ["Kevin Pratt"], "summary": "2 January: Minimum Charge To Rise 20% To \u00a36 For 10 Minutes Gatwick Airport is increasing its minimum drop-off charge by 20% from 5 January, when it will increase from \u00a35 to \u00a36. The minimum charge covers the first 10 minutes and must be paid by midnight the day after the visit.", "banner_image": "https://thumbor.forbes.com/thumbor/fit-in/x/https://www.forbes.com/uk/advisor/wp-content/uploads/2022/02/ET-Ski-Resort-Map.jpg", "source": "Forbes", "category_within_source": "n/a", "source_domain": "www.forbes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Energy & Transportation", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}, {"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Economy - Fiscal", "relevance_score": "0.576289"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}], "overall_sentiment_score": 0.007163, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "DRTGF", "relevance_score": "0.000901", "ticker_sentiment_score": "-0.050149", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.000901", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.000901", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAL", "relevance_score": "0.001803", "ticker_sentiment_score": "0.060776", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.004506", "ticker_sentiment_score": "0.034618", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.002704", "ticker_sentiment_score": "0.054221", "ticker_sentiment_label": "Neutral"}, {"ticker": "SHTDF", "relevance_score": "0.000901", "ticker_sentiment_score": "0.124796", "ticker_sentiment_label": "Neutral"}, {"ticker": "MA", "relevance_score": "0.000901", "ticker_sentiment_score": "0.01804", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.004506", "ticker_sentiment_score": "0.034618", "ticker_sentiment_label": "Neutral"}, {"ticker": "DSSMY", "relevance_score": "0.000901", "ticker_sentiment_score": "-0.150718", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "YUGVF", "relevance_score": "0.001803", "ticker_sentiment_score": "0.049842", "ticker_sentiment_label": "Neutral"}, {"ticker": "AXP", "relevance_score": "0.000901", "ticker_sentiment_score": "0.01804", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.004506", "ticker_sentiment_score": "0.034618", "ticker_sentiment_label": "Neutral"}, {"ticker": "RYAOF", "relevance_score": "0.003605", "ticker_sentiment_score": "-0.032104", "ticker_sentiment_label": "Neutral"}, {"ticker": "UBER", "relevance_score": "0.000901", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Allorion Therapeutics Announces Exclusive Option and Global License Agreement for Novel Preclinical-Stage EGFR L858R Allosteric Inhibitor Program with AstraZeneca", "url": "https://www.prnewswire.com/news-releases/allorion-therapeutics-announces-exclusive-option-and-global-license-agreement-for-novel-preclinical-stage-egfr-l858r-allosteric-inhibitor-program-with-astrazeneca-302023562.html", "time_published": "20240102T140000", "authors": ["Allorion Therapeutics"], "summary": "Allorion Therapeutics Announces Exclusive Option and Global License Agreement for Novel Preclinical-Stage EGFR ... PR ...", "banner_image": "https://mma.prnewswire.com/media/2245014/Allorion_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.14393, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.502207", "ticker_sentiment_score": "0.185606", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Allorion Therapeutics Announces Exclusive Option and Global License Agreement for Novel Preclinical-Stage EGFR L858R Allosteric Inhibitor Program with AstraZeneca", "url": "https://www.newswire.ca/news-releases/allorion-therapeutics-announces-exclusive-option-and-global-license-agreement-for-novel-preclinical-stage-egfr-l858r-allosteric-inhibitor-program-with-astrazeneca-852596029.html", "time_published": "20240102T140000", "authors": ["Allorion Therapeutics"], "summary": "Allorion Therapeutics Announces Exclusive Option and Global License Agreement for Novel Preclinical-Stage EGFR ... Canada ...", "banner_image": "https://mma.prnewswire.com/media/2245014/Allorion_Logo.jpg?p=facebook", "source": "Canada Newswire", "category_within_source": "n/a", "source_domain": "www.newswire.ca", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.14393, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.502207", "ticker_sentiment_score": "0.185606", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Biora Therapeutics Progresses Research Collaboration for the BioJet\u2122 Systemic Oral Delivery Platform", "url": "https://www.globenewswire.com/news-release/2024/01/02/2802633/0/en/Biora-Therapeutics-Progresses-Research-Collaboration-for-the-BioJet-Systemic-Oral-Delivery-Platform.html", "time_published": "20240102T130000", "authors": ["Inc.", "Biora Therapeutics"], "summary": "Biora's BioJet\u2122 drug delivery platform exceeded performance targets for delivery of collaborator AstraZeneca's molecule in preclinical study.", "banner_image": "https://ml.globenewswire.com/Resource/Download/74f7c790-2ce7-4964-8bc9-9a41f6818600", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.122563, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.043108", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIOR", "relevance_score": "0.254307", "ticker_sentiment_score": "0.181901", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Biora Therapeutics Progresses Research Collaboration for the BioJet\u2122 Systemic Oral Delivery Platform - Biora Therapeutics  ( NASDAQ:BIOR ) ", "url": "https://www.benzinga.com/pressreleases/24/01/g36449557/biora-therapeutics-progresses-research-collaboration-for-the-biojet-systemic-oral-delivery-platfor", "time_published": "20240102T130000", "authors": ["Globe Newswire"], "summary": "SAN DIEGO, Jan. 02, 2024 ( GLOBE NEWSWIRE ) -- Biora Therapeutics, Inc. BIOR, the biotech company that is reimagining therapeutic delivery, today announced that its BioJet\u2122 Systemic Oral Delivery Platform has met key performance milestones as part of its research collaboration with AstraZeneca.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": 0.117782, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.041323", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIOR", "relevance_score": "0.283167", "ticker_sentiment_score": "0.187968", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Perspective Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference", "url": "https://www.globenewswire.com/news-release/2024/01/02/2802628/0/en/Perspective-Therapeutics-to-Present-at-the-42nd-Annual-J-P-Morgan-Healthcare-Conference.html", "time_published": "20240102T130000", "authors": ["Inc.", "Perspective Therapeutics"], "summary": "SEATTLE, Jan. 02, 2024 ( GLOBE NEWSWIRE ) -- Perspective Therapeutics, Inc. ( \"Perspective\" or \"the Company\" ) ( NYSE AMERICAN: CATX ) , today announced that Thijs Spoor, the Company's Chief Executive Officer, will present at the 42nd Annual J.P.", "banner_image": "https://ml.globenewswire.com/Resource/Download/e8b42463-3d31-441e-8c09-6b88826fe1c6", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.495866"}], "overall_sentiment_score": 0.168717, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.038407", "ticker_sentiment_score": "0.204125", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.038407", "ticker_sentiment_score": "0.204125", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SNY", "relevance_score": "0.038407", "ticker_sentiment_score": "0.204125", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "China Approves AstraZeneca-Sanofi's Respiratory Syncytial Virus Drug To Prevent Infection In Infants - AstraZeneca  ( NASDAQ:AZN ) , Sanofi  ( NASDAQ:SNY ) ", "url": "https://www.benzinga.com/general/biotech/24/01/36448253/china-approves-astrazeneca-sanofis-respiratory-syncytial-virus-drug-to-prevent-infection-in-infan", "time_published": "20240102T125327", "authors": ["Vandana Singh"], "summary": "Tuesday, China's National Medical Products Administration approved AstraZeneca Plc AZN and Sanofi SA's SNY Beyfortus ( nirsevimab ) , a long-acting monoclonal antibody for the prevention of respiratory syncytial virus ( RSV ) lower respiratory tract infection ( LRTI ) in neonates and infants ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2024/01/02/azn-sny.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.086066, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.416844", "ticker_sentiment_score": "-0.107582", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.416844", "ticker_sentiment_score": "-0.107582", "ticker_sentiment_label": "Neutral"}]}, {"title": "Voyager Therapeutics Enters Capsid License Agreement and Strategic Collaboration with Novartis to Advance Novel Gene Therapies", "url": "https://www.globenewswire.com/news-release/2024/01/02/2802564/36461/en/Voyager-Therapeutics-Enters-Capsid-License-Agreement-and-Strategic-Collaboration-with-Novartis-to-Advance-Novel-Gene-Therapies.html", "time_published": "20240102T120000", "authors": ["Inc.", "Voyager Therapeutics"], "summary": "- Collaboration with gene therapy leader Novartis aims to discover and develop new approaches for Huntington's disease and spinal muscular atrophy ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/f775f55a-83dd-4b38-bf92-bb9b588522bd", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.495866"}], "overall_sentiment_score": 0.189604, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SGMO", "relevance_score": "0.030331", "ticker_sentiment_score": "0.040077", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVS", "relevance_score": "0.060617", "ticker_sentiment_score": "0.107063", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.030331", "ticker_sentiment_score": "0.040077", "ticker_sentiment_label": "Neutral"}, {"ticker": "VYGR", "relevance_score": "0.15078", "ticker_sentiment_score": "0.084818", "ticker_sentiment_label": "Neutral"}, {"ticker": "NBIX", "relevance_score": "0.030331", "ticker_sentiment_score": "0.040077", "ticker_sentiment_label": "Neutral"}]}, {"title": "China approves AstraZeneca, Sanofi shot to prevent RSV infection", "url": "https://www.financialexpress.com/healthcare/pharma-healthcare/china-approves-astrazeneca-sanofi-shot-to-prevent-rsv-infection/3353248/", "time_published": "20240102T105706", "authors": ["Bloomberg"], "summary": "China approved a shot co-developed by AstraZeneca Plc and Sanofi to ward off respiratory syncytial virus in a broad swath of infants, a first in the nation to thwart the highly contagious and potentially fatal infection.", "banner_image": "https://www.financialexpress.com/wp-content/uploads/2024/01/pills-g5a602a81d_1920.jpg", "source": "The Financial Express", "category_within_source": "n/a", "source_domain": "www.financialexpress.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}], "overall_sentiment_score": -0.206141, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "PTAIF", "relevance_score": "0.170878", "ticker_sentiment_score": "0.041482", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.170878", "ticker_sentiment_score": "-0.373847", "ticker_sentiment_label": "Bearish"}, {"ticker": "SNY", "relevance_score": "0.170878", "ticker_sentiment_score": "-0.373847", "ticker_sentiment_label": "Bearish"}]}, {"title": "Alembic Pharmaceuticals gets 8 USFDA approvals in Q3FY24", "url": "https://www.financialexpress.com/healthcare/pharma-healthcare/alembic-pharmaceuticals-gets-8-usfda-approvals-in-q3fy24/3353021/", "time_published": "20240102T084006", "authors": ["Health Desk"], "summary": "Alembic Pharmaceuticals Limited on Tuesday announced that it has received US Food & Drug Administration ( USFDA ) approvals on eight of its Abbreviated New Drug Application ( ANDA ) in Q3FY24.", "banner_image": "https://www.financialexpress.com/wp-content/uploads/2024/01/painkillers-g0651a5da2_1920.jpg", "source": "The Financial Express", "category_within_source": "n/a", "source_domain": "www.financialexpress.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.119297, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.054359", "ticker_sentiment_score": "-0.032969", "ticker_sentiment_label": "Neutral"}, {"ticker": "LBTSF", "relevance_score": "0.054359", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Ascentage Pharma to Present at 42nd J.P. Morgan Healthcare Conference", "url": "https://www.prnewswire.com/news-releases/ascentage-pharma-to-present-at-42nd-jp-morgan-healthcare-conference-302024292.html", "time_published": "20240102T035800", "authors": ["Ascentage Pharma"], "summary": "SUZHOU, China and ROCKVILLE, Md., Jan. 1, 2024 /PRNewswire/ -- Ascentage Pharma ( 6855.HK ) , a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B ( CHB ) , and age-related diseases, announced today that it will attend the 42nd J.P.", "banner_image": "https://mma.prnewswire.com/media/891219/Ascentage_Pharma_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.684621"}], "overall_sentiment_score": 0.052481, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.053749", "ticker_sentiment_score": "0.083014", "ticker_sentiment_label": "Neutral"}, {"ticker": "ASPHF", "relevance_score": "0.581478", "ticker_sentiment_score": "0.059277", "ticker_sentiment_label": "Neutral"}, {"ticker": "UBX", "relevance_score": "0.053749", "ticker_sentiment_score": "0.083014", "ticker_sentiment_label": "Neutral"}]}, {"title": "SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ICVX, CVLY, RAIN, X - Icosavax  ( NASDAQ:ICVX ) , Codorus Valley Bancorp  ( NASDAQ:CVLY ) ", "url": "https://www.benzinga.com/pressreleases/24/01/g36443681/shareholder-investigation-halper-sadeh-llc-investigates-icvx-cvly-rain-x", "time_published": "20240101T142333", "authors": ["Globe Newswire"], "summary": "NEW YORK, Jan. 01, 2024 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Icosavax, Inc.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.77141"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.165154, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ORRF", "relevance_score": "0.109956", "ticker_sentiment_score": "0.085289", "ticker_sentiment_label": "Neutral"}, {"ticker": "RAIN", "relevance_score": "0.109956", "ticker_sentiment_score": "0.190126", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.109956", "ticker_sentiment_score": "0.173526", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NISTF", "relevance_score": "0.109956", "ticker_sentiment_score": "0.088586", "ticker_sentiment_label": "Neutral"}, {"ticker": "X", "relevance_score": "0.109956", "ticker_sentiment_score": "0.088586", "ticker_sentiment_label": "Neutral"}, {"ticker": "ICVX", "relevance_score": "0.217834", "ticker_sentiment_score": "0.259543", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CVLY", "relevance_score": "0.109956", "ticker_sentiment_score": "0.085289", "ticker_sentiment_label": "Neutral"}]}, {"title": "2 Gene-Editing Stocks That Might Be the Next CRISPR Therapeutics", "url": "https://www.fool.com/investing/2023/12/31/gene-editing-stocks-that-might-be-the-next-crispr/", "time_published": "20231231T134500", "authors": ["Alex Carchidi"], "summary": "Curing rare inherited illnesses could be a lucrative business model.", "banner_image": "https://g.foolcdn.com/editorial/images/759577/scientist-researcher-microscope-lab.jpg", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.236539, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BEAM", "relevance_score": "0.056275", "ticker_sentiment_score": "0.214987", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.112269", "ticker_sentiment_score": "0.157128", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VERV", "relevance_score": "0.112269", "ticker_sentiment_score": "0.071337", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.056275", "ticker_sentiment_score": "0.161027", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NTLA", "relevance_score": "0.112269", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Astrazeneca  ( AZN )  Ascends While Market Falls: Some Facts to Note", "url": "https://www.zacks.com/stock/news/2203910/astrazeneca-azn-ascends-while-market-falls-some-facts-to-note", "time_published": "20231229T225019", "authors": ["Zacks Equity Research"], "summary": "Astrazeneca (AZN) closed the most recent trading day at $67.35, moving +0.07% from the previous trading session.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default184.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.961735"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.213736, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.549988", "ticker_sentiment_score": "0.26268", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "2023 Will Go Down As The Year Pharma Showed Its Determination To Beat Cancer - AstraZeneca  ( NASDAQ:AZN ) ", "url": "https://www.benzinga.com/markets/penny-stocks/23/12/36431167/2023-will-go-down-as-the-year-pharma-showed-its-determination-to-beat-cancer", "time_published": "20231229T174858", "authors": ["Upwallstreet"], "summary": "During the last week of 2023, AstraZeneca PLC AZN agreed to acquire Chinese cancer therapy developer Gracell Biotechnologies Inc. as it continues its efforts to tap pharma innovations from China's biotech industry.", "banner_image": "https://cdn.benzinga.com/files/7774_0.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": -0.113696, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SGEN", "relevance_score": "0.052685", "ticker_sentiment_score": "-0.057229", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.356317", "ticker_sentiment_score": "-0.326566", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "AZN", "relevance_score": "0.402941", "ticker_sentiment_score": "-0.025176", "ticker_sentiment_label": "Neutral"}, {"ticker": "GRCL", "relevance_score": "0.052685", "ticker_sentiment_score": "-0.081067", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.572194", "ticker_sentiment_score": "-0.069952", "ticker_sentiment_label": "Neutral"}]}, {"title": "Fortress Biotech Announces Pricing of $11 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - Fortress Biotech  ( NASDAQ:FBIO ) ", "url": "https://www.benzinga.com/pressreleases/23/12/g36426346/fortress-biotech-announces-pricing-of-11-million-registered-direct-offering-priced-at-the-market-u", "time_published": "20231229T132029", "authors": ["Globe Newswire"], "summary": "MIAMI, Dec. 29, 2023 ( GLOBE NEWSWIRE ) -- Fortress Biotech, Inc.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.938793"}], "overall_sentiment_score": 0.284285, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.065685", "ticker_sentiment_score": "0.192935", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FBIO", "relevance_score": "0.319725", "ticker_sentiment_score": "0.390918", "ticker_sentiment_label": "Bullish"}]}, {"title": "Fortress Biotech Announces Pricing of $11 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules", "url": "https://www.globenewswire.com/news-release/2023/12/29/2802052/28889/en/Fortress-Biotech-Announces-Pricing-of-11-Million-Registered-Direct-Offering-Priced-At-the-Market-Under-Nasdaq-Rules.html", "time_published": "20231229T132000", "authors": ["Inc.", "Fortress Biotech"], "summary": "MIAMI, Dec. 29, 2023 ( GLOBE NEWSWIRE ) -- Fortress Biotech, Inc. ( Nasdaq: FBIO ) ( \"Fortress\" or \"Company\" ) , an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/d82bf2ce-81b7-4989-9e6b-08e6bb6e1f95", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.99246"}], "overall_sentiment_score": 0.266071, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.038717", "ticker_sentiment_score": "0.191622", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FBIO", "relevance_score": "0.115787", "ticker_sentiment_score": "0.211765", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Stock Market Ending 2023 On High Note: Weekly Review", "url": "https://www.investors.com/news/stock-market-ending-2023-on-high-note-tesla-drug-ma-in-focus-weekly-review/", "time_published": "20231229T123300", "authors": ["IBD STAFF", "Investor's Business Daily"], "summary": "Stock Market Ending 2023 On High Note. Tesla, Drug M&A In Focus: Weekly Review Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2017/08/WallStreetFinance2-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.684621"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.078906, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "XPEV", "relevance_score": "0.138464", "ticker_sentiment_score": "-0.009828", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.206392", "ticker_sentiment_score": "-0.244108", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "KRTX", "relevance_score": "0.138464", "ticker_sentiment_score": "-0.03182", "ticker_sentiment_label": "Neutral"}, {"ticker": "RYZB", "relevance_score": "0.272788", "ticker_sentiment_score": "-0.052248", "ticker_sentiment_label": "Neutral"}, {"ticker": "TCTZF", "relevance_score": "0.069495", "ticker_sentiment_score": "0.157837", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BMY", "relevance_score": "0.337197", "ticker_sentiment_score": "0.007167", "ticker_sentiment_label": "Neutral"}, {"ticker": "NTES", "relevance_score": "0.138464", "ticker_sentiment_score": "0.194908", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TSLA", "relevance_score": "0.458446", "ticker_sentiment_score": "0.029772", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.138464", "ticker_sentiment_score": "-0.03182", "ticker_sentiment_label": "Neutral"}, {"ticker": "GRCL", "relevance_score": "0.206392", "ticker_sentiment_score": "-0.04174", "ticker_sentiment_label": "Neutral"}, {"ticker": "NIO", "relevance_score": "0.138464", "ticker_sentiment_score": "-0.009828", "ticker_sentiment_label": "Neutral"}, {"ticker": "INTC", "relevance_score": "0.138464", "ticker_sentiment_score": "0.082302", "ticker_sentiment_label": "Neutral"}, {"ticker": "LI", "relevance_score": "0.138464", "ticker_sentiment_score": "-0.009828", "ticker_sentiment_label": "Neutral"}]}, {"title": "Pharma lobby bats for drug approvals in India to align with global markets", "url": "https://www.business-standard.com/industry/news/pharma-lobby-bats-for-drug-approvals-in-india-to-align-with-global-markets-123122900247_1.html", "time_published": "20231229T065133", "authors": ["BS Web Team"], "summary": "To hasten the launch of new medicines in India, the Organisation of Pharmaceutical Producers of India ( OPPI ) , which represents key multinational pharmaceutical companies, has urged the drug controller to enable parallel approval of drugs in sync with global markets, reported The Economic ...", "banner_image": "https://bsmedia.business-standard.com/_media/bs/img/article/2023-06/18/full/1687106818-6297.jpg?im=FeatureCrop,size=(826,465)", "source": "Business Standard", "category_within_source": "GoogleRSS", "source_domain": "www.business-standard.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.235111, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.097062", "ticker_sentiment_score": "0.088504", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.097062", "ticker_sentiment_score": "0.088504", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why Fusion Pharmaceuticals  ( FUSN )  Stock Was Up 14% on Wednesday", "url": "https://www.zacks.com/stock/news/2203322/why-fusion-pharmaceuticals-fusn-stock-was-up-14-on-wednesday", "time_published": "20231228T181100", "authors": ["Zacks Equity Research"], "summary": "Fusion Pharmaceuticals (FUSN) surges to a new record level 52-week high after analysts at Raymond James upgraded its rating following the buyout announcements for two comparable companies.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/34/973.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.254463, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.289748", "ticker_sentiment_score": "0.099799", "ticker_sentiment_label": "Neutral"}, {"ticker": "RYZB", "relevance_score": "0.074001", "ticker_sentiment_score": "0.048346", "ticker_sentiment_label": "Neutral"}, {"ticker": "FUSN", "relevance_score": "0.806505", "ticker_sentiment_score": "0.457704", "ticker_sentiment_label": "Bullish"}, {"ticker": "AZN", "relevance_score": "0.289748", "ticker_sentiment_score": "0.264795", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Why Is Blood Purification Focused CytoSorbents  ( CTSO )  Trading Lower Today? - CytoSorbents  ( NASDAQ:CTSO ) ", "url": "https://www.benzinga.com/markets/equities/23/12/36410011/why-is-blood-purification-focused-cytosorbents-trading-lower-today", "time_published": "20231228T140141", "authors": ["Vandana Singh"], "summary": "CytoSorbents Corporation CTSO released an update on the initial data analysis of primary safety and effectiveness endpoints and the final independent Data and Safety Monitoring Board for the pivotal U.S. and Canadian STAR-T trial.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/12/28/ctso_logo.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.097827, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CTSO", "relevance_score": "0.327366", "ticker_sentiment_score": "0.383252", "ticker_sentiment_label": "Bullish"}, {"ticker": "AZN", "relevance_score": "0.221819", "ticker_sentiment_score": "0.115372", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.221819", "ticker_sentiment_score": "0.139011", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.221819", "ticker_sentiment_score": "0.139011", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biden administration's Medicare drug price negotiations will face major tests in 2024", "url": "https://www.cnbc.com/2023/12/28/medicare-drug-price-negotiations-whats-ahead-in-2024.html", "time_published": "20231228T120001", "authors": ["Annika Kim Constantino"], "summary": "Next year could set the precedent for the Inflation Reduction Act's controversial talks, which could affect dozens of medications by the end of the decade.", "banner_image": "https://image.cnbcfm.com/api/v1/image/107130655-1665090556176-gettyimages-1431082899-_m021740_4b5641b7-17d1-48f7-8db3-6aef2e513b99.jpeg?v=1702616299&w=1920&h=1080", "source": "CNBC", "category_within_source": "Business", "source_domain": "www.cnbc.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "0.538269"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.021634, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GOOG", "relevance_score": "0.029399", "ticker_sentiment_score": "0.166075", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABBV", "relevance_score": "0.029399", "ticker_sentiment_score": "0.173879", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.088039", "ticker_sentiment_score": "0.008287", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.058759", "ticker_sentiment_score": "-0.059983", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.1172", "ticker_sentiment_score": "-0.026135", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.1172", "ticker_sentiment_score": "-0.026135", "ticker_sentiment_label": "Neutral"}]}, {"title": "CytoSorbents Provides Update on the STAR-T Trial and Reports Final Independent Data and Safety Monitoring Board Recommendation", "url": "https://www.globenewswire.com/news-release/2023/12/28/2801649/25359/en/CytoSorbents-Provides-Update-on-the-STAR-T-Trial-and-Reports-Final-Independent-Data-and-Safety-Monitoring-Board-Recommendation.html", "time_published": "20231228T120000", "authors": ["CytoSorbents"], "summary": "CytoSorbents Provides Update on STAR-T Trial and Final Independent DSMB Recommendation ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/cdc85520-2323-4660-a277-24c73f2f24d5", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.110866, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.023533", "ticker_sentiment_score": "-0.011165", "ticker_sentiment_label": "Neutral"}, {"ticker": "CTSO", "relevance_score": "0.117257", "ticker_sentiment_score": "0.09986", "ticker_sentiment_label": "Neutral"}, {"ticker": "ILST", "relevance_score": "0.023533", "ticker_sentiment_score": "0.097208", "ticker_sentiment_label": "Neutral"}]}, {"title": "'A huge shock to the system': Doctors warn about asthma inhaler switch coming in January", "url": "https://www.cnn.com/2023/12/28/health/asthma-inhaler-generic-switch/index.html", "time_published": "20231228T113200", "authors": ["Meg Tirrell"], "summary": "Starting January 1, a drug that thousands of patients depend on to help them breathe will disappear from pharmacy shelves, and doctors are concerned patients may have delays switching to alternatives and getting them covered by insurance.", "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/231218130335-clinic-shot-stock.jpg?c=16x9&q=h_144,w_256,c_fill", "source": "CNN", "category_within_source": "Markets", "source_domain": "www.cnn.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": -0.021597, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "WBD", "relevance_score": "0.17108", "ticker_sentiment_score": "-0.005682", "ticker_sentiment_label": "Neutral"}, {"ticker": "CVS", "relevance_score": "0.057421", "ticker_sentiment_score": "0.026018", "ticker_sentiment_label": "Neutral"}, {"ticker": "GDRX", "relevance_score": "0.028729", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "C", "relevance_score": "0.028729", "ticker_sentiment_score": "-0.142353", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.028729", "ticker_sentiment_score": "-0.052028", "ticker_sentiment_label": "Neutral"}]}, {"title": "Buy AstraZeneca Stock. It Looks Much Better Going Into 2024.", "url": "https://www.barrons.com/articles/buy-astrazeneca-stock-2024-ozempic-2614c9bf", "time_published": "20231228T080000", "authors": ["Teresa Rivas"], "summary": "Big pharmaceutical companies create the medications that keep countless people around the world healthy, but that hasn't helped their ailing stock prices this year. The United Kingdom-based AstraZeneca has been no exception, but its shares could get a shot in the arm in 2024.", "banner_image": "https://images.barrons.com/im-09133990/social", "source": "Barrons", "category_within_source": "n/a", "source_domain": "www.barrons.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.371631, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.699089", "ticker_sentiment_score": "0.550574", "ticker_sentiment_label": "Bullish"}]}, {"title": "Astrazeneca  ( AZN )  Surpasses Market Returns: Some Facts Worth Knowing", "url": "https://www.zacks.com/stock/news/2202895/astrazeneca-azn-surpasses-market-returns-some-facts-worth-knowing", "time_published": "20231227T230018", "authors": ["Zacks Equity Research"], "summary": "In the most recent trading session, Astrazeneca (AZN) closed at $67.35, indicating a +1.28% shift from the previous trading day.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default196.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.938793"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.182695, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.568435", "ticker_sentiment_score": "0.216895", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CERE, HOLI, ICVX, CVLY - Cerevel Therapeutics Hldg  ( NASDAQ:CERE ) , Codorus Valley Bancorp  ( NASDAQ:CVLY ) ", "url": "https://www.benzinga.com/pressreleases/23/12/g36403236/shareholder-investigation-halper-sadeh-llc-investigates-cere-holi-icvx-cvly", "time_published": "20231227T195112", "authors": ["Globe Newswire"], "summary": "NEW YORK, Dec. 27, 2023 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Cerevel Therapeutics Holdings, Inc.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.77141"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.13255, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ORRF", "relevance_score": "0.116914", "ticker_sentiment_score": "0.087269", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.116914", "ticker_sentiment_score": "0.177565", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HOLI", "relevance_score": "0.116914", "ticker_sentiment_score": "0.081648", "ticker_sentiment_label": "Neutral"}, {"ticker": "CERE", "relevance_score": "0.116914", "ticker_sentiment_score": "0.087269", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.116914", "ticker_sentiment_score": "0.087269", "ticker_sentiment_label": "Neutral"}, {"ticker": "ICVX", "relevance_score": "0.231332", "ticker_sentiment_score": "0.27165", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CVLY", "relevance_score": "0.116914", "ticker_sentiment_score": "0.087269", "ticker_sentiment_label": "Neutral"}]}, {"title": "Recent M&A Bodes Well For Targeted Cancer Therapy Player Fusion Pharmaceuticals, Analyst Say AstraZeneca Is Favorably Positioned - Fusion Pharmaceuticals  ( NASDAQ:FUSN ) ", "url": "https://www.benzinga.com/analyst-ratings/analyst-color/23/12/36400490/recent-m-a-bodes-well-for-targeted-cancer-therapy-player-fusion-pharmaceuticals-ana", "time_published": "20231227T174214", "authors": ["Vandana Singh"], "summary": "With recent merger and acquisition deals in the targeted radiopharmaceutical therapy ( TRT ) space, on Tuesday, Oppenheimer noted that Fusion Pharmaceuticals Inc FUSN is potentially the sole remaining clinical-stage player with a robust supply chain.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/12/27/fusn.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Real Estate & Construction", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.38899, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.280615", "ticker_sentiment_score": "0.169807", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RYZB", "relevance_score": "0.280615", "ticker_sentiment_score": "0.354095", "ticker_sentiment_label": "Bullish"}, {"ticker": "FUSN", "relevance_score": "0.630923", "ticker_sentiment_score": "0.561656", "ticker_sentiment_label": "Bullish"}, {"ticker": "AZN", "relevance_score": "0.52759", "ticker_sentiment_score": "0.601171", "ticker_sentiment_label": "Bullish"}, {"ticker": "BMY", "relevance_score": "0.280615", "ticker_sentiment_score": "0.354095", "ticker_sentiment_label": "Bullish"}, {"ticker": "PNT", "relevance_score": "0.280615", "ticker_sentiment_score": "0.169807", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "AstraZeneca  ( AZN )  Set to Acquire Gracell for $1.2 Billion", "url": "https://www.zacks.com/stock/news/2202697/astrazeneca-azn-set-to-acquire-gracell-for-12-billion", "time_published": "20231227T154000", "authors": ["Zacks Equity Research"], "summary": "AstraZeneca (AZN) is set to acquire clinical-stage biopharmaceutical company, Gracell, for a total deal value of up to $1.2 billion.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/e5/1416.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.278866, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ABBV", "relevance_score": "0.162255", "ticker_sentiment_score": "0.007352", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.526455", "ticker_sentiment_score": "0.407806", "ticker_sentiment_label": "Bullish"}, {"ticker": "GRCL", "relevance_score": "0.162255", "ticker_sentiment_score": "0.196124", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRTX", "relevance_score": "0.081552", "ticker_sentiment_score": "0.175775", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "AstraZeneca PLC  ( AZN )  is Attracting Investor Attention: Here is What You Should Know", "url": "https://www.zacks.com/stock/news/2202566/astrazeneca-plc-azn-is-attracting-investor-attention-here-is-what-you-should-know", "time_published": "20231227T140006", "authors": ["Zacks Equity Research"], "summary": "Astrazeneca (AZN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default351.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999999"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.5855"}], "overall_sentiment_score": 0.246222, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.484798", "ticker_sentiment_score": "0.134304", "ticker_sentiment_label": "Neutral"}]}, {"title": "Investor Sentiment Improves; Dow Jumps Over 150 Points - Bridgeline Digital  ( NASDAQ:BLIN ) , AstraZeneca  ( NASDAQ:AZN ) ", "url": "https://www.benzinga.com/news/earnings/23/12/36393433/investor-sentiment-improves-dow-jumps-over-150-points", "time_published": "20231227T082814", "authors": ["Avi Kapoor"], "summary": "The CNN Money Fear and Greed index showed an increase in overall market sentiment, while the index remained in the \"Extreme Greed\" zone on Tuesday. U.S. stocks closed higher on Tuesday, with the S&P 500 moving closer to record levels.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/12/26/image11.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": -0.026501, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BLIN", "relevance_score": "0.231332", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "WBD", "relevance_score": "0.116914", "ticker_sentiment_score": "-0.239764", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "RYZB", "relevance_score": "0.231332", "ticker_sentiment_score": "0.363608", "ticker_sentiment_label": "Bullish"}, {"ticker": "AZN", "relevance_score": "0.231332", "ticker_sentiment_score": "0.363608", "ticker_sentiment_label": "Bullish"}, {"ticker": "GRCL", "relevance_score": "0.231332", "ticker_sentiment_score": "0.363608", "ticker_sentiment_label": "Bullish"}, {"ticker": "BMY", "relevance_score": "0.116914", "ticker_sentiment_score": "0.240979", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "AstraZeneca to buy cancer drug developer for up to $1.2 billion", "url": "https://www.financialexpress.com/healthcare/pharma-healthcare/astrazeneca-to-buy-cancer-drug-developer-for-up-to-1-2-billion/3347920/", "time_published": "20231227T033000", "authors": ["Bloomberg"], "summary": "AstraZeneca Plc agreed to acquire Chinese cell therapy developer Gracell Biotechnologies Inc. for as much as $1.2 billion as the British drug giant bolsters its bets on medical innovation in the world's second-biggest economy.", "banner_image": "https://www.financialexpress.com/wp-content/uploads/2023/12/cancer-gc50db6a0c_1920-1.jpg", "source": "The Financial Express", "category_within_source": "n/a", "source_domain": "www.financialexpress.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.289381, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PTAIF", "relevance_score": "0.263942", "ticker_sentiment_score": "0.286876", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.133841", "ticker_sentiment_score": "0.165942", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GRCL", "relevance_score": "0.133841", "ticker_sentiment_score": "0.165942", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVO", "relevance_score": "0.133841", "ticker_sentiment_score": "0.10071", "ticker_sentiment_label": "Neutral"}]}, {"title": "Wall Street ends higher in final stretch of 2023, rate cuts in view", "url": "https://www.moneycontrol.com/news/business/markets/wall-street-ends-higher-in-final-stretch-of-2023-rate-cuts-in-view-11959421.html", "time_published": "20231227T003324", "authors": [], "summary": "All three major U.S. stock indexes rose in light trading a day after the Christmas holiday, with the SP 500 touching its highest intraday level since January 2022. All three are on track for monthly, quarterly and annual gains.", "banner_image": "https://images.moneycontrol.com/static-mcnews/2020/08/wall-street-1.jpg?impolicy=website&width=168&height=118", "source": "Money Control", "category_within_source": "Markets", "source_domain": "www.moneycontrol.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.682689"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.858979"}, {"topic": "Manufacturing", "relevance_score": "0.5"}], "overall_sentiment_score": 0.154, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MANU", "relevance_score": "0.075397", "ticker_sentiment_score": "0.084017", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.075397", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GRCL", "relevance_score": "0.075397", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "INTC", "relevance_score": "0.075397", "ticker_sentiment_score": "0.188321", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: RayzeBio, Inc.  ( Nasdaq - RYZB ) , Gracell Biotechnologies Inc.  ( Nasdaq - GRCL ) , Daseke, Inc.  ( Nasdaq - DSKE ) , Karuna Therapeutics, Inc.  ( Nasdaq - KRTX )  - Bristol-Myers Squibb  ( NYSE:BMY ) ", "url": "https://www.benzinga.com/pressreleases/23/12/g36389876/brodsky-smith-shareholder-update-notifying-investors-of-the-following-investigations-rayzebio-inc-", "time_published": "20231226T194338", "authors": ["Globe Newswire"], "summary": "BALA CYNWYD, Pa., Dec. 26, 2023 ( GLOBE NEWSWIRE ) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( jbrodsky@brodskysmith.com ) or Marc Ackerman ( mackerman@brodskysmith.com ) at 855-576-4847.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.796627"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.253359, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.219477", "ticker_sentiment_score": "0.254532", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DSSMY", "relevance_score": "0.219477", "ticker_sentiment_score": "0.065552", "ticker_sentiment_label": "Neutral"}, {"ticker": "GRCL", "relevance_score": "0.074001", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TFII", "relevance_score": "0.289748", "ticker_sentiment_score": "0.312329", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "KRTX", "relevance_score": "0.289748", "ticker_sentiment_score": "0.239609", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DSKE", "relevance_score": "0.289748", "ticker_sentiment_score": "0.289118", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RYZB", "relevance_score": "0.289748", "ticker_sentiment_score": "0.288414", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BMY", "relevance_score": "0.422661", "ticker_sentiment_score": "0.372368", "ticker_sentiment_label": "Bullish"}]}, {"title": "Nasdaq Surges 75 Points; Inspira Technologies Shares Spike Higher - AstraZeneca  ( NASDAQ:AZN ) , Gracell Biotechnologies  ( NASDAQ:GRCL ) ", "url": "https://www.benzinga.com/news/earnings/23/12/36389860/nasdaq-surges-75-points-inspira-technologies-shares-spike-higher", "time_published": "20231226T194336", "authors": ["Avi Kapoor"], "summary": "U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 150 points on Tuesday. The Dow traded up 0.50% to 37,574.66 while the NASDAQ rose 0.50% to 15,068.50. The S&P 500 also rose, gaining, 0.45% to 4,776.17. Energy shares jumped by 1.3% on Tuesday.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/12/26/image34.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.21737, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MIST", "relevance_score": "0.183895", "ticker_sentiment_score": "0.007457", "ticker_sentiment_label": "Neutral"}, {"ticker": "RYZB", "relevance_score": "0.183895", "ticker_sentiment_score": "0.344227", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.183895", "ticker_sentiment_score": "0.435556", "ticker_sentiment_label": "Bullish"}, {"ticker": "GRCL", "relevance_score": "0.272788", "ticker_sentiment_score": "0.559101", "ticker_sentiment_label": "Bullish"}, {"ticker": "BMY", "relevance_score": "0.092569", "ticker_sentiment_score": "0.250626", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Icosavax, Inc.  ( Nasdaq - ICVX ) , Rain Oncology, Inc.  ( Nasdaq - RAIN ) , Consolidated Communications Holdings, Inc.  ( Nasdaq - CNSL ) , Cerevel Therapeutics Holdings, Inc.  ( Nasdaq - CERE ) ", "url": "https://www.benzinga.com/pressreleases/23/12/g36389726/brodsky-smith-shareholder-update-notifying-investors-of-the-following-investigations-icosavax-inc-", "time_published": "20231226T192744", "authors": ["Globe Newswire"], "summary": "BALA CYNWYD, Pa., Dec. 26, 2023 ( GLOBE NEWSWIRE ) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( jbrodsky@brodskysmith.com ) or Marc Ackerman ( mackerman@brodskysmith.com ) at 855-576-4847.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.87644"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.858979"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.228424, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "RAIN", "relevance_score": "0.284696", "ticker_sentiment_score": "0.284328", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.215574", "ticker_sentiment_score": "0.234287", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DSSMY", "relevance_score": "0.215574", "ticker_sentiment_score": "0.064631", "ticker_sentiment_label": "Neutral"}, {"ticker": "CERE", "relevance_score": "0.072655", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.215574", "ticker_sentiment_score": "0.237772", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CNSL", "relevance_score": "0.215574", "ticker_sentiment_score": "0.131303", "ticker_sentiment_label": "Neutral"}, {"ticker": "ICVX", "relevance_score": "0.215574", "ticker_sentiment_score": "0.21893", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Crude Oil Rises Over 3%; US Home Prices Increase In October - AstraZeneca  ( NASDAQ:AZN ) , Adit Edtech Acquisition  ( AMEX:ADEX ) ", "url": "https://www.benzinga.com/news/earnings/23/12/36387899/crude-oil-rises-over-3-us-home-prices-increase-in-october", "time_published": "20231226T172049", "authors": ["Avi Kapoor"], "summary": "U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 100 points on Tuesday. The Dow traded up 0.34% to 37,511.87 while the NASDAQ rose 0.43% to 15,057.13. The S&P 500 also rose, gaining, 0.34% to 4,770.79. Energy shares jumped by 0.8% on Tuesday.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/12/26/crude_oil_4-_logo.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.169359, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MIST", "relevance_score": "0.178459", "ticker_sentiment_score": "0.007296", "ticker_sentiment_label": "Neutral"}, {"ticker": "SSYS", "relevance_score": "0.178459", "ticker_sentiment_score": "0.266769", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.178459", "ticker_sentiment_score": "0.427596", "ticker_sentiment_label": "Bullish"}, {"ticker": "GRCL", "relevance_score": "0.264897", "ticker_sentiment_score": "0.549098", "ticker_sentiment_label": "Bullish"}, {"ticker": "NNDM", "relevance_score": "0.089797", "ticker_sentiment_score": "0.195498", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ONCT", "relevance_score": "0.348103", "ticker_sentiment_score": "-0.224132", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "CRYPTO:NANO", "relevance_score": "0.089797", "ticker_sentiment_score": "0.195498", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CRYPTO:ADX", "relevance_score": "0.089797", "ticker_sentiment_score": "0.102568", "ticker_sentiment_label": "Neutral"}]}, {"title": "Santa Claus Rally In Gear For Dow, Other Indexes; Tesla Eyes New Record To Wrap Up The Year", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-gains-after-economic-data-tesla-eyes-new-record/", "time_published": "20231226T160600", "authors": ["Investor's Business Daily", "VIDYA RAMAKRISHNAN"], "summary": "Dow Jones Gains After Economic Data. Tesla Eyes New Record Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2017/11/stock-homeSales-01-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Energy & Transportation", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Economy - Fiscal", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.999606"}, {"topic": "Manufacturing", "relevance_score": "0.2"}], "overall_sentiment_score": 0.203709, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DKNG", "relevance_score": "0.167709", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "FRO", "relevance_score": "0.112269", "ticker_sentiment_score": "-0.369773", "ticker_sentiment_label": "Bearish"}, {"ticker": "CVX", "relevance_score": "0.112269", "ticker_sentiment_score": "0.124747", "ticker_sentiment_label": "Neutral"}, {"ticker": "KRTX", "relevance_score": "0.112269", "ticker_sentiment_score": "0.191551", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RYZB", "relevance_score": "0.167709", "ticker_sentiment_score": "0.23572", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MDB", "relevance_score": "0.167709", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.112269", "ticker_sentiment_score": "0.124747", "ticker_sentiment_label": "Neutral"}, {"ticker": "UNH", "relevance_score": "0.112269", "ticker_sentiment_score": "0.124747", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.112269", "ticker_sentiment_score": "0.191551", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TNK", "relevance_score": "0.112269", "ticker_sentiment_score": "-0.369773", "ticker_sentiment_label": "Bearish"}, {"ticker": "DHT", "relevance_score": "0.112269", "ticker_sentiment_score": "-0.369773", "ticker_sentiment_label": "Bearish"}, {"ticker": "TSLA", "relevance_score": "0.222327", "ticker_sentiment_score": "0.220284", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.112269", "ticker_sentiment_score": "0.003614", "ticker_sentiment_label": "Neutral"}, {"ticker": "NIO", "relevance_score": "0.167709", "ticker_sentiment_score": "0.137038", "ticker_sentiment_label": "Neutral"}, {"ticker": "INTC", "relevance_score": "0.112269", "ticker_sentiment_score": "-0.056081", "ticker_sentiment_label": "Neutral"}, {"ticker": "CAT", "relevance_score": "0.167709", "ticker_sentiment_score": "0.153994", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TK", "relevance_score": "0.056275", "ticker_sentiment_score": "-0.333032", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "MIST", "relevance_score": "0.112269", "ticker_sentiment_score": "0.003614", "ticker_sentiment_label": "Neutral"}]}, {"title": "Evaluating AstraZeneca Against Peers In Pharmaceuticals Industry - AstraZeneca  ( NASDAQ:AZN ) ", "url": "https://www.benzinga.com/news/23/12/36386712/evaluating-astrazeneca-against-peers-in-pharmaceuticals-industry", "time_published": "20231226T160035", "authors": ["Benzinga Insights"], "summary": "In today's rapidly changing and highly competitive business world, it is vital for investors and industry enthusiasts to carefully assess companies. In this article, we will perform a comprehensive industry comparison, evaluating AstraZeneca AZN against its key competitors in the Pharmaceuticals ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.938793"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.623304"}], "overall_sentiment_score": 0.077452, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "PTAIF", "relevance_score": "0.068896", "ticker_sentiment_score": "0.018207", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.396052", "ticker_sentiment_score": "0.317645", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "McKesson  ( MCK )  Announces Availability of PNH's FDA-Approved Drug", "url": "https://www.zacks.com/stock/news/2202243/mckesson-mck-announces-availability-of-pnhs-fda-approved-drug", "time_published": "20231226T154300", "authors": ["Zacks Equity Research"], "summary": "The availability of the FDA-approved drug via McKesson's (MCK) independent specialty pharmacy is expected to give patients more treatment options for PNH.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/08/595.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.614606"}], "overall_sentiment_score": 0.154564, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "HQY", "relevance_score": "0.269776", "ticker_sentiment_score": "0.05221", "ticker_sentiment_label": "Neutral"}, {"ticker": "ITGR", "relevance_score": "0.269776", "ticker_sentiment_score": "0.164538", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MCK", "relevance_score": "0.699089", "ticker_sentiment_score": "-0.06825", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.068698", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DVA", "relevance_score": "0.204072", "ticker_sentiment_score": "0.147529", "ticker_sentiment_label": "Neutral"}, {"ticker": "SWTX", "relevance_score": "0.068698", "ticker_sentiment_score": "-0.079241", "ticker_sentiment_label": "Neutral"}]}, {"title": "Health Care Company AstraZeneca Announces Acquisition of Gracell Biotechnologies - AstraZeneca  ( NASDAQ:AZN ) , Gracell Biotechnologies  ( NASDAQ:GRCL ) ", "url": "https://www.benzinga.com/m-a/23/12/36385975/health-care-company-astrazeneca-announces-acquisition-of-gracell-biotechnologies", "time_published": "20231226T151011", "authors": ["Benzinga Insights"], "summary": "AstraZeneca AZN has announced an acquisition of Gracell Biotechnologies GRCL that is expected to be completed in Q1 of 2024. Under the terms of the agreement, AstraZeneca has agreed to give Gracell Biotechnologies $1.20 billion in in exchange for GRCL stock.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Mergers & Acquisitions", "relevance_score": "0.576289"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.071285, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "PTAIF", "relevance_score": "0.133841", "ticker_sentiment_score": "-0.046954", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.499789", "ticker_sentiment_score": "0.116982", "ticker_sentiment_label": "Neutral"}, {"ticker": "GRCL", "relevance_score": "0.600602", "ticker_sentiment_score": "0.042939", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why Sentage Holdings Shares Are Trading Lower By 5%; Here Are 20 Stocks Moving Premarket - Alarum Technologies  ( NASDAQ:ALAR ) , ARB IOT Group  ( NASDAQ:ARBB ) ", "url": "https://www.benzinga.com/news/23/12/36383191/why-sentage-holdings-shares-are-trading-lower-by-5-here-are-20-stocks-moving-premarket", "time_published": "20231226T130058", "authors": ["Avi Kapoor"], "summary": "Shares of Sentage Holdings Inc. SNTG shares moved lower in pre-market trading following results for the six months ended June 30, 2023. Sentage reported a loss of 46 cents per share in the six months, versus a year-ago loss of 41 cents per share.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/12/26/image15.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Energy & Transportation", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}], "overall_sentiment_score": 0.165576, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ALAR", "relevance_score": "0.15347", "ticker_sentiment_score": "0.375529", "ticker_sentiment_label": "Bullish"}, {"ticker": "NXTP", "relevance_score": "0.15347", "ticker_sentiment_score": "-0.056794", "ticker_sentiment_label": "Neutral"}, {"ticker": "PBLA", "relevance_score": "0.228431", "ticker_sentiment_score": "0.350719", "ticker_sentiment_label": "Bullish"}, {"ticker": "AWIN", "relevance_score": "0.15347", "ticker_sentiment_score": "0.265392", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SNTG", "relevance_score": "0.301315", "ticker_sentiment_score": "0.032313", "ticker_sentiment_label": "Neutral"}, {"ticker": "VLCN", "relevance_score": "0.15347", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ZJYL", "relevance_score": "0.15347", "ticker_sentiment_score": "-0.2577", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "CNXA", "relevance_score": "0.15347", "ticker_sentiment_score": "0.315129", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ASST", "relevance_score": "0.15347", "ticker_sentiment_score": "-0.24229", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "ARBB", "relevance_score": "0.15347", "ticker_sentiment_score": "0.202494", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AREB", "relevance_score": "0.15347", "ticker_sentiment_score": "-0.35049", "ticker_sentiment_label": "Bearish"}, {"ticker": "VRM", "relevance_score": "0.228431", "ticker_sentiment_score": "-0.001814", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.077094", "ticker_sentiment_score": "0.196944", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GRCL", "relevance_score": "0.228431", "ticker_sentiment_score": "0.32816", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BCEL", "relevance_score": "0.15347", "ticker_sentiment_score": "0.252567", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BACK", "relevance_score": "0.15347", "ticker_sentiment_score": "0.346718", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SINT", "relevance_score": "0.15347", "ticker_sentiment_score": "0.215252", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "US Stocks Set To Start Final Trading Week Of Year On Positive Note As Santa Claus Rally Gets Going: Analyst Confident Of Market Finishing Year At Highs - Invesco QQQ Trust, Series 1  ( NASDAQ:QQQ ) , SPDR S&P 500  ( ARCA:SPY ) ", "url": "https://www.benzinga.com/markets/equities/23/12/36382639/us-stocks-set-to-start-final-trading-week-of-year-on-positive-note-as-santa-claus-rally-gets-goi", "time_published": "20231226T122218", "authors": ["Shanthi Rexaline"], "summary": "The Santa Claus rally period is poised to continue on a positive note, with index futures pointing to a modestly higher opening on Tuesday. The market was closed on Monday for the Christmas holiday.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/StockMarket-Up-Shutterstock_5.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}, {"topic": "Economy - Monetary", "relevance_score": "0.451494"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.986714"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.081686, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRM", "relevance_score": "0.105604", "ticker_sentiment_score": "-0.246613", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "XPEV", "relevance_score": "0.105604", "ticker_sentiment_score": "0.10911", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.105604", "ticker_sentiment_score": "0.195216", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.105604", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GRCL", "relevance_score": "0.105604", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NIO", "relevance_score": "0.157827", "ticker_sentiment_score": "0.132255", "ticker_sentiment_label": "Neutral"}, {"ticker": "INTC", "relevance_score": "0.105604", "ticker_sentiment_score": "0.085233", "ticker_sentiment_label": "Neutral"}, {"ticker": "MU", "relevance_score": "0.105604", "ticker_sentiment_score": "-0.030197", "ticker_sentiment_label": "Neutral"}, {"ticker": "NKE", "relevance_score": "0.105604", "ticker_sentiment_score": "-0.030197", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.052918", "ticker_sentiment_score": "0.219753", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "LI", "relevance_score": "0.105604", "ticker_sentiment_score": "0.10911", "ticker_sentiment_label": "Neutral"}]}, {"title": "Bristol Myers to Acquire RayzeBio in Deal Valued at $4.1 Billion", "url": "https://www.barrons.com/amp/articles/bristol-myers-rayzebio-acquisition-358de5bf", "time_published": "20231226T121600", "authors": ["Angela Palumbo", "Joe Woelfel"], "summary": "Bristol Myers Squibb will acquire radiopharmaceutical therapeutics company RayzeBio for $62.50 a share in cash. The acquisition price is more than a 100% premium over RayZeBio stock's closing price of $30.57 on Friday. In a press release on Tuesday, the companies said the total equity value of ...", "banner_image": "https://images.barrons.com/im-376465/social", "source": "Barrons", "category_within_source": "n/a", "source_domain": "www.barrons.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.309466, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "KRTX", "relevance_score": "0.18967", "ticker_sentiment_score": "0.278214", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RYZB", "relevance_score": "0.528475", "ticker_sentiment_score": "0.249781", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.18967", "ticker_sentiment_score": "0.114339", "ticker_sentiment_label": "Neutral"}, {"ticker": "GRCL", "relevance_score": "0.18967", "ticker_sentiment_score": "0.114339", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.18967", "ticker_sentiment_score": "0.229959", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Why China-Based Gracell Biotechnologies  ( GRCL )  Stock Is Soaring Today - AstraZeneca  ( NASDAQ:AZN ) , Gracell Biotechnologies  ( NASDAQ:GRCL ) ", "url": "https://www.benzinga.com/general/biotech/23/12/36381457/astrazeneca-bolsters-cell-therapy-pipeline-with-over-1b-deal-for-china-based-gracell-biotechnolog", "time_published": "20231226T114659", "authors": ["Vandana Singh"], "summary": "AstraZeneca Plc AZN has agreed to acquire Gracell Biotechnologies Inc GRCL, further strengthening AstraZeneca's cell therapy portfolio. The deal value is $2.00/share ( equivalent to $10/ADS ADS of Gracell ) plus a non-tradable contingent value right of $0.30/share ( equivalent to $1.50/ADS of ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/12/26/grcl.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.234187, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.47672", "ticker_sentiment_score": "0.22134", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GRCL", "relevance_score": "0.367865", "ticker_sentiment_score": "0.481515", "ticker_sentiment_label": "Bullish"}]}, {"title": "Gracell Biotechnologies, Stratasys, Hollysys Automation Technologies And Other Big Stocks Moving Higher In Tuesday's Pre-Market Session - Canadian Solar  ( NASDAQ:CSIQ ) , Altimmune  ( NASDAQ:ALT ) ", "url": "https://www.benzinga.com/news/23/12/36381855/gracell-biotechnologies-stratasys-hollysys-automation-technologies-and-other-big-stocks-moving-highe", "time_published": "20231226T110552", "authors": ["Avi Kapoor"], "summary": "U.S. stock futures were higher this morning, with the Dow Jones futures gaining more than 40 points on Tuesday. Shares of Gracell Biotechnologies Inc. GRCL shares rose sharply in pre-market trading after AstraZeneca announced plans to buy Gracell Biotechnologies for up to $1.2 billion.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/12/26/image27.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.623304"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Energy & Transportation", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}], "overall_sentiment_score": 0.406014, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "SES", "relevance_score": "0.269776", "ticker_sentiment_score": "0.070684", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.136888", "ticker_sentiment_score": "0.119018", "ticker_sentiment_label": "Neutral"}, {"ticker": "GRCL", "relevance_score": "0.509589", "ticker_sentiment_score": "0.558706", "ticker_sentiment_label": "Bullish"}, {"ticker": "HOLI", "relevance_score": "0.269776", "ticker_sentiment_score": "0.622263", "ticker_sentiment_label": "Bullish"}, {"ticker": "CSIQ", "relevance_score": "0.269776", "ticker_sentiment_score": "0.374482", "ticker_sentiment_label": "Bullish"}, {"ticker": "HP", "relevance_score": "0.269776", "ticker_sentiment_score": "0.374482", "ticker_sentiment_label": "Bullish"}, {"ticker": "MANU", "relevance_score": "0.395012", "ticker_sentiment_score": "0.290515", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ALT", "relevance_score": "0.269776", "ticker_sentiment_score": "0.512337", "ticker_sentiment_label": "Bullish"}, {"ticker": "SSYS", "relevance_score": "0.395012", "ticker_sentiment_score": "0.606138", "ticker_sentiment_label": "Bullish"}, {"ticker": "LI", "relevance_score": "0.269776", "ticker_sentiment_score": "0.164538", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NNDM", "relevance_score": "0.136888", "ticker_sentiment_score": "0.313097", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CRYPTO:NANO", "relevance_score": "0.136888", "ticker_sentiment_score": "0.313097", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "RayzeBio, Gracell, NIO, Intel, Manchester United, Arm, FedEx, and More Stock Market Movers", "url": "https://www.barrons.com/amp/articles/stock-market-movers-cf8aacfa", "time_published": "20231226T094000", "authors": ["Joe Woelfel"], "summary": "Gracell, Ansys, NIO, Manchester United, and More Stock Market Movers ...", "banner_image": "https://images.barrons.com/im-807692/social", "source": "Barrons", "category_within_source": "n/a", "source_domain": "www.barrons.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.796627"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.161647"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.277859, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.21686", "ticker_sentiment_score": "0.36708", "ticker_sentiment_label": "Bullish"}, {"ticker": "GRCL", "relevance_score": "0.109455", "ticker_sentiment_score": "0.249556", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HOLI", "relevance_score": "0.109455", "ticker_sentiment_score": "0.118117", "ticker_sentiment_label": "Neutral"}, {"ticker": "NIO", "relevance_score": "0.109455", "ticker_sentiment_score": "0.061049", "ticker_sentiment_label": "Neutral"}, {"ticker": "MANU", "relevance_score": "0.320279", "ticker_sentiment_score": "0.133837", "ticker_sentiment_label": "Neutral"}, {"ticker": "ARM", "relevance_score": "0.109455", "ticker_sentiment_score": "0.099426", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.109455", "ticker_sentiment_score": "0.269473", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Gracell Biotechnologies to be acquired by AstraZeneca, furthering cell therapy ambition across oncology and autoimmune diseases", "url": "https://www.globenewswire.com/news-release/2023/12/26/2801029/0/en/Gracell-Biotechnologies-to-be-acquired-by-AstraZeneca-furthering-cell-therapy-ambition-across-oncology-and-autoimmune-diseases.html", "time_published": "20231226T070000", "authors": ["Gracell Biotechnologies Inc."], "summary": "Proposed acquisition will enrich the AstraZeneca cell therapy pipeline with clinical-stage autologous BCMA/CD19 CAR-T therapy targeting haematologic malignancies and autoimmune diseases, and proprietary cell therapy manufacturing platform", "banner_image": "https://ml.globenewswire.com/Resource/Download/5ff80249-a1d6-4342-b90a-9e99b4e85d92", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.650727"}], "overall_sentiment_score": 0.22441, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.228365", "ticker_sentiment_score": "0.117628", "ticker_sentiment_label": "Neutral"}, {"ticker": "GRCL", "relevance_score": "0.063091", "ticker_sentiment_score": "0.136543", "ticker_sentiment_label": "Neutral"}]}, {"title": "Gracell Biotechnologies to be acquired by AstraZeneca, furthering cell therapy ambition across oncology and autoimmune diseases - Gracell Biotechnologies  ( NASDAQ:GRCL ) ", "url": "https://www.benzinga.com/pressreleases/23/12/g36380994/gracell-biotechnologies-to-be-acquired-by-astrazeneca-furthering-cell-therapy-ambition-across-onco", "time_published": "20231226T070000", "authors": ["Globe Newswire"], "summary": "Proposed acquisition will enrich the AstraZeneca cell therapy pipeline with clinical-stage autologous BCMA/CD19 CAR-T therapy targeting haematologic malignancies and autoimmune diseases, and proprietary cell therapy manufacturing platform", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "Mergers", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.77141"}], "overall_sentiment_score": 0.217431, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.226046", "ticker_sentiment_score": "0.111541", "ticker_sentiment_label": "Neutral"}, {"ticker": "GRCL", "relevance_score": "0.041646", "ticker_sentiment_score": "0.130559", "ticker_sentiment_label": "Neutral"}]}, {"title": "Non-tech companies are seeking AI talent and offering 6-figure salaries. Here's who's hiring - including one role that pays more than $300,000.", "url": "https://africa.businessinsider.com/careers/non-tech-companies-are-seeking-ai-talent-and-offering-6-figure-salaries-heres-whos/9456gqe", "time_published": "20231224T132408", "authors": ["Sindhu Sundar", "Aaron Mok"], "summary": "Companies are on the hunt for job candidates whose knowledge of AI can help them use their in-house data more extensively - for instance, to make better predictions and decisions, said Aaron Sines, a director at the Austin-based tech-recruiting company Razoroo.", "banner_image": "https://ocdn.eu/pulscms-transforms/1/KmTktkuTURBXy8wNTk0YWFjMy1mMTExLTQ3NjUtOGYxNC03MjMzZTk5M2M1NGMuanBlZ5GTBc0DFs0Brg", "source": "Business Insider", "category_within_source": "GoogleRSS", "source_domain": "africa.businessinsider.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.217694, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ACN", "relevance_score": "0.095517", "ticker_sentiment_score": "0.119817", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.095517", "ticker_sentiment_score": "0.128275", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.095517", "ticker_sentiment_score": "0.064738", "ticker_sentiment_label": "Neutral"}]}, {"title": "Cellectis Reports Results from Shareholders Meeting Held on December 22, 2023", "url": "https://www.globenewswire.com/news-release/2023/12/22/2800843/0/en/Cellectis-Reports-Results-from-Shareholders-Meeting-Held-on-December-22-2023.html", "time_published": "20231222T213000", "authors": ["Cellectis Inc."], "summary": "NEW YORK, Dec. 22, 2023 ( GLOBE NEWSWIRE ) -- Cellectis ( Euronext Growth: ALCLS. Nasdaq: CLLS ) , a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, held today a shareholders general meeting at 2:30 p.m.", "banner_image": "https://ml.globenewswire.com/Resource/Download/a84ce25b-a774-4635-9b79-d45241f5decc", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Economy - Fiscal", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.99393"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.150139, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ADCT", "relevance_score": "0.041828", "ticker_sentiment_score": "0.08814", "ticker_sentiment_label": "Neutral"}, {"ticker": "ORTX", "relevance_score": "0.041828", "ticker_sentiment_score": "0.015457", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.206862", "ticker_sentiment_score": "0.152887", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CLLS", "relevance_score": "0.537213", "ticker_sentiment_score": "0.235011", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JCRRF", "relevance_score": "0.041828", "ticker_sentiment_score": "0.015457", "ticker_sentiment_label": "Neutral"}]}, {"title": "Pricing Projections And Market Potential For Ionis' Newly Approved Nerve Damage Drug - Analyst Sees Over $700M Potential - Ionis Pharmaceuticals  ( NASDAQ:IONS ) ", "url": "https://www.benzinga.com/analyst-ratings/analyst-color/23/12/36364906/pricing-projections-and-market-potential-for-ionis-newly-approved-nerve-damage-drug", "time_published": "20231222T170450", "authors": ["Vandana Singh"], "summary": "Friday, the FDA approved AstraZeneca Plc AZN and Ionis Pharmaceuticals Inc's IONS Wainua ( eplontersen ) for polyneuropathy ( nerve damage ) of hereditary transthyretin-mediated amyloidosis in adults ( hATTR-PN or ATTRv-PN ) .", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/12/22/azn-ions_0.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.169017, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ALNY", "relevance_score": "0.297661", "ticker_sentiment_score": "0.218281", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.297661", "ticker_sentiment_score": "-0.024545", "ticker_sentiment_label": "Neutral"}, {"ticker": "IONS", "relevance_score": "0.433523", "ticker_sentiment_score": "0.104906", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biotech stocks set for a rebound in 2024, analysts say", "url": "https://www.marketwatch.com/story/biotech-stocks-set-for-a-rebound-in-2024-analysts-say-24df6236", "time_published": "20231222T160600", "authors": ["Eleanor Laise"], "summary": "A more favorable interest-rate outlook, an uptick in deals, and innovations in key areas like cancer and immunology are setting up biotech for a brighter 2024, analysts say.", "banner_image": "https://images.mktw.net/im-15783720/social", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.495866"}], "overall_sentiment_score": 0.133016, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NVO", "relevance_score": "0.089129", "ticker_sentiment_score": "0.156557", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRUS", "relevance_score": "0.089129", "ticker_sentiment_score": "0.080617", "ticker_sentiment_label": "Neutral"}, {"ticker": "KRTX", "relevance_score": "0.089129", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.089129", "ticker_sentiment_score": "-0.1576", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "IRON", "relevance_score": "0.089129", "ticker_sentiment_score": "0.033685", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.17715", "ticker_sentiment_score": "0.070894", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.089129", "ticker_sentiment_score": "-0.009465", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.089129", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "VKTX", "relevance_score": "0.089129", "ticker_sentiment_score": "0.203569", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.089129", "ticker_sentiment_score": "0.085373", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMRN", "relevance_score": "0.089129", "ticker_sentiment_score": "-0.1576", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "LLY", "relevance_score": "0.089129", "ticker_sentiment_score": "0.111772", "ticker_sentiment_label": "Neutral"}, {"ticker": "BPMC", "relevance_score": "0.089129", "ticker_sentiment_score": "-0.1576", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "SGEN", "relevance_score": "0.044634", "ticker_sentiment_score": "-0.008934", "ticker_sentiment_label": "Neutral"}]}, {"title": "Ionis  ( IONS ) , AstraZeneca's Eplontersen Receives FDA Nod", "url": "https://www.zacks.com/stock/news/2201529/ionis-ions-astrazenecas-eplontersen-receives-fda-nod", "time_published": "20231222T143400", "authors": ["Zacks Equity Research"], "summary": "FDA approves Ionis (IONS) and partner AstraZeneca's (AZN) Wainua for treating ATTRv-PN. Ionis stock rises on this important milestone.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f5/952.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.137041, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ALNY", "relevance_score": "0.160633", "ticker_sentiment_score": "0.198852", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "IONS", "relevance_score": "0.238913", "ticker_sentiment_score": "0.099539", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.521961", "ticker_sentiment_score": "0.243374", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.387674", "ticker_sentiment_score": "0.139475", "ticker_sentiment_label": "Neutral"}]}, {"title": "Pharma Stock Roundup: FDA Nod to AZN's Eplontersen, CRL to MRK's Cough Candidate", "url": "https://www.zacks.com/stock/news/2201507/pharma-stock-roundup-fda-nod-to-azns-eplontersen-crl-to-mrks-cough-candidate", "time_published": "20231222T142100", "authors": ["Kinjel Shah"], "summary": "FDA approves AstraZeneca (AZN) and Ionis' (IONS) Wainua (eplontersen) for ATTRv-PN and gives CRL to Merck's chronic cough candidate, gefapixant.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/5d/2633.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.058124, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.253866", "ticker_sentiment_score": "0.14725", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.04303", "ticker_sentiment_score": "-0.117624", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.04303", "ticker_sentiment_score": "-0.122577", "ticker_sentiment_label": "Neutral"}, {"ticker": "SGEN", "relevance_score": "0.085936", "ticker_sentiment_score": "-0.08266", "ticker_sentiment_label": "Neutral"}, {"ticker": "ICVX", "relevance_score": "0.04303", "ticker_sentiment_score": "-0.211222", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "PFE", "relevance_score": "0.170878", "ticker_sentiment_score": "-0.179093", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "SNY", "relevance_score": "0.170878", "ticker_sentiment_score": "-0.109563", "ticker_sentiment_label": "Neutral"}]}, {"title": "The Chinese market remains an attractive investment hub. Why?", "url": "https://www.prnewswire.com/news-releases/the-chinese-market-remains-an-attractive-investment-hub-why-302021742.html", "time_published": "20231222T140000", "authors": ["China.org.cn"], "summary": "BEIJING, Dec. 22, 2023 /PRNewswire/ -- A news report from China.org.cn on why China remains an attractive investment hub: Siemens, a German multinational technology conglomerate, added another 1.1 billion RMB to its total investment in fixed assets to build an industrial automation production ...", "banner_image": "https://i.ytimg.com/vi/PmZpCkpe6Jg/hqdefault.jpg", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.413559"}], "overall_sentiment_score": 0.288583, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SBUX", "relevance_score": "0.073773", "ticker_sentiment_score": "0.079608", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.073773", "ticker_sentiment_score": "0.079608", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why Ionis Pharmaceuticals  ( IONS )  Stock Is Trading Higher Today - AstraZeneca  ( NASDAQ:AZN ) , Ionis Pharmaceuticals  ( NASDAQ:IONS ) ", "url": "https://www.benzinga.com/general/biotech/23/12/36358256/new-hope-for-nerve-damage-patients-as-astrazenecaionis-eplontersen-receives-fda-nod-for-hereditar", "time_published": "20231222T124908", "authors": ["Vandana Singh"], "summary": "Friday, FDA approved AstraZeneca Plc AZN and Ionis Pharmaceuticals Inc's IONS Wainua ( eplontersen ) for polyneuropathy ( nerve damage ) of hereditary transthyretin-mediated amyloidosis in adults ( hATTR-PN or ATTRv-PN ) .", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/12/22/azn-ions.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.29021, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.614086", "ticker_sentiment_score": "0.403262", "ticker_sentiment_label": "Bullish"}, {"ticker": "IONS", "relevance_score": "0.397098", "ticker_sentiment_score": "0.176462", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "These 3 Big Pharma Stocks Are Making Big Plays With AI", "url": "https://www.fool.com/investing/2023/12/22/3-big-pharma-stocks-are-making-big-plays-with-ai/", "time_published": "20231222T121500", "authors": ["Alex Carchidi"], "summary": "Opportunity is in the air with AI, and these pharma giants are seizing the moment.", "banner_image": "https://g.foolcdn.com/editorial/images/758794/biotech-pharma-researchers-talk-lab.jpg", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Economy - Fiscal", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.171475, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.207571", "ticker_sentiment_score": "0.149466", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.052455", "ticker_sentiment_score": "-0.026011", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABSI", "relevance_score": "0.104683", "ticker_sentiment_score": "0.099062", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.104683", "ticker_sentiment_score": "0.068798", "ticker_sentiment_label": "Neutral"}, {"ticker": "ILMN", "relevance_score": "0.052455", "ticker_sentiment_score": "0.04473", "ticker_sentiment_label": "Neutral"}]}, {"title": "Autolus Therapeutics Announces Changes to its Board of Directors - Autolus Therapeutics  ( NASDAQ:AUTL ) ", "url": "https://www.benzinga.com/pressreleases/23/12/g36359167/autolus-therapeutics-announces-changes-to-its-board-of-directors", "time_published": "20231222T120000", "authors": ["Globe Newswire"], "summary": "- Appointment of Elisabeth ( \"Lis\" ) Leiderman, M.D. LONDON, Dec. 22, 2023 ( GLOBE NEWSWIRE ) -- Autolus Therapeutics plc AUTL, a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced the appointment of Elisabeth Leiderman, M.D. to ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.108336, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AUTL", "relevance_score": "0.199584", "ticker_sentiment_score": "0.066716", "ticker_sentiment_label": "Neutral"}, {"ticker": "FBIO", "relevance_score": "0.067158", "ticker_sentiment_score": "-0.014089", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.067158", "ticker_sentiment_score": "-0.014089", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLUE", "relevance_score": "0.067158", "ticker_sentiment_score": "-0.014089", "ticker_sentiment_label": "Neutral"}, {"ticker": "DBTX", "relevance_score": "0.067158", "ticker_sentiment_score": "-0.014089", "ticker_sentiment_label": "Neutral"}]}, {"title": "Autolus Therapeutics Announces Changes to its Board of Directors", "url": "https://www.globenewswire.com/news-release/2023/12/22/2800539/0/en/Autolus-Therapeutics-Announces-Changes-to-its-Board-of-Directors.html", "time_published": "20231222T120000", "authors": ["Autolus Inc."], "summary": "LONDON, Dec. 22, 2023 ( GLOBE NEWSWIRE ) -- Autolus Therapeutics plc ( Nasdaq: AUTL ) , a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced the appointment of Elisabeth Leiderman, M.D. to the Board of Directors.", "banner_image": "https://ml.globenewswire.com/Resource/Download/680b5e1a-9aba-4e38-b280-e43036561ef1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.744043"}], "overall_sentiment_score": 0.095383, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AUTL", "relevance_score": "0.091335", "ticker_sentiment_score": "0.036276", "ticker_sentiment_label": "Neutral"}, {"ticker": "FBIO", "relevance_score": "0.045743", "ticker_sentiment_score": "-0.013891", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.045743", "ticker_sentiment_score": "-0.013891", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLUE", "relevance_score": "0.045743", "ticker_sentiment_score": "-0.013891", "ticker_sentiment_label": "Neutral"}, {"ticker": "DBTX", "relevance_score": "0.045743", "ticker_sentiment_score": "-0.013891", "ticker_sentiment_label": "Neutral"}]}, {"title": "Gainers & Losers: 10 stocks that moved the most on December 22", "url": "https://www.moneycontrol.com/news/photos/business/stocks/gainers-losers-10-stocks-that-moved-the-most-on-december-22-4-11944601.html", "time_published": "20231222T111607", "authors": [], "summary": "About 2163 shares advanced, 1457 shares declined, and 114 shares remained unchanged on December 22.", "banner_image": "https://images.moneycontrol.com/static-mcnews/2023/12/Sensex-Nifty-Markets-1-770x433.jpg", "source": "Money Control", "category_within_source": "Buzzing Stocks", "source_domain": "www.moneycontrol.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.929393"}], "overall_sentiment_score": 0.150484, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.086245", "ticker_sentiment_score": "-0.03837", "ticker_sentiment_label": "Neutral"}]}, {"title": "Pharma stocks rally up to 8% to 52-week highs amid rise in fresh Covid cases", "url": "https://www.moneycontrol.com/news/business/markets/pharma-stocks-rally-up-to-8-to-52-week-highs-amid-rise-in-fresh-covid-cases-11943551.html", "time_published": "20231222T083445", "authors": [], "summary": "The pharma industry is one of the few defensive industries and investor interest in it is also rising, as concerns about COVID-19 gain momentum, said Aamar Deo Singh, Senior Vice President, Research, Angel One.", "banner_image": "https://images.moneycontrol.com/static-mcnews/2023/10/bank_cards_banking_financial-services2.jpg?impolicy=website&width=168&height=118", "source": "Money Control", "category_within_source": "Buzzing Stocks", "source_domain": "www.moneycontrol.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.684621"}], "overall_sentiment_score": 0.240856, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.097854", "ticker_sentiment_score": "-0.045", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.097854", "ticker_sentiment_score": "0.211238", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Pharma industry optimistic, expects more collaborative efforts in New Year", "url": "https://www.business-standard.com/industry/news/pharma-industry-optimistic-expects-more-collaborative-efforts-in-new-year-123122200253_1.html", "time_published": "20231222T060249", "authors": ["Press Trust of India"], "summary": "The domestic pharmaceutical industry expects another year of sustained growth in 2024 amid various challenges, including maintaining quality standards, while moving from volume to value leadership.", "banner_image": "https://bsmedia.business-standard.com/_media/bs/img/article/2023-12/04/full/1701712189-5262.jpg?im=FeatureCrop,size=(826,465)", "source": "Business Standard", "category_within_source": "GoogleRSS", "source_domain": "www.business-standard.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.33044, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.055751", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.055751", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Serum Institute of India to apply for licence of JN.1 Covid variant vaccine", "url": "https://www.business-standard.com/india-news/serum-institute-of-india-to-apply-for-license-of-jn-1-covid-variant-vaccine-123122200250_1.html", "time_published": "20231222T054212", "authors": ["BS Web Team"], "summary": "A spokesperson of the company was cited in the report as saying that the Serum Institute currently offers a vaccine against the XBB1 variant of Covid-19. It is \"very similar\" to the JN.1 variant. \"In the coming months, we are aiming to obtain licensure for this vaccine in India,\" they said.", "banner_image": "https://bsmedia.business-standard.com/_media/bs/img/article/2023-05/03/full/1683122654-0391.jpg?im=FeatureCrop,size=(826,465)", "source": "Business Standard", "category_within_source": "GoogleRSS", "source_domain": "www.business-standard.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.089686, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.195814", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "WAINUA\u2122  ( eplontersen )  granted regulatory approval in the U.S. for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis", "url": "https://www.prnewswire.com/news-releases/wainua-eplontersen-granted-regulatory-approval-in-the-us-for-the-treatment-of-adults-with-polyneuropathy-of-hereditary-transthyretin-mediated-amyloidosis-302021385.html", "time_published": "20231221T235500", "authors": ["Ionis Pharmaceuticals", "Inc."], "summary": "WAINUA\u2122 ( eplontersen ) granted regulatory approval in the U.S. for the treatment of adults with polyneuropathy of ... PR ...", "banner_image": "https://mma.prnewswire.com/media/882077/Ionis_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.147466, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.136577", "ticker_sentiment_score": "0.099353", "ticker_sentiment_label": "Neutral"}, {"ticker": "IONS", "relevance_score": "0.109455", "ticker_sentiment_score": "0.056673", "ticker_sentiment_label": "Neutral"}]}, {"title": "Weighing Their Chances: 5 Leading Healthcare Companies Fight for Market Share in the $100 Billion Weight-Loss Industry", "url": "https://www.fool.com/investing/2023/12/21/weighing-their-chances-5-leading-healthcare-compan/", "time_published": "20231221T144500", "authors": ["David Jagielski"], "summary": "Which weight-loss stocks are good buys today?", "banner_image": "https://g.foolcdn.com/editorial/images/758496/a-doctor-looking-at-a-tablet-with-another-person.jpg", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.18264, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.290607", "ticker_sentiment_score": "0.215295", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GS", "relevance_score": "0.049526", "ticker_sentiment_score": "0.131126", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.33628", "ticker_sentiment_score": "0.091332", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.290607", "ticker_sentiment_score": "0.215295", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.243864", "ticker_sentiment_score": "0.100877", "ticker_sentiment_label": "Neutral"}]}, {"title": "New partnership aims to advance vaccine against MERS coronavirus", "url": "https://www.globenewswire.com/news-release/2023/12/21/2799930/0/en/New-partnership-aims-to-advance-vaccine-against-MERS-coronavirus.html", "time_published": "20231221T123100", "authors": ["Barinthus Biotherapeutics (UK) Limited"], "summary": "CEPI to invest funding of up to $34.8 million to Barinthus Bio in addition to funds previously committed to University of Oxford to develop ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/284aac16-bab8-47d0-8077-929f11b0088b", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.070426, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.042234", "ticker_sentiment_score": "0.113855", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.021124", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BRNS", "relevance_score": "0.042234", "ticker_sentiment_score": "-0.082483", "ticker_sentiment_label": "Neutral"}]}, {"title": "Gainers and Losers: 10 stocks that moved the most on December 21", "url": "https://www.moneycontrol.com/news/photos/business/stocks/gainers-and-losers-10-stocks-that-moved-the-most-on-december-21-11939101.html", "time_published": "20231221T103815", "authors": [], "summary": "Among sectors, Information Technology, bank, FMCG up 0.5 percent each, while metal, pharma, realty, power and oil gas, capital goods up 1-2 percent.", "banner_image": "https://images.moneycontrol.com/static-mcnews/2023/12/Stock-Market-1-5-770x433.jpg", "source": "Money Control", "category_within_source": "Buzzing Stocks", "source_domain": "www.moneycontrol.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.277605, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.17715", "ticker_sentiment_score": "-0.186755", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "AstraZeneca Pharma India to launch cancer drug Enhertu in January", "url": "https://www.business-standard.com/companies/news/astrazeneca-pharma-india-to-launch-cancer-drug-enhertu-in-january-123122100407_1.html", "time_published": "20231221T080529", "authors": ["BS Web Team"], "summary": "The company received clearance from the Central Drugs Standard Control Organisation ( CDSCO ) to import and sell Enhertu in May 2023.", "banner_image": "https://bsmedia.business-standard.com/_media/bs/img/article/2020-10/27/full/1603777503-3088.jpg?im=FeatureCrop,size=(826,465)", "source": "Business Standard", "category_within_source": "GoogleRSS", "source_domain": "www.business-standard.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.107566, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.414559", "ticker_sentiment_score": "0.211687", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "3 Climate Change Developments Facing Business Leaders In 2024", "url": "https://www.forbes.com/sites/globalcitizen/2023/12/21/3-cop28-insights-for-corporate-sustainability-in-2024/", "time_published": "20231221T070147", "authors": ["Michael Sheldrick"], "summary": "The most recent 2023 United Nations Climate Change Conference in the United Arab Emirates , more commonly known as COP28, delivered several pivotal developments that will warrant the attention of every corporate sustainability leader in 2024.", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/6583dfbdf5cab13f8b496fd8/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds", "source": "Forbes", "category_within_source": "n/a", "source_domain": "www.forbes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.269553, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.029292", "ticker_sentiment_score": "0.155304", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "AstraZeneca Pharma to launch breast cancer drug, shares jump 6%", "url": "https://www.moneycontrol.com/news/business/astrazeneca-pharma-to-launch-breast-cancer-drug-shares-jump-6-11937141.html", "time_published": "20231221T063921", "authors": [], "summary": "The pharma company will launch Enhertu, a breast cancer drug, in January 2024 in India.", "banner_image": "https://images.moneycontrol.com/static-mcnews/2023/08/Piramal-ent.jpg?impolicy=website&width=168&height=118", "source": "Money Control", "category_within_source": "Buzzing Stocks", "source_domain": "www.moneycontrol.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.163835, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.76367", "ticker_sentiment_score": "0.391603", "ticker_sentiment_label": "Bullish"}]}, {"title": "Stocks to Watch: Allcargo Logistics, Mazagon Dock, Cochin Ship, Inox India", "url": "https://www.business-standard.com/markets/news/stocks-to-watch-allcargo-logistics-mazagon-dock-cochin-ship-inox-india-123122100085_1.html", "time_published": "20231221T020105", "authors": ["Harshita Singh"], "summary": "At 7:30 am, the Gift Nifty futures were down 70 points to 21,143 over Nifty futures' last close. The new Covid-19 scare with the detection of new variant JN.1 in states like Goa, Kerala and Maharashtra may keep sentiment muted.", "banner_image": "https://bsmedia.business-standard.com/_media/bs/img/article/2023-12/19/full/1703007926-8131.jpg?im=FeatureCrop,size=(826,465)", "source": "Business Standard", "category_within_source": "GoogleRSS", "source_domain": "www.business-standard.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.070202, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SNEJF", "relevance_score": "0.069495", "ticker_sentiment_score": "0.170895", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "IBN", "relevance_score": "0.069495", "ticker_sentiment_score": "0.149726", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.069495", "ticker_sentiment_score": "-0.136631", "ticker_sentiment_label": "Neutral"}, {"ticker": "UCLQF", "relevance_score": "0.069495", "ticker_sentiment_score": "0.270926", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Buzzing Stocks: Mazagon Dock, ICICI Bank, BSE, Embassy, and others in the news", "url": "https://www.moneycontrol.com/news/photos/business/stocks/buzzing-stocks-mazagon-dock-icici-bank-bse-embassy-and-others-in-the-news-11935501.html", "time_published": "20231221T015528", "authors": [], "summary": "Stocks to watch: Check out the companies making headlines before the opening bell today, December 21.", "banner_image": "https://images.moneycontrol.com/static-mcnews/2023/12/Nifty_sensex_marketup-9-770x433.jpg", "source": "Money Control", "category_within_source": "Buzzing Stocks", "source_domain": "www.moneycontrol.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.796627"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.232836, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AON", "relevance_score": "0.061315", "ticker_sentiment_score": "0.144039", "ticker_sentiment_label": "Neutral"}, {"ticker": "IBN", "relevance_score": "0.061315", "ticker_sentiment_score": "0.150044", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ALIZF", "relevance_score": "0.061315", "ticker_sentiment_score": "0.133173", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.061315", "ticker_sentiment_score": "-0.027017", "ticker_sentiment_label": "Neutral"}, {"ticker": "UCLQF", "relevance_score": "0.061315", "ticker_sentiment_score": "0.295395", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "10 Best ETFs For 2024", "url": "https://www.forbes.com/sites/investor-hub/article/best-etfs-2024/", "time_published": "20231220T222815", "authors": ["Catherine Brock"], "summary": "Exchange-traded funds ( ETFs ) are an easy entry point into investing. They provide quick, broad exposure to the financial markets. Even better, ETFs are far easier to manage than a diversified portfolio of individual assets. If ETF investing is on your list of New Year's resolutions, you're in ...", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/65835efbc5419677f9a39a2b/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds", "source": "Forbes", "category_within_source": "n/a", "source_domain": "www.forbes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.289051, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MSFT", "relevance_score": "0.054483", "ticker_sentiment_score": "0.128", "ticker_sentiment_label": "Neutral"}, {"ticker": "SSNLF", "relevance_score": "0.018173", "ticker_sentiment_score": "0.043554", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.018173", "ticker_sentiment_score": "0.174829", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TSLA", "relevance_score": "0.018173", "ticker_sentiment_score": "0.174829", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.018173", "ticker_sentiment_score": "0.043554", "ticker_sentiment_label": "Neutral"}, {"ticker": "MORN", "relevance_score": "0.018173", "ticker_sentiment_score": "0.0762", "ticker_sentiment_label": "Neutral"}, {"ticker": "NSRGF", "relevance_score": "0.018173", "ticker_sentiment_score": "0.043554", "ticker_sentiment_label": "Neutral"}]}, {"title": "ACELYRIN, INC. Appoints Lynn Tetrault to Board of Directors", "url": "https://www.globenewswire.com/news-release/2023/12/20/2799659/0/en/ACELYRIN-INC-Appoints-Lynn-Tetrault-to-Board-of-Directors.html", "time_published": "20231220T213000", "authors": ["ACELYRIN", "INC."], "summary": "Former Executive Vice President of Human Resources and Corporate Affairs at AstraZeneca PLC brings more than 30 years of strategic expertise in human resources, business operations, and corporate affairs alongside public board experience Former Executive Vice President of Human Resources and ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/3226683a-18cb-4ea7-859a-30a2c09c8f37", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.19178, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "NEO", "relevance_score": "0.068306", "ticker_sentiment_score": "0.036078", "ticker_sentiment_label": "Neutral"}, {"ticker": "SLRN", "relevance_score": "0.451494", "ticker_sentiment_score": "0.174582", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.136113", "ticker_sentiment_score": "0.100086", "ticker_sentiment_label": "Neutral"}, {"ticker": "RYTM", "relevance_score": "0.068306", "ticker_sentiment_score": "0.036078", "ticker_sentiment_label": "Neutral"}]}, {"title": "ACELYRIN, INC. Appoints Lynn Tetrault to Board of Directors - Acelyrin  ( NASDAQ:SLRN ) ", "url": "https://www.benzinga.com/pressreleases/23/12/g36334443/acelyrin-inc-appoints-lynn-tetrault-to-board-of-directors", "time_published": "20231220T213000", "authors": ["Globe Newswire"], "summary": "LOS ANGELES, Dec. 20, 2023 ( GLOBE NEWSWIRE ) -- ACELYRIN, INC. SLRN, a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced the appointment of Lynn Tetrault to its board of directors.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": 0.184664, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "NEO", "relevance_score": "0.064104", "ticker_sentiment_score": "0.036013", "ticker_sentiment_label": "Neutral"}, {"ticker": "SLRN", "relevance_score": "0.530849", "ticker_sentiment_score": "0.182845", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.127795", "ticker_sentiment_score": "0.096903", "ticker_sentiment_label": "Neutral"}, {"ticker": "RYTM", "relevance_score": "0.064104", "ticker_sentiment_score": "0.036013", "ticker_sentiment_label": "Neutral"}]}, {"title": "Fusion's Pharma's Targeted Cancer Therapy Potential Gets This Analyst Bullish, Sees 100% Upside - Fusion Pharmaceuticals  ( NASDAQ:FUSN ) ", "url": "https://www.benzinga.com/analyst-ratings/analyst-color/23/12/36330070/fusions-pharmas-targeted-cancer-therapy-potential-gets-this-analyst-bullish-sees-10", "time_published": "20231220T191714", "authors": ["Vandana Singh"], "summary": "RBC Capital Markets initiated coverage on Fusion Pharmaceuticals Inc FUSN, saying the radiopharmaceutical industry is a burgeoning area in therapeutics following the green light for Novartis AG's NVS Pluvicto, providing an influx of capital from strategic ventures and new company establishments.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/12/20/fusn.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.284204, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.247838", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "FUSN", "relevance_score": "0.364275", "ticker_sentiment_score": "0.102035", "ticker_sentiment_label": "Neutral"}]}, {"title": "Five obesity-drug trends to watch in 2024: Who can compete with Eli Lilly and Novo Nordisk?", "url": "https://www.marketwatch.com/story/five-obesity-drug-trends-to-watch-in-2024-who-can-compete-with-eli-lilly-and-novo-nordisk-1dc62a7d", "time_published": "20231220T161700", "authors": ["Eleanor Laise"], "summary": "The obesity drugs that powered huge investor gains in 2023 are poised to inspire more corporate dealmaking, scientific breakthroughs and better patient access in the year ahead, analysts say.", "banner_image": "https://images.mktw.net/im-80508866/social", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.119145, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VKTX", "relevance_score": "0.043778", "ticker_sentiment_score": "0.087169", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.043778", "ticker_sentiment_score": "-0.046832", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.087424", "ticker_sentiment_score": "0.081911", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.237288", "ticker_sentiment_score": "0.153064", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ALT", "relevance_score": "0.043778", "ticker_sentiment_score": "0.083222", "ticker_sentiment_label": "Neutral"}, {"ticker": "GPCR", "relevance_score": "0.043778", "ticker_sentiment_score": "-0.018675", "ticker_sentiment_label": "Neutral"}, {"ticker": "MORN", "relevance_score": "0.021897", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.043778", "ticker_sentiment_score": "0.200504", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.065625", "ticker_sentiment_score": "-0.017049", "ticker_sentiment_label": "Neutral"}]}, {"title": "4 Drug Stocks Rising More Than 40% in 2023 With Room to Grow", "url": "https://www.zacks.com/stock/news/2200461/4-drug-stocks-rising-more-than-40-in-2023-with-room-to-grow", "time_published": "20231220T134500", "authors": ["Kinjel Shah"], "summary": "Novo Nordisk (NVO), Journey Medical Corporation (DERM), Lyra Therapeutics (LYRA) and Fusion Pharmaceuticals (FUSN) have returned 40% or higher year to date and have room for more growth in 2024.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/39/612.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}, {"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.451494"}], "overall_sentiment_score": 0.202206, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DERM", "relevance_score": "0.196079", "ticker_sentiment_score": "0.131587", "ticker_sentiment_label": "Neutral"}, {"ticker": "FUSN", "relevance_score": "0.163909", "ticker_sentiment_score": "0.131476", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.033006", "ticker_sentiment_score": "0.167425", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVO", "relevance_score": "0.22792", "ticker_sentiment_score": "0.139365", "ticker_sentiment_label": "Neutral"}, {"ticker": "LYRA", "relevance_score": "0.098794", "ticker_sentiment_score": "0.040116", "ticker_sentiment_label": "Neutral"}]}, {"title": "SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ICVX, X, PGTI - PGT Innovations  ( NYSE:PGTI ) , Icosavax  ( NASDAQ:ICVX ) ", "url": "https://www.benzinga.com/pressreleases/23/12/g36323987/shareholder-investigation-halper-sadeh-llc-investigates-icvx-x-pgti", "time_published": "20231220T134351", "authors": ["Globe Newswire"], "summary": "NEW YORK, Dec. 20, 2023 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Icosavax, Inc.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Manufacturing", "relevance_score": "0.5"}], "overall_sentiment_score": 0.156568, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "X", "relevance_score": "0.136113", "ticker_sentiment_score": "0.097237", "ticker_sentiment_label": "Neutral"}, {"ticker": "PGTI", "relevance_score": "0.136113", "ticker_sentiment_score": "0.167382", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.136113", "ticker_sentiment_score": "0.190389", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DOOR", "relevance_score": "0.136113", "ticker_sentiment_score": "0.167382", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ICVX", "relevance_score": "0.268294", "ticker_sentiment_score": "0.304168", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NISTF", "relevance_score": "0.136113", "ticker_sentiment_score": "0.097237", "ticker_sentiment_label": "Neutral"}]}, {"title": "Martin Glensbjerg takes up new position at ChemoMetec", "url": "https://www.globenewswire.com/news-release/2023/12/20/2799277/0/en/Martin-Glensbjerg-takes-up-new-position-at-ChemoMetec.html", "time_published": "20231220T133500", "authors": ["Chemometec A/S"], "summary": "ANNOUNCEMENT NO. ...", "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/dda6d08e-1d43-433e-bc7b-b1e84b4963be", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": 0.237334, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.090474", "ticker_sentiment_score": "0.042426", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.090474", "ticker_sentiment_score": "0.042426", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.090474", "ticker_sentiment_score": "0.042426", "ticker_sentiment_label": "Neutral"}]}, {"title": "Weight loss drugs, Alzheimer's treatments and gene editing: Enormous firsts defined 2023 in pharma", "url": "https://www.cnbc.com/2023/12/20/weight-loss-drugs-covid-downturn-pharma-had-a-year-full-of-firsts.html", "time_published": "20231220T120001", "authors": ["Annika Kim Constantino"], "summary": "Wall Street turned its focus to a handful of newer treatments in different disease areas in 2023, including weight loss medications and a new Alzheimer's drug.", "banner_image": "https://image.cnbcfm.com/api/v1/image/107347356-1702499004188-gettyimages-1839792823-roy-notitle231211_np5rX.jpeg?v=1702499083&w=1920&h=1080", "source": "CNBC", "category_within_source": "Business", "source_domain": "www.cnbc.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}, {"topic": "Earnings", "relevance_score": "0.938793"}], "overall_sentiment_score": 0.016958, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.053992", "ticker_sentiment_score": "0.045817", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.08091", "ticker_sentiment_score": "-0.013704", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.053992", "ticker_sentiment_score": "-0.015961", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.027011", "ticker_sentiment_score": "0.172126", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.053992", "ticker_sentiment_score": "-0.091089", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.107736", "ticker_sentiment_score": "0.068154", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.08091", "ticker_sentiment_score": "0.132047", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.08091", "ticker_sentiment_score": "0.05643", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.053992", "ticker_sentiment_score": "-0.015961", "ticker_sentiment_label": "Neutral"}]}, {"title": "Deka Biosciences Adds Industry Veterans to its Executive Leadership Team and Board of Directors - PR Newswire", "url": "https://www.prnewswire.com/news-releases/deka-biosciences-adds-industry-veterans-to-its-executive-leadership-team-and-board-of-directors-302019378.html", "time_published": "20231219T190900", "authors": [], "summary": "Deka Biosciences Adds Industry Veterans to its Executive Leadership Team and Board of Directors PR ...", "banner_image": null, "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.137095, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "KYMR", "relevance_score": "0.044386", "ticker_sentiment_score": "-0.022424", "ticker_sentiment_label": "Neutral"}, {"ticker": "BGNE", "relevance_score": "0.044386", "ticker_sentiment_score": "-0.030348", "ticker_sentiment_label": "Neutral"}, {"ticker": "DTIL", "relevance_score": "0.044386", "ticker_sentiment_score": "-0.030348", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.044386", "ticker_sentiment_score": "-0.030348", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADAG", "relevance_score": "0.044386", "ticker_sentiment_score": "-0.030348", "ticker_sentiment_label": "Neutral"}, {"ticker": "STRO", "relevance_score": "0.044386", "ticker_sentiment_score": "-0.030348", "ticker_sentiment_label": "Neutral"}, {"ticker": "PRAX", "relevance_score": "0.044386", "ticker_sentiment_score": "-0.022424", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.044386", "ticker_sentiment_score": "-0.022424", "ticker_sentiment_label": "Neutral"}]}, {"title": "Ionis  ( IONS )  Out Licenses Europe Rights for HAE Drug to Otsuka", "url": "https://www.zacks.com/stock/news/2200063/ionis-ions-out-licenses-europe-rights-for-hae-drug-to-otsuka", "time_published": "20231219T154500", "authors": ["Zacks Equity Research"], "summary": "Per the agreement, Ionis (IONS) will be responsible for the clinical development of the HAE drug. Otsuka will be responsible for all regulatory filings and commercialization activities in Europe.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.140302, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.358669", "ticker_sentiment_score": "0.100847", "ticker_sentiment_label": "Neutral"}, {"ticker": "IONS", "relevance_score": "0.290607", "ticker_sentiment_score": "0.227701", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.423843", "ticker_sentiment_score": "0.161527", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Why Is Cancer Immunotherapy-Focused Compugen Stock Is Trading Higher Today? - Compugen  ( NASDAQ:CGEN ) ", "url": "https://www.benzinga.com/general/biotech/23/12/36302707/why-is-cancer-immunotherapy-focused-compugen-stock-is-trading-higher-today", "time_published": "20231219T153645", "authors": ["Vandana Singh"], "summary": "Gilead Sciences Inc GILD announced an agreement with Compugen Ltd CGEN to license its pre-clinical antibody program against IL-18 binding protein exclusively, including the COM503 drug candidate.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/12/19/cgen.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.161647"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.09063, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.285526", "ticker_sentiment_score": "0.153867", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CGEN", "relevance_score": "0.900307", "ticker_sentiment_score": "0.309158", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.285526", "ticker_sentiment_score": "0.248491", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Related Sciences Adds 8 New Senior Advisors Including Former CEOs and Heads of R&D from Genentech, Novartis, Seagen, Pfizer, Celgene, and AstraZeneca", "url": "https://www.benzinga.com/pressreleases/23/12/g36305665/related-sciences-adds-8-new-senior-advisors-including-former-ceos-and-heads-of-r-d-from-genentech-", "time_published": "20231219T150000", "authors": ["Globe Newswire"], "summary": "DENVER, Dec. 19, 2023 ( GLOBE NEWSWIRE ) -- Related Sciences ( RS ) , a leading data science-driven drug discovery firm, today announced the appointment of 8 leading biopharma executives as senior advisors to support its growing portfolio of drug programs, data science capabilities, and R&D ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.351488, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.070105", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.070105", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SGEN", "relevance_score": "0.070105", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Astrazeneca  ( AZN )  Exceeds Market Returns: Some Facts to Consider", "url": "https://www.zacks.com/stock/news/2199634/astrazeneca-azn-exceeds-market-returns-some-facts-to-consider", "time_published": "20231218T225019", "authors": ["Zacks Equity Research"], "summary": "In the most recent trading session, Astrazeneca (AZN) closed at $65.95, indicating a +1.77% shift from the previous trading day.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default161.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.972476"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.413559"}], "overall_sentiment_score": 0.187697, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.708432", "ticker_sentiment_score": "0.339629", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Eagle Bulk Shipping Inc.  ( NYSE - EGLE ) , Icosavax, Inc.  ( Nasdaq - ICVX ) , Evofem Biosciences, Inc.  ( OTC - EVFM ) , CapStar Financial Holdings, Inc.  ( Nasdaq - CSTR ) ", "url": "https://www.benzinga.com/pressreleases/23/12/g36288170/brodsky-smith-shareholder-update-notifying-investors-of-the-following-investigations-eagle-bulk-sh", "time_published": "20231218T175733", "authors": ["Globe Newswire"], "summary": "BALA CYNWYD, Pa., Dec. 18, 2023 ( GLOBE NEWSWIRE ) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( jbrodsky@brodskysmith.com ) or Marc Ackerman ( mackerman@brodskysmith.com ) at 855-576-4847.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.999862"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.858979"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.24098, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CSTR", "relevance_score": "0.191675", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ONB", "relevance_score": "0.128478", "ticker_sentiment_score": "0.189141", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.191675", "ticker_sentiment_score": "0.214742", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DSSMY", "relevance_score": "0.191675", "ticker_sentiment_score": "0.059038", "ticker_sentiment_label": "Neutral"}, {"ticker": "SBLK", "relevance_score": "0.128478", "ticker_sentiment_score": "0.141065", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADTX", "relevance_score": "0.314017", "ticker_sentiment_score": "0.223355", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "EGLE", "relevance_score": "0.064449", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ICVX", "relevance_score": "0.191675", "ticker_sentiment_score": "0.200566", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "These Are the 3 Hottest Biopharma Trends of 2024. Should You Invest?", "url": "https://www.fool.com/investing/2023/12/18/these-are-the-3-hottest-biopharma-trends-of-2024/", "time_published": "20231218T141500", "authors": ["Alex Carchidi"], "summary": "2024 is going to be a sizzler in the biopharma sector.", "banner_image": "https://g.foolcdn.com/editorial/images/758306/business-people-and-doctors-talking-on-a-meeting-in-hospital.jpg", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}, {"topic": "Manufacturing", "relevance_score": "0.5"}], "overall_sentiment_score": 0.216785, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "NVDA", "relevance_score": "0.049424", "ticker_sentiment_score": "0.1381", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.098659", "ticker_sentiment_score": "0.04645", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.147516", "ticker_sentiment_score": "0.224328", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "LLY", "relevance_score": "0.147516", "ticker_sentiment_score": "0.051851", "ticker_sentiment_label": "Neutral"}, {"ticker": "GPCR", "relevance_score": "0.049424", "ticker_sentiment_score": "0.088711", "ticker_sentiment_label": "Neutral"}, {"ticker": "RXRX", "relevance_score": "0.098659", "ticker_sentiment_score": "0.147487", "ticker_sentiment_label": "Neutral"}, {"ticker": "SDGR", "relevance_score": "0.098659", "ticker_sentiment_score": "0.147487", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.049424", "ticker_sentiment_score": "0.043511", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.098659", "ticker_sentiment_score": "0.04645", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.049424", "ticker_sentiment_score": "0.043511", "ticker_sentiment_label": "Neutral"}]}, {"title": "Is Amgen Stock a Buy Now?", "url": "https://www.fool.com/investing/2023/12/17/is-amgen-stock-a-buy-now/", "time_published": "20231217T140000", "authors": ["Prosper Junior Bakiny"], "summary": "Boring businesses can be successful, too.", "banner_image": "https://media.ycharts.com/charts/7cad83689ad7550ccb0480a680c774cc.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.316726"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.684621"}], "overall_sentiment_score": 0.204173, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.539641", "ticker_sentiment_score": "0.261984", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.053509", "ticker_sentiment_score": "0.028078", "ticker_sentiment_label": "Neutral"}]}, {"title": "The weight loss drug boom isn't over yet - here's what to expect in the year ahead", "url": "https://www.cnbc.com/2023/12/17/weight-loss-drugs-2024-expectations-for-wegovy-ozempic-zepbound.html", "time_published": "20231217T130001", "authors": ["Annika Kim Constantino"], "summary": "2024 will be another big year for weight loss drugs, which soared in popularity despite hefty price tags, mixed insurance coverage and unpleasant side effects.", "banner_image": "https://image.cnbcfm.com/api/v1/image/107346441-1702395741776-gettyimages-1807240143-WEIGHT_LOSS_DRUGS.jpeg?v=1702458927&w=1920&h=1080", "source": "CNBC", "category_within_source": "Business", "source_domain": "www.cnbc.com", "topics": [{"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.050321, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BCS", "relevance_score": "0.016564", "ticker_sentiment_score": "0.005187", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAC", "relevance_score": "0.016564", "ticker_sentiment_score": "0.065627", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.033121", "ticker_sentiment_score": "0.10225", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.016564", "ticker_sentiment_score": "-0.056181", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.016564", "ticker_sentiment_score": "0.065627", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.306761", "ticker_sentiment_score": "0.04074", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALT", "relevance_score": "0.033121", "ticker_sentiment_score": "-0.000946", "ticker_sentiment_label": "Neutral"}, {"ticker": "GPCR", "relevance_score": "0.016564", "ticker_sentiment_score": "-0.094366", "ticker_sentiment_label": "Neutral"}, {"ticker": "GS", "relevance_score": "0.016564", "ticker_sentiment_score": "-0.017151", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.082677", "ticker_sentiment_score": "0.014482", "ticker_sentiment_label": "Neutral"}]}, {"title": "Pharma Stock Roundup: PFE Issues Weak 2024 View, AZN to Buy Icosavax & More", "url": "https://www.zacks.com/stock/news/2198513/pharma-stock-roundup-pfe-issues-weak-2024-view-azn-to-buy-icosavax-more", "time_published": "20231215T133400", "authors": ["Kinjel Shah"], "summary": "Pfizer (PFE) issues a disappointing outlook for 2024. AstraZeneca (AZN) announces that it is buying vaccine company, Icosavax.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/52/873.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.938793"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.156532, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.271489", "ticker_sentiment_score": "0.219964", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "LLY", "relevance_score": "0.079", "ticker_sentiment_score": "-0.064902", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.079", "ticker_sentiment_score": "-0.065918", "ticker_sentiment_label": "Neutral"}, {"ticker": "SGEN", "relevance_score": "0.195814", "ticker_sentiment_score": "0.070548", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.195814", "ticker_sentiment_score": "-0.045716", "ticker_sentiment_label": "Neutral"}, {"ticker": "ICVX", "relevance_score": "0.157227", "ticker_sentiment_score": "0.105049", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.344606", "ticker_sentiment_score": "0.047034", "ticker_sentiment_label": "Neutral"}]}, {"title": "Neuropathy Pain Treatment Market size to grow by USD 5.84 billion from 2023 to 2028, North America accounts for 33 ... - PR Newswire", "url": "https://www.prnewswire.com/news-releases/neuropathy-pain-treatment-market-size-to-grow-by-usd-5-84-billion-from-2023-to-2028--north-america-accounts-for-33-of-market-growth--technavio-302015282.html", "time_published": "20231214T221500", "authors": [], "summary": "Neuropathy Pain Treatment Market size to grow by USD 5.84 billion from 2023 to 2028, North America accounts for 33 ... PR ...", "banner_image": null, "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.177123, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "0.078099", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.078099", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALPMF", "relevance_score": "0.078099", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SKXJF", "relevance_score": "0.078099", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DSKYF", "relevance_score": "0.078099", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ENDPQ", "relevance_score": "0.078099", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "VTGN", "relevance_score": "0.078099", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.078099", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.078099", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABT", "relevance_score": "0.078099", "ticker_sentiment_score": "-0.22385", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "AZN", "relevance_score": "0.078099", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAX", "relevance_score": "0.078099", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.078099", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.078099", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "More doses of new RSV immunization for babies are on the way, White House announces", "url": "https://www.cnn.com/2023/12/14/health/rsv-immunization-beyfortus-doses/index.html", "time_published": "20231214T220100", "authors": ["Brenda Goodman"], "summary": "More hard-to-find doses of Beyfortus, the new immunization against respiratory syncytial virus ( RSV ) for infants, will be available in January, the White House says. The announcement comes as RSV season is in full swing in the United States.", "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/231204220940-baby-stethoscope-stock-120423.jpg?c=16x9&q=h_144,w_256,c_fill", "source": "CNN", "category_within_source": "Markets", "source_domain": "www.cnn.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.179498, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "WBD", "relevance_score": "0.081276", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.16171", "ticker_sentiment_score": "0.080548", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.240489", "ticker_sentiment_score": "0.136903", "ticker_sentiment_label": "Neutral"}]}, {"title": "Envista Holdings Corporation Appoints Three New Members to Leadership Team", "url": "https://www.prnewswire.com/news-releases/envista-holdings-corporation-appoints-three-new-members-to-leadership-team-302015992.html", "time_published": "20231214T211000", "authors": ["Envista Holdings Corporation"], "summary": "BREA, Calif., Dec. 14, 2023 /PRNewswire/ -- Envista Holdings Corporation ( NYSE: NVST ) today announced the expansion of its leadership team, with the recent appointments of Robert Befidi as President, Diagnostics. Suraj Satpathy as Chief Human Resources Officer. and Andrew Chen as Chief ...", "banner_image": "https://mma.prnewswire.com/media/1008600/Envista_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.382989, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.058047", "ticker_sentiment_score": "0.018019", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAC", "relevance_score": "0.058047", "ticker_sentiment_score": "0.029973", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.058047", "ticker_sentiment_score": "0.029973", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVST", "relevance_score": "0.656158", "ticker_sentiment_score": "0.569572", "ticker_sentiment_label": "Bullish"}, {"ticker": "JPM", "relevance_score": "0.058047", "ticker_sentiment_score": "0.029973", "ticker_sentiment_label": "Neutral"}, {"ticker": "DHR", "relevance_score": "0.058047", "ticker_sentiment_score": "0.018019", "ticker_sentiment_label": "Neutral"}]}, {"title": "The Zacks Analyst Blog Highlights Adobe, AstraZeneca, Intel, Morgan Stanley and EOG Resources", "url": "https://www.zacks.com/stock/news/2198070/the-zacks-analyst-blog-highlights-adobe-astrazeneca-intel-morgan-stanley-and-eog-resources", "time_published": "20231214T154700", "authors": ["Zacks Equity Research"], "summary": "Adobe, AstraZeneca, Intel, Morgan Stanley and EOG Resources are part of the Zacks top Analyst Blog.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/60/445.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Energy & Transportation", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}], "overall_sentiment_score": 0.191726, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ADBE", "relevance_score": "0.269776", "ticker_sentiment_score": "0.054915", "ticker_sentiment_label": "Neutral"}, {"ticker": "EOG", "relevance_score": "0.136888", "ticker_sentiment_score": "0.033574", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.453789", "ticker_sentiment_score": "0.138735", "ticker_sentiment_label": "Neutral"}, {"ticker": "INTC", "relevance_score": "0.269776", "ticker_sentiment_score": "0.054915", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.136888", "ticker_sentiment_score": "0.033574", "ticker_sentiment_label": "Neutral"}]}, {"title": "Velia Therapeutics Appoints Michael York as Chief Business Officer", "url": "https://www.prnewswire.com/news-releases/velia-therapeutics-appoints-michael-york-as-chief-business-officer-302013115.html", "time_published": "20231214T133000", "authors": ["Velia"], "summary": "Mr. York brings over 30 years of experience leading business development, strategic planning and commercial functions across pharmaceutical and biotech companies", "banner_image": "https://mma.prnewswire.com/media/2156100/Velia_Logo_horizontal_white_background_4_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "IPO", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.325119, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.06211", "ticker_sentiment_score": "0.050003", "ticker_sentiment_label": "Neutral"}, {"ticker": "MTCR", "relevance_score": "0.06211", "ticker_sentiment_score": "0.050003", "ticker_sentiment_label": "Neutral"}]}, {"title": "Top Analyst Reports for Adobe, AstraZeneca & Intel", "url": "https://www.zacks.com/research-daily/2197308/top-analyst-reports-for-adobe-astrazeneca-intel", "time_published": "20231214T132600", "authors": ["Mark Vickery"], "summary": "Today's Research Daily features new research reports on 16 major stocks, including Adobe Inc. (ADBE), AstraZeneca PLC (AZN) and Intel Corporation (INTC).", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/2b/4052.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.238247, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.28664", "ticker_sentiment_score": "0.145752", "ticker_sentiment_label": "Neutral"}]}, {"title": "SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ICVX, ROVR, ESMT, SLGC - Engagesmart  ( NYSE:ESMT ) , Icosavax  ( NASDAQ:ICVX ) ", "url": "https://www.benzinga.com/pressreleases/23/12/g36217089/shareholder-investigation-halper-sadeh-llc-investigates-icvx-rovr-esmt-slgc", "time_published": "20231213T145459", "authors": ["Globe Newswire"], "summary": "NEW YORK, Dec. 13, 2023 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Icosavax, Inc.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.858979"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.139838, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SLGC", "relevance_score": "0.371523", "ticker_sentiment_score": "0.292647", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.128135", "ticker_sentiment_score": "0.184789", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ESMT", "relevance_score": "0.252987", "ticker_sentiment_score": "0.122874", "ticker_sentiment_label": "Neutral"}, {"ticker": "BX", "relevance_score": "0.128135", "ticker_sentiment_score": "0.084983", "ticker_sentiment_label": "Neutral"}, {"ticker": "LAB", "relevance_score": "0.252987", "ticker_sentiment_score": "0.218772", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ICVX", "relevance_score": "0.252987", "ticker_sentiment_score": "0.290861", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ROVR", "relevance_score": "0.128135", "ticker_sentiment_score": "0.084983", "ticker_sentiment_label": "Neutral"}]}, {"title": "Here's Why You Should Retain McKesson  ( MCK )  Stock for Now", "url": "https://www.zacks.com/stock/news/2197165/heres-why-you-should-retain-mckesson-mck-stock-for-now", "time_published": "20231213T120900", "authors": ["Zacks Equity Research"], "summary": "McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/6e/37920.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Earnings", "relevance_score": "0.928139"}], "overall_sentiment_score": 0.238892, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "HQY", "relevance_score": "0.159569", "ticker_sentiment_score": "0.09612", "ticker_sentiment_label": "Neutral"}, {"ticker": "MCK", "relevance_score": "0.497869", "ticker_sentiment_score": "0.169161", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.053509", "ticker_sentiment_score": "0.267896", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BDSX", "relevance_score": "0.159569", "ticker_sentiment_score": "0.048288", "ticker_sentiment_label": "Neutral"}, {"ticker": "SKXJF", "relevance_score": "0.053509", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DSGR", "relevance_score": "0.211652", "ticker_sentiment_score": "-0.017259", "ticker_sentiment_label": "Neutral"}, {"ticker": "DSKYF", "relevance_score": "0.053509", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.159569", "ticker_sentiment_score": "0.109351", "ticker_sentiment_label": "Neutral"}, {"ticker": "HCSG", "relevance_score": "0.053509", "ticker_sentiment_score": "0.099702", "ticker_sentiment_label": "Neutral"}, {"ticker": "SWTX", "relevance_score": "0.053509", "ticker_sentiment_score": "0.267896", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Poonawalla set to buy London mansion for Rupees 1446 crore", "url": "https://www.financialexpress.com/business/industry-poonawalla-set-to-buy-london-mansion-for-rupees-1446-crore-3336953/", "time_published": "20231212T231000", "authors": ["Raghavendra Kamath"], "summary": "In what could be one of the most expensive residential purchases by an Indian, Serum Institute of India chief executive officer Adar Poonawalla has reportedly reached a deal to buy a 25,000-square-foot mansion in London's Mayfair for 138 million pounds ( \u20b91446 crore ) .", "banner_image": "https://www.financialexpress.com/wp-content/uploads/2023/12/adar-poonawala.jpg", "source": "The Financial Express", "category_within_source": "n/a", "source_domain": "www.financialexpress.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.028097, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.115787", "ticker_sentiment_score": "0.070146", "ticker_sentiment_label": "Neutral"}]}, {"title": "Crude Oil Down 4%; Aditxt Shares Spike Higher - Aditxt  ( NASDAQ:ADTX ) , Achieve Life Sciences  ( NASDAQ:ACHV ) ", "url": "https://www.benzinga.com/news/earnings/23/12/36204725/crude-oil-down-4-aditxt-shares-spike-higher", "time_published": "20231212T192300", "authors": ["Avi Kapoor"], "summary": "U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining over 100 points on Tuesday. The Dow traded up 0.32% to 36,520.57 while the NASDAQ rose 0.46% to 14,498.23. The S&P 500 also rose, gaining, 0.26% to 4,634.47. Materials shares rose by 0.5% on Tuesday.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/12/12/crude_oil_4-_logo.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.918141"}, {"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.140161, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "JCI", "relevance_score": "0.188683", "ticker_sentiment_score": "-0.014058", "ticker_sentiment_label": "Neutral"}, {"ticker": "GGE", "relevance_score": "0.12645", "ticker_sentiment_score": "-0.111236", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.063425", "ticker_sentiment_score": "0.287686", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ADTX", "relevance_score": "0.188683", "ticker_sentiment_score": "0.26123", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ORCL", "relevance_score": "0.188683", "ticker_sentiment_score": "0.185335", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ACHV", "relevance_score": "0.249744", "ticker_sentiment_score": "0.079562", "ticker_sentiment_label": "Neutral"}, {"ticker": "ICVX", "relevance_score": "0.188683", "ticker_sentiment_score": "0.416847", "ticker_sentiment_label": "Bullish"}, {"ticker": "CCCC", "relevance_score": "0.188683", "ticker_sentiment_score": "0.148612", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why Johnson Controls International Shares Are Trading Lower By Over 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session - African Agriculture Hldgs  ( NASDAQ:AAGR ) , Achieve Life Sciences  ( NASDAQ:ACHV ) ", "url": "https://www.benzinga.com/news/23/12/36203637/why-johnson-controls-international-shares-are-trading-lower-by-over-6-here-are-other-stocks-moving-i", "time_published": "20231212T182222", "authors": ["Avi Kapoor"], "summary": "Shares of Johnson Controls International plc JCI moved lower during Tuesday's session following weak quarterly results. Johnson Controls reported fourth-quarter FY23 sales growth of 2.7% year-on-year to $6.91 billion ( +2% organically ) , missing the consensus of $7.09 billion.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/12/12/johnson_controls_-_logo_0.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.142857"}, {"topic": "Energy & Transportation", "relevance_score": "0.142857"}, {"topic": "Technology", "relevance_score": "0.142857"}, {"topic": "Finance", "relevance_score": "0.142857"}, {"topic": "IPO", "relevance_score": "0.310843"}, {"topic": "Retail & Wholesale", "relevance_score": "0.142857"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}, {"topic": "Manufacturing", "relevance_score": "0.142857"}, {"topic": "Earnings", "relevance_score": "0.650727"}, {"topic": "Real Estate & Construction", "relevance_score": "0.142857"}], "overall_sentiment_score": -0.004915, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GPRO", "relevance_score": "0.147818", "ticker_sentiment_score": "-0.23201", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "HRYU", "relevance_score": "0.098862", "ticker_sentiment_score": "0.177522", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "IONM", "relevance_score": "0.098862", "ticker_sentiment_score": "-0.05508", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOTU", "relevance_score": "0.098862", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BQ", "relevance_score": "0.098862", "ticker_sentiment_score": "-0.527993", "ticker_sentiment_label": "Bearish"}, {"ticker": "ODC", "relevance_score": "0.098862", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "IXHL", "relevance_score": "0.098862", "ticker_sentiment_score": "-0.355698", "ticker_sentiment_label": "Bearish"}, {"ticker": "SBOW", "relevance_score": "0.147818", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLBD", "relevance_score": "0.098862", "ticker_sentiment_score": "0.302021", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AAGR", "relevance_score": "0.098862", "ticker_sentiment_score": "-0.400682", "ticker_sentiment_label": "Bearish"}, {"ticker": "HPCO", "relevance_score": "0.098862", "ticker_sentiment_score": "-0.091847", "ticker_sentiment_label": "Neutral"}, {"ticker": "CAVA", "relevance_score": "0.098862", "ticker_sentiment_score": "0.365348", "ticker_sentiment_label": "Bullish"}, {"ticker": "CLINR", "relevance_score": "0.049526", "ticker_sentiment_score": "0.26031", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SPEC", "relevance_score": "0.147818", "ticker_sentiment_score": "0.38753", "ticker_sentiment_label": "Bullish"}, {"ticker": "CCCC", "relevance_score": "0.098862", "ticker_sentiment_score": "0.112349", "ticker_sentiment_label": "Neutral"}, {"ticker": "BON", "relevance_score": "0.098862", "ticker_sentiment_score": "-0.527993", "ticker_sentiment_label": "Bearish"}, {"ticker": "HCDI", "relevance_score": "0.147818", "ticker_sentiment_score": "-0.293471", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "GGE", "relevance_score": "0.098862", "ticker_sentiment_score": "-0.200022", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "INAB", "relevance_score": "0.049526", "ticker_sentiment_score": "0.101192", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.049526", "ticker_sentiment_score": "-0.183132", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "VPGLF", "relevance_score": "0.049526", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ORCL", "relevance_score": "0.147818", "ticker_sentiment_score": "-0.130193", "ticker_sentiment_label": "Neutral"}, {"ticker": "APPS", "relevance_score": "0.098862", "ticker_sentiment_score": "0.365348", "ticker_sentiment_label": "Bullish"}, {"ticker": "ICG", "relevance_score": "0.098862", "ticker_sentiment_score": "0.08632", "ticker_sentiment_label": "Neutral"}, {"ticker": "ACHV", "relevance_score": "0.196212", "ticker_sentiment_score": "-0.042783", "ticker_sentiment_label": "Neutral"}, {"ticker": "ACLX", "relevance_score": "0.147818", "ticker_sentiment_score": "-0.189072", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "JCI", "relevance_score": "0.196212", "ticker_sentiment_score": "-0.029817", "ticker_sentiment_label": "Neutral"}, {"ticker": "LCID", "relevance_score": "0.147818", "ticker_sentiment_score": "-0.005696", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.049526", "ticker_sentiment_score": "-0.001993", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALTNF", "relevance_score": "0.049526", "ticker_sentiment_score": "0.26031", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ADTX", "relevance_score": "0.098862", "ticker_sentiment_score": "0.268718", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CADL", "relevance_score": "0.098862", "ticker_sentiment_score": "-0.00791", "ticker_sentiment_label": "Neutral"}, {"ticker": "KNTK", "relevance_score": "0.147818", "ticker_sentiment_score": "0.111895", "ticker_sentiment_label": "Neutral"}, {"ticker": "BRSH", "relevance_score": "0.098862", "ticker_sentiment_score": "0.333164", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "EGLE", "relevance_score": "0.147818", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ICVX", "relevance_score": "0.196212", "ticker_sentiment_score": "-0.00313", "ticker_sentiment_label": "Neutral"}, {"ticker": "CLNE", "relevance_score": "0.098862", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMND", "relevance_score": "0.147818", "ticker_sentiment_score": "-0.210557", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "CRYPTO:ADX", "relevance_score": "0.049526", "ticker_sentiment_score": "-0.272347", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "LLY Down as Patients Regain Weight After Stopping Zepbound", "url": "https://www.zacks.com/stock/news/2196988/lly-down-as-patients-regain-weight-after-stopping-zepbound", "time_published": "20231212T181900", "authors": ["Zacks Equity Research"], "summary": "Full results from a late-stage study show that patients who stopped taking Eli Lilly's (LLY) weight-loss drug for over a year slowly started to regain their lost weight.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.155041, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.504646", "ticker_sentiment_score": "0.199782", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.266828", "ticker_sentiment_score": "0.222446", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVO", "relevance_score": "0.266828", "ticker_sentiment_score": "0.30101", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Macy's Could Be On An Investor Group's Wish List", "url": "https://www.forbes.com/sites/meganpoinski/2023/12/12/macys-could-be-on-an-investor-groups-wish-list/", "time_published": "20231212T180229", "authors": ["Megan Poinski"], "summary": "This is the published version of Forbes' CFO newsletter, which offers the latest news for chief finance officers and other leaders focused on the budget. Sign up here to get it delivered to your inbox every Tuesday. It's the holiday season, so it's not surprising that everyone is buzzing about ...", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/65789f872e59628a4f1ff69b/0x0.jpg?format=jpg&crop=969,545,x0,y8,safe&height=900&width=1600&fit=bounds", "source": "Forbes", "category_within_source": "n/a", "source_domain": "www.forbes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "Economy - Monetary", "relevance_score": "0.890401"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.891286"}], "overall_sentiment_score": 0.134868, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "EVR", "relevance_score": "0.029008", "ticker_sentiment_score": "0.155115", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MSFT", "relevance_score": "0.115648", "ticker_sentiment_score": "0.175676", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HUM", "relevance_score": "0.057977", "ticker_sentiment_score": "0.061002", "ticker_sentiment_label": "Neutral"}, {"ticker": "MO", "relevance_score": "0.029008", "ticker_sentiment_score": "-0.070416", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.057977", "ticker_sentiment_score": "0.102019", "ticker_sentiment_label": "Neutral"}, {"ticker": "BTI", "relevance_score": "0.057977", "ticker_sentiment_score": "-0.075008", "ticker_sentiment_label": "Neutral"}, {"ticker": "M", "relevance_score": "0.200926", "ticker_sentiment_score": "0.074179", "ticker_sentiment_label": "Neutral"}, {"ticker": "PM", "relevance_score": "0.029008", "ticker_sentiment_score": "-0.070416", "ticker_sentiment_label": "Neutral"}, {"ticker": "ICVX", "relevance_score": "0.029008", "ticker_sentiment_score": "0.046781", "ticker_sentiment_label": "Neutral"}]}, {"title": "Dow Jumps Over 100 Points; Oracle Posts Mixed Q2 Results - Aditxt  ( NASDAQ:ADTX ) , Achieve Life Sciences  ( NASDAQ:ACHV ) ", "url": "https://www.benzinga.com/news/earnings/23/12/36201828/dow-jumps-over-100-points-oracle-posts-mixed-q2-results", "time_published": "20231212T165848", "authors": ["Avi Kapoor"], "summary": "U.S. stocks turned higher midway through trading, with the Dow Jones index gaining more than 100 points on Tuesday. The Dow traded up 0.35% to 36,533.63 while the NASDAQ rose 0.16% to 14,455.15 The S&P 500 also rose, gaining, 0.10% to 4,627.04 Industrials shares rose by 0.3% on Tuesday.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/12/12/image39.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.918141"}, {"topic": "Earnings", "relevance_score": "0.614606"}, {"topic": "Real Estate & Construction", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.177111, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "HCDI", "relevance_score": "0.189175", "ticker_sentiment_score": "0.051066", "ticker_sentiment_label": "Neutral"}, {"ticker": "GGE", "relevance_score": "0.126784", "ticker_sentiment_score": "-0.111372", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.063594", "ticker_sentiment_score": "0.287715", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ADTX", "relevance_score": "0.189175", "ticker_sentiment_score": "0.261711", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ORCL", "relevance_score": "0.189175", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ACHV", "relevance_score": "0.250386", "ticker_sentiment_score": "0.079725", "ticker_sentiment_label": "Neutral"}, {"ticker": "ICVX", "relevance_score": "0.189175", "ticker_sentiment_score": "0.417542", "ticker_sentiment_label": "Bullish"}, {"ticker": "CCCC", "relevance_score": "0.189175", "ticker_sentiment_score": "0.148896", "ticker_sentiment_label": "Neutral"}]}, {"title": "BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Eagle Bulk Shipping Inc.  ( NYSE - EGLE ) , Icosavax, Inc.  ( Nasdaq - ICVX ) , Evofem Biosciences, Inc.  ( OTC - EVFM ) , CapStar Financial Holdings, Inc.  ( Nasdaq - CSTR ) ", "url": "https://www.benzinga.com/pressreleases/23/12/g36201659/brodsky-smith-shareholder-update-notifying-investors-of-the-following-investigations-eagle-bulk-sh", "time_published": "20231212T164758", "authors": ["Globe Newswire"], "summary": "BALA CYNWYD, Pa., Dec. 12, 2023 ( GLOBE NEWSWIRE ) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( jbrodsky@brodskysmith.com ) or Marc Ackerman ( mackerman@brodskysmith.com ) at 855-576-4847.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.999862"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.858979"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.24098, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CSTR", "relevance_score": "0.191675", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ONB", "relevance_score": "0.128478", "ticker_sentiment_score": "0.189141", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.191675", "ticker_sentiment_score": "0.214742", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DSSMY", "relevance_score": "0.191675", "ticker_sentiment_score": "0.059038", "ticker_sentiment_label": "Neutral"}, {"ticker": "SBLK", "relevance_score": "0.128478", "ticker_sentiment_score": "0.141065", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADTX", "relevance_score": "0.314017", "ticker_sentiment_score": "0.223355", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "EGLE", "relevance_score": "0.064449", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ICVX", "relevance_score": "0.191675", "ticker_sentiment_score": "0.200566", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Pediatric Health Care Products and Services Market Set to Surge at 6.9% CAGR, to Reach USD 173.5 billion by 2031| Transparency Market Research, Inc.", "url": "https://www.benzinga.com/pressreleases/23/12/g36201229/pediatric-health-care-products-and-services-market-set-to-surge-at-6-9-cagr-to-reach-usd-173-5-bil", "time_published": "20231212T163000", "authors": ["Globe Newswire"], "summary": "Wilmington, Delaware, United States, Dec. 12, 2023 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - The market for pediatric health care products and services is projected to thrive with an anticipated CAGR of 6.9% between 2023 and 2031.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.414749, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "NVS", "relevance_score": "0.067064", "ticker_sentiment_score": "0.230447", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.033562", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.033562", "ticker_sentiment_score": "0.195607", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HCSG", "relevance_score": "0.033562", "ticker_sentiment_score": "0.269025", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.067064", "ticker_sentiment_score": "0.146108", "ticker_sentiment_label": "Neutral"}]}, {"title": "Analyzing AstraZeneca In Comparison To Competitors In Pharmaceuticals Industry - AstraZeneca  ( NASDAQ:AZN ) ", "url": "https://www.benzinga.com/news/23/12/36200388/analyzing-astrazeneca-in-comparison-to-competitors-in-pharmaceuticals-industry", "time_published": "20231212T160054", "authors": ["Benzinga Insights"], "summary": "Amidst today's fast-paced and highly competitive business environment, it is crucial for investors and industry enthusiasts to conduct comprehensive company evaluations. In this article, we will delve into an extensive industry comparison, evaluating AstraZeneca AZN in comparison to its major ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.99737"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.723405"}], "overall_sentiment_score": 0.146159, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "PTAIF", "relevance_score": "0.06179", "ticker_sentiment_score": "0.018067", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.412619", "ticker_sentiment_score": "0.182368", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Empowering South East Asia: Jitterbit Partners with Lancia Consult to Drive Digital Innovation, Automation and AI Connectivity in the Region", "url": "https://markets.businessinsider.com/news/stocks/empowering-south-east-asia-jitterbit-partners-with-lancia-consult-to-drive-digital-innovation-automation-and-ai-connectivity-in-the-region-1032893213", "time_published": "20231212T152747", "authors": ["Plentisoft"], "summary": "Melbourne, Australia, December 11th 2023 - Jitterbit, a global leader in empowering transformation through automation, today announced its strategic partnership with Lancia Consult, a global consultancy firm specializing in digital transformation solutions.", "banner_image": "https://storage.googleapis.com/mmstudio-images/gallery/featured/pr-empowering-south-eas-1702305304.jpeg", "source": "Business Insider", "category_within_source": "RSS", "source_domain": "markets.businessinsider.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.409108, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.050572", "ticker_sentiment_score": "0.210383", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BRDCF", "relevance_score": "0.050572", "ticker_sentiment_score": "0.210383", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Blue Bird Posts Upbeat Results, Joins Oil-Dri Corporation of America, Eagle Bulk Shipping And Other Big Stocks Moving Higher On Tuesday - Bitfarms  ( NASDAQ:BITF ) , Digital Turbine  ( NASDAQ:APPS ) ", "url": "https://www.benzinga.com/news/23/12/36199022/blue-bird-posts-upbeat-results-joins-oil-dri-corporation-of-america-eagle-bulk-shipping-and-other-bi", "time_published": "20231212T151310", "authors": ["Avi Kapoor"], "summary": "U.S. stocks traded higher, with the Dow Jones index gaining around 50 points on Tuesday. Shares of Blue Bird Corporation BLBD shares rose sharply during Tuesday's session after the company reported better-than-expected financial results for its fourth quarter and increased its FY24 revenue forecast.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/12/12/blue_bird_-_logo.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.142857"}, {"topic": "Energy & Transportation", "relevance_score": "0.142857"}, {"topic": "Technology", "relevance_score": "0.142857"}, {"topic": "Finance", "relevance_score": "0.142857"}, {"topic": "Retail & Wholesale", "relevance_score": "0.142857"}, {"topic": "Manufacturing", "relevance_score": "0.142857"}, {"topic": "Earnings", "relevance_score": "0.744043"}, {"topic": "Real Estate & Construction", "relevance_score": "0.142857"}], "overall_sentiment_score": 0.278476, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BRP", "relevance_score": "0.310843", "ticker_sentiment_score": "0.661716", "ticker_sentiment_label": "Bullish"}, {"ticker": "BITF", "relevance_score": "0.210274", "ticker_sentiment_score": "0.523303", "ticker_sentiment_label": "Bullish"}, {"ticker": "GOTU", "relevance_score": "0.210274", "ticker_sentiment_score": "0.523303", "ticker_sentiment_label": "Bullish"}, {"ticker": "IRON", "relevance_score": "0.210274", "ticker_sentiment_score": "0.150965", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "INVZ", "relevance_score": "0.210274", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "APPS", "relevance_score": "0.210274", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ICG", "relevance_score": "0.210274", "ticker_sentiment_score": "-0.380145", "ticker_sentiment_label": "Bearish"}, {"ticker": "ODC", "relevance_score": "0.210274", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MOR", "relevance_score": "0.210274", "ticker_sentiment_score": "-0.067373", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLBD", "relevance_score": "0.406197", "ticker_sentiment_score": "0.572562", "ticker_sentiment_label": "Bullish"}, {"ticker": "AZN", "relevance_score": "0.10607", "ticker_sentiment_score": "-0.002195", "ticker_sentiment_label": "Neutral"}, {"ticker": "CAVA", "relevance_score": "0.210274", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "EGLE", "relevance_score": "0.310843", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ICVX", "relevance_score": "0.406197", "ticker_sentiment_score": "-0.005527", "ticker_sentiment_label": "Neutral"}, {"ticker": "ML", "relevance_score": "0.210274", "ticker_sentiment_score": "0.523303", "ticker_sentiment_label": "Bullish"}, {"ticker": "SAVA", "relevance_score": "0.210274", "ticker_sentiment_score": "0.523303", "ticker_sentiment_label": "Bullish"}]}, {"title": "Health Care Company AstraZeneca Announces Acquisition of Icosavax - AstraZeneca  ( NASDAQ:AZN ) , Icosavax  ( NASDAQ:ICVX ) ", "url": "https://www.benzinga.com/m-a/23/12/36198956/health-care-company-astrazeneca-announces-acquisition-of-icosavax", "time_published": "20231212T151005", "authors": ["Benzinga Insights"], "summary": "AstraZeneca AZN has announced an acquisition of Icosavax ICVX that is expected to be completed in Q1 of 2024. Under the terms of the agreement, AstraZeneca has agreed to give Icosavax $838.00 million in cash in exchange for ICVX stock.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Mergers & Acquisitions", "relevance_score": "0.576289"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.145882, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "PTAIF", "relevance_score": "0.149656", "ticker_sentiment_score": "-0.050109", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.549581", "ticker_sentiment_score": "0.147303", "ticker_sentiment_label": "Neutral"}, {"ticker": "ICVX", "relevance_score": "0.654522", "ticker_sentiment_score": "0.415322", "ticker_sentiment_label": "Bullish"}]}, {"title": "Oracle's Falling, but You Won't Want to Miss This Soaring Biotech Stock", "url": "https://www.fool.com/investing/2023/12/12/oracles-falling-but-you-wont-want-to-miss-this-soa/", "time_published": "20231212T143725", "authors": ["Dan Caplinger"], "summary": "Tuesday brought favorable inflation data, and bullish investors are looking for stock winners.", "banner_image": "https://g.foolcdn.com/editorial/images/758014/biotech-scientist-microscope-getty.jpg", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.769861"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.962106"}, {"topic": "Earnings", "relevance_score": "0.839681"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.297532, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.254973", "ticker_sentiment_score": "0.356298", "ticker_sentiment_label": "Bullish"}, {"ticker": "ORCL", "relevance_score": "0.315628", "ticker_sentiment_score": "0.220958", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ICVX", "relevance_score": "0.583787", "ticker_sentiment_score": "0.481759", "ticker_sentiment_label": "Bullish"}]}, {"title": "AstraZeneca  ( AZN )  to Acquire Vaccine Maker Icosavax for $1.1B", "url": "https://www.zacks.com/stock/news/2196741/astrazeneca-azn-to-acquire-vaccine-maker-icosavax-for-11b", "time_published": "20231212T143300", "authors": ["Zacks Equity Research"], "summary": "AstraZeneca (AZN) is set to acquire clinical-stage biopharmaceutical company, Icosavax, for a total deal value of up to $1.1 billion.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/e5/1416.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.769861"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.279245, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.642977", "ticker_sentiment_score": "0.410963", "ticker_sentiment_label": "Bullish"}, {"ticker": "ICVX", "relevance_score": "0.207571", "ticker_sentiment_score": "0.138568", "ticker_sentiment_label": "Neutral"}, {"ticker": "PBYI", "relevance_score": "0.156461", "ticker_sentiment_score": "0.160254", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SNY", "relevance_score": "0.257805", "ticker_sentiment_score": "0.262188", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Daily: How AI Is Making The Job Market More Competitive", "url": "https://www.forbes.com/sites/daniellechemtob/2023/12/12/forbes-daily-how-ai-is-making-the-job-market-more-competitive/", "time_published": "20231212T130831", "authors": ["Danielle Chemtob"], "summary": "Forbes Daily: How AI platforms like ChatGPT is affecting job market Forbes ...", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/65785a561b1a7826a8f96a2f/0x0.jpg?format=jpg&crop=3202,1803,x0,y83,safe&height=900&width=1600&fit=bounds", "source": "Forbes", "category_within_source": "n/a", "source_domain": "www.forbes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.108179"}, {"topic": "Technology", "relevance_score": "0.25"}], "overall_sentiment_score": 0.104482, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MSFT", "relevance_score": "0.022368", "ticker_sentiment_score": "0.051256", "ticker_sentiment_label": "Neutral"}, {"ticker": "NFLX", "relevance_score": "0.067033", "ticker_sentiment_score": "-0.035051", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOOG", "relevance_score": "0.022368", "ticker_sentiment_score": "0.06289", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.022368", "ticker_sentiment_score": "0.045808", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.044718", "ticker_sentiment_score": "0.044521", "ticker_sentiment_label": "Neutral"}, {"ticker": "DSSMY", "relevance_score": "0.022368", "ticker_sentiment_score": "0.111565", "ticker_sentiment_label": "Neutral"}, {"ticker": "M", "relevance_score": "0.067033", "ticker_sentiment_score": "0.048196", "ticker_sentiment_label": "Neutral"}, {"ticker": "ICVX", "relevance_score": "0.044718", "ticker_sentiment_score": "0.044521", "ticker_sentiment_label": "Neutral"}, {"ticker": "NSRGF", "relevance_score": "0.022368", "ticker_sentiment_score": "-0.135063", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why Icosavax Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket - Assembly Biosciences  ( NASDAQ:ASMB ) , Achieve Life Sciences  ( NASDAQ:ACHV ) ", "url": "https://www.benzinga.com/news/23/12/36194643/why-icosavax-shares-are-trading-higher-by-around-45-here-are-20-stocks-moving-premarket", "time_published": "20231212T130008", "authors": ["Avi Kapoor"], "summary": "Shares of Icosavax, Inc. ICVX rose sharply in pre-market trading after AstraZeneca announced plans to buy Icosavax in a deal valued at up to $1.1 billion. Icosavax also reported topline interim Phase 2 results for combination VLP vaccine candidate IVX-A12 against RSV and hMPV in older adults.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/12/12/image34.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.865346"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Real Estate & Construction", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}], "overall_sentiment_score": 0.085257, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "HCDI", "relevance_score": "0.232069", "ticker_sentiment_score": "-0.174061", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "XCUR", "relevance_score": "0.155954", "ticker_sentiment_score": "-0.057391", "ticker_sentiment_label": "Neutral"}, {"ticker": "INAB", "relevance_score": "0.078354", "ticker_sentiment_score": "0.092273", "ticker_sentiment_label": "Neutral"}, {"ticker": "CNTB", "relevance_score": "0.232069", "ticker_sentiment_score": "0.043077", "ticker_sentiment_label": "Neutral"}, {"ticker": "ONTX", "relevance_score": "0.155954", "ticker_sentiment_score": "0.143868", "ticker_sentiment_label": "Neutral"}, {"ticker": "HRYU", "relevance_score": "0.155954", "ticker_sentiment_score": "0.176959", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "IONM", "relevance_score": "0.155954", "ticker_sentiment_score": "-0.057391", "ticker_sentiment_label": "Neutral"}, {"ticker": "ORCL", "relevance_score": "0.232069", "ticker_sentiment_score": "-0.155597", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "ACHV", "relevance_score": "0.232069", "ticker_sentiment_score": "-0.158367", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "KAVL", "relevance_score": "0.155954", "ticker_sentiment_score": "0.135185", "ticker_sentiment_label": "Neutral"}, {"ticker": "WULF", "relevance_score": "0.155954", "ticker_sentiment_score": "0.239698", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BLBD", "relevance_score": "0.155954", "ticker_sentiment_score": "0.333386", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.078354", "ticker_sentiment_score": "0.109398", "ticker_sentiment_label": "Neutral"}, {"ticker": "HPCO", "relevance_score": "0.155954", "ticker_sentiment_score": "-0.087203", "ticker_sentiment_label": "Neutral"}, {"ticker": "ASMB", "relevance_score": "0.155954", "ticker_sentiment_score": "-0.387681", "ticker_sentiment_label": "Bearish"}, {"ticker": "ATXI", "relevance_score": "0.155954", "ticker_sentiment_score": "0.084576", "ticker_sentiment_label": "Neutral"}, {"ticker": "BRSH", "relevance_score": "0.155954", "ticker_sentiment_score": "0.341018", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TENX", "relevance_score": "0.155954", "ticker_sentiment_score": "0.255", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ICVX", "relevance_score": "0.377142", "ticker_sentiment_score": "0.3247", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CMND", "relevance_score": "0.232069", "ticker_sentiment_score": "-0.247013", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "CRYPTO:PAY", "relevance_score": "0.078354", "ticker_sentiment_score": "0.199374", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Here's what hit the Magnificent 7 stocks, and why the selling may continue.", "url": "https://www.marketwatch.com/story/heres-what-hit-the-magnificent-7-stocks-and-why-the-selling-may-continue-dde654b1", "time_published": "20231212T115100", "authors": ["Barbara Kollmeyer"], "summary": "A Nasdaq rebalancing may be behind Monday's collective pullback for the Magnificent Seven stocks.", "banner_image": "https://images.mktw.net/im-87817916?width=700&height=528", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "Economy - Monetary", "relevance_score": "0.451494"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.796627"}, {"topic": "Manufacturing", "relevance_score": "0.2"}], "overall_sentiment_score": 0.0409, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MAT", "relevance_score": "0.105372", "ticker_sentiment_score": "-0.032555", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.157483", "ticker_sentiment_score": "0.111917", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.157483", "ticker_sentiment_score": "0.111917", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.052801", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ORCL", "relevance_score": "0.105372", "ticker_sentiment_score": "-0.267216", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "MSFT", "relevance_score": "0.157483", "ticker_sentiment_score": "0.111917", "ticker_sentiment_label": "Neutral"}, {"ticker": "BCS", "relevance_score": "0.105372", "ticker_sentiment_score": "0.083999", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLBD", "relevance_score": "0.105372", "ticker_sentiment_score": "0.455379", "ticker_sentiment_label": "Bullish"}, {"ticker": "TSLA", "relevance_score": "0.157483", "ticker_sentiment_score": "0.111917", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.105372", "ticker_sentiment_score": "0.093844", "ticker_sentiment_label": "Neutral"}, {"ticker": "HAS", "relevance_score": "0.052801", "ticker_sentiment_score": "-0.029014", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.157483", "ticker_sentiment_score": "0.111917", "ticker_sentiment_label": "Neutral"}, {"ticker": "ICVX", "relevance_score": "0.157483", "ticker_sentiment_score": "0.113689", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:JPY", "relevance_score": "0.052801", "ticker_sentiment_score": "0.152029", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FOREX:USD", "relevance_score": "0.052801", "ticker_sentiment_score": "0.152029", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 billion deal", "url": "https://www.financialexpress.com/healthcare/pharma-healthcare/astrazeneca-buys-respiratory-vaccine-developer-icosavax-in-1-1-billion-deal/3336616/", "time_published": "20231212T105737", "authors": ["Health Desk"], "summary": "Pharma major AstraZeneca on Tuesday announced that it had agreed to buy respiratory syncytial virus ( RSV ) vaccine developer Icosavax in a deal valued at up to $1.1 billion. Icosavax is developing a combination vaccine candidate targeting RSV and human metapneumovirus ( hMPV ) .", "banner_image": "https://www.financialexpress.com/wp-content/uploads/2023/12/AstraZeneca-covid-19-drug.jpg", "source": "The Financial Express", "category_within_source": "n/a", "source_domain": "www.financialexpress.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.183402, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.543004", "ticker_sentiment_score": "0.261223", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ICVX", "relevance_score": "0.464633", "ticker_sentiment_score": "0.265519", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.098659", "ticker_sentiment_score": "0.237441", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SNY", "relevance_score": "0.098659", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why Respiratory Vaccine Player Icosavax  ( ICVX )  Shares Are Surging Today - AstraZeneca  ( NASDAQ:AZN ) ", "url": "https://www.benzinga.com/general/biotech/23/12/36191238/astrazeneca-to-acquire-us-respiratory-vaccine-player-icosavax-for-over-800m", "time_published": "20231212T105542", "authors": ["Vandana Singh"], "summary": "AstraZeneca Plc AZN has agreed to acquire Icosavax Inc ICVX at $15.00 per share in cash at closing, plus a non-tradable contingent value right to receive up to $5.00 in cash, payable upon achievement of specified regulatory and net sales milestones.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/12/12/azn_co.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.186748, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.447528", "ticker_sentiment_score": "0.41745", "ticker_sentiment_label": "Bullish"}, {"ticker": "ICVX", "relevance_score": "0.542261", "ticker_sentiment_score": "0.24344", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "AstraZeneca Will Acquire RSV Vaccine Developer Icosavax For $1.1 Billion", "url": "https://www.forbes.com/sites/siladityaray/2023/12/12/astrazeneca-will-acquire-rsv-vaccine-developer-icosavax-for-11-billion/", "time_published": "20231212T092932", "authors": ["Siladitya Ray"], "summary": "AstraZeneca has agreed to acquire U.S.-based vaccine developer Icosavax for $1.1 billion, the companies announced Tuesday, to gain access to experimental vaccines targeting common respiratory disease-causing viruses.", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/657826d4f5be72c2cf22d9ce/0x0.jpg?format=jpg&crop=3211,1808,x0,y271,safe&height=900&width=1600&fit=bounds", "source": "Forbes", "category_within_source": "n/a", "source_domain": "www.forbes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.252238, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.48268", "ticker_sentiment_score": "0.324894", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ICVX", "relevance_score": "0.170878", "ticker_sentiment_score": "0.246091", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Icosavax, Inc. Announces Agreement to be Acquired by AstraZeneca", "url": "https://www.globenewswire.com/news-release/2023/12/12/2794422/0/en/Icosavax-Inc-Announces-Agreement-to-be-Acquired-by-AstraZeneca.html", "time_published": "20231212T070500", "authors": ["Inc.", "Icosavax"], "summary": "Icosavax, Inc. Announces Agreement to be Acquired by ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/baa98495-ae4e-46a7-927a-18191eef9c59", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Mergers & Acquisitions", "relevance_score": "0.999682"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.986714"}], "overall_sentiment_score": 0.187074, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.260559", "ticker_sentiment_score": "0.137173", "ticker_sentiment_label": "Neutral"}, {"ticker": "ICVX", "relevance_score": "0.515103", "ticker_sentiment_score": "0.276541", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Icosavax, Inc. Announces Agreement to be Acquired by AstraZeneca - Icosavax  ( NASDAQ:ICVX ) ", "url": "https://www.benzinga.com/pressreleases/23/12/g36190259/icosavax-inc-announces-agreement-to-be-acquired-by-astrazeneca", "time_published": "20231212T070500", "authors": ["Globe Newswire"], "summary": "- Icosavax stockholders to receive $15.00 per share in cash at closing plus non-tradeable contingent value right ( CVR ) of up to $5.00 per share - - Representing a total equity value of up to $1.1 billion including the CVR - SEATTLE, Dec. 11, 2023 ( GLOBE NEWSWIRE ) -- Icosavax, Inc.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Mergers & Acquisitions", "relevance_score": "0.999682"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.99393"}], "overall_sentiment_score": 0.182286, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.257532", "ticker_sentiment_score": "0.131938", "ticker_sentiment_label": "Neutral"}, {"ticker": "ICVX", "relevance_score": "0.509826", "ticker_sentiment_score": "0.268766", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "AstraZeneca to buy RSV vaccine maker Icosavax for $1.1 bln", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/astrazeneca-buy-rsv-vaccine-maker-icosavax-11-bln-2023-12-12/", "time_published": "20231212T070034", "authors": ["Reuters"], "summary": "AstraZeneca to buy RSV vaccine maker Icosavax for ...", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/QHVYHCIPSNK4DGFXXPVN3BZEFI.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.322248, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.776097", "ticker_sentiment_score": "0.226654", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ICVX", "relevance_score": "0.582526", "ticker_sentiment_score": "0.66859", "ticker_sentiment_label": "Bullish"}, {"ticker": "GERN", "relevance_score": "0.31482", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "McKesson  ( MCK )  Announces Availability of FDA-Approved Drug", "url": "https://www.zacks.com/stock/news/2196237/mckesson-mck-announces-availability-of-fda-approved-drug", "time_published": "20231211T152400", "authors": ["Zacks Equity Research"], "summary": "The availability of the FDA-approved drug via McKesson's (MCK) independent specialty pharmacy is expected to give patients more treatment options for desmoid tumors.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/08/595.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.614606"}], "overall_sentiment_score": 0.192248, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ITGR", "relevance_score": "0.262522", "ticker_sentiment_score": "0.094382", "ticker_sentiment_label": "Neutral"}, {"ticker": "MCK", "relevance_score": "0.597963", "ticker_sentiment_score": "0.059973", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.066784", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DVA", "relevance_score": "0.198493", "ticker_sentiment_score": "0.145992", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.198493", "ticker_sentiment_score": "0.06135", "ticker_sentiment_label": "Neutral"}, {"ticker": "SWTX", "relevance_score": "0.066784", "ticker_sentiment_score": "-0.05709", "ticker_sentiment_label": "Neutral"}]}, {"title": "Neurology Focused Pasithea Therapeutics Stock Soars Over 150% Today - Here's Why - Pasithea Therapeutics  ( NASDAQ:KTTA ) ", "url": "https://www.benzinga.com/general/biotech/23/12/36175794/neurology-focused-pasithea-therapeutics-stock-soars-over-150-today-heres-why", "time_published": "20231211T140535", "authors": ["Vandana Singh"], "summary": "Pasithea Therapeutics Corp KTTA announced preclinical results from two in vivo studies evaluating the antitumor efficacy of PAS-004 in NRAS mutation cancer xenograft models. In the first study, PAS-004 exhibited dose-dependent antitumor efficacy in the lung cancer NCI-H1299 cell-line-derived ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/12/11/ktta_0.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": -0.004796, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.340915", "ticker_sentiment_score": "0.232118", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "KTTA", "relevance_score": "0.491878", "ticker_sentiment_score": "-0.156479", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "PFE", "relevance_score": "0.340915", "ticker_sentiment_score": "0.232118", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "AstraZeneca's Investigational Drug Shows Durable Clinical Benefit In Patients With Rare Blood Disease - AstraZeneca  ( NASDAQ:AZN ) ", "url": "https://www.benzinga.com/general/biotech/23/12/36175287/astrazenecas-investigational-drug-shows-durable-clinical-benefit-in-patients-with-rare-blood-dise", "time_published": "20231211T135811", "authors": ["Vandana Singh"], "summary": "AstraZeneca Plc AZN released results from the 24-week and long-term extension ( LTE ) period of the ALPHA Phase 3 trial of danicopan as an add-on to C5 inhibitor therapy Ultomiris or Soliris in patients with paroxysmal nocturnal hemoglobinuria ( PNH ) who experience clinically significant ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/12/11/azn_co.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.177987, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.362505", "ticker_sentiment_score": "0.127537", "ticker_sentiment_label": "Neutral"}]}, {"title": "ChatGPT passes neurology exam for first time", "url": "https://cointelegraph.com/news/chatgpt-passes-neurology-exam-for-first-time", "time_published": "20231211T135753", "authors": ["David Attlee"], "summary": "LLM 4.0 from OpenAI answered 85% of the American Board of Psychiatry and Neurology's questions correctly, implying potentially \"significant\" future uses for the technology.", "banner_image": "https://images.cointelegraph.com/cdn-cgi/image/format=auto,onerror=redirect,quality=90,width=1200/https://s3.cointelegraph.com/uploads/2023-12/dd727329-de27-41ad-bf10-76300da5a30f.jpg", "source": "Cointelegraph", "category_within_source": "n/a", "source_domain": "cointelegraph.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.002412, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.120431", "ticker_sentiment_score": "-0.100438", "ticker_sentiment_label": "Neutral"}]}, {"title": "Live from ASH 2023 | Ascentage Pharma Presents Updated Data from US Study of Olverembatinib, Further Validating Encouraging Efficacy in Patients Resistant to Ponatinib or Asciminib", "url": "https://www.prnewswire.com/news-releases/live-from-ash-2023--ascentage-pharma-presents-updated-data-from-us-study-of-olverembatinib-further-validating-encouraging-efficacy-in-patients-resistant-to-ponatinib-or-asciminib-302011011.html", "time_published": "20231211T053000", "authors": ["Ascentage Pharma"], "summary": "Live from ASH 2023 | Ascentage Pharma Presents Updated Data from US Study of Olverembatinib, Further Validating ... PR ...", "banner_image": "https://mma.prnewswire.com/media/891219/Ascentage_Pharma_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}], "overall_sentiment_score": 0.040567, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.022859", "ticker_sentiment_score": "0.07732", "ticker_sentiment_label": "Neutral"}, {"ticker": "ASPHF", "relevance_score": "0.269033", "ticker_sentiment_score": "0.089392", "ticker_sentiment_label": "Neutral"}, {"ticker": "UBX", "relevance_score": "0.022859", "ticker_sentiment_score": "0.07732", "ticker_sentiment_label": "Neutral"}]}, {"title": "Live from ASH 2023 | Ascentage Pharma Releases Encouraging Long-Term Data of Bcl-2 Inhibitor Lisaftoclax in R/R CLL, Including an ORR of 73.3%", "url": "https://www.prnewswire.com/news-releases/live-from-ash-2023--ascentage-pharma-releases-encouraging-long-term-data-of-bcl-2-inhibitor-lisaftoclax-in-rr-cll-including-an-orr-of-73-3-302010995.html", "time_published": "20231211T051400", "authors": ["Ascentage Pharma"], "summary": "Live from ASH 2023 | Ascentage Pharma Releases Encouraging Long-Term Data of Bcl-2 Inhibitor Lisaftoclax in R/R ... PR ...", "banner_image": "https://mma.prnewswire.com/media/891219/Ascentage_Pharma_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}], "overall_sentiment_score": 0.095291, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.024956", "ticker_sentiment_score": "0.078105", "ticker_sentiment_label": "Neutral"}, {"ticker": "ASPHF", "relevance_score": "0.269235", "ticker_sentiment_score": "0.099775", "ticker_sentiment_label": "Neutral"}, {"ticker": "UBX", "relevance_score": "0.024956", "ticker_sentiment_score": "0.078105", "ticker_sentiment_label": "Neutral"}]}, {"title": "Live from ASH 2023 | Ascentage Pharma Releases the First Dataset of Bcl-2 Inhibitor Lisaftoclax in Patients with R/R MM, Demonstrating Encouraging ORR and VGPR", "url": "https://www.prnewswire.com/news-releases/live-from-ash-2023--ascentage-pharma-releases-the-first-dataset-of-bcl-2-inhibitor-lisaftoclax-in-patients-with-rr-mm-demonstrating-encouraging-orr-and-vgpr-302010980.html", "time_published": "20231211T045600", "authors": ["Ascentage Pharma"], "summary": "Live from ASH 2023 | Ascentage Pharma Releases the First Dataset of Bcl-2 Inhibitor Lisaftoclax in Patients with R/R ... PR ...", "banner_image": "https://mma.prnewswire.com/media/891219/Ascentage_Pharma_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}], "overall_sentiment_score": 0.082756, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.026155", "ticker_sentiment_score": "0.078529", "ticker_sentiment_label": "Neutral"}, {"ticker": "ASPHF", "relevance_score": "0.281643", "ticker_sentiment_score": "0.069628", "ticker_sentiment_label": "Neutral"}, {"ticker": "UBX", "relevance_score": "0.026155", "ticker_sentiment_score": "0.078529", "ticker_sentiment_label": "Neutral"}]}, {"title": "AstraZeneca Just Joined the AI Drug Development Craze, but Is It a Buy in 2024?", "url": "https://www.fool.com/investing/2023/12/10/astrazeneca-just-joined-the-ai-drug-development/", "time_published": "20231210T134500", "authors": ["Alex Carchidi"], "summary": "It'll take a few years for its latest moves to pay off, assuming they do.", "banner_image": "https://g.foolcdn.com/editorial/images/757523/two-investors-meet-and-discuss.jpg", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.228775, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ABSI", "relevance_score": "0.110717", "ticker_sentiment_score": "0.077865", "ticker_sentiment_label": "Neutral"}, {"ticker": "SDGR", "relevance_score": "0.055492", "ticker_sentiment_score": "0.29", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.272181", "ticker_sentiment_score": "0.100053", "ticker_sentiment_label": "Neutral"}, {"ticker": "ILMN", "relevance_score": "0.055492", "ticker_sentiment_score": "0.008996", "ticker_sentiment_label": "Neutral"}]}, {"title": "Is Now the Right Time to Buy AstraZeneca Stock?", "url": "https://www.fool.com/investing/2023/12/10/is-now-the-right-time-to-buy-astrazeneca-stock/", "time_published": "20231210T121500", "authors": ["Alex Carchidi"], "summary": "The pharmaceutical giant is making strident moves to compete in hot markets, but it's not a cheap stock.", "banner_image": "https://g.foolcdn.com/editorial/images/757516/two-investors-consult-papers-and-laptop.jpg", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.744043"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.996023"}], "overall_sentiment_score": 0.221013, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.351985", "ticker_sentiment_score": "0.296111", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CLLS", "relevance_score": "0.051999", "ticker_sentiment_score": "0.060995", "ticker_sentiment_label": "Neutral"}]}, {"title": "FibroGen Presents Data from Phase 3 MATTERHORN Trial of Roxadustat in Patients with Anemia of Lower Risk Transfusion-Dependent Myelodysplastic Syndromes at American Society of Hematology Annual Meeting - FibroGen  ( NASDAQ:FGEN ) ", "url": "https://www.benzinga.com/pressreleases/23/12/g36167413/fibrogen-presents-data-from-phase-3-matterhorn-trial-of-roxadustat-in-patients-with-anemia-of-lowe", "time_published": "20231209T220200", "authors": ["Globe Newswire"], "summary": "A post hoc analysis of patients with higher transfusion burden at baseline showed a larger percentage of patients achieved transfusion independence \u2265 56 days with roxadustat vs. placebo ( 36.1% vs 11.5%; p=0.047\u01c2 ) . Dr. Moshe Mittelman's presentation was selected for the \"2024 Highlights of ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.075794, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.067823", "ticker_sentiment_score": "0.00702", "ticker_sentiment_label": "Neutral"}, {"ticker": "FGEN", "relevance_score": "0.201523", "ticker_sentiment_score": "0.10488", "ticker_sentiment_label": "Neutral"}]}, {"title": "FibroGen Presents Data from Phase 3 MATTERHORN Trial of Roxadustat in Patients with Anemia of Lower Risk Transfusion-Dependent Myelodysplastic Syndromes at American Society of Hematology Annual Meeting", "url": "https://www.globenewswire.com/news-release/2023/12/09/2793446/33525/en/FibroGen-Presents-Data-from-Phase-3-MATTERHORN-Trial-of-Roxadustat-in-Patients-with-Anemia-of-Lower-Risk-Transfusion-Dependent-Myelodysplastic-Syndromes-at-American-Society-of-Hema.html", "time_published": "20231209T220200", "authors": ["Inc.", "FibroGen"], "summary": "please call Meichiel Keenan@650-219-6482 with any questions.", "banner_image": "https://ml.globenewswire.com/Resource/Download/55a392f2-81c7-4e85-a884-d9be38871c5c", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.08289, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.058615", "ticker_sentiment_score": "0.006999", "ticker_sentiment_label": "Neutral"}, {"ticker": "FGEN", "relevance_score": "0.231332", "ticker_sentiment_score": "0.097575", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why Cassava Sciences Stock Soared Today", "url": "https://www.fool.com/investing/2023/12/08/why-cassava-sciences-stock-soared-today/", "time_published": "20231209T003108", "authors": ["Eric Volkman"], "summary": "Investors cheered the arrival of a trio of new board members.", "banner_image": "https://g.foolcdn.com/editorial/images/757733/two-people-seated-at-a-lab-desk-featuring-a-pc-screen-and-microscope.jpg", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Real Estate & Construction", "relevance_score": "0.5"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}], "overall_sentiment_score": 0.047431, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "PTCT", "relevance_score": "0.120431", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PWP", "relevance_score": "0.120431", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.120431", "ticker_sentiment_score": "-0.065597", "ticker_sentiment_label": "Neutral"}, {"ticker": "SAVA", "relevance_score": "0.238133", "ticker_sentiment_score": "0.226148", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Merck's  ( MRK )  Keytruda-Lynparza Combo Fails Lung Cancer Study", "url": "https://www.zacks.com/stock/news/2195640/mercks-mrk-keytruda-lynparza-combo-fails-lung-cancer-study", "time_published": "20231208T164400", "authors": ["Zacks Equity Research"], "summary": "After a late-stage study fails to show any improvement in its primary endpoints, Merck (MRK) decides to stop evaluating the Keytruda-Lynparza combination in metastatic squamous NSCLC.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.96136"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.062494, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.24289", "ticker_sentiment_score": "-0.094988", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.18343", "ticker_sentiment_score": "0.129012", "ticker_sentiment_label": "Neutral"}, {"ticker": "CTMX", "relevance_score": "0.300946", "ticker_sentiment_score": "0.077697", "ticker_sentiment_label": "Neutral"}]}, {"title": "Active Pharmaceutical Ingredients Market to Surpass $372.4 Billion, Globally, by 2030 at 6.8% CAGR: Coherent Market Insights  ( CMI ) ", "url": "https://www.prnewswire.com/news-releases/active-pharmaceutical-ingredients-market-to-surpass-372-4-billion-globally-by-2030-at-6-8-cagr-coherent-market-insights-cmi-302010044.html", "time_published": "20231208T150100", "authors": ["Coherent Market Insights"], "summary": "Active Pharmaceutical Ingredients Market to Surpass $372.4 Billion, Globally, by 2030 at 6.8% CAGR: Coherent Market ... PR ...", "banner_image": "https://mma.prnewswire.com/media/902389/Coherent_Market_Insights_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.142757, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "EVKIF", "relevance_score": "0.021679", "ticker_sentiment_score": "-0.0702", "ticker_sentiment_label": "Neutral"}, {"ticker": "FSNUF", "relevance_score": "0.021679", "ticker_sentiment_score": "-0.0702", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.021679", "ticker_sentiment_score": "0.058937", "ticker_sentiment_label": "Neutral"}, {"ticker": "HKMPF", "relevance_score": "0.021679", "ticker_sentiment_score": "-0.0702", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVS", "relevance_score": "0.021679", "ticker_sentiment_score": "-0.0702", "ticker_sentiment_label": "Neutral"}, {"ticker": "PPCB", "relevance_score": "0.021679", "ticker_sentiment_score": "-0.19869", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "TEVA", "relevance_score": "0.043342", "ticker_sentiment_score": "0.049486", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMRX", "relevance_score": "0.021679", "ticker_sentiment_score": "-0.0702", "ticker_sentiment_label": "Neutral"}, {"ticker": "ENDPQ", "relevance_score": "0.021679", "ticker_sentiment_score": "-0.0702", "ticker_sentiment_label": "Neutral"}, {"ticker": "TARO", "relevance_score": "0.021679", "ticker_sentiment_score": "-0.0702", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.043342", "ticker_sentiment_score": "-0.088711", "ticker_sentiment_label": "Neutral"}]}, {"title": "Novo, Lilly rivals explore booming weight-loss drug market entry", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/novo-lilly-rivals-explore-booming-weight-loss-drug-market-entry-2023-12-08/", "time_published": "20231208T145800", "authors": ["Reuters"], "summary": "[1/2] An Eli Lilly and Company pharmaceutical manufacturing plant is pictured at 50 ImClone Drive in Branchburg, New Jersey, March 5, 2021. REUTERS/Mike Segar Acquire Licensing Rights", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/SM4NXZJ3KNLUVFGCLYVI3X4SGU.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.16254, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.067347", "ticker_sentiment_score": "0.107057", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.067347", "ticker_sentiment_score": "0.041069", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.067347", "ticker_sentiment_score": "-0.05009", "ticker_sentiment_label": "Neutral"}]}, {"title": "Red Biotechnology Market to Reach $1,513.22 Billion, Globally, by 2030 at 10.7% CAGR: Coherent Market Insights", "url": "https://www.prnewswire.com/news-releases/red-biotechnology-market-to-reach-1-513-22-billion-globally-by-2030-at-10-7-cagr-coherent-market-insights-302009313.html", "time_published": "20231208T071400", "authors": ["Coherent Market Insights"], "summary": "BURLINGAME, Calif., Dec. 8, 2023 /PRNewswire/ -- According to Coherent Market Insights, The global red biotechnology market was valued at US$ 742.80 Billion in 2023 and is forecast to reach a value of US$ 1,513.22 Billion by 2030 at a CAGR of 10.7% between 2023 and 2030.", "banner_image": "https://mma.prnewswire.com/media/902389/Coherent_Market_Insights_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": 0.196644, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BAYZF", "relevance_score": "0.028833", "ticker_sentiment_score": "0.001897", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.028833", "ticker_sentiment_score": "0.001897", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.028833", "ticker_sentiment_score": "0.001897", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALPMF", "relevance_score": "0.028833", "ticker_sentiment_score": "0.001897", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVS", "relevance_score": "0.028833", "ticker_sentiment_score": "0.001897", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.028833", "ticker_sentiment_score": "0.001897", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.028833", "ticker_sentiment_score": "0.001897", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.028833", "ticker_sentiment_score": "0.001897", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.028833", "ticker_sentiment_score": "0.001897", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.028833", "ticker_sentiment_score": "0.001897", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.028833", "ticker_sentiment_score": "0.001897", "ticker_sentiment_label": "Neutral"}, {"ticker": "TEVA", "relevance_score": "0.028833", "ticker_sentiment_score": "0.001897", "ticker_sentiment_label": "Neutral"}, {"ticker": "GSK", "relevance_score": "0.028833", "ticker_sentiment_score": "0.001897", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.028833", "ticker_sentiment_score": "0.001897", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.028833", "ticker_sentiment_score": "0.001897", "ticker_sentiment_label": "Neutral"}, {"ticker": "TAK", "relevance_score": "0.028833", "ticker_sentiment_score": "0.001897", "ticker_sentiment_label": "Neutral"}]}, {"title": "Sanofi  ( SNY )  Posts Upbeat Long-Term Outlook, Enhances R&D Focus", "url": "https://www.zacks.com/stock/news/2195113/sanofi-sny-posts-upbeat-long-term-outlook-enhances-rd-focus", "time_published": "20231207T201600", "authors": ["Zacks Equity Research"], "summary": "Sanofi (SNY) aims to generate annual sales of over 10 billion euros by 2030, driven by recently launched and potential new products. It intends to enhance R&D focus to become a market leader in immunology.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/8d/2080.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.890401"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.206543, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.184363", "ticker_sentiment_score": "0.075391", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.184363", "ticker_sentiment_score": "0.138235", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.56296", "ticker_sentiment_score": "0.273461", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Altimmune's stock pops as analysts see obesity-drug partnership potential", "url": "https://www.marketwatch.com/story/altimmune-shares-pop-as-analysts-see-obesity-drug-partnership-potential-524ea4f4", "time_published": "20231207T173300", "authors": ["Eleanor Laise"], "summary": "Altimmune shares have jumped this week as analysts see potential for the company to find a partner for its experimental weight-loss drug.", "banner_image": "https://images.mktw.net/im-520633/social", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.12606, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "EVR", "relevance_score": "0.09439", "ticker_sentiment_score": "-0.093546", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.187463", "ticker_sentiment_score": "0.055818", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.187463", "ticker_sentiment_score": "0.055818", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.187463", "ticker_sentiment_score": "0.055818", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALT", "relevance_score": "0.593484", "ticker_sentiment_score": "0.244327", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GS", "relevance_score": "0.09439", "ticker_sentiment_score": "0.199794", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.187463", "ticker_sentiment_score": "0.023005", "ticker_sentiment_label": "Neutral"}]}, {"title": "US urges RSV vaccine makers to meet winter demand, White House says", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/us-urges-rsv-vaccine-makers-meet-winter-demand-white-house-says-2023-12-07/", "time_published": "20231207T161600", "authors": ["Reuters"], "summary": "WASHINGTON, Dec 7 ( Reuters ) - U.S. officials met again with RSV vaccine manufacturers this week amid ongoing efforts to boost access to the shots, the White House said in a statement on Thursday after senior Biden administration officials met with the companies last week.", "banner_image": "https://www.reuters.com/pf/resources/images/reuters/reuters-default.webp?d=165", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.139409, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.428632", "ticker_sentiment_score": "0.170444", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SNY", "relevance_score": "0.428632", "ticker_sentiment_score": "0.170444", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "AbelZeta Pharma Announces Agreement with AstraZeneca to Co-Develop a novel Glypican 3  ( GPC3 )  Armored CAR-T Therapy in China", "url": "https://www.prnewswire.com/news-releases/abelzeta-pharma-announces-agreement-with-astrazeneca-to-co-develop-a-novel-glypican-3-gpc3-armored-car-t-therapy-in-china-302008822.html", "time_published": "20231207T130000", "authors": ["Inc.", "AbelZeta Pharma"], "summary": "AbelZeta Pharma Announces Agreement with AstraZeneca to Co-Develop a novel Glypican 3 ( GPC3 ) Armored CAR-T ... PR ...", "banner_image": "https://mma.prnewswire.com/media/2281429/AbelZeta_Pharma_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.034059, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.308246", "ticker_sentiment_score": "0.234552", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Pharma Industry on Alert as Biden Administration Explores Patent Seizure Powers - AstraZeneca  ( NASDAQ:AZN ) , Bristol-Myers Squibb  ( NYSE:BMY ) ", "url": "https://www.benzinga.com/general/biotech/23/12/36130073/pharma-industry-on-alert-as-biden-administration-explores-patent-seizure-powers", "time_published": "20231207T123314", "authors": ["Vandana Singh"], "summary": "The White House is endorsing a contentious power that permits the government to reclaim patents for specific high-cost medications.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/12/07/pills-image_by_steve_buissinne_from_pixabay.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.050084, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.235823", "ticker_sentiment_score": "0.203533", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BMY", "relevance_score": "0.235823", "ticker_sentiment_score": "0.203533", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "InnovationRx: Jewel In The Metaverse", "url": "https://www.forbes.com/sites/katiejennings/2023/12/06/innovationrx-jewel-in-the-metaverse/", "time_published": "20231206T220614", "authors": ["Alex Knapp"], "summary": "InnovationRx is your weekly digest of healthcare news. To get it in your inbox, subscribe here. hink back to 1995. Scrunchies. Beanie Babies. And Jewel's first album \"Pieces of You.\" The singer and songwriter, who also started a nonprofit to help at-risk youth, is now a digital health startup ...", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/6570ef7df9d3d00b413cc852/0x0.jpg?format=jpg&crop=3000,1687,x0,y0,safe&height=900&width=1600&fit=bounds", "source": "Forbes", "category_within_source": "n/a", "source_domain": "www.forbes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.156514, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CVS", "relevance_score": "0.154703", "ticker_sentiment_score": "0.125046", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.038906", "ticker_sentiment_score": "-0.053757", "ticker_sentiment_label": "Neutral"}, {"ticker": "XM", "relevance_score": "0.116348", "ticker_sentiment_score": "0.198791", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CI", "relevance_score": "0.038906", "ticker_sentiment_score": "0.070154", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABSI", "relevance_score": "0.038906", "ticker_sentiment_score": "-0.053757", "ticker_sentiment_label": "Neutral"}, {"ticker": "UNH", "relevance_score": "0.038906", "ticker_sentiment_score": "0.070154", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.077719", "ticker_sentiment_score": "0.04486", "ticker_sentiment_label": "Neutral"}]}, {"title": "MAKE IN INDIA: Can we take pride in our products?", "url": "https://www.financialexpress.com/business/industry-make-in-india-can-we-take-pride-in-our-products-3330061/", "time_published": "20231206T190500", "authors": ["Guest"], "summary": "We have heard a lot about Aatmanirbharta and Make-in-India, and yet, we see Indians and the world readily buy Apple and Samsung made in India but think twice about Indian products designed and made in India. The Europeans and the Japanese are known to buy their own products, before any other's.", "banner_image": "https://www.financialexpress.com/wp-content/uploads/2023/12/dsasc-1.jpg", "source": "The Financial Express", "category_within_source": "n/a", "source_domain": "www.financialexpress.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.204322, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SSNLF", "relevance_score": "0.082963", "ticker_sentiment_score": "0.058157", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.082963", "ticker_sentiment_score": "0.05313", "ticker_sentiment_label": "Neutral"}]}, {"title": "Kao Data Partners with Jisc to Accelerate UK Public Sector, Academia, and Scientific Research Computing", "url": "https://www.benzinga.com/pressreleases/23/12/n36116666/kao-data-partners-with-jisc-to-accelerate-uk-public-sector-academia-and-scientific-research-comput", "time_published": "20231206T163900", "authors": ["PRNewswire"], "summary": "Unique partnership builds upon Kao Data's industry-leading high performance colocation capabilities, providing public sector, academic and scientific research organisations with access to immediate, sustainable, and scalable data centre capacity.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Manufacturing", "relevance_score": "0.5"}], "overall_sentiment_score": 0.303563, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "NVDA", "relevance_score": "0.064536", "ticker_sentiment_score": "0.097455", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.032294", "ticker_sentiment_score": "0.010387", "ticker_sentiment_label": "Neutral"}, {"ticker": "NRC", "relevance_score": "0.064536", "ticker_sentiment_score": "0.138299", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.032294", "ticker_sentiment_score": "0.010387", "ticker_sentiment_label": "Neutral"}]}, {"title": "Cyprium Therapeutics, a Fortress Biotech Subsidiary Company, Completes Asset Transfer of CUTX-101 Copper Histidinate Product Candidate for Treatment of Menkes Disease, to Sentynl Therapeutics, a Wholly-owned Subsidiary of Zydus Lifesciences Ltd.", "url": "https://www.globenewswire.com/news-release/2023/12/06/2791767/28889/en/Cyprium-Therapeutics-a-Fortress-Biotech-Subsidiary-Company-Completes-Asset-Transfer-of-CUTX-101-Copper-Histidinate-Product-Candidate-for-Treatment-of-Menkes-Disease-to-Sentynl-Ther.html", "time_published": "20231206T133000", "authors": ["Fortress Biotech", "Inc."], "summary": "Cyprium received $4.5 million payment upon closing and remains eligible to receive royalties and up to $129 million in aggregate development and sales milestones ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/d82bf2ce-81b7-4989-9e6b-08e6bb6e1f95", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.614606"}], "overall_sentiment_score": 0.213726, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.025113", "ticker_sentiment_score": "0.183451", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FBIO", "relevance_score": "0.125069", "ticker_sentiment_score": "0.133102", "ticker_sentiment_label": "Neutral"}]}, {"title": "Voyager Therapeutics Announces Selection of Development Candidate for SOD1 Amyotrophic Lateral Sclerosis Gene Therapy Program - Voyager Therapeutics  ( NASDAQ:VYGR ) ", "url": "https://www.benzinga.com/pressreleases/23/12/g36109128/voyager-therapeutics-announces-selection-of-development-candidate-for-sod1-amyotrophic-lateral-scl", "time_published": "20231206T120000", "authors": ["Globe Newswire"], "summary": "LEXINGTON, Mass., Dec. 06, 2023 ( GLOBE NEWSWIRE ) -- Voyager Therapeutics, Inc. VYGR, a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced that it has selected a lead development candidate for its superoxide dismutase 1 ( SOD1 ) -mutated ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": 0.134469, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SGMO", "relevance_score": "0.028626", "ticker_sentiment_score": "0.019762", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.057215", "ticker_sentiment_score": "0.082044", "ticker_sentiment_label": "Neutral"}, {"ticker": "VYGR", "relevance_score": "0.114137", "ticker_sentiment_score": "0.028207", "ticker_sentiment_label": "Neutral"}, {"ticker": "NBIX", "relevance_score": "0.028626", "ticker_sentiment_score": "0.019762", "ticker_sentiment_label": "Neutral"}]}, {"title": "Voyager Therapeutics Announces Selection of Development Candidate for SOD1 Amyotrophic Lateral Sclerosis Gene Therapy Program", "url": "https://www.globenewswire.com/news-release/2023/12/06/2791626/36461/en/Voyager-Therapeutics-Announces-Selection-of-Development-Candidate-for-SOD1-Amyotrophic-Lateral-Sclerosis-Gene-Therapy-Program.html", "time_published": "20231206T120000", "authors": ["Inc.", "Voyager Therapeutics"], "summary": "- IND filing expected in mid-2025 - - IND filing expected in ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/3fe5c08d-e9d5-4ef6-944b-503007d056b0", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.14161, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SGMO", "relevance_score": "0.02786", "ticker_sentiment_score": "0.019714", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.055686", "ticker_sentiment_score": "0.083016", "ticker_sentiment_label": "Neutral"}, {"ticker": "VYGR", "relevance_score": "0.138623", "ticker_sentiment_score": "0.032274", "ticker_sentiment_label": "Neutral"}, {"ticker": "NBIX", "relevance_score": "0.02786", "ticker_sentiment_score": "0.019714", "ticker_sentiment_label": "Neutral"}]}, {"title": "Axogen Announces Transition of Finance Team Leadership - Axogen  ( NASDAQ:AXGN ) ", "url": "https://www.benzinga.com/pressreleases/23/12/g36109129/axogen-announces-transition-of-finance-team-leadership", "time_published": "20231206T120000", "authors": ["Globe Newswire"], "summary": "ALACHUA, Fla. and TAMPA, Fla., Dec. 06, 2023 ( GLOBE NEWSWIRE ) -- Axogen, Inc. AXGN, a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the appointment of Mr. Nir Naor as Chief Financial Officer, effective immediately.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.918141"}, {"topic": "Earnings", "relevance_score": "0.684621"}], "overall_sentiment_score": 0.133742, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AXGN", "relevance_score": "0.294575", "ticker_sentiment_score": "0.195757", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.027413", "ticker_sentiment_score": "0.09954", "ticker_sentiment_label": "Neutral"}]}, {"title": "Fallopian Tube Cancer Therapeutics Market size to grow by USD 832.01 million from 2023-2028| AbbVie Inc., Amgen ... - PR Newswire", "url": "https://www.prnewswire.com/news-releases/fallopian-tube-cancer-therapeutics-market-size-to-grow-by-usd-832-01-million-from-2023-2028-abbvie-inc-amgen-inc-arrien-pharmaceuticals-llc-and-more-among-the-key-companies-in-the-market---technavio-302006567.html", "time_published": "20231205T221500", "authors": [], "summary": "Fallopian Tube Cancer Therapeutics Market size to grow by USD 832.01 million from 2023-2028| AbbVie Inc., Amgen ... PR ...", "banner_image": null, "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.026585, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.057628", "ticker_sentiment_score": "-0.003", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.057628", "ticker_sentiment_score": "-0.003", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAX", "relevance_score": "0.114956", "ticker_sentiment_score": "-0.045307", "ticker_sentiment_label": "Neutral"}, {"ticker": "IMGN", "relevance_score": "0.057628", "ticker_sentiment_score": "-0.003", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVS", "relevance_score": "0.057628", "ticker_sentiment_score": "-0.003", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.057628", "ticker_sentiment_score": "-0.003", "ticker_sentiment_label": "Neutral"}, {"ticker": "SEMHF", "relevance_score": "0.057628", "ticker_sentiment_score": "-0.003", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.057628", "ticker_sentiment_score": "-0.003", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.057628", "ticker_sentiment_score": "-0.003", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.057628", "ticker_sentiment_score": "-0.003", "ticker_sentiment_label": "Neutral"}, {"ticker": "CLVSQ", "relevance_score": "0.057628", "ticker_sentiment_score": "-0.003", "ticker_sentiment_label": "Neutral"}]}, {"title": "Altimmune open to partnerships, deals with drugmakers, says CEO", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/altimmune-open-partnerships-deals-with-drugmakers-says-ceo-2023-12-05/", "time_published": "20231205T182200", "authors": ["Pratik Jain", "Khushi Mandowara"], "summary": "Dec 5 ( Reuters ) - Weight-loss drug developer Altimmune ( ALT.O ) is open to deals and collaborations with large drugmakers as it actively looks for partners to launch and develop its experimental obesity drug, CEO Vipin Garg told Reuters on Tuesday.", "banner_image": "https://www.reuters.com/pf/resources/images/reuters/reuters-default.webp?d=165", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.163644, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ALT", "relevance_score": "0.28442", "ticker_sentiment_score": "0.13484", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.096671", "ticker_sentiment_score": "0.207373", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVO", "relevance_score": "0.096671", "ticker_sentiment_score": "0.016513", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.096671", "ticker_sentiment_score": "-0.085243", "ticker_sentiment_label": "Neutral"}]}, {"title": "AstraZeneca PLC  ( AZN )  Is a Trending Stock: Facts to Know Before Betting on It", "url": "https://www.zacks.com/stock/news/2193506/astrazeneca-plc-azn-is-a-trending-stock-facts-to-know-before-betting-on-it", "time_published": "20231205T140006", "authors": ["Zacks Equity Research"], "summary": "Zacks.com users have recently been watching Astrazeneca (AZN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default219.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999999"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.54554"}], "overall_sentiment_score": 0.233066, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.483888", "ticker_sentiment_score": "0.119287", "ticker_sentiment_label": "Neutral"}]}, {"title": "Absci  ( ABSI )  Up on AstraZeneca Deal to Design New Cancer Therapy", "url": "https://www.zacks.com/stock/news/2193427/absci-absi-up-on-astrazeneca-deal-to-design-new-cancer-therapy", "time_published": "20231205T131100", "authors": ["Zacks Equity Research"], "summary": "Absci (ABSI) announces a collaboration agreement with AstraZeneca to develop an AI-designed antibody for an undisclosed oncology target. The stock rises 13%.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f5/284.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.14095, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.255641", "ticker_sentiment_score": "0.130419", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABSI", "relevance_score": "0.615462", "ticker_sentiment_score": "0.34484", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.413199", "ticker_sentiment_score": "0.299485", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Biden-Xi Summit Opens \"Window\" For Collaboration In Cancer Fight - Kevin Rudd", "url": "https://www.forbes.com/sites/russellflannery/2023/12/04/biden-xi-summit-opens-window-for-collaboration-in-cancer-fight--kevin-rudd/", "time_published": "20231205T000101", "authors": ["Russell Flannery"], "summary": "The \"stabilizing\" summit between U.S. President Joe Biden and Chinese President Xi Jinping at the APEC leaders gathering in San Francisco last month has opened a \"small window\" between the two for collaboration in the fight against cancer, China policy expert and Australia's Ambassador to the U.S.", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/656e5f6487f4b5460f9d88da/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds", "source": "Forbes", "category_within_source": "n/a", "source_domain": "www.forbes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": -0.046832, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.043499", "ticker_sentiment_score": "0.005947", "ticker_sentiment_label": "Neutral"}, {"ticker": "BGNE", "relevance_score": "0.043499", "ticker_sentiment_score": "-0.02793", "ticker_sentiment_label": "Neutral"}]}, {"title": "Roche Will Buy Obesity And Diabetes Drugmaker Carmot Therapeutics In $2.7 Billion Deal", "url": "https://www.forbes.com/sites/britneynguyen/2023/12/04/roche-will-buy-obesity-and-diabetes-drugmaker-carmot-therapeutics-in-27-billion-deal/", "time_published": "20231204T192410", "authors": ["Britney Nguyen"], "summary": "Swiss pharmaceuticals company Roche agreed to acquire U.S.-based weight-loss drugmaker Carmot Therapeutics, which develops anti-obesity and diabetes drugs, for $2.7 million, according to a press release, as drug makers seek to challenge Novo Nordisk and Eli Lilly, which remain the dominant ...", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/656e25a4ad16afaa37edede2/0x0.jpg?format=jpg&crop=1272,716,x0,y127,safe&height=900&width=1600&fit=bounds", "source": "Forbes", "category_within_source": "n/a", "source_domain": "www.forbes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.11584, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.057628", "ticker_sentiment_score": "0.013012", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.227538", "ticker_sentiment_score": "0.02842", "ticker_sentiment_label": "Neutral"}, {"ticker": "SGTX", "relevance_score": "0.057628", "ticker_sentiment_score": "0.013012", "ticker_sentiment_label": "Neutral"}]}, {"title": "Lilly  ( LLY )  Gets Second FDA Nod for Lymphoma Drug Jaypirca", "url": "https://www.zacks.com/stock/news/2193151/lilly-lly-gets-second-fda-nod-for-lymphoma-drug-jaypirca", "time_published": "20231204T171900", "authors": ["Zacks Equity Research"], "summary": "Following the latest approval, Lilly's (LLY) Jaypirca is the first and the only non-covalent BTK inhibitor to extend the benefit of targeting the BTK pathway.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ff/2922.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.106483, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.591449", "ticker_sentiment_score": "0.228092", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABBV", "relevance_score": "0.380012", "ticker_sentiment_score": "0.153731", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BGNE", "relevance_score": "0.065866", "ticker_sentiment_score": "0.080525", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.131284", "ticker_sentiment_score": "0.087912", "ticker_sentiment_label": "Neutral"}]}, {"title": "McKesson  ( MCK )  Announces Availability of FDA-Cleared Drug", "url": "https://www.zacks.com/stock/news/2192847/mckesson-mck-announces-availability-of-fda-cleared-drug", "time_published": "20231204T135300", "authors": ["Zacks Equity Research"], "summary": "The availability of the FDA-approved drug via McKesson's (MCK) independent specialty pharmacy is expected to give patients more treatment options for breast cancer.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/2a/3899.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.614606"}], "overall_sentiment_score": 0.158141, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CAH", "relevance_score": "0.196344", "ticker_sentiment_score": "0.060843", "ticker_sentiment_label": "Neutral"}, {"ticker": "ITGR", "relevance_score": "0.259727", "ticker_sentiment_score": "0.093571", "ticker_sentiment_label": "Neutral"}, {"ticker": "MCK", "relevance_score": "0.544246", "ticker_sentiment_score": "0.141396", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.066047", "ticker_sentiment_score": "0.00201", "ticker_sentiment_label": "Neutral"}, {"ticker": "DVA", "relevance_score": "0.196344", "ticker_sentiment_score": "0.144802", "ticker_sentiment_label": "Neutral"}]}, {"title": "Absci Announces Collaboration with AstraZeneca to Advance AI-Driven Oncology Candidate", "url": "https://www.globenewswire.com/news-release/2023/12/04/2789911/0/en/Absci-Announces-Collaboration-with-AstraZeneca-to-Advance-AI-Driven-Oncology-Candidate.html", "time_published": "20231204T123000", "authors": ["ABSCI Corporation"], "summary": "Collaboration Combines Absci's AI Antibody Drug Creation Platform with AstraZeneca's Expertise in Oncology Research and Development Collaboration Combines Absci's AI Antibody Drug Creation Platform with AstraZeneca's Expertise in Oncology Research and Development ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/8a7eb744-ee7b-4c4b-89cf-387103eed7ab", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.838487"}], "overall_sentiment_score": 0.245884, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ABSI", "relevance_score": "0.327366", "ticker_sentiment_score": "0.287201", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.185591", "ticker_sentiment_score": "0.120975", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOOG", "relevance_score": "0.074809", "ticker_sentiment_score": "0.156684", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Absci Announces Collaboration with AstraZeneca to Advance AI-Driven Oncology Candidate - Absci  ( NASDAQ:ABSI ) ", "url": "https://www.benzinga.com/pressreleases/23/12/g36066644/absci-announces-collaboration-with-astrazeneca-to-advance-ai-driven-oncology-candidate", "time_published": "20231204T123000", "authors": ["Globe Newswire"], "summary": "VANCOUVER, Wash., Dec. 04, 2023 ( GLOBE NEWSWIRE ) -- Absci Corporation ABSI, a leader in generative AI antibody discovery, today announced a collaboration with AstraZeneca, a global biopharmaceutical company, to deliver an AI-designed antibody against an oncology target.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.904684"}], "overall_sentiment_score": 0.243432, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ABSI", "relevance_score": "0.351558", "ticker_sentiment_score": "0.245846", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.180325", "ticker_sentiment_score": "0.112512", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOOG", "relevance_score": "0.072655", "ticker_sentiment_score": "0.148181", "ticker_sentiment_label": "Neutral"}]}, {"title": "AstraZeneca Strikes Deal With Absci To Leverage AI In Cancer Drug Discovery: Report - AstraZeneca  ( NASDAQ:AZN ) , Absci  ( NASDAQ:ABSI ) ", "url": "https://www.benzinga.com/general/biotech/23/12/36064768/astrazeneca-strikes-deal-with-absci-to-leverage-ai-in-cancer-drug-discovery-report", "time_published": "20231204T115831", "authors": ["Vandana Singh"], "summary": "AstraZeneca plc AZN has reportedly finalized a partnership deal valued at up to $247 million with Absci Corporation ABSI, a U.S.-based firm specializing in artificial intelligence ( AI ) applications, aiming to develop an antibody to combat cancer.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/12/04/azn_co.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Manufacturing", "relevance_score": "0.5"}], "overall_sentiment_score": 0.194568, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ABSI", "relevance_score": "0.532941", "ticker_sentiment_score": "0.184398", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVDA", "relevance_score": "0.28387", "ticker_sentiment_score": "0.343976", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TRMNF", "relevance_score": "0.144275", "ticker_sentiment_score": "0.099221", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.28387", "ticker_sentiment_score": "-0.040019", "ticker_sentiment_label": "Neutral"}]}, {"title": "Roche strikes $3.1 billion deal to buy obesity-drug maker Carmot Therapeutics in race to rival Novo Nordisk's Ozempic", "url": "https://www.marketwatch.com/story/roche-strikes-3-1-billion-deal-to-buy-obesity-drug-maker-carmot-therapeutics-billion-in-race-to-rival-novo-nordisks-ozempic-6b88b8c9", "time_published": "20231204T104000", "authors": ["Louis Goss"], "summary": "The race for weight-loss drugs stepped up Monday after Roche said it would buy obesity-drug developer Carmot Therapeutics for up to $3.1 billion.", "banner_image": "https://images.mktw.net/im-740245/social", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.140301, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.175859", "ticker_sentiment_score": "0.105946", "ticker_sentiment_label": "Neutral"}, {"ticker": "BCS", "relevance_score": "0.059049", "ticker_sentiment_score": "0.201018", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.175859", "ticker_sentiment_score": "0.132332", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.232996", "ticker_sentiment_score": "0.219072", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.232996", "ticker_sentiment_score": "-0.013105", "ticker_sentiment_label": "Neutral"}, {"ticker": "WMT", "relevance_score": "0.117774", "ticker_sentiment_score": "-0.072874", "ticker_sentiment_label": "Neutral"}]}, {"title": "AstraZeneca partners with AI company to find cure for cancer", "url": "https://cointelegraph.com/news/astra-zeneca-partners-ai-company-cancer-cure", "time_published": "20231204T094235", "authors": ["David Attlee"], "summary": "The collaboration aims to create a zero-shot generative AI model, which would work on creating new antibody therapeutics and enhancing the existing ones.", "banner_image": "https://images.cointelegraph.com/cdn-cgi/image/format=auto,onerror=redirect,quality=90,width=1200/https://s3.cointelegraph.com/uploads/2023-12/f30bb657-210b-4cc7-8964-0e1ce6a6d202.jpg", "source": "Cointelegraph", "category_within_source": "n/a", "source_domain": "cointelegraph.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.177604, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ABSI", "relevance_score": "0.517168", "ticker_sentiment_score": "0.179994", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.517168", "ticker_sentiment_score": "0.18816", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Stocks to Watch today, Dec 4: SBI, HUL, Salasar Techno, Tata Power, Alkem", "url": "https://www.business-standard.com/markets/news/stocks-to-watch-today-dec-4-sbi-hul-salasar-techno-tata-power-alkem-123120400078_1.html", "time_published": "20231204T022640", "authors": ["Nikita Vashisht"], "summary": "Stocks to Watch on Monday, December 4: Hopes of political stability amid a clean sweep by the Bharatiya Janata Party in three states may lead to a gap-up start in the markets on Monday. At 7:35 AM, Gift Nifty was ruling 263 points higher at 20,638 levels.", "banner_image": "https://bsmedia.business-standard.com/_media/bs/img/article/2022-11/08/full/1667930235-4251.jpg?im=FeatureCrop,size=(826,465)", "source": "Business Standard", "category_within_source": "GoogleRSS", "source_domain": "www.business-standard.com", "topics": [{"topic": "Real Estate & Construction", "relevance_score": "0.5"}, {"topic": "Life Sciences", "relevance_score": "0.5"}], "overall_sentiment_score": 0.204664, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PGPGF", "relevance_score": "0.057215", "ticker_sentiment_score": "0.208618", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.170475", "ticker_sentiment_score": "-0.083969", "ticker_sentiment_label": "Neutral"}, {"ticker": "UL", "relevance_score": "0.057215", "ticker_sentiment_score": "0.218168", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "APG", "relevance_score": "0.057215", "ticker_sentiment_score": "0.073943", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABSI", "relevance_score": "0.057215", "ticker_sentiment_score": "-0.04727", "ticker_sentiment_label": "Neutral"}, {"ticker": "SBKFF", "relevance_score": "0.057215", "ticker_sentiment_score": "0.307046", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "UCLQF", "relevance_score": "0.057215", "ticker_sentiment_score": "0.307046", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "AstraZeneca, AI biologics firm Absci tie up on cancer drug - FT", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/astrazeneca-ai-biologics-firm-absci-tie-up-cancer-drug-ft-2023-12-03/", "time_published": "20231203T060026", "authors": ["Reuters"], "summary": "The AstraZeneca logo is pictured outside the AstraZeneca office building in Brussels as part of the coronavirus disease ( COVID-19 ) vaccination campaign, Belgium, January 28, 2021. REUTERS/Johanna Geron/File Photo Acquire Licensing Rights", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/XGWS6OYYDBKFLFL4QNEZLWTLJQ.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.161062, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ABSI", "relevance_score": "0.629492", "ticker_sentiment_score": "0.334128", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.737032", "ticker_sentiment_score": "-0.131884", "ticker_sentiment_label": "Neutral"}, {"ticker": "GERN", "relevance_score": "0.17715", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Everyone Is Talking About This Stock. Is It a Good Long-Term Option?", "url": "https://www.fool.com/investing/2023/12/02/everyone-is-talking-about-this-stock-is-it-a-good/", "time_published": "20231202T143000", "authors": ["Prosper Junior Bakiny"], "summary": "This company famously helps manage a prevalent chronic illness.", "banner_image": "https://g.foolcdn.com/editorial/images/756325/doctor-and-patient-talking.jpg", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}], "overall_sentiment_score": 0.340093, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.055751", "ticker_sentiment_score": "0.142026", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.598621", "ticker_sentiment_score": "0.488158", "ticker_sentiment_label": "Bullish"}, {"ticker": "PFE", "relevance_score": "0.055751", "ticker_sentiment_score": "0.142026", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:DKK", "relevance_score": "0.055751", "ticker_sentiment_score": "0.153914", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FOREX:NOK", "relevance_score": "0.055751", "ticker_sentiment_score": "0.153914", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Smart Inhaler Technology Market size to grow by USD 46.37 million from 2022-2027, North America to account for 37 ... - PR Newswire", "url": "https://www.prnewswire.com/news-releases/smart-inhaler-technology-market-size-to-grow-by-usd-46-37-million-from-2022-2027--north-america-to-account-for-37-of-market-growth---technavio-302002805.html", "time_published": "20231201T231500", "authors": [], "summary": "Smart Inhaler Technology Market size to grow by USD 46.37 million from 2022-2027, North America to account for 37 ... PR ...", "banner_image": null, "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Manufacturing", "relevance_score": "0.5"}], "overall_sentiment_score": 0.319037, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.064623", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "RMD", "relevance_score": "0.064623", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVS", "relevance_score": "0.064623", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "OPK", "relevance_score": "0.064623", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TEVA", "relevance_score": "0.064623", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MMM", "relevance_score": "0.128822", "ticker_sentiment_score": "0.128686", "ticker_sentiment_label": "Neutral"}, {"ticker": "ATR", "relevance_score": "0.064623", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Laryngeal Cancer Therapeutics Market size to grow by USD 575.25 million from 2022-2027| Accord Healthcare Ltd ... - PR Newswire", "url": "https://www.prnewswire.com/news-releases/laryngeal-cancer-therapeutics-market-size-to-grow-by-usd-575-25-million-from-2022-2027-accord-healthcare-ltd-amgen-inc-astrazeneca-plc-athenex-inc-and-more-among-the-major-companies-in-the-market--technavio-302002789.html", "time_published": "20231201T223500", "authors": [], "summary": "Laryngeal Cancer Therapeutics Market size to grow by USD 575.25 million from 2022-2027| Accord Healthcare Ltd ... PR ...", "banner_image": null, "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.054932, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CLDX", "relevance_score": "0.066414", "ticker_sentiment_score": "-0.02104", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAYZF", "relevance_score": "0.066414", "ticker_sentiment_score": "-0.02104", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.132368", "ticker_sentiment_score": "-0.053456", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.066414", "ticker_sentiment_score": "-0.02104", "ticker_sentiment_label": "Neutral"}, {"ticker": "ATNXQ", "relevance_score": "0.066414", "ticker_sentiment_score": "-0.02104", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.066414", "ticker_sentiment_score": "-0.02104", "ticker_sentiment_label": "Neutral"}, {"ticker": "FSNUF", "relevance_score": "0.066414", "ticker_sentiment_score": "-0.02104", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.066414", "ticker_sentiment_score": "-0.02104", "ticker_sentiment_label": "Neutral"}, {"ticker": "HKMPF", "relevance_score": "0.066414", "ticker_sentiment_score": "-0.02104", "ticker_sentiment_label": "Neutral"}, {"ticker": "TEVA", "relevance_score": "0.066414", "ticker_sentiment_score": "-0.02104", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.066414", "ticker_sentiment_score": "-0.02104", "ticker_sentiment_label": "Neutral"}, {"ticker": "ANL", "relevance_score": "0.066414", "ticker_sentiment_score": "-0.02104", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.066414", "ticker_sentiment_score": "-0.02104", "ticker_sentiment_label": "Neutral"}]}, {"title": "Weight Loss Drugs And Associated Suicidal Thoughts - European Drug Regulator Seeks Clarifications From Drug Makers - AstraZeneca  ( NASDAQ:AZN ) , Eli Lilly  ( NYSE:LLY ) ", "url": "https://www.benzinga.com/general/biotech/23/12/36046376/weight-loss-drugs-and-associated-suicidal-thoughts-european-drug-regulator-seeks-clarifications-f", "time_published": "20231201T174334", "authors": ["Vandana Singh"], "summary": "European Medicines Agency ( EMA ) will request further clarifications from drugmakers of GLP-1 receptor agonists for diabetes and weight loss, including Novo Nordisk A/S's NVO popular therapies Ozempic and Wegovy, to investigate suicidal thoughts further.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/12/01/weight-loss-photo_by_vidmir_rais_via_pixabay.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.113612, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.297661", "ticker_sentiment_score": "0.198834", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.297661", "ticker_sentiment_score": "0.198834", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVO", "relevance_score": "0.297661", "ticker_sentiment_score": "-0.211382", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "SNY", "relevance_score": "0.297661", "ticker_sentiment_score": "0.198834", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "AstraZeneca  ( AZN )  to Discontinue Two Studies on Lokelma", "url": "https://www.zacks.com/stock/news/2192314/astrazeneca-azn-to-discontinue-two-studies-on-lokelma", "time_published": "20231201T162700", "authors": ["Zacks Equity Research"], "summary": "Owing to increased enrollment timelines and low event rates, AstraZeneca (AZN) plans to stop the STABILIZE-CKD and DIALIZE-Outcomes phase III evidence studies for the hyperkalemia drug Lokelma.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/e5/1416.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.99489"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.026523, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CTMX", "relevance_score": "0.443626", "ticker_sentiment_score": "0.056386", "ticker_sentiment_label": "Neutral"}, {"ticker": "TRDA", "relevance_score": "0.443626", "ticker_sentiment_score": "0.056432", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.305058", "ticker_sentiment_score": "0.018063", "ticker_sentiment_label": "Neutral"}, {"ticker": "PBYI", "relevance_score": "0.376005", "ticker_sentiment_score": "0.18837", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "AstraZeneca Stops Two Lokelma Late-Stage Trials After Evaluating Potential Benefits - AstraZeneca  ( NASDAQ:AZN ) ", "url": "https://www.benzinga.com/general/biotech/23/12/36040089/astrazeneca-stops-two-lokelma-late-stage-trials-after-evaluating-potential-benefits", "time_published": "20231201T124837", "authors": ["Vandana Singh"], "summary": "AstraZeneca Plc AZN discontinued the STABILIZE-CKD and DIALIZE-Outcomes Phase 3 evidence trials for Lokelma ( sodium zirconium cyclosilicate ) .", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/12/01/azn.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.187932, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.539306", "ticker_sentiment_score": "0.023461", "ticker_sentiment_label": "Neutral"}]}, {"title": "Stock Upgrades: GSK ADR Shows Rising Relative Strength", "url": "https://www.investors.com/ibd-data-stories/stock-upgrades-gsk-adr-shows-rising-relative-strength/", "time_published": "20231201T080000", "authors": ["Investor's Business Daily", "INVESTOR'S BUSINESS DAILY"], "summary": "On Friday, GSK ADR ( GSK ) received a positive adjustment to its Relative Strength ( RS ) Rating, from 64 to 72. X When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength. IBD's unique rating measures share price performance with a 1 ( worst ...", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.408831, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.323078", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AWON", "relevance_score": "0.165031", "ticker_sentiment_score": "0.21849", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "AstraZeneca to scrap two trials on drug that curbs potassium", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/astrazeneca-scrap-two-trials-drug-that-curbs-potassium-2023-12-01/", "time_published": "20231201T074558", "authors": ["Reuters"], "summary": "The AstraZeneca logo is pictured outside the AstraZeneca office building in Brussels as part of the coronavirus disease ( COVID-19 ) vaccination campaign, Belgium, January 28, 2021. REUTERS/Johanna Geron/File Photo Acquire Licensing Rights", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/N5ANISFYRRJMDFIA6SJZTHI7JI.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.174601, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.742397", "ticker_sentiment_score": "0.177553", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GERN", "relevance_score": "0.222838", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Best Penny Stocks Today? 3 To Watch Under $4 Now", "url": "https://pennystocks.com/featured/2023/11/30/best-penny-stocks-today-3-to-watch-under-4-now-november-2023/", "time_published": "20231130T192203", "authors": ["J. Phillip"], "summary": "Searching to Buy the Best Penny Stocks? How to Find Potential Winners Penny stocks can offer traders massive profits through their sheer price volatility. With prices below $5 per share, these tiny companies allow you to snap up many shares. Of course, they can explode in value on market ...", "banner_image": "https://pennystocks.com/wp-content/uploads/2021/11/best-penny-stocks-to-buy-watch-under-4-dollars.jpg", "source": "PennyStocks.com", "category_within_source": "n/a", "source_domain": "pennystocks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.5855"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.359105, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "AIMFF", "relevance_score": "0.029618", "ticker_sentiment_score": "0.022808", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.059194", "ticker_sentiment_score": "0.119049", "ticker_sentiment_label": "Neutral"}, {"ticker": "LMDX", "relevance_score": "0.059194", "ticker_sentiment_score": "0.119049", "ticker_sentiment_label": "Neutral"}, {"ticker": "BKR", "relevance_score": "0.08869", "ticker_sentiment_score": "0.202324", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FCCO", "relevance_score": "0.029618", "ticker_sentiment_score": "0.112656", "ticker_sentiment_label": "Neutral"}, {"ticker": "AWON", "relevance_score": "0.029618", "ticker_sentiment_score": "0.138078", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDT", "relevance_score": "0.029618", "ticker_sentiment_score": "0.370622", "ticker_sentiment_label": "Bullish"}]}, {"title": "AbbVie  ( ABBV )  Posts Encouraging Data From Lung Cancer Study", "url": "https://www.zacks.com/stock/news/2191706/abbvie-abbv-posts-encouraging-data-from-lung-cancer-study", "time_published": "20231130T165600", "authors": ["Zacks Equity Research"], "summary": "Data from a mid-stage study on AbbVie's (ABBV) experimental ADC drug demonstrates compelling clinical benefits across key endpoints in certain lung cancer patients.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/d5/8276.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.890401"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.097728, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ABBV", "relevance_score": "0.453501", "ticker_sentiment_score": "0.089073", "ticker_sentiment_label": "Neutral"}, {"ticker": "CTMX", "relevance_score": "0.293741", "ticker_sentiment_score": "0.078444", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.11983", "ticker_sentiment_score": "0.132592", "ticker_sentiment_label": "Neutral"}, {"ticker": "PBYI", "relevance_score": "0.236972", "ticker_sentiment_score": "0.133777", "ticker_sentiment_label": "Neutral"}]}, {"title": "Turkey launches investigation into 19 pharma companies", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/turkey-launches-investigation-into-19-pharma-companies-2023-11-30/", "time_published": "20231130T161900", "authors": ["Reuters"], "summary": "ANKARA, Nov 30 ( Reuters ) - Turkey's competition authority said on Thursday it had launched an investigation into 19 pharmaceutical companies to determine whether they had violated competition law.", "banner_image": "https://www.reuters.com/pf/resources/images/reuters/reuters-default.webp?d=165", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.061418, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "PCRFF", "relevance_score": "0.211191", "ticker_sentiment_score": "-0.075673", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.211191", "ticker_sentiment_score": "-0.075673", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.407844", "ticker_sentiment_score": "0.063531", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.407844", "ticker_sentiment_score": "-0.090206", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.407844", "ticker_sentiment_score": "-0.090206", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.407844", "ticker_sentiment_score": "-0.041052", "ticker_sentiment_label": "Neutral"}]}, {"title": "AbbVie Should Consider a Dividend Cut -- Here's Why", "url": "https://www.fool.com/investing/2023/11/30/abbvie-should-consider-a-dividend-cut-heres-why/", "time_published": "20231130T131500", "authors": ["George Budwell"], "summary": "Dividend Kings with above-average yields have been badly underperforming the broader markets.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F756473%2Fbiotech-researcher.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.127606, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ABBV", "relevance_score": "0.515636", "ticker_sentiment_score": "0.182566", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABT", "relevance_score": "0.055751", "ticker_sentiment_score": "0.104", "ticker_sentiment_label": "Neutral"}, {"ticker": "TEVA", "relevance_score": "0.055751", "ticker_sentiment_score": "0.084997", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.055751", "ticker_sentiment_score": "0.084997", "ticker_sentiment_label": "Neutral"}]}, {"title": "TFF Pharmaceuticals Appoints Catherine Lee, J.D. to Board of Directors", "url": "https://www.globenewswire.com/news-release/2023/11/30/2788519/0/en/TFF-Pharmaceuticals-Appoints-Catherine-Lee-J-D-to-Board-of-Directors.html", "time_published": "20231130T130000", "authors": ["Inc.", "TFF Pharmaceuticals"], "summary": "FORT WORTH, Texas, Nov. 30, 2023 ( GLOBE NEWSWIRE ) -- TFF Pharmaceuticals, Inc. ( NASDAQ: TFFP ) , a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing ( TFF ) technology platform, today announced ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/81d7c318-42a7-47c2-83ff-cb2a534c17a5", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "IPO", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.200057, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.067347", "ticker_sentiment_score": "0.106928", "ticker_sentiment_label": "Neutral"}, {"ticker": "MTCR", "relevance_score": "0.067347", "ticker_sentiment_score": "0.106928", "ticker_sentiment_label": "Neutral"}, {"ticker": "TFFP", "relevance_score": "0.417198", "ticker_sentiment_score": "0.223381", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "TFF Pharmaceuticals Appoints Catherine Lee, J.D. to Board of Directors - TFF Pharmaceuticals  ( NASDAQ:TFFP ) ", "url": "https://www.benzinga.com/pressreleases/23/11/g36020844/tff-pharmaceuticals-appoints-catherine-lee-j-d-to-board-of-directors", "time_published": "20231130T130000", "authors": ["Globe Newswire"], "summary": "FORT WORTH, Texas, Nov. 30, 2023 ( GLOBE NEWSWIRE ) -- TFF Pharmaceuticals, Inc. TFFP, a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing ( TFF ) technology platform, today announced that Catherine ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "IPO", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.192942, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.065957", "ticker_sentiment_score": "0.106759", "ticker_sentiment_label": "Neutral"}, {"ticker": "MTCR", "relevance_score": "0.065957", "ticker_sentiment_score": "0.106759", "ticker_sentiment_label": "Neutral"}, {"ticker": "TFFP", "relevance_score": "0.409375", "ticker_sentiment_score": "0.215073", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Aurobindo Pharma unit gets USFDA nod to market generic asthma medication", "url": "https://www.business-standard.com/companies/news/aurobindo-pharma-unit-gets-usfda-nod-to-market-generic-asthma-medication-123113000567_1.html", "time_published": "20231130T102244", "authors": ["Press Trust of India"], "summary": "Aurobindo Pharma on Thursday said its subsidiary has received approval from the US health regulator to market a generic medication to treat asthma in children.", "banner_image": "https://bsmedia.business-standard.com/_media/bs/img/article/2022-04/07/full/1649353971-1669.jpg?im=FeatureCrop,size=(826,465)", "source": "Business Standard", "category_within_source": "GoogleRSS", "source_domain": "www.business-standard.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.163783, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.154455", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biotech Stocks Facing FDA Decision In December 2023", "url": "https://markets.businessinsider.com/news/stocks/biotech-stocks-facing-fda-decision-in-december-2023-1032861195", "time_published": "20231130T082051", "authors": ["markets.businessinsider.com"], "summary": "( RTTNews ) - The month of November witnessed a couple of notable firsts, including the approval of the first treatment for congenital thrombotic thrombocytopenic purpura, the first chikungunya vaccine and the first treatment for progressing desmoid tumors.", "banner_image": "https://markets.businessinsider.com/Images/FacebookIcon.jpg", "source": "Business Insider", "category_within_source": "GoogleRSS", "source_domain": "markets.businessinsider.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.021517, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GKOS", "relevance_score": "0.028868", "ticker_sentiment_score": "-0.115532", "ticker_sentiment_label": "Neutral"}, {"ticker": "ARQT", "relevance_score": "0.028868", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSVT", "relevance_score": "0.057698", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.057698", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "OPTN", "relevance_score": "0.057698", "ticker_sentiment_score": "0.094132", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.115094", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Aurobindo Pharma gets USFDA nod to make, market asthma drug, stock up 2%", "url": "https://www.moneycontrol.com/news/business/stocks/aurobindo-pharma-gets-usfda-nod-to-make-market-asthma-drug-stock-up-2-11833711.html", "time_published": "20231130T080437", "authors": [], "summary": "The nod for Budesonide inhalation suspension a day after the company got the US regulator's nod to market a generic medication for the treatment of HIV-1 infection ...", "banner_image": "https://images.moneycontrol.com/static-mcnews/2023/11/tata-tech.png?impolicy=website&width=168&height=118", "source": "Money Control", "category_within_source": "Buzzing Stocks", "source_domain": "www.moneycontrol.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.052043, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.141726", "ticker_sentiment_score": "-0.061207", "ticker_sentiment_label": "Neutral"}]}, {"title": "Zealand Pharma appoints Enrique Conterno and Elaine Sullivan as board observers", "url": "https://www.benzinga.com/pressreleases/23/11/g36016457/zealand-pharma-appoints-enrique-conterno-and-elaine-sullivan-as-board-observers", "time_published": "20231130T070000", "authors": ["Globe Newswire"], "summary": "Copenhagen, Denmark, November 30, 2023 - a Zealand Pharma A/S ( CVR-no. 20045078 ) , a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced the appointment of pharmaceutical industry veterans Enrique Conterno and Elaine Sullivan as ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.090911, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "FGEN", "relevance_score": "0.073098", "ticker_sentiment_score": "-0.007051", "ticker_sentiment_label": "Neutral"}, {"ticker": "IPZYF", "relevance_score": "0.073098", "ticker_sentiment_score": "-0.013151", "ticker_sentiment_label": "Neutral"}, {"ticker": "OPORF", "relevance_score": "0.073098", "ticker_sentiment_score": "-0.013151", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.145583", "ticker_sentiment_score": "-0.016516", "ticker_sentiment_label": "Neutral"}, {"ticker": "EVO", "relevance_score": "0.073098", "ticker_sentiment_score": "-0.013151", "ticker_sentiment_label": "Neutral"}, {"ticker": "ZLDPF", "relevance_score": "0.145583", "ticker_sentiment_score": "0.157322", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Zhang Yu with Tencent Health: AI-Driven Customer Interaction Solution NGES Effectively Supports Pharmaceutical Enterprises' Smart Operations", "url": "https://www.prnewswire.com/news-releases/zhang-yu-with-tencent-health-ai-driven-customer-interaction-solution-nges-effectively-supports-pharmaceutical-enterprises-smart-operations-302000461.html", "time_published": "20231129T094900", "authors": ["Tencent Health"], "summary": "Zhang Yu with Tencent Health: AI-Driven Customer Interaction Solution NGES Effectively Supports Pharmaceutical ... PR ...", "banner_image": "https://mma.prnewswire.com/media/2288080/Zhang_Yu_Tencent_Health.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.354344, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.035929", "ticker_sentiment_score": "0.14523", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.089662", "ticker_sentiment_score": "0.166179", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TCTZF", "relevance_score": "0.331296", "ticker_sentiment_score": "0.362451", "ticker_sentiment_label": "Bullish"}]}, {"title": "Sermonix Pharmaceuticals Announces Five Abstracts Accepted for Presentation at 2023 San Antonio Breast Cancer Symposium - Ligand Pharmaceuticals  ( NASDAQ:LGND ) ", "url": "https://www.benzinga.com/pressreleases/23/11/g35978604/sermonix-pharmaceuticals-announces-five-abstracts-accepted-for-presentation-at-2023-san-antonio-br", "time_published": "20231128T140100", "authors": ["Globe Newswire"], "summary": "COLUMBUS, Ohio, Nov. 28, 2023 ( GLOBE NEWSWIRE ) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast cancers harboring ESR1 mutations, today announced that it had five abstracts accepted as poster ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.071641, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.047185", "ticker_sentiment_score": "-0.005976", "ticker_sentiment_label": "Neutral"}, {"ticker": "LGND", "relevance_score": "0.094204", "ticker_sentiment_score": "0.094176", "ticker_sentiment_label": "Neutral"}]}, {"title": "Rakovina Therapeutics Inc. Announces Q3 2023 Financial Results and Provides Corporate Update", "url": "https://www.globenewswire.com/news-release/2023/11/28/2786571/0/en/Rakovina-Therapeutics-Inc-Announces-Q3-2023-Financial-Results-and-Provides-Corporate-Update.html", "time_published": "20231128T004300", "authors": ["Rakovina Therapeutics Inc"], "summary": "VANCOUVER, British Columbia, Nov. 27, 2023 ( GLOBE NEWSWIRE ) -- Rakovina Therapeutics Inc. ( TSX-V: RKV, the \"Company\" ) , a biopharmaceutical company dedicated to improving the lives of cancer patients through development of novel DNA-damage response inhibitor therapeutics, announced financial ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/e94148e0-0631-403b-9597-c742d43dca13", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.684621"}], "overall_sentiment_score": 0.088887, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.03068", "ticker_sentiment_score": "-0.036535", "ticker_sentiment_label": "Neutral"}]}, {"title": "Industry Comparison: Evaluating AstraZeneca Against Competitors In Pharmaceuticals Industry - AstraZeneca  ( NASDAQ:AZN ) ", "url": "https://www.benzinga.com/news/23/11/35962201/industry-comparison-evaluating-astrazeneca-against-competitors-in-pharmaceuticals-industry", "time_published": "20231127T160040", "authors": ["Benzinga Insights"], "summary": "In the ever-changing and fiercely competitive business landscape, conducting thorough company analysis is crucial for investors and industry experts. In this article, we will undertake a comprehensive industry comparison, evaluating AstraZeneca AZN and its primary competitors in the ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.938793"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.54554"}], "overall_sentiment_score": 0.065114, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "PTAIF", "relevance_score": "0.072217", "ticker_sentiment_score": "0.018298", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.413425", "ticker_sentiment_score": "0.274606", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Theseus  ( THRX )  Up 57% in a Month on Strategic Restructuring Plan", "url": "https://www.zacks.com/stock/news/2189784/theseus-thrx-up-57-in-a-month-on-strategic-restructuring-plan", "time_published": "20231127T151600", "authors": ["Zacks Equity Research"], "summary": "Theseus (THRX) gains 57% in a month after announcing plans to conduct a process exploring strategic alternatives to maximize shareholder value. The company cuts its workforce by 72%.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/86/1981.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.9545"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.103953, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LGND", "relevance_score": "0.207571", "ticker_sentiment_score": "0.230007", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ACAD", "relevance_score": "0.257805", "ticker_sentiment_score": "0.102471", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.207571", "ticker_sentiment_score": "0.126389", "ticker_sentiment_label": "Neutral"}, {"ticker": "THRX", "relevance_score": "0.354862", "ticker_sentiment_score": "-0.068076", "ticker_sentiment_label": "Neutral"}]}, {"title": "Miners, energy stocks drag UK's FTSE 100 lower", "url": "https://www.reuters.com/markets/miners-energy-stocks-drag-uks-ftse-100-lower-2023-11-27/", "time_published": "20231127T081900", "authors": ["Reuters"], "summary": "A man wearing a protective face mask walks past the London Stock Exchange Group building in the City of London financial district, whilst British stocks tumble as investors fear that the coronavirus outbreak could stall the global economy, in London, Britain, March 9, 2020.", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/BC5VULNBJFJMZPAKC3OH73DDSI.jpg", "source": "Reuters", "category_within_source": "Markets", "source_domain": "www.reuters.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.77141"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": -0.133233, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "RTMVF", "relevance_score": "0.192694", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GMVHF", "relevance_score": "0.192694", "ticker_sentiment_score": "0.192319", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "LDNXF", "relevance_score": "0.192694", "ticker_sentiment_score": "-0.227818", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "GS", "relevance_score": "0.192694", "ticker_sentiment_score": "0.192319", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.192694", "ticker_sentiment_score": "-0.154817", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Digital Health Market Size Anticipated to Hit USD 939.54 Billion by 2032| Precedence Research", "url": "https://www.prnewswire.com/news-releases/digital-health-market-size-anticipated-to-hit-usd-939-54-billion-by-2032--precedence-research-301997312.html", "time_published": "20231124T181400", "authors": ["Precedence Research"], "summary": "OTTAWA, ON, Nov. 24, 2023 /PRNewswire/ -- The global digital health market size surpassed USD 262.63 billion in 2022 and is anticipated to hit around USD 939.54 billion by 2032. The global digital health market is expected to expand at a remarkable CAGR of 13.1% over the forecast period 2023 to ...", "banner_image": "https://mma.prnewswire.com/media/2264617/Precedence_Research_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}, {"topic": "Earnings", "relevance_score": "0.214378"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.347686, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MOOIF", "relevance_score": "0.01429", "ticker_sentiment_score": "0.202066", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DTST", "relevance_score": "0.01429", "ticker_sentiment_score": "0.202066", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "WLDS", "relevance_score": "0.042851", "ticker_sentiment_score": "0.105196", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.01429", "ticker_sentiment_score": "0.171904", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "EHTH", "relevance_score": "0.01429", "ticker_sentiment_score": "0.057796", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:UGX", "relevance_score": "0.01429", "ticker_sentiment_score": "0.064707", "ticker_sentiment_label": "Neutral"}]}, {"title": "Securing A Healthy Future: Leaders' Sustainability Priorities For 2024", "url": "https://www.forbes.com/sites/sallypercy/2023/11/24/securing-a-healthy-future-leaders-sustainability-priorities-for-2024/", "time_published": "20231124T150355", "authors": ["Sally Percy"], "summary": "More than two-thirds of CEOs globally ( 69% ) have fully embedded environmental, social and governance ( ESG ) considerations into their business, according to recent research by professional services firm KMPG. This is because they see ESG as a means to create value and make their brand more ...", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/6560b929d596d6735a950108/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds", "source": "Forbes", "category_within_source": "n/a", "source_domain": "www.forbes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.267967, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.090474", "ticker_sentiment_score": "0.055879", "ticker_sentiment_label": "Neutral"}]}, {"title": "Novo Nordisk  ( NVO )  to Expand Manufacturing Site in France", "url": "https://www.zacks.com/stock/news/2189006/novo-nordisk-nvo-to-expand-manufacturing-site-in-france", "time_published": "20231124T143000", "authors": ["Zacks Equity Research"], "summary": "Novo Nordisk (NVO) announces that it is initiating plans to expand its existing manufacturing facility in Chartres, France, for the current and future product portfolio within serious chronic diseases.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/de/2471.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.198265, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.307603", "ticker_sentiment_score": "0.290043", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.307603", "ticker_sentiment_score": "0.104707", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.531716", "ticker_sentiment_score": "0.191818", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.208017", "ticker_sentiment_score": "0.087543", "ticker_sentiment_label": "Neutral"}]}, {"title": "Investors Heavily Search AstraZeneca PLC  ( AZN ) : Here is What You Need to Know", "url": "https://www.zacks.com/stock/news/2188959/investors-heavily-search-astrazeneca-plc-azn-here-is-what-you-need-to-know", "time_published": "20231124T140006", "authors": ["Zacks Equity Research"], "summary": "Astrazeneca (AZN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default172.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.5855"}], "overall_sentiment_score": 0.226475, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.484798", "ticker_sentiment_score": "0.14639", "ticker_sentiment_label": "Neutral"}]}, {"title": "Ascentage Pharma Hosts Ceremony Marking the Launch of Olverembatinib in Newly Approved Indication and the Dispatch of First Batch for the New Indication", "url": "https://www.prnewswire.com/news-releases/ascentage-pharma-hosts-ceremony-marking-the-launch-of-olverembatinib-in-newly-approved-indication-and-the-dispatch-of-first-batch-for-the-new-indication-301997142.html", "time_published": "20231124T115700", "authors": ["Ascentage Pharma"], "summary": "Ascentage Pharma Hosts Ceremony Marking the Launch of Olverembatinib in Newly Approved Indication and the ... PR ...", "banner_image": "https://mma.prnewswire.com/media/891219/Ascentage_Pharma_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}], "overall_sentiment_score": 0.175286, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "UBX", "relevance_score": "0.021679", "ticker_sentiment_score": "0.076855", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.021679", "ticker_sentiment_score": "0.076855", "ticker_sentiment_label": "Neutral"}, {"ticker": "ASPHF", "relevance_score": "0.33628", "ticker_sentiment_score": "0.177578", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "IVBXF", "relevance_score": "0.021679", "ticker_sentiment_score": "0.195643", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Pulmonary Drug Delivery Devices Market to Exceed Value of USD 49.5 Billion by 2031, TMR Study", "url": "https://www.benzinga.com/pressreleases/23/11/g35930486/pulmonary-drug-delivery-devices-market-to-exceed-value-of-usd-49-5-billion-by-2031-tmr-study", "time_published": "20231123T133000", "authors": ["Globe Newswire"], "summary": "Wilmington, Delaware, United States, Nov. 23, 2023 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. -The global pulmonary drug delivery devices market is projected to flourish at a CAGR of 4.7% from 2022 to 2031. As per the report published by TMR, a valuation of US$ 49.5 billion is ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}, {"topic": "Manufacturing", "relevance_score": "0.5"}], "overall_sentiment_score": 0.332981, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "TEVA", "relevance_score": "0.037329", "ticker_sentiment_score": "0.069901", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.037329", "ticker_sentiment_score": "0.306669", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JBL", "relevance_score": "0.037329", "ticker_sentiment_score": "0.069901", "ticker_sentiment_label": "Neutral"}, {"ticker": "MNKD", "relevance_score": "0.037329", "ticker_sentiment_score": "0.069901", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.037329", "ticker_sentiment_score": "0.069901", "ticker_sentiment_label": "Neutral"}]}, {"title": "The Evolving Market Dynamics of B-cell Lymphomas: Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia, and Burkitt Lymphoma | DelveInsight", "url": "https://www.prnewswire.com/news-releases/the-evolving-market-dynamics-of-b-cell-lymphomas-diffuse-large-b-cell-lymphoma-follicular-lymphoma-chronic-lymphocytic-leukemia-mantle-cell-lymphoma-marginal-zone-lymphoma-waldenstrom-macroglobulinemia-and-burkitt-lymphoma--301995626.html", "time_published": "20231122T220100", "authors": ["DelveInsight Business Research", "LLP"], "summary": "The Evolving Market Dynamics of B-cell Lymphomas: Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Chronic ... PR ...", "banner_image": "https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.129719, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "IPHA", "relevance_score": "0.013173", "ticker_sentiment_score": "-0.019011", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.013173", "ticker_sentiment_score": "0.026023", "ticker_sentiment_label": "Neutral"}, {"ticker": "RSSS", "relevance_score": "0.013173", "ticker_sentiment_score": "0.120239", "ticker_sentiment_label": "Neutral"}, {"ticker": "SKXJF", "relevance_score": "0.013173", "ticker_sentiment_score": "-0.019011", "ticker_sentiment_label": "Neutral"}, {"ticker": "DAWN", "relevance_score": "0.013173", "ticker_sentiment_score": "0.040164", "ticker_sentiment_label": "Neutral"}, {"ticker": "INO", "relevance_score": "0.013173", "ticker_sentiment_score": "0.040164", "ticker_sentiment_label": "Neutral"}, {"ticker": "DSKYF", "relevance_score": "0.013173", "ticker_sentiment_score": "-0.019011", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRTX", "relevance_score": "0.013173", "ticker_sentiment_score": "-0.019011", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.013173", "ticker_sentiment_score": "0.026023", "ticker_sentiment_label": "Neutral"}, {"ticker": "SWTX", "relevance_score": "0.013173", "ticker_sentiment_score": "0.040164", "ticker_sentiment_label": "Neutral"}, {"ticker": "CGEM", "relevance_score": "0.013173", "ticker_sentiment_score": "-0.019011", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRTHF", "relevance_score": "0.013173", "ticker_sentiment_score": "0.026023", "ticker_sentiment_label": "Neutral"}, {"ticker": "CNSP", "relevance_score": "0.013173", "ticker_sentiment_score": "0.040164", "ticker_sentiment_label": "Neutral"}, {"ticker": "CCCC", "relevance_score": "0.013173", "ticker_sentiment_score": "0.026023", "ticker_sentiment_label": "Neutral"}, {"ticker": "BGNE", "relevance_score": "0.026343", "ticker_sentiment_score": "0.037824", "ticker_sentiment_label": "Neutral"}, {"ticker": "KZIA", "relevance_score": "0.013173", "ticker_sentiment_score": "0.040164", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.039505", "ticker_sentiment_score": "0.102193", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.052656", "ticker_sentiment_score": "0.017928", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMRX", "relevance_score": "0.013173", "ticker_sentiment_score": "0.040164", "ticker_sentiment_label": "Neutral"}, {"ticker": "ACLX", "relevance_score": "0.013173", "ticker_sentiment_score": "0.026023", "ticker_sentiment_label": "Neutral"}, {"ticker": "VBIV", "relevance_score": "0.013173", "ticker_sentiment_score": "0.040164", "ticker_sentiment_label": "Neutral"}, {"ticker": "BYSI", "relevance_score": "0.013173", "ticker_sentiment_score": "-0.019011", "ticker_sentiment_label": "Neutral"}, {"ticker": "RAIN", "relevance_score": "0.013173", "ticker_sentiment_score": "-0.019011", "ticker_sentiment_label": "Neutral"}, {"ticker": "IOVA", "relevance_score": "0.013173", "ticker_sentiment_score": "-0.019011", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.039505", "ticker_sentiment_score": "0.022299", "ticker_sentiment_label": "Neutral"}, {"ticker": "TIL", "relevance_score": "0.013173", "ticker_sentiment_score": "-0.019011", "ticker_sentiment_label": "Neutral"}, {"ticker": "RNAC", "relevance_score": "0.013173", "ticker_sentiment_score": "0.026023", "ticker_sentiment_label": "Neutral"}, {"ticker": "INCY", "relevance_score": "0.013173", "ticker_sentiment_score": "0.040164", "ticker_sentiment_label": "Neutral"}, {"ticker": "KPTI", "relevance_score": "0.013173", "ticker_sentiment_score": "0.040164", "ticker_sentiment_label": "Neutral"}, {"ticker": "KTRA", "relevance_score": "0.013173", "ticker_sentiment_score": "0.040164", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.039505", "ticker_sentiment_score": "-0.000967", "ticker_sentiment_label": "Neutral"}, {"ticker": "RVMD", "relevance_score": "0.013173", "ticker_sentiment_score": "-0.019011", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.013173", "ticker_sentiment_score": "0.040164", "ticker_sentiment_label": "Neutral"}]}, {"title": "Eli Lilly and Novo Nordisk Are Big Names in Weight Loss, but Investors Shouldn't Count Out This Healthcare Giant", "url": "https://www.fool.com/investing/2023/11/22/eli-lilly-and-novo-nordisk-are-big-names-in-weight/", "time_published": "20231122T131500", "authors": ["David Jagielski"], "summary": "Could AstraZeneca be an under-rated buy right now?", "banner_image": "https://g.foolcdn.com/editorial/images/755562/doctor-giving-a-patient-medication.jpg", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.684621"}], "overall_sentiment_score": 0.13857, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.463792", "ticker_sentiment_score": "0.157023", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVO", "relevance_score": "0.195419", "ticker_sentiment_score": "0.100559", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 No-Brainer Stocks to Buy With $1,000 Right Now", "url": "https://www.fool.com/investing/2023/11/22/3-no-brainer-stocks-to-buy-with-1000-right-now/", "time_published": "20231122T102100", "authors": ["Sean Williams"], "summary": "A modest amount of money can go a long way when it's invested in industry-leading businesses with sustained, long-term catalysts.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F755604%2Fperson-holding-cash-bills-money-hundred-dollar-fifty-dividend-income-invest-retire-spend-getty.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.962106"}, {"topic": "Earnings", "relevance_score": "0.614606"}], "overall_sentiment_score": 0.262689, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.245031", "ticker_sentiment_score": "0.194217", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "V", "relevance_score": "0.33217", "ticker_sentiment_score": "0.224885", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "USFDA grants tentative approval to Lupin's generic drug for Type 2 Diabetes", "url": "https://www.financialexpress.com/healthcare/pharma-healthcare/usfda-grants-tentative-approval-to-lupins-generic-drug-for-type-2-diabetes/3313644/", "time_published": "20231122T025649", "authors": ["Health Desk"], "summary": "Global pharma major Lupin Limited on Tuesday announced that it has received tentative approval from the United States Food and Drug Administration ( U.S. FDA ) for its Abbreviated New Drug Application for Dapagliflozin Tablets, 5 mg, and 10 mg. Dapagliflozin is a medication used to treat type 2 ...", "banner_image": "https://www.financialexpress.com/wp-content/uploads/2023/06/lupin-bloomberg-1200-1.jpg", "source": "The Financial Express", "category_within_source": "n/a", "source_domain": "www.financialexpress.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.203706, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.377142", "ticker_sentiment_score": "0.358938", "ticker_sentiment_label": "Bullish"}]}, {"title": "RSV Cases And Hospitalizations Spike In The Southeast: CDC Says Rest Of U.S. Is Next", "url": "https://www.forbes.com/sites/ariannajohnson/2023/11/21/rsv-cases-and-hospitalizations-spike-in-the-southeast-cdc-says-rest-of-us-is-next/", "time_published": "20231121T221334", "authors": ["Arianna Johnson"], "summary": "Respiratory syncytial virus cases are rising all over the country as the fall and winter months settle in, but the Southeast is experiencing the brunt of the spike, signaling a return to pre-pandemic patterns.", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/655d2ac402d218571a5aad99/0x0.jpg?format=jpg&crop=5320,2991,x0,y253,safe&height=900&width=1600&fit=bounds", "source": "Forbes", "category_within_source": "n/a", "source_domain": "www.forbes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.03091, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.11894", "ticker_sentiment_score": "-0.001178", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.059636", "ticker_sentiment_score": "-0.001004", "ticker_sentiment_label": "Neutral"}]}, {"title": "Colorectal Cancer Treatment Drug Market to Show Immense Growth During the Study Period  ( 2019-2032 )  | DelveInsight", "url": "https://www.prnewswire.com/news-releases/colorectal-cancer-treatment-drug-market-to-show-immense-growth-during-the-study-period-20192032--delveinsight-301994315.html", "time_published": "20231121T220100", "authors": ["DelveInsight Business Research", "LLP"], "summary": "Apart from the already existing players such as Pfizer, Sanofi, Taiho Pharma, Ono Pharma, along with others, there are several emerging key players, that are expected to change the dynamics of the metastatic colorectal cancer market in the coming years owing to the positive outcomes of the ...", "banner_image": "https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.130418, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "KZR", "relevance_score": "0.023102", "ticker_sentiment_score": "-0.093525", "ticker_sentiment_label": "Neutral"}, {"ticker": "RCUS", "relevance_score": "0.046184", "ticker_sentiment_score": "-0.090173", "ticker_sentiment_label": "Neutral"}, {"ticker": "SKXJF", "relevance_score": "0.046184", "ticker_sentiment_score": "-0.012968", "ticker_sentiment_label": "Neutral"}, {"ticker": "DSKYF", "relevance_score": "0.046184", "ticker_sentiment_score": "-0.012968", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRTX", "relevance_score": "0.115121", "ticker_sentiment_score": "-0.033205", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRDF", "relevance_score": "0.092213", "ticker_sentiment_score": "-0.022317", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.092213", "ticker_sentiment_score": "-0.055925", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.023102", "ticker_sentiment_score": "-0.093525", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.069227", "ticker_sentiment_score": "-0.026334", "ticker_sentiment_label": "Neutral"}, {"ticker": "DNPUF", "relevance_score": "0.023102", "ticker_sentiment_score": "-0.075172", "ticker_sentiment_label": "Neutral"}, {"ticker": "NGM", "relevance_score": "0.023102", "ticker_sentiment_score": "-0.093525", "ticker_sentiment_label": "Neutral"}, {"ticker": "SSUMF", "relevance_score": "0.069227", "ticker_sentiment_score": "-0.052389", "ticker_sentiment_label": "Neutral"}, {"ticker": "LYEL", "relevance_score": "0.023102", "ticker_sentiment_score": "-0.093525", "ticker_sentiment_label": "Neutral"}, {"ticker": "EXEL", "relevance_score": "0.023102", "ticker_sentiment_score": "-0.093525", "ticker_sentiment_label": "Neutral"}, {"ticker": "AADI", "relevance_score": "0.023102", "ticker_sentiment_score": "-0.075172", "ticker_sentiment_label": "Neutral"}, {"ticker": "GTHX", "relevance_score": "0.046184", "ticker_sentiment_score": "-0.032778", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.046184", "ticker_sentiment_score": "-0.032778", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.046184", "ticker_sentiment_score": "-0.032778", "ticker_sentiment_label": "Neutral"}]}, {"title": "Sutro Biopharma Promotes Jane Chung to President and Chief Operating Officer", "url": "https://www.globenewswire.com/news-release/2023/11/21/2784421/0/en/Sutro-Biopharma-Promotes-Jane-Chung-to-President-and-Chief-Operating-Officer.html", "time_published": "20231121T210500", "authors": ["Inc.", "Sutro Biopharma"], "summary": "SOUTH SAN FRANCISCO, Calif., Nov. 21, 2023 ( GLOBE NEWSWIRE ) -- Sutro Biopharma, Inc. ( Sutro or the Company ) ( NASDAQ: STRO ) , a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates ( ADCs ) , today announced the promotion of Jane Chung to ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/b29d64ff-a5d8-41ff-9d46-e0e332cc7f28", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.614606"}], "overall_sentiment_score": 0.371358, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "PCVX", "relevance_score": "0.046273", "ticker_sentiment_score": "0.082739", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.138198", "ticker_sentiment_score": "0.048128", "ticker_sentiment_label": "Neutral"}, {"ticker": "STRO", "relevance_score": "0.138198", "ticker_sentiment_score": "0.186364", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Here's Why Astrazeneca  ( AZN )  is a Strong Value Stock", "url": "https://www.zacks.com/stock/news/2187264/heres-why-astrazeneca-azn-is-a-strong-value-stock", "time_published": "20231121T144007", "authors": ["Zacks Equity Research"], "summary": "Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default22.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.682689"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.989041"}], "overall_sentiment_score": 0.383557, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "PTAIF", "relevance_score": "0.077343", "ticker_sentiment_score": "-0.052591", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.372634", "ticker_sentiment_score": "0.085554", "ticker_sentiment_label": "Neutral"}]}, {"title": "AstraZeneca starts health-tech business to add AI to pharma", "url": "https://www.financialexpress.com/healthcare/pharma-healthcare/astrazeneca-starts-health-tech-business-to-add-ai-to-pharma/3312198/", "time_published": "20231121T033000", "authors": ["Bloomberg"], "summary": "AstraZeneca Plc has formed a health-technology unit that strives to bring digital solutions and artificial intelligence to clinical trials. The unit, dubbed Evinova, will reduce the cost and time of clinical trials, Astra said Monday.", "banner_image": "https://www.financialexpress.com/wp-content/uploads/2023/06/1x250.jpg", "source": "The Financial Express", "category_within_source": "n/a", "source_domain": "www.financialexpress.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.199904, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "FTRE", "relevance_score": "0.285526", "ticker_sentiment_score": "0.252454", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PTAIF", "relevance_score": "0.856646", "ticker_sentiment_score": "0.24347", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.285526", "ticker_sentiment_score": "0.452709", "ticker_sentiment_label": "Bullish"}, {"ticker": "RSSS", "relevance_score": "0.285526", "ticker_sentiment_score": "0.31879", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Drug Giant AstraZeneca Launches Evinova to Quicken Clinical Trials", "url": "https://decrypt.co/206789/astrazeneca-launches-evinova-faster-clinical-trials", "time_published": "20231121T010316", "authors": ["Jason Nelson"], "summary": "Evinova aims to use AI to design studies, automate cost calculations, and determine feasibility for drug testing.", "banner_image": "https://cdn.decrypt.co/resize/1024/height/512/wp-content/uploads/2023/11/Decrypt-Wallpaper-Format-2023-11-20T154449.391-gID_7.png", "source": "Decrypt.co", "category_within_source": "n/a", "source_domain": "decrypt.co", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.258382, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "FTRE", "relevance_score": "0.074692", "ticker_sentiment_score": "0.030226", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.148731", "ticker_sentiment_score": "0.032148", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOOG", "relevance_score": "0.074692", "ticker_sentiment_score": "0.219671", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "WLDS", "relevance_score": "0.074692", "ticker_sentiment_score": "0.265519", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.546745", "ticker_sentiment_score": "0.329855", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "The Good, Bad, And Ugly From Supercomputing '23, Or Nearby", "url": "https://www.forbes.com/sites/karlfreund/2023/11/20/the-good-bad-and-ugly-from-supercomputing-23-or-nearby/", "time_published": "20231120T225646", "authors": ["Karl Freund"], "summary": "This year's event was as much about AI as it was about HPC. The only booths not talking about AI were, well, nobody. Everyone was touting the miracles of AI, from CPUs to accelerators to system companies to networking vendors to storage to clouds to water cooling systems to the U.S.", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/6556a818401dffd9f953e269/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds", "source": "Forbes", "category_within_source": "n/a", "source_domain": "www.forbes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.169779, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LNVGF", "relevance_score": "0.029436", "ticker_sentiment_score": "0.088203", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.175221", "ticker_sentiment_score": "0.095985", "ticker_sentiment_label": "Neutral"}, {"ticker": "SSNLF", "relevance_score": "0.029436", "ticker_sentiment_score": "0.071203", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.175221", "ticker_sentiment_score": "0.15722", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GETY", "relevance_score": "0.029436", "ticker_sentiment_score": "-0.014034", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.029436", "ticker_sentiment_score": "0.067442", "ticker_sentiment_label": "Neutral"}, {"ticker": "DSSMY", "relevance_score": "0.029436", "ticker_sentiment_score": "0.067442", "ticker_sentiment_label": "Neutral"}, {"ticker": "QCOM", "relevance_score": "0.029436", "ticker_sentiment_score": "0.270477", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DOX", "relevance_score": "0.029436", "ticker_sentiment_score": "-0.014034", "ticker_sentiment_label": "Neutral"}]}, {"title": "Lilly  ( LLY )  to Build $2.5B Plant to Meet Increased Drug Demand", "url": "https://www.zacks.com/stock/news/2186768/lilly-lly-to-build-25b-plant-to-meet-increased-drug-demand", "time_published": "20231120T163100", "authors": ["Zacks Equity Research"], "summary": "Through this expansion, Eli Lilly (LLY) intends to expand its global manufacturing footprint to support the rising demand for its diabetes and obesity portfolio.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ff/2922.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.206281, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.554365", "ticker_sentiment_score": "0.435138", "ticker_sentiment_label": "Bullish"}, {"ticker": "AZN", "relevance_score": "0.388879", "ticker_sentiment_score": "0.184577", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVO", "relevance_score": "0.328236", "ticker_sentiment_score": "0.044137", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.265378", "ticker_sentiment_score": "0.198716", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Rakovina Therapeutics Announces Appointment of New Scientific Advisory Board Member", "url": "https://www.globenewswire.com/news-release/2023/11/20/2783325/0/en/Rakovina-Therapeutics-Announces-Appointment-of-New-Scientific-Advisory-Board-Member.html", "time_published": "20231120T141300", "authors": ["Rakovina Therapeutics Inc"], "summary": "VANCOUVER, British Columbia, Nov. 20, 2023 ( GLOBE NEWSWIRE ) -- Rakovina Therapeutics Inc. ( TSX-V: RKV ) ( \"the Company\" ) , a biopharmaceutical company focused on the development of novel DNA-damage response ( DDR ) inhibitors to address high unmet medical needs in the treatment of cancer, ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/e94148e0-0631-403b-9597-c742d43dca13", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": 0.079798, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.121241", "ticker_sentiment_score": "-0.037365", "ticker_sentiment_label": "Neutral"}]}, {"title": "AstraZeneca Launches Evinova Healthtech Business", "url": "https://markets.businessinsider.com/news/stocks/astrazeneca-launches-evinova-healthtech-business-1032835685", "time_published": "20231120T140802", "authors": ["markets.businessinsider.com"], "summary": "( RTTNews ) - AstraZeneca ( AZN ) Monday launched the health-tech business Evinova to cater to the needs of healthcare professionals, regulators and patients. Evinova has been developed with the backing of AstraZeneca and strategic collaborations with Parexel and Fortrea.", "banner_image": "https://markets.businessinsider.com/Images/FacebookIcon.jpg", "source": "Business Insider", "category_within_source": "RSS", "source_domain": "markets.businessinsider.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.404429, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "FTRE", "relevance_score": "0.209365", "ticker_sentiment_score": "0.247231", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.815635", "ticker_sentiment_score": "0.619172", "ticker_sentiment_label": "Bullish"}]}, {"title": "Eli Lilly Just Got One Step Closer to Dethroning Ozempic. Time to Buy the Stock?", "url": "https://www.fool.com/investing/2023/11/19/eli-lilly-just-got-one-step-closer-to-dethroning-o/", "time_published": "20231119T110500", "authors": ["Adam Spatacco"], "summary": "Eli Lilly just received FDA approval for its obesity medication Zepbound, the sister treatment to its blockbuster drug Mounjaro.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F755134%2Fa-doctor-writing-a-prescription.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.210864, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BCS", "relevance_score": "0.033328", "ticker_sentiment_score": "0.130891", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.033328", "ticker_sentiment_score": "0.105236", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.033328", "ticker_sentiment_score": "0.130891", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.132733", "ticker_sentiment_score": "0.064572", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.522486", "ticker_sentiment_score": "0.289301", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.033328", "ticker_sentiment_score": "0.105236", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.033328", "ticker_sentiment_score": "0.105236", "ticker_sentiment_label": "Neutral"}]}, {"title": "US CDC Rolls Out Additional Doses For Sanofi/AstraZeneca Recently Approved Respiratory Infection Drug As Demand Surges - AstraZeneca  ( NASDAQ:AZN ) , Sanofi  ( NASDAQ:SNY ) ", "url": "https://www.benzinga.com/general/biotech/23/11/35851000/us-cdc-rolls-out-additional-doses-for-sanofiastrazeneca-recently-approved-respiratory-infection-d", "time_published": "20231117T184730", "authors": ["Vandana Singh"], "summary": "The U.S. Centers for Disease Control and Prevention ( CDC ) released more than 77,000 additional doses of Beyfortus ( nirsevimab ) , a respiratory syncytial virus ( RSV ) drug developed in collaboration between Sanofi SA SNY and AstraZeneca Plc AZN.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/11/17/sny-infants.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.030835, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.541149", "ticker_sentiment_score": "-0.046704", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.421485", "ticker_sentiment_score": "-0.036657", "ticker_sentiment_label": "Neutral"}]}, {"title": "FTSE indexes eye sharp weekly gains on peak-rate optimism", "url": "https://www.reuters.com/markets/ftse-indexes-look-end-week-positive-note-2023-11-17/", "time_published": "20231117T171600", "authors": ["Sruthi Shankar", "Johann Cherian"], "summary": "A man wearing a protective face mask walks past the London Stock Exchange Group building in the City of London financial district, whilst British stocks tumble as investors fear that the coronavirus outbreak could stall the global economy, in London, Britain, March 9, 2020.", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/BC5VULNBJFJMZPAKC3OH73DDSI.jpg", "source": "Reuters", "category_within_source": "Markets", "source_domain": "www.reuters.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.976913"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.021896, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "TSCDF", "relevance_score": "0.089129", "ticker_sentiment_score": "0.089955", "ticker_sentiment_label": "Neutral"}, {"ticker": "BCS", "relevance_score": "0.089129", "ticker_sentiment_score": "0.089955", "ticker_sentiment_label": "Neutral"}, {"ticker": "FGROF", "relevance_score": "0.089129", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "LDNXF", "relevance_score": "0.17715", "ticker_sentiment_score": "-0.061102", "ticker_sentiment_label": "Neutral"}, {"ticker": "HTHIF", "relevance_score": "0.089129", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.089129", "ticker_sentiment_score": "-0.047695", "ticker_sentiment_label": "Neutral"}]}, {"title": "Penny Stocks To Buy? 4 Under $5 To Watch Right Now", "url": "https://pennystocks.com/featured/2023/11/17/penny-stocks-to-buy-4-under-5-to-watch-right-now/", "time_published": "20231117T161916", "authors": ["J. Samuel"], "summary": "When it comes to finding penny stocks to buy, there are plenty of things you'll need to make note of. Sure, broader stock market news trends don't directly influence cheap stocks. Even if the stock market is down like it is today, there are sure to be at least a few cheap stocks to watch.", "banner_image": "https://pennystocks.com/wp-content/uploads/2021/02/best-penny-stocks-to-watch-biotechnology.jpg", "source": "PennyStocks.com", "category_within_source": "n/a", "source_domain": "pennystocks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.682689"}, {"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.999999"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.248309, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BABA", "relevance_score": "0.031696", "ticker_sentiment_score": "0.072867", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.063341", "ticker_sentiment_score": "0.119267", "ticker_sentiment_label": "Neutral"}, {"ticker": "LMDX", "relevance_score": "0.063341", "ticker_sentiment_score": "0.119267", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.031696", "ticker_sentiment_score": "-0.134061", "ticker_sentiment_label": "Neutral"}, {"ticker": "FCCO", "relevance_score": "0.031696", "ticker_sentiment_score": "0.113608", "ticker_sentiment_label": "Neutral"}, {"ticker": "ARDX", "relevance_score": "0.063341", "ticker_sentiment_score": "0.195556", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MDT", "relevance_score": "0.031696", "ticker_sentiment_score": "0.372353", "ticker_sentiment_label": "Bullish"}, {"ticker": "CYTO", "relevance_score": "0.031696", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "HRTX", "relevance_score": "0.031696", "ticker_sentiment_score": "0.179366", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "AstraZeneca Is Trying to Make an Ozempic Competitor  ( Again ) , but Don't Rush to Buy the Stock", "url": "https://www.fool.com/investing/2023/11/17/astrazeneca-trying-to-make-an-ozempic-competitor-a/", "time_published": "20231117T145300", "authors": ["Alex Carchidi"], "summary": "It might have a hard time finding a home in the market.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.239279, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.44266", "ticker_sentiment_score": "0.313016", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "CDC expedites release of more doses of infant RSV drug from Sanofi, AstraZeneca amid shortage", "url": "https://www.cnbc.com/2023/11/17/rsv-cdc-expedites-release-of-sanofi-astrazeneca-drug-amid-shortage.html", "time_published": "20231117T134439", "authors": ["Annika Kim Constantino"], "summary": "The CDC's move to increase availability of Beyfortus, a monoclonal antibody from Sanofi and AstraZeneca, comes as RSV cases rise in some parts of the country.", "banner_image": "https://image.cnbcfm.com/api/v1/image/107160369-16699949192022-12-02t135820z_1175064686_rc2mxx9bklwy_rtrmadp_0_health-rsv.jpeg?v=1691071833&w=1920&h=1080", "source": "CNBC", "category_within_source": "Business", "source_domain": "www.cnbc.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.072615, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.183895", "ticker_sentiment_score": "0.237075", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SNY", "relevance_score": "0.272788", "ticker_sentiment_score": "0.078613", "ticker_sentiment_label": "Neutral"}]}, {"title": "Pharma Stock Roundup: FDA Okays AZN's Capivasertib & MRK's Keytruda Expanded Use", "url": "https://www.zacks.com/stock/news/2185842/pharma-stock-roundup-fda-okays-azns-capivasertib-mrks-keytruda-expanded-use", "time_published": "20231117T131400", "authors": ["Kinjel Shah"], "summary": "FDA approves AstraZeneca's (AZN) new breast cancer drug, Truqap, and the expanded use of Merck's (MRK) Keytruda in a gastric cancer indication ...", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/cf/2377.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.036697, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.113597", "ticker_sentiment_score": "0.002274", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.113597", "ticker_sentiment_score": "-0.068544", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.224903", "ticker_sentiment_score": "-0.061435", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.113597", "ticker_sentiment_score": "0.002274", "ticker_sentiment_label": "Neutral"}]}, {"title": "AstraZeneca's  ( AZN )  Capivasertib Gets FDA Nod for Breast Cancer", "url": "https://www.zacks.com/stock/news/2185834/astrazenecas-azn-capivasertib-gets-fda-nod-for-breast-cancer", "time_published": "20231117T130600", "authors": ["Zacks Equity Research"], "summary": "AstraZeneca's (AZN) capivasertib gets approval in combination with Faslodex for HR-positive, HER2-negative metastatic breast cancer.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/12/31139.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.9545"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.009846, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "DVAX", "relevance_score": "0.392948", "ticker_sentiment_score": "0.188996", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MEIP", "relevance_score": "0.331765", "ticker_sentiment_score": "0.232123", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.451494", "ticker_sentiment_score": "0.054804", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.268294", "ticker_sentiment_score": "0.061489", "ticker_sentiment_label": "Neutral"}]}, {"title": "FDA Approves AstraZeneca's Truqap/Faslodex Combo Therapy For Breast Cancer, Competes With Gilead's Drug - AstraZeneca  ( NASDAQ:AZN ) ", "url": "https://www.benzinga.com/general/biotech/23/11/35846020/fda-approves-astrazenecas-truqapfaslodex-combo-therapy-for-breast-cancer-competes-with-gileads-dr", "time_published": "20231117T124609", "authors": ["Vandana Singh"], "summary": "FDA approves AstraZeneca Plc's AZN Truqap ( capivasertib ) in combination with Faslodex ( fulvestrant ) for the treatment of adult patients with hormone receptor ( HR ) -positive, HER2-negative locally advanced or metastatic breast cancer with one or more biomarker alterations ( PIK3CA, AKT1 or ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/11/17/azn.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.064706, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.654522", "ticker_sentiment_score": "0.240388", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Novavax Makes Changes to Executive Leadership Team to Enhance Focus on Delivery of Strategic Priorities", "url": "https://www.prnewswire.com/news-releases/novavax-makes-changes-to-executive-leadership-team-to-enhance-focus-on-delivery-of-strategic-priorities-301991645.html", "time_published": "20231117T121500", "authors": ["NOVAVAX", "INC"], "summary": "\u2022 New organizational structure for executive leadership team designed to facilitate a leaner and more focused approach to annual execution of business plans \u2022 to join as Chief Legal Officer and Corporate Secretary", "banner_image": "https://mma.prnewswire.com/media/1506866/Novavax_High_Res_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.168532, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "HOLX", "relevance_score": "0.03468", "ticker_sentiment_score": "0.079721", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVAX", "relevance_score": "0.457274", "ticker_sentiment_score": "0.160069", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HSIC", "relevance_score": "0.03468", "ticker_sentiment_score": "-0.056161", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.03468", "ticker_sentiment_score": "-0.056161", "ticker_sentiment_label": "Neutral"}, {"ticker": "BSX", "relevance_score": "0.03468", "ticker_sentiment_score": "0.079721", "ticker_sentiment_label": "Neutral"}]}, {"title": "European shares gain on healthcare boost, euro zone inflation data eyed", "url": "https://www.reuters.com/markets/europe/european-shares-gain-healthcare-boost-euro-zone-inflation-data-eyed-2023-11-17/", "time_published": "20231117T083100", "authors": ["Reuters"], "summary": "A TV presenter gets ready for the daily reporting from the floor of the German share price index DAX at the stock exchange in Frankfurt, Germany, November 15, 2023. REUTERS/Staff/File Photo Acquire Licensing Rights", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/CI5JN74QNVLAHCPIJ2QHQNIZAA.jpg", "source": "Reuters", "category_within_source": "Markets", "source_domain": "www.reuters.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.769861"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}], "overall_sentiment_score": 0.146909, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.199037", "ticker_sentiment_score": "0.446739", "ticker_sentiment_label": "Bullish"}, {"ticker": "NVO", "relevance_score": "0.199037", "ticker_sentiment_score": "0.446739", "ticker_sentiment_label": "Bullish"}, {"ticker": "SNY", "relevance_score": "0.199037", "ticker_sentiment_score": "0.446739", "ticker_sentiment_label": "Bullish"}]}, {"title": "CDC expedites release of 77,000 additional doses of Sanofi-AstraZeneca's RSV drug", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/cdc-releases-77000-additional-doses-sanofi-astrazenecas-rsv-drug-2023-11-16/", "time_published": "20231117T020200", "authors": ["Reuters"], "summary": "CDC expedites release of 77000 additional doses of Sanofi-AstraZeneca's RSV drug ...", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/ZKVKLP44JRKCZBZDQ77XYAIGNE.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.040275, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.117486", "ticker_sentiment_score": "-0.050329", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.445569", "ticker_sentiment_score": "-0.132095", "ticker_sentiment_label": "Neutral"}]}, {"title": "RSV is straining some hospitals, and US officials are releasing more shots for newborns", "url": "https://apnews.com/article/rsv-surge-shots-newborns-c0183aa026f968807401d6f5ddf44954", "time_published": "20231116T215100", "authors": ["KENYA HUNTER", "MIKE STOBBE"], "summary": "NEW YORK ( AP ) - RSV infections are rising sharply in some parts of the country, nearly filling hospital emergency departments in Georgia, Texas and some other states. To help counter the surge, federal officials on Thursday announced they were releasing more doses of a new RSV shot for ...", "banner_image": "https://dims.apnews.com/dims4/default/5069c3e/2147483647/strip/true/crop/4850x3231+0+174/resize/599x399!/quality/90/?url=https%3A%2F%2Fassets.apnews.com%2F0a%2F97%2Fd39cdf5b14dcdbeec3c84fcaf0f0%2F9d1800cef58c456c96e711447b3dbdb8", "source": "Associated Press", "category_within_source": "Markets", "source_domain": "apnews.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": -0.086044, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.046273", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "HHH", "relevance_score": "0.046273", "ticker_sentiment_score": "0.137397", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.046273", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "AstraZeneca Pharma India plans to sell its production plant in Bengaluru", "url": "https://www.business-standard.com/companies/news/astrazeneca-pharma-india-plans-to-sell-its-production-plant-in-bengaluru-123111600801_1.html", "time_published": "20231116T131434", "authors": ["Press Trust of India"], "summary": "AstraZeneca Pharma India plans to sell its production facility in Bengaluru as part of a strategic review of global manufacturing and supply network by its parent, according to a regulatory filing.", "banner_image": "https://bsmedia.business-standard.com/_media/bs/img/article/2023-07/03/full/1688369760-8407.jpg?im=FeatureCrop,size=(826,465)", "source": "Business Standard", "category_within_source": "GoogleRSS", "source_domain": "www.business-standard.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.181243, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.692465", "ticker_sentiment_score": "0.466256", "ticker_sentiment_label": "Bullish"}]}, {"title": "FDA Approves Bristol-Myers' Lung Cancer Drug Acquired Via $4B Turning Point Deal: Competes With Roche, Merck, AstraZeneca - Bristol-Myers Squibb  ( NYSE:BMY ) ", "url": "https://www.benzinga.com/general/biotech/23/11/35822094/fda-approves-bristol-myers-lung-cancer-drug-acquired-via-4b-turning-point-deal-competes-with-roch", "time_published": "20231116T114833", "authors": ["Vandana Singh"], "summary": "The FDA approved Bristol Myers Squibb And Co's BMY Augtyro ( repotrectinib ) for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer ( NSCLC ) . The pharma giant added the drug via a $4.1 billion buyout of Turning Point Therapeutics ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/11/16/bmy_1.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.15791, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.27432", "ticker_sentiment_score": "-0.586056", "ticker_sentiment_label": "Bearish"}, {"ticker": "BMY", "relevance_score": "0.401331", "ticker_sentiment_score": "0.156825", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Fusion Pharmaceuticals Strengthens Actinium Supply with Onsite Isotope Production through Expanded BWXT Medical Collaboration", "url": "https://www.newswire.ca/news-releases/fusion-pharmaceuticals-strengthens-actinium-supply-with-onsite-isotope-production-through-expanded-bwxt-medical-collaboration-808792837.html", "time_published": "20231116T114500", "authors": ["Fusion Pharmaceuticals"], "summary": "Fusion Pharmaceuticals Strengthens Actinium Supply with Onsite Isotope Production through Expanded BWXT ... Canada ...", "banner_image": "https://mma.prnewswire.com/media/1196797/Fusion_Logo.jpg?p=facebook", "source": "Canada Newswire", "category_within_source": "n/a", "source_domain": "www.newswire.ca", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.684621"}], "overall_sentiment_score": 0.182176, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.031487", "ticker_sentiment_score": "0.070861", "ticker_sentiment_label": "Neutral"}, {"ticker": "BWXT", "relevance_score": "0.522622", "ticker_sentiment_score": "0.383102", "ticker_sentiment_label": "Bullish"}, {"ticker": "FUSN", "relevance_score": "0.12546", "ticker_sentiment_score": "0.009541", "ticker_sentiment_label": "Neutral"}]}, {"title": "Fusion Pharmaceuticals Strengthens Actinium Supply with Onsite Isotope Production through Expanded BWXT Medical Collaboration - Fusion Pharmaceuticals  ( NASDAQ:FUSN ) , BWX Technologies  ( NYSE:BWXT ) ", "url": "https://www.benzinga.com/pressreleases/23/11/n35823216/fusion-pharmaceuticals-strengthens-actinium-supply-with-onsite-isotope-production-through-expanded", "time_published": "20231116T114500", "authors": ["PRNewswire"], "summary": "Collaboration enables Fusion to produce high purity actinium-225 at Company's GMP manufacturing facility Agreement furthers BWXT Medical's position as a global leader in medical isotope supply HAMILTON, ON and BOSTON, Nov. 16, 2023 /PRNewswire/ -- Fusion Pharmaceuticals Inc.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.796627"}], "overall_sentiment_score": 0.177142, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.029691", "ticker_sentiment_score": "0.066422", "ticker_sentiment_label": "Neutral"}, {"ticker": "BWXT", "relevance_score": "0.520555", "ticker_sentiment_score": "0.376422", "ticker_sentiment_label": "Bullish"}, {"ticker": "FUSN", "relevance_score": "0.118354", "ticker_sentiment_score": "0.009273", "ticker_sentiment_label": "Neutral"}]}, {"title": "US FDA approves Bristol-Myers' lung cancer drug", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-bristol-myers-lung-cancer-drug-2023-11-15/", "time_published": "20231115T224300", "authors": ["Reuters"], "summary": "A sign stands outside a Bristol Myers Squibb facility in Cambridge, Massachusetts, U.S., May 20, 2021. REUTERS/Brian Snyder/File Photo/File Photo Acquire Licensing Rights Nov 15 ( Reuters ) - The U.S.", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/GFWI6STKHJMH3I3AD6W3HZVHD4.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.130664, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.158519", "ticker_sentiment_score": "-0.420049", "ticker_sentiment_label": "Bearish"}, {"ticker": "BMY", "relevance_score": "0.158519", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Type 1 Diabetes Market to Accelerate Substantially During the Study Period  ( 2019-2032 ) , Predicts DelveInsight | Leading Companies Developing Therapies - Eli Lilly, Vertex, Bayer, Novo Nordisk, Rise, Tolerion, BioKier, Domp\u00e9 Farmaceutici", "url": "https://www.prnewswire.com/news-releases/type-1-diabetes-market-to-accelerate-substantially-during-the-study-period-20192032-predicts-delveinsight--leading-companies-developing-therapies---eli-lilly-vertex-bayer-novo-nordisk-rise-tolerion-biokier-dompe-farmac-301989755.html", "time_published": "20231115T220100", "authors": ["DelveInsight Business Research", "LLP"], "summary": "Type 1 Diabetes Market to Accelerate Substantially During the Study Period ( 2019-2032 ) , Predicts DelveInsight ... PR ...", "banner_image": "https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.208545, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LABP", "relevance_score": "0.026042", "ticker_sentiment_score": "0.027777", "ticker_sentiment_label": "Neutral"}, {"ticker": "PBLA", "relevance_score": "0.026042", "ticker_sentiment_score": "0.027777", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.026042", "ticker_sentiment_score": "0.027777", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADOCY", "relevance_score": "0.026042", "ticker_sentiment_score": "0.027777", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.129655", "ticker_sentiment_score": "0.093706", "ticker_sentiment_label": "Neutral"}, {"ticker": "HSTO", "relevance_score": "0.026042", "ticker_sentiment_score": "0.027777", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.052056", "ticker_sentiment_score": "0.078585", "ticker_sentiment_label": "Neutral"}, {"ticker": "CELZ", "relevance_score": "0.052056", "ticker_sentiment_score": "0.092557", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.026042", "ticker_sentiment_score": "0.044133", "ticker_sentiment_label": "Neutral"}]}, {"title": "Boston Properties  ( BXP )  to Sell 45% Stake in Two Life-Science Assets", "url": "https://www.zacks.com/stock/news/2184827/boston-properties-bxp-to-sell-45-stake-in-two-life-science-assets", "time_published": "20231115T174000", "authors": ["Zacks Equity Research"], "summary": "Boston Properties (BXP) announces a 45% stake sale in 290 Binney Street and 300 Binney Street in Kendall Square, MA, to Norges Bank Investment Management for a gross valuation of $1.66 billion.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/03/29840.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}, {"topic": "Real Estate & Construction", "relevance_score": "0.5"}], "overall_sentiment_score": 0.243408, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "STAG", "relevance_score": "0.126784", "ticker_sentiment_score": "0.043415", "ticker_sentiment_label": "Neutral"}, {"ticker": "BXP", "relevance_score": "0.423504", "ticker_sentiment_score": "0.317198", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.063594", "ticker_sentiment_score": "0.048102", "ticker_sentiment_label": "Neutral"}, {"ticker": "EGP", "relevance_score": "0.189175", "ticker_sentiment_score": "0.075172", "ticker_sentiment_label": "Neutral"}]}, {"title": "AstraZeneca's  ( AZN )  Imfinzi Early-Stage Lung Cancer Study Fails", "url": "https://www.zacks.com/stock/news/2184672/astrazenecas-azn-imfinzi-early-stage-lung-cancer-study-fails", "time_published": "20231115T151000", "authors": ["Zacks Equity Research"], "summary": "AstraZeneca's (AZN) PACIFIC-2 study on Imfinzi fails to achieve statistical significance for the primary endpoint of progression-free survival.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/5d/2633.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.838487"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.086134, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "DVAX", "relevance_score": "0.330876", "ticker_sentiment_score": "0.202196", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MEIP", "relevance_score": "0.267559", "ticker_sentiment_score": "0.161746", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.391923", "ticker_sentiment_score": "0.085119", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.202366", "ticker_sentiment_score": "0.071637", "ticker_sentiment_label": "Neutral"}]}, {"title": "Belgium limits Novo's Ozempic to diabetes, obesity patients", "url": "https://www.financialexpress.com/healthcare/pharma-healthcare/belgium-limits-novos-ozempic-to-diabetes-obesity-patients/3307365/", "time_published": "20231115T093000", "authors": ["Bloomberg"], "summary": "Belgium tightened rules around prescribing Novo Nordisk A/S's Ozempic and other diabetes medications amid shortages driven by competing demand for the drugs as a popular remedy for weight loss.", "banner_image": "https://www.financialexpress.com/wp-content/uploads/2023/11/vitamins-g81bff71f1_1920-2.jpg", "source": "The Financial Express", "category_within_source": "n/a", "source_domain": "www.financialexpress.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.126896, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.160633", "ticker_sentiment_score": "0.168315", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVO", "relevance_score": "0.160633", "ticker_sentiment_score": "-0.026185", "ticker_sentiment_label": "Neutral"}]}, {"title": "Myricx Bio Appoints Dr Chris Martin, Biotech Entrepreneur and ADC Pioneer, as Chairman of its Board of Directors - ADC Therapeutics  ( NYSE:ADCT ) ", "url": "https://www.benzinga.com/pressreleases/23/11/g35797782/myricx-bio-appoints-dr-chris-martin-biotech-entrepreneur-and-adc-pioneer-as-chairman-of-its-board-", "time_published": "20231115T080000", "authors": ["Globe Newswire"], "summary": "LONDON, Nov. 15, 2023 ( GLOBE NEWSWIRE ) -- Myricx Bio ( 'Myricx' ) , a UK biotech company focused on the discovery and development of a completely novel class of antibody-drug conjugate ( ADC ) payloads based on N-Myristoyltransferase inhibition ( NMTi ) , today announces the appointment of Dr ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.684621"}], "overall_sentiment_score": 0.218117, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.046633", "ticker_sentiment_score": "0.048177", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADCT", "relevance_score": "0.184951", "ticker_sentiment_score": "0.200001", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Cellectis Announces the execution of the Subsequent Investment Agreement with AstraZeneca", "url": "https://www.globenewswire.com/news-release/2023/11/15/2780728/0/en/Cellectis-Announces-the-execution-of-the-Subsequent-Investment-Agreement-with-AstraZeneca.html", "time_published": "20231115T073000", "authors": ["Cellectis Inc."], "summary": "NEW YORK, Nov. 15, 2023 ( GLOBE NEWSWIRE ) -- Cellectis ( Euronext Growth: ALCLS - NASDAQ: CLLS ) today anounced that, following the consultation of its works council, it has now signed a binding Subsequent Investment Agreement with AstraZeneca ( LSE/STO/Nasdaq: AZN ) regarding the contemplated ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/a84ce25b-a774-4635-9b79-d45241f5decc", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Economy - Fiscal", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.999967"}], "overall_sentiment_score": 0.16257, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.303175", "ticker_sentiment_score": "0.33927", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CLLS", "relevance_score": "0.650245", "ticker_sentiment_score": "0.282551", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Cellectis Announces the execution of the Subsequent Investment Agreement with AstraZeneca - AstraZeneca  ( NASDAQ:AZN ) , Cellectis  ( NASDAQ:CLLS ) ", "url": "https://www.benzinga.com/pressreleases/23/11/g35797650/cellectis-announces-the-execution-of-the-subsequent-investment-agreement-with-astrazeneca", "time_published": "20231115T073000", "authors": ["Globe Newswire"], "summary": "Execution of binding subsequent investment agreement regarding contemplated additional equity investment of $140M by AstraZeneca, previously announced on November 1, 2023. Extraordinary shareholders' meeting of Cellectis to be held on or around December 22, 2023 to approve such investment.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Economy - Fiscal", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.99999"}], "overall_sentiment_score": 0.134482, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.290262", "ticker_sentiment_score": "0.281574", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CLLS", "relevance_score": "0.587133", "ticker_sentiment_score": "0.233092", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Airfinity gives decision makers big picture on health", "url": "https://www.ft.com/content/f7b3f9ff-b57a-4fcd-8dd7-83301b1908b9", "time_published": "20231115T050014", "authors": ["Hannah Kuchler"], "summary": "Covid may have abated, but emerging diseases and new drug categories are keeping the analytics firm busy ...", "banner_image": "https://www.ft.com/__origami/service/image/v2/images/raw/https%3A%2F%2Fd1e00ek4ebabms.cloudfront.net%2Fproduction%2F3f0f18a7-b1df-4b7c-8b6a-ce5452759122.jpg?source=next-article&fit=scale-down&quality=highest&width=700&dpr=1", "source": "Financial Times", "category_within_source": "Companies", "source_domain": "www.ft.com", "topics": [{"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.098107, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.083251", "ticker_sentiment_score": "0.007231", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.083251", "ticker_sentiment_score": "0.128339", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.041682", "ticker_sentiment_score": "0.031358", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.041682", "ticker_sentiment_score": "0.031358", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why ESG Is A Top Priority Of CFOs", "url": "https://www.forbes.com/sites/meganpoinski/2023/11/14/why-esg-is-a-top-priority-of-cfos/", "time_published": "20231114T171550", "authors": ["Megan Poinski"], "summary": "This is the published version of Forbes' CFO newsletter, which offers the latest news for chief finance officers and other leaders focused on the budget. Sign-up here to get it delivered to your inbox every Tuesday. In Washington, D.C. the countdown is back on.", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/6553aa2509d0bd6309540f8e/0x0.jpg?format=jpg&crop=2394,1346,x0,y498,safe&height=900&width=1600&fit=bounds", "source": "Forbes", "category_within_source": "n/a", "source_domain": "www.forbes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Energy & Transportation", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "Blockchain", "relevance_score": "0.158519"}, {"topic": "Economy - Monetary", "relevance_score": "0.838487"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.684621"}, {"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Economy - Macro", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.102358, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "FI", "relevance_score": "0.019618", "ticker_sentiment_score": "-0.016619", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.019618", "ticker_sentiment_score": "0.01423", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.019618", "ticker_sentiment_score": "0.17744", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MCO", "relevance_score": "0.019618", "ticker_sentiment_score": "-0.137343", "ticker_sentiment_label": "Neutral"}, {"ticker": "TRUE", "relevance_score": "0.019618", "ticker_sentiment_score": "-0.073366", "ticker_sentiment_label": "Neutral"}, {"ticker": "GS", "relevance_score": "0.019618", "ticker_sentiment_score": "-0.026226", "ticker_sentiment_label": "Neutral"}, {"ticker": "WMT", "relevance_score": "0.019618", "ticker_sentiment_score": "0.058825", "ticker_sentiment_label": "Neutral"}]}, {"title": "AstraZeneca's Flagship Cancer Drug Imfinzi Fails On Main Goal In Lung Cancer Trial When Combined With Chemoradiotherapy - AstraZeneca  ( NASDAQ:AZN ) ", "url": "https://www.benzinga.com/general/biotech/23/11/35770581/astrazenecas-flagship-cancer-drug-imfinzi-fails-on-main-goal-in-lung-cancer-trial-when-combined-w", "time_published": "20231114T151858", "authors": ["Vandana Singh"], "summary": "AstraZeneca Plc AZN said its PACIFIC-2 Phase 3 trial for Imfinzi ( durvalumab ) concurrently administered with chemoradiotherapy ( CRT ) did not achieve statistical significance for the primary endpoint of progression-free survival versus CRT alone for unresectable, Stage III non-small cell lung ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/11/14/azn.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.033976, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.377142", "ticker_sentiment_score": "-0.166145", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Ocean Biomedical  ( NASDAQ: OCEA )  Announces Positive Preclinical Oncology Data for VRON-0300, Presented at SITC 2023 Annual Meeting, and Clinical Updates by 50/50 Joint Venture Partner Virion Therapeutics", "url": "https://www.globenewswire.com/news-release/2023/11/14/2780045/0/en/Ocean-Biomedical-NASDAQ-OCEA-Announces-Positive-Preclinical-Oncology-Data-for-VRON-0300-Presented-at-SITC-2023-Annual-Meeting-and-Clinical-Updates-by-50-50-Joint-Venture-Partner-Vi.html", "time_published": "20231114T130100", "authors": ["Ocean Biomedical", "Inc."], "summary": "Providence, Rhode Island, Nov. 14, 2023 ( GLOBE NEWSWIRE ) -- Ocean Biomedical, Inc. ( NASDAQ: OCEA ) , a biopharmaceutical company working to accelerate the development of compelling discoveries from top research scientists, today announced that its joint venture partner, Virion Therapeutics, ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/9fde1644-853f-443e-9646-0394624b6dc8", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.082276, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "OCEA", "relevance_score": "0.177896", "ticker_sentiment_score": "0.105467", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.025624", "ticker_sentiment_score": "-0.054059", "ticker_sentiment_label": "Neutral"}]}, {"title": "AstraZeneca's Imfinzi plus chemoradiotherapy fail main goal in late stage trial", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/astrazenecas-imfinzi-plus-chemoradiotherapy-fail-main-goal-late-stage-trial-2023-11-14/", "time_published": "20231114T071700", "authors": ["Reuters"], "summary": "A company logo is seen at the AstraZeneca site in Macclesfield, Britain, May 11, 2021. REUTERS/Phil Noble/File Photo Acquire Licensing Rights", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/FE5VXPAKRZJ6FK3FLVLIPUIVLU.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.284683, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.7887", "ticker_sentiment_score": "-0.512903", "ticker_sentiment_label": "Bearish"}]}, {"title": "RHHBY: 3 Booming Pharma Stocks Making Waves in November", "url": "https://stocknews.com/news/rhhby-azn-bmy-3-booming-pharma-stocks-making-waves-in-november/", "time_published": "20231113T171841", "authors": ["StockNews.com Staff"], "summary": "Due to rising medical requirements and technical improvements, the pharmaceutical industry's long-term growth prospects remain promising. Also, the growing global population and rising number of chronic diseases are adding to the industry's positive outlook.", "banner_image": "https://stocknews.com/wp-content/uploads/2022/10/Rashmi-Kumari_headshot_2-1.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "stocknews.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999987"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.503496"}], "overall_sentiment_score": 0.188618, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.200134", "ticker_sentiment_score": "0.285411", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BMY", "relevance_score": "0.10087", "ticker_sentiment_score": "0.212812", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Investigating AstraZeneca's Standing In Pharmaceuticals Industry Compared To Competitors - AstraZeneca  ( NASDAQ:AZN ) ", "url": "https://www.benzinga.com/news/23/11/35754360/investigating-astrazenecas-standing-in-pharmaceuticals-industry-compared-to-competitors", "time_published": "20231113T160038", "authors": ["Benzinga Insights"], "summary": "In the dynamic and cutthroat world of business, conducting thorough company analysis is essential for investors and industry experts. In this article, we will undertake a comprehensive industry comparison, evaluating AstraZeneca AZN and its primary competitors in the Pharmaceuticals industry.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.938793"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.5855"}], "overall_sentiment_score": 0.07262, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "PTAIF", "relevance_score": "0.072217", "ticker_sentiment_score": "0.018298", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.413425", "ticker_sentiment_score": "0.217607", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Ionis  ( IONS )  Early-Stage Genetic Disorder Data Shows Promise", "url": "https://www.zacks.com/stock/news/2183312/ionis-ions-early-stage-genetic-disorder-data-shows-promise", "time_published": "20231113T144600", "authors": ["Zacks Equity Research"], "summary": "Preliminary data from a phase I/IIa study on Ionis' (IONS) pipeline candidate, ION582, shows encouraging EEG and clinical observations in a phase I/IIa study.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/98/2216.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.09529, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "IONS", "relevance_score": "0.342093", "ticker_sentiment_score": "-0.067359", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.342093", "ticker_sentiment_score": "0.13504", "ticker_sentiment_label": "Neutral"}, {"ticker": "GSK", "relevance_score": "0.342093", "ticker_sentiment_score": "0.048762", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.420083", "ticker_sentiment_score": "0.216924", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Here is What to Know Beyond Why AstraZeneca PLC  ( AZN )  is a Trending Stock", "url": "https://www.zacks.com/stock/news/2183217/here-is-what-to-know-beyond-why-astrazeneca-plc-azn-is-a-trending-stock", "time_published": "20231113T140006", "authors": ["Zacks Equity Research"], "summary": "Recently, Zacks.com users have been paying close attention to Astrazeneca (AZN). This makes it worthwhile to examine what the stock has in store.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default91.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.54554"}], "overall_sentiment_score": 0.202171, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.493128", "ticker_sentiment_score": "0.096343", "ticker_sentiment_label": "Neutral"}]}, {"title": "David Cameron's return brings his role for fallen Greensill back to the fore", "url": "https://www.marketwatch.com/story/david-camerons-return-brings-his-role-for-fallen-greensill-back-to-the-fore-a1529c1d", "time_published": "20231113T133400", "authors": ["Steve Goldstein"], "summary": "The surprise return of former Prime Minister David Cameron as the U.K.'s new foreign secretary brings his work for the fallen Greensill Capital back to the limelight.", "banner_image": "https://images.mktw.net/im-886027/social", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Manufacturing", "relevance_score": "0.5"}], "overall_sentiment_score": 0.012121, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.11983", "ticker_sentiment_score": "-0.005933", "ticker_sentiment_label": "Neutral"}, {"ticker": "F", "relevance_score": "0.11983", "ticker_sentiment_score": "-0.005933", "ticker_sentiment_label": "Neutral"}]}, {"title": "AstraZeneca prioritizes US for RSV drug amid surge in cases", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/astrazeneca-prioritizes-us-rsv-drug-amid-surge-cases-2023-11-10/", "time_published": "20231110T192200", "authors": ["Patrick Wingrove", "Maggie Fick"], "summary": "NEW YORK, Nov 10 ( Reuters ) - AstraZeneca ( AZN.L ) on Friday said it was prioritizing the U.S. market for additional doses of its respiratory syncytial virus ( RSV ) drug Beyfortus, which was approved in July to prevent the disease in infants and toddlers, as a surge of cases is outpacing ...", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/L4L6T5NUWFOKVJ6D6OVP2WMR2U.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.112387, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.241684", "ticker_sentiment_score": "0.016471", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.241684", "ticker_sentiment_score": "-0.025485", "ticker_sentiment_label": "Neutral"}]}, {"title": "Who's afraid of Ozempic? From restaurants to package makers, companies work to calm investors' GLP-1 jitters.", "url": "https://www.marketwatch.com/story/whos-afraid-of-ozempic-from-restaurants-to-package-makers-companies-work-to-calm-investors-glp-1-jitters-0599dba5", "time_published": "20231110T161300", "authors": ["Eleanor Laise"], "summary": "With Eli Lilly's Zepbound set to enter the fray, companies are flooded with weight-loss drug questions ...", "banner_image": "https://images.mktw.net/im-884373/social", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.990678"}], "overall_sentiment_score": 0.0, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MDLZ", "relevance_score": "0.077677", "ticker_sentiment_score": "0.002046", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.05183", "ticker_sentiment_score": "0.024949", "ticker_sentiment_label": "Neutral"}, {"ticker": "TFX", "relevance_score": "0.05183", "ticker_sentiment_score": "-0.113802", "ticker_sentiment_label": "Neutral"}, {"ticker": "CCK", "relevance_score": "0.05183", "ticker_sentiment_score": "-0.025973", "ticker_sentiment_label": "Neutral"}, {"ticker": "DASH", "relevance_score": "0.05183", "ticker_sentiment_score": "-0.03176", "ticker_sentiment_label": "Neutral"}, {"ticker": "FMS", "relevance_score": "0.05183", "ticker_sentiment_score": "0.071582", "ticker_sentiment_label": "Neutral"}, {"ticker": "HSY", "relevance_score": "0.05183", "ticker_sentiment_score": "0.056973", "ticker_sentiment_label": "Neutral"}, {"ticker": "BUD", "relevance_score": "0.05183", "ticker_sentiment_score": "-0.046958", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABT", "relevance_score": "0.077677", "ticker_sentiment_score": "0.07861", "ticker_sentiment_label": "Neutral"}, {"ticker": "FSNUF", "relevance_score": "0.025929", "ticker_sentiment_score": "0.065219", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.077677", "ticker_sentiment_score": "0.025463", "ticker_sentiment_label": "Neutral"}, {"ticker": "KDP", "relevance_score": "0.05183", "ticker_sentiment_score": "-0.010993", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.05183", "ticker_sentiment_score": "0.024949", "ticker_sentiment_label": "Neutral"}, {"ticker": "DRI", "relevance_score": "0.05183", "ticker_sentiment_score": "0.162516", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PEP", "relevance_score": "0.05183", "ticker_sentiment_score": "-0.054643", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMG", "relevance_score": "0.05183", "ticker_sentiment_score": "0.119502", "ticker_sentiment_label": "Neutral"}]}, {"title": "Ironwood's  ( IRWD )  Q3 Earnings Miss Mark, Linzess Volume Rises", "url": "https://www.zacks.com/stock/news/2182441/ironwoods-irwd-q3-earnings-miss-mark-linzess-volume-rises", "time_published": "20231110T160900", "authors": ["Zacks Equity Research"], "summary": "Ironwood's (IRWD) third-quarter 2023 earnings miss estimates, while revenues beat the same. Linzess collaboration revenues drive the top line.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/5d/2633.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.96136"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.06669, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ALPMF", "relevance_score": "0.05339", "ticker_sentiment_score": "0.1427", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.211191", "ticker_sentiment_score": "0.227581", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MEIP", "relevance_score": "0.26224", "ticker_sentiment_score": "0.162813", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "IRWD", "relevance_score": "0.211191", "ticker_sentiment_score": "0.076495", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.211191", "ticker_sentiment_score": "0.104263", "ticker_sentiment_label": "Neutral"}]}, {"title": "DNA-Reading Giant Crashes As Macro Pressures Guidance - Again", "url": "https://www.investors.com/news/technology/illumina-stock-crashes-after-pointing-to-slow-growth-again/", "time_published": "20231110T154200", "authors": ["Investor's Business Daily", "ALLISON GATLIN"], "summary": "Illumina Stock Crashes After Pointing To Slow Growth - Again Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2021/04/Stock-illumina-01-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.744043"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.980922"}], "overall_sentiment_score": -0.023964, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.061159", "ticker_sentiment_score": "-0.133025", "ticker_sentiment_label": "Neutral"}, {"ticker": "ILMN", "relevance_score": "0.855104", "ticker_sentiment_score": "-0.107239", "ticker_sentiment_label": "Neutral"}]}, {"title": "Oncology Drugs Market worth $520 billion by 2033 - Exclusive Report by We Market Research", "url": "https://www.prnewswire.com/news-releases/oncology-drugs-market-worth-520-billion-by-2033---exclusive-report-by-we-market-research-301984776.html", "time_published": "20231110T150100", "authors": ["We Market Research"], "summary": "CHICAGO, Nov. 10, 2023 /PRNewswire/ -- According to the latest findings from We Market Research, the oncology drug market is on track to achieve a value of USD 205 billion by the year 2023.", "banner_image": "https://mma.prnewswire.com/media/2267296/We_Market_Research_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.227297, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.040622", "ticker_sentiment_score": "0.059987", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.040622", "ticker_sentiment_score": "0.059987", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALPMF", "relevance_score": "0.040622", "ticker_sentiment_score": "0.059987", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.081138", "ticker_sentiment_score": "0.083483", "ticker_sentiment_label": "Neutral"}, {"ticker": "SGEN", "relevance_score": "0.040622", "ticker_sentiment_score": "0.029936", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.040622", "ticker_sentiment_score": "0.059987", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.081138", "ticker_sentiment_score": "0.046543", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.040622", "ticker_sentiment_score": "0.059987", "ticker_sentiment_label": "Neutral"}]}, {"title": "Daily: Fed's War On Inflation Isn't Over Despite Market Gains", "url": "https://www.forbes.com/sites/daniellechemtob/2023/11/10/forbes-daily-feds-war-on-inflation-isnt-over-despite-market-gains/", "time_published": "20231110T131704", "authors": ["Danielle Chemtob"], "summary": "This is a published version of the Forbes Daily newsletter, you can sign-up to get Forbes Daily in your inbox here. The busy holiday retail season is already in full swing, and one surprising demographic could be filling the stores this year: Gen Z.", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/654e28773590d9370c3f3262/0x0.jpg?format=jpg&crop=1248,703,x0,y14,safe&height=900&width=1600&fit=bounds", "source": "Forbes", "category_within_source": "n/a", "source_domain": "www.forbes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Finance", "relevance_score": "0.166667"}, {"topic": "Economy - Monetary", "relevance_score": "0.682689"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "0.684621"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Real Estate & Construction", "relevance_score": "0.166667"}], "overall_sentiment_score": 0.086653, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MSFT", "relevance_score": "0.023372", "ticker_sentiment_score": "-0.024875", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOOG", "relevance_score": "0.046724", "ticker_sentiment_score": "-0.004935", "ticker_sentiment_label": "Neutral"}, {"ticker": "MGM", "relevance_score": "0.023372", "ticker_sentiment_score": "-0.001854", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.023372", "ticker_sentiment_score": "0.112195", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.023372", "ticker_sentiment_score": "0.019409", "ticker_sentiment_label": "Neutral"}, {"ticker": "BBW", "relevance_score": "0.023372", "ticker_sentiment_score": "0.070901", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.023372", "ticker_sentiment_score": "0.031656", "ticker_sentiment_label": "Neutral"}, {"ticker": "CZR", "relevance_score": "0.023372", "ticker_sentiment_score": "-0.001854", "ticker_sentiment_label": "Neutral"}, {"ticker": "WYNN", "relevance_score": "0.023372", "ticker_sentiment_score": "-0.001854", "ticker_sentiment_label": "Neutral"}]}, {"title": "AstraZeneca  ( AZN )  Buys Global Rights to Oral Obesity Candidate", "url": "https://www.zacks.com/stock/news/2182200/astrazeneca-azn-buys-global-rights-to-oral-obesity-candidate", "time_published": "20231110T131100", "authors": ["Zacks Equity Research"], "summary": "To cash in on the rising demand for obesity drugs, AstraZeneca (AZN) in-licenses exclusive rights to ECC5004, a novel oral GLP-1RA therapy, from private Chinese biotech Eccogene.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/82/41137.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.141645, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.604596", "ticker_sentiment_score": "0.236528", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MS", "relevance_score": "0.067727", "ticker_sentiment_score": "0.175463", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.266101", "ticker_sentiment_score": "0.097013", "ticker_sentiment_label": "Neutral"}]}, {"title": "AstraZeneca  ( AZN )  Beats on Q3 Earnings & Sales, Ups 2023 View", "url": "https://www.zacks.com/stock/news/2182194/astrazeneca-azn-beats-on-q3-earnings-sales-ups-2023-view", "time_published": "20231110T130500", "authors": ["Zacks Equity Research"], "summary": "AstraZeneca (AZN) beats third-quarter estimates for earnings and sales. The company raises its sales and EPS guidance for 2023.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/12/31139.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.990786"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}], "overall_sentiment_score": 0.048286, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.347165", "ticker_sentiment_score": "0.163239", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVO", "relevance_score": "0.082677", "ticker_sentiment_score": "0.105218", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRYPTO:NXC", "relevance_score": "0.027603", "ticker_sentiment_score": "-0.218593", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "The Stock-Split Stock Behind Ozempic and Wegovy Could Be Yours for Just $100", "url": "https://www.fool.com/investing/2023/11/10/the-stock-split-stock-behind-ozempic-and-wegovy-co/", "time_published": "20231110T115400", "authors": ["Adam Spatacco"], "summary": "Novo Nordisk just reported financial and operating results through the first nine months of the year. One thing is clear: Demand is not an issue.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F753587%2Fa-doctor-writing-a-prescription.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.891286"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.999997"}], "overall_sentiment_score": 0.247377, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.135921", "ticker_sentiment_score": "0.09358", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.068209", "ticker_sentiment_score": "0.076597", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.50649", "ticker_sentiment_score": "0.335147", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.068209", "ticker_sentiment_score": "0.076597", "ticker_sentiment_label": "Neutral"}]}, {"title": "Gainers and Losers: 10 stocks that moved the most on November 10", "url": "https://www.moneycontrol.com/news/photos/business/stocks/gainers-and-losers-10-stocks-that-moved-the-most-on-november-10-11721121.html", "time_published": "20231110T104934", "authors": [], "summary": "Auto, IT, oil and gas companies saw selling pressure, while metal, capital goods and power witnessed buying ...", "banner_image": "https://images.moneycontrol.com/static-mcnews/2023/11/Diwali-Stock-Market-3-1-1-770x433.jpg", "source": "Money Control", "category_within_source": "Buzzing Stocks", "source_domain": "www.moneycontrol.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999162"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.17001, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.145583", "ticker_sentiment_score": "0.242948", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Solid results, despite considerably lower prices", "url": "https://www.globenewswire.com/news-release/2023/11/10/2778064/0/en/Solid-results-despite-considerably-lower-prices.html", "time_published": "20231110T070000", "authors": ["Statkraft AS"], "summary": "Statkraft delivered solid results in the third quarter even though power prices were significantly down. Value creation was particularly strong from energy management and market activities. Statkraft continues to deliver on its ambitious growth strategy.", "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/83e51edf-56e2-4b17-a5f7-7127fce40649", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.684621"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.214378"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.307569, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.043186", "ticker_sentiment_score": "0.171742", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "LTH", "relevance_score": "0.043186", "ticker_sentiment_score": "0.020393", "ticker_sentiment_label": "Neutral"}]}, {"title": "AstraZeneca Pharma fall 3% despite healthy Q2 net profit, revenue growth", "url": "https://www.moneycontrol.com/news/business/markets/astrazeneca-pharma-fall-3-despite-healthy-q2-net-profit-revenue-growth-11715131.html", "time_published": "20231110T052405", "authors": [], "summary": "The stock slipped amid reports of the Oxford-AstraZeneca COVID-19 vaccine, known as Vaxzevria in Europe and licensed as Covishield in India, facing a legal challenge the UK ...", "banner_image": "https://images.moneycontrol.com/static-mcnews/2023/11/market_stocks_sensex_Nifty-3.jpg?impolicy=website&width=168&height=118", "source": "Money Control", "category_within_source": "Buzzing Stocks", "source_domain": "www.moneycontrol.com", "topics": [{"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.87644"}], "overall_sentiment_score": 0.233935, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.777888", "ticker_sentiment_score": "0.332534", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "AstraZeneca Plc  ( AZN )  Q3 2023 Earnings Call Transcript", "url": "https://www.fool.com/earnings/call-transcripts/2023/11/09/astrazeneca-plc-azn-q3-2023-earnings-call-transcri/", "time_published": "20231109T230017", "authors": ["Motley Fool Transcribing"], "summary": "AZN earnings call for the period ending September 30, 2023.", "banner_image": "https://g.foolcdn.com/misc-assets/fool-transcripts-logo.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.256502, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BCS", "relevance_score": "0.002767", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "C", "relevance_score": "0.002767", "ticker_sentiment_score": "0.11231", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAC", "relevance_score": "0.002767", "ticker_sentiment_score": "0.177233", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FTS", "relevance_score": "0.002767", "ticker_sentiment_score": "-0.087292", "ticker_sentiment_label": "Neutral"}, {"ticker": "PTAIF", "relevance_score": "0.002767", "ticker_sentiment_score": "0.034742", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.0166", "ticker_sentiment_score": "0.147909", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.002767", "ticker_sentiment_score": "0.157488", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SKXJF", "relevance_score": "0.002767", "ticker_sentiment_score": "0.1566", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DSKYF", "relevance_score": "0.002767", "ticker_sentiment_score": "0.1566", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CLLS", "relevance_score": "0.005534", "ticker_sentiment_score": "0.097034", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.008301", "ticker_sentiment_score": "0.050736", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRYPTO:MCAP", "relevance_score": "0.011067", "ticker_sentiment_score": "0.045026", "ticker_sentiment_label": "Neutral"}]}, {"title": "Fortress Biotech Announces Launch of Proposed Public Offering - Fortress Biotech  ( NASDAQ:FBIO ) ", "url": "https://www.benzinga.com/pressreleases/23/11/g35715833/fortress-biotech-announces-launch-of-proposed-public-offering", "time_published": "20231109T220518", "authors": ["Globe Newswire"], "summary": "MIAMI, Nov. 09, 2023 ( GLOBE NEWSWIRE ) -- Fortress Biotech, Inc.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.938793"}], "overall_sentiment_score": 0.272503, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.06515", "ticker_sentiment_score": "0.188809", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FBIO", "relevance_score": "0.129866", "ticker_sentiment_score": "0.183606", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "The Lower Respiratory Tract Therapeutics Market Is Set To Reach $44.6 Billion By 2027 At A CAGR Of More Than 7% As Per The Business Research Company's Lower Respiratory Tract Therapeutics Global Market Report 2023", "url": "https://www.benzinga.com/pressreleases/23/11/g35705026/the-lower-respiratory-tract-therapeutics-market-is-set-to-reach-44-6-billion-by-2027-at-a-cagr-of-", "time_published": "20231109T163000", "authors": ["Globe Newswire"], "summary": "LONDON, Nov. 09, 2023 ( GLOBE NEWSWIRE ) -- The global lower respiratory tract therapeutics market is poised for significant growth, fueled by the escalating prevalence of respiratory diseases.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.085078, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.061631", "ticker_sentiment_score": "0.05895", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.061631", "ticker_sentiment_score": "0.05895", "ticker_sentiment_label": "Neutral"}]}, {"title": "Oxford-AstraZeneca covid vaccine faces legal challenge in UK: Report", "url": "https://www.business-standard.com/companies/news/oxford-astrazeneca-covid-vaccine-faces-legal-challenge-in-uk-report-123110901324_1.html", "time_published": "20231109T161150", "authors": ["Press Trust of India"], "summary": "The Oxford-AstraZeneca COVID-19 vaccine, known as Vaxzevria in Europe and licensed as Covishield in India, is facing a legal challenge in the High Court in London, a UK media report said on Thursday.", "banner_image": "https://bsmedia.business-standard.com/_media/bs/img/article/2021-12/23/full/1640255704-1323.jpg?im=FeatureCrop,size=(826,465)", "source": "Business Standard", "category_within_source": "GoogleRSS", "source_domain": "www.business-standard.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.009847, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.352557", "ticker_sentiment_score": "-0.020552", "ticker_sentiment_label": "Neutral"}]}, {"title": "Jobless Claims Decreased More Than Expected", "url": "https://www.zacks.com/stock/news/2181775/jobless-claims-decreased-more-than-expected", "time_published": "20231109T160600", "authors": ["Zacks Equity Research"], "summary": "Pre-market futures again are coming in slightly higher, working through a two-week period ( so far ) of generally higher market indices. Although the Dow broke an eight-day winning streak yesterday, it is up another 75 points at this hour, while the S&P 500 and Nasdaq - both with ongoing winning ...", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/be/54779.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.796627"}], "overall_sentiment_score": 0.232383, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.18046", "ticker_sentiment_score": "0.280062", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "AstraZeneca raises stakes in obesity drug race with Eccogene deal", "url": "https://www.foxbusiness.com/markets/astrazeneca-raises-stakes-obesity-drug-race-eccogene-deal", "time_published": "20231109T155800", "authors": ["Reuters"], "summary": "AstraZeneca moved on Thursday to boost its drugs pipeline in the booming anti-obesity market, saying it would pay China's Eccogene up to about $2 billion for an exclusive license to develop an experimental oral drug in the field.", "banner_image": "https://static.foxbusiness.com/foxbusiness.com/content/uploads/2022/07/astrazeneca-logo.jpg", "source": "Fox Business News", "category_within_source": "n/a", "source_domain": "www.foxbusiness.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.184273, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PTAIF", "relevance_score": "0.369685", "ticker_sentiment_score": "0.194319", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.127456", "ticker_sentiment_score": "0.136538", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.127456", "ticker_sentiment_score": "0.078563", "ticker_sentiment_label": "Neutral"}]}, {"title": "The $2 Billion Bet AstraZeneca Is Making In Weight Loss", "url": "https://www.investors.com/news/technology/azn-stock-astrazeneca-earnings-q3-2023/", "time_published": "20231109T152800", "authors": ["Investor's Business Daily", "ALLISON GATLIN"], "summary": "AZN Stock Jumps On $2 Billion Bet In Weight-Loss Drugs Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2020/12/Stock-AstraZeneca-03-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.983783"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.929393"}], "overall_sentiment_score": 0.097418, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.18046", "ticker_sentiment_score": "0.238014", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.828945", "ticker_sentiment_score": "0.133769", "ticker_sentiment_label": "Neutral"}]}, {"title": "AstraZeneca Paying Up To $2 Billion For Experimental Obesity Pill-As Weight Loss Drug Market Grows", "url": "https://www.forbes.com/sites/tylerroush/2023/11/09/astrazeneca-paying-up-to-2-billion-for-experimental-obesity-pill-as-weight-loss-drug-market-grows/", "time_published": "20231109T145637", "authors": ["Ty Roush"], "summary": "AstraZeneca has agreed to pay up to $2 billion for an experimental pill used to treat obesity and type 2 diabetes-the latest pharmaceutical firm to bet on treatment similar to popular weight-loss and diabetes drugs Ozempic and Wegovy.", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/654cf2c20626cef0fdb57226/0x0.jpg?format=jpg&crop=3211,1808,x0,y164,safe&height=900&width=1600&fit=bounds", "source": "Forbes", "category_within_source": "n/a", "source_domain": "www.forbes.com", "topics": [{"topic": "Earnings", "relevance_score": "0.938793"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.291553, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.653656", "ticker_sentiment_score": "0.448915", "ticker_sentiment_label": "Bullish"}, {"ticker": "NVO", "relevance_score": "0.107016", "ticker_sentiment_score": "0.144577", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why AstraZeneca  ( AZN )  Shares Are Trading Higher Today? - AstraZeneca  ( NASDAQ:AZN ) ", "url": "https://www.benzinga.com/general/biotech/23/11/35694148/astrazeneca-joins-anti-obesity-race-dominated-by-eli-lilly-and-novo-nordisk-reports-mixed-q3-earn", "time_published": "20231109T141031", "authors": ["Vandana Singh"], "summary": "AstraZeneca Plc AZN has reported Q3 FY23 core EPS of $1.73, up 4% Y/Y ( +9% on constant currency ) . On the ADR basis, core earnings are $0.86 per share, beating the consensus of $0.84. Total revenue in the quarter was $11.49 billion, up 5% ( +6% CER ) , missing the analyst estimates of ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/11/09/astra_covid_vaccine-photo_by_paul_mcmanus_from_pixabay.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.99246"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.219354, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.725935", "ticker_sentiment_score": "0.389932", "ticker_sentiment_label": "Bullish"}]}, {"title": "S&P 500, Nasdaq Futures Mixed: Wall Street To Snap Longest Rally Since 2021? - Invesco QQQ Trust, Series 1  ( NASDAQ:QQQ ) , SPDR S&P 500  ( ARCA:SPY ) ", "url": "https://www.benzinga.com/news/earnings/23/11/35697040/wall-streets-longest-winning-streak-since-2021-to-snap-today-earnings-bond-yields-in-focus-ahead-of", "time_published": "20231109T122502", "authors": ["Shanthi Rexaline"], "summary": "The stock market's momentum appears to be waning, and futures suggest a mixed opening for Thursday. Earnings reports have generally been positive, with companies like Walt Disney Co. DIS posting encouraging quarterly results.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/nyse-shutter.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.142857"}, {"topic": "Energy & Transportation", "relevance_score": "0.142857"}, {"topic": "Technology", "relevance_score": "0.142857"}, {"topic": "Finance", "relevance_score": "0.142857"}, {"topic": "Blockchain", "relevance_score": "0.158519"}, {"topic": "Economy - Monetary", "relevance_score": "0.928139"}, {"topic": "Retail & Wholesale", "relevance_score": "0.142857"}, {"topic": "Financial Markets", "relevance_score": "0.999975"}, {"topic": "Manufacturing", "relevance_score": "0.142857"}, {"topic": "Earnings", "relevance_score": "0.682689"}, {"topic": "Real Estate & Construction", "relevance_score": "0.142857"}], "overall_sentiment_score": 0.053097, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "DNUT", "relevance_score": "0.082535", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "WYNN", "relevance_score": "0.082535", "ticker_sentiment_score": "-0.051986", "ticker_sentiment_label": "Neutral"}, {"ticker": "WB", "relevance_score": "0.082535", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.041323", "ticker_sentiment_score": "0.151745", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HBI", "relevance_score": "0.082535", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "LAZR", "relevance_score": "0.082535", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "LGF-A", "relevance_score": "0.041323", "ticker_sentiment_score": "-0.049395", "ticker_sentiment_label": "Neutral"}, {"ticker": "DV", "relevance_score": "0.082535", "ticker_sentiment_score": "-0.051986", "ticker_sentiment_label": "Neutral"}, {"ticker": "SOUN", "relevance_score": "0.082535", "ticker_sentiment_score": "-0.051986", "ticker_sentiment_label": "Neutral"}, {"ticker": "U", "relevance_score": "0.082535", "ticker_sentiment_score": "-0.051986", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMC", "relevance_score": "0.082535", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BDX", "relevance_score": "0.082535", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLNK", "relevance_score": "0.082535", "ticker_sentiment_score": "-0.051986", "ticker_sentiment_label": "Neutral"}, {"ticker": "VSAT", "relevance_score": "0.082535", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SPCE", "relevance_score": "0.082535", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVAX", "relevance_score": "0.082535", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVTS", "relevance_score": "0.082535", "ticker_sentiment_score": "-0.051986", "ticker_sentiment_label": "Neutral"}, {"ticker": "ILMN", "relevance_score": "0.082535", "ticker_sentiment_score": "-0.051986", "ticker_sentiment_label": "Neutral"}, {"ticker": "PLUG", "relevance_score": "0.082535", "ticker_sentiment_score": "-0.051986", "ticker_sentiment_label": "Neutral"}, {"ticker": "HOLX", "relevance_score": "0.082535", "ticker_sentiment_score": "-0.051986", "ticker_sentiment_label": "Neutral"}, {"ticker": "MGM", "relevance_score": "0.082535", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.082535", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "USFD", "relevance_score": "0.082535", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "HUBS", "relevance_score": "0.082535", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "LI", "relevance_score": "0.082535", "ticker_sentiment_score": "0.123655", "ticker_sentiment_label": "Neutral"}, {"ticker": "AFRM", "relevance_score": "0.082535", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRYPTO:BTC", "relevance_score": "0.123526", "ticker_sentiment_score": "0.204878", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Asia Mostly Up, Europe Gains On Strong Earnings, Crude Above $75 Again - Global Markets Today While US Was Sleeping - SmartETFs Asia Pacific Dividend Builder ETF  ( ARCA:ADIV ) , ETC Gavekal Asia Pacific Government Bond ETF  ( ARCA:AGOV ) ", "url": "https://www.benzinga.com/markets/asia/23/11/35695450/asia-mostly-up-europe-gains-on-strong-earnings-crude-above-75-again-global-markets-today-while-us-wa", "time_published": "20231109T115143", "authors": ["Akanksha Bakshi"], "summary": "On Wednesday, November 9th, the U.S. stock markets closed mixed after the Dow Jones Industrial Average ended its seven-day winning streak. In economic data, U.S. wholesale inventories experienced a 0.2% uptick in September month-to-month, marking an improvement from the 0.1% decrease seen in the ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/11/09/euro_stocks_photo_by_markus_spiske_on_pexels.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.796627"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Economy - Macro", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.07186, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.118647", "ticker_sentiment_score": "-0.012034", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADYYF", "relevance_score": "0.118647", "ticker_sentiment_score": "-0.012034", "ticker_sentiment_label": "Neutral"}, {"ticker": "SZIHF", "relevance_score": "0.118647", "ticker_sentiment_score": "0.10251", "ticker_sentiment_label": "Neutral"}]}, {"title": "AstraZeneca raises stakes in obesity drug race with Eccogene deal", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/astrazeneca-raises-stakes-obesity-drug-race-with-eccogene-deal-2023-11-09/", "time_published": "20231109T112700", "authors": ["Ludwig Burger"], "summary": "[1/2] A company logo is seen at the AstraZeneca site in Macclesfield, Britain, May 11, 2021. REUTERS/Phil Noble/File Photo Acquire Licensing Rights", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/BYKY5TU5CRNZPF75PEOHCTMUAQ.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.177267, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PTAIF", "relevance_score": "0.357293", "ticker_sentiment_score": "0.189525", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.24289", "ticker_sentiment_score": "0.129673", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.122894", "ticker_sentiment_score": "0.073648", "ticker_sentiment_label": "Neutral"}]}, {"title": "Virgin Galactic shares surge as space firm doubles revenue while Walt Disney stock jumps on spike in streaming customers", "url": "https://www.marketwatch.com/story/virgin-galactic-shares-surge-as-space-firm-doubles-revenue-while-walt-disney-stock-jumps-on-spike-in-streaming-customers-b9e6c612", "time_published": "20231109T103300", "authors": ["MarketWatch"], "summary": "Shares in Virgin Galactic, Bill Holdings, Walt Disney Co, AstraZeneca, Topgolf Callaway, Allbirds, Bill Holdings, and Lyft shares were all active in pre-market trading ...", "banner_image": "https://images.mktw.net/im-884175/social", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Earnings", "relevance_score": "0.917436"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.019702, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BILL", "relevance_score": "0.33628", "ticker_sentiment_score": "-0.099914", "ticker_sentiment_label": "Neutral"}, {"ticker": "MODG", "relevance_score": "0.33628", "ticker_sentiment_score": "0.525824", "ticker_sentiment_label": "Bullish"}, {"ticker": "SPCE", "relevance_score": "0.33628", "ticker_sentiment_score": "-0.007292", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.33628", "ticker_sentiment_score": "-0.007627", "ticker_sentiment_label": "Neutral"}]}, {"title": "AstraZeneca hikes earnings forecast as surging cancer drug sales offset plunging revenue from COVID vaccines", "url": "https://www.marketwatch.com/story/astrazeneca-hikes-earnings-forecast-as-surging-cancer-drug-sales-offset-plunging-revenue-from-covid-vaccines-446bf363", "time_published": "20231109T100500", "authors": ["Louis Goss"], "summary": "AstraZeneca shares jumped 3% after the Anglo-Swedish drugmaker said it expects its full-year revenues will increase at a higher rate than previously forecast ...", "banner_image": "https://images.mktw.net/im-884166/social", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Earnings", "relevance_score": "0.795202"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.079222, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.485711", "ticker_sentiment_score": "0.254649", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "AstraZeneca ups profit outlook and boosts anti-obesity pipeline", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/astrazeneca-hikes-annual-profit-outlook-2023-11-09/", "time_published": "20231109T090800", "authors": ["Maggie Fick", "Eva Mathews"], "summary": "A sign is seen at an AstraZeneca site in Macclesfield, central England May 19, 2014. REUTERS/Phil Noble/File Photo Acquire Licensing Rights", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/DYQMHJQYVZKQ3KVMU6N4SM3WLU.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Earnings", "relevance_score": "0.996718"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.267796, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.250386", "ticker_sentiment_score": "0.289034", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "European shares open flat as investors await cues on policy outlook", "url": "https://www.reuters.com/markets/europe/european-shares-open-flat-investors-await-cues-policy-outlook-2023-11-09/", "time_published": "20231109T082800", "authors": ["Reuters"], "summary": "The German share price index DAX graph is pictured at the stock exchange in Frankfurt, Germany, November 8, 2023. REUTERS/Staff/File Photo Acquire Licensing Rights", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/FQCY5PVVXNKGLKXZYLJNDYCEUU.jpg", "source": "Reuters", "category_within_source": "Markets", "source_domain": "www.reuters.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.576289"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}, {"topic": "Earnings", "relevance_score": "0.614606"}], "overall_sentiment_score": 0.23959, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.207571", "ticker_sentiment_score": "0.643411", "ticker_sentiment_label": "Bullish"}]}, {"title": "Eccogene Enters Exclusive License Agreement With AstraZeneca to Develop and Commercialize Small Molecule GLP-1 Receptor Agonist ECC5004 for Cardiometabolic Diseases", "url": "https://www.prnewswire.com/news-releases/eccogene-enters-exclusive-license-agreement-with-astrazeneca-to-develop-and-commercialize-small-molecule-glp-1-receptor-agonist-ecc5004-for-cardiometabolic-diseases-301982778.html", "time_published": "20231109T070500", "authors": ["Inc.", "Eccogene"], "summary": "Eccogene Enters Exclusive License Agreement With AstraZeneca to Develop and Commercialize Small Molecule GLP ... PR ...", "banner_image": "https://mma.prnewswire.com/media/2271998/Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.242031, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.596796", "ticker_sentiment_score": "0.367158", "ticker_sentiment_label": "Bullish"}, {"ticker": "TSOI", "relevance_score": "0.074001", "ticker_sentiment_score": "0.161593", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Stocks to Watch Today: Vedanta, Adani Ports, Lupin, Tata Power, MCX, BHEL, IFCI", "url": "https://www.business-standard.com/markets/news/stocks-to-watch-vedanta-adani-ports-lupin-tata-power-mcx-bhel-ifci-123110900114_1.html", "time_published": "20231109T022446", "authors": ["Rex Cano"], "summary": "Stocks to Watch: Vedanta, Adani Ports, Lupin, Tata Power, MCX, BHEL, IFCI Business Standard ...", "banner_image": "https://bsmedia.business-standard.com/_media/bs/img/article/2021-09/12/full/1631463208-1967.jpg?im=FeatureCrop,size=(826,465)", "source": "Business Standard", "category_within_source": "GoogleRSS", "source_domain": "www.business-standard.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999938"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.129583, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.058759", "ticker_sentiment_score": "0.045982", "ticker_sentiment_label": "Neutral"}]}, {"title": "Global Precision Medicine Market Size Demonstrates Consistent Growth with a CAGR of 11.12%, with North America Taking a Leading Role - Illumina  ( NASDAQ:ILMN ) , Bristol-Myers Squibb  ( NYSE:BMY ) ", "url": "https://www.benzinga.com/pressreleases/23/11/g35674541/global-precision-medicine-market-size-demonstrates-consistent-growth-with-a-cagr-of-11-12-with-nor", "time_published": "20231108T145000", "authors": ["Globe Newswire"], "summary": "New York, United States, Nov. 08, 2023 ( GLOBE NEWSWIRE ) -- Precision medicine is a new approach to treating and preventing disease that considers each individual's genetic, environmental, and lifestyle differences. Giving the proper treatment to the right patient at the right time is the goal ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.360215"}, {"topic": "Earnings", "relevance_score": "0.108179"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.145794, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "META", "relevance_score": "0.039353", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.039353", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.039353", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ILMN", "relevance_score": "0.194868", "ticker_sentiment_score": "0.144939", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.039353", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "QGEN", "relevance_score": "0.039353", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.156461", "ticker_sentiment_score": "0.115839", "ticker_sentiment_label": "Neutral"}]}, {"title": "Fusion Pharmaceuticals to Present at Upcoming Investor Conferences", "url": "https://www.newswire.ca/news-releases/fusion-pharmaceuticals-to-present-at-upcoming-investor-conferences-852584328.html", "time_published": "20231108T131500", "authors": ["Fusion Pharmaceuticals"], "summary": "HAMILTON, ON and BOSTON, Nov. 8, 2023 /CNW/ -- Fusion Pharmaceuticals Inc. ( Nasdaq: FUSN ) , a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company will participate in two upcoming investor ...", "banner_image": "https://mma.prnewswire.com/media/1196797/Fusion_Logo.jpg?p=facebook", "source": "Canada Newswire", "category_within_source": "n/a", "source_domain": "www.newswire.ca", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.10803, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.109956", "ticker_sentiment_score": "0.047097", "ticker_sentiment_label": "Neutral"}, {"ticker": "FUSN", "relevance_score": "0.321673", "ticker_sentiment_score": "0.087909", "ticker_sentiment_label": "Neutral"}]}, {"title": "Gilead Sciences  ( GILD )  Q3 2023 Earnings Call Transcript", "url": "https://www.fool.com/earnings/call-transcripts/2023/11/07/gilead-sciences-gild-q3-2023-earnings-call-transcr/", "time_published": "20231108T021517", "authors": ["Motley Fool Transcribing"], "summary": "GILD earnings call for the period ending September 30, 2023.", "banner_image": "https://g.foolcdn.com/misc-assets/fool-transcripts-logo.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.977154"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.266143"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.250013, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ACLX", "relevance_score": "0.018108", "ticker_sentiment_score": "0.099955", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.004527", "ticker_sentiment_score": "0.085", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAC", "relevance_score": "0.004527", "ticker_sentiment_score": "0.158791", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GS", "relevance_score": "0.013582", "ticker_sentiment_score": "0.065942", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.004527", "ticker_sentiment_score": "-0.006494", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.004527", "ticker_sentiment_score": "0.099576", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biotech Stock Surges As Activist Reportedly Builds $1 Billion Stake", "url": "https://www.investors.com/news/technology/bmrn-stock-rockets-as-activist-investor-reportedly-builds-stake/", "time_published": "20231107T191600", "authors": ["Investor's Business Daily", "ALLISON GATLIN"], "summary": "BMRN Stock Rockets As Activist Investor Reportedly Builds $1 ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2020/11/Stock-biomarin-03-shutt.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.989041"}], "overall_sentiment_score": 0.095292, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BMRN", "relevance_score": "0.389889", "ticker_sentiment_score": "0.100781", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.134968", "ticker_sentiment_score": "0.137726", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.134968", "ticker_sentiment_score": "0.137726", "ticker_sentiment_label": "Neutral"}, {"ticker": "CTLT", "relevance_score": "0.201244", "ticker_sentiment_score": "0.178521", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Q1 2023/24 - Lower revenue in a challenging market", "url": "https://www.globenewswire.com/news-release/2023/11/07/2775449/0/en/Q1-2023-24-Lower-revenue-in-a-challenging-market.html", "time_published": "20231107T190000", "authors": ["Chemometec A/S"], "summary": "ANNOUNCEMENT NO. ...", "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/dda6d08e-1d43-433e-bc7b-b1e84b4963be", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Economy - Macro", "relevance_score": "0.576289"}], "overall_sentiment_score": -0.033238, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.029951", "ticker_sentiment_score": "0.037699", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.029951", "ticker_sentiment_score": "0.037699", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.029951", "ticker_sentiment_score": "0.037699", "ticker_sentiment_label": "Neutral"}]}, {"title": "US FTC disputes listing for more than 100 patents in FDA Orange Book", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/us-ftc-disputes-listing-more-than-100-patents-fda-orange-book-2023-11-07/", "time_published": "20231107T173600", "authors": ["Reuters"], "summary": "Signage is seen outside of the Food and Drug Administration ( FDA ) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly/File Photo Acquire Licensing Rights WASHINGTON, Nov 7 ( Reuters ) - The U.S.", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/NUEICFBUOVK2BL5ME456ZTJSCA.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.038416, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.151539", "ticker_sentiment_score": "-0.066195", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.151539", "ticker_sentiment_score": "-0.066195", "ticker_sentiment_label": "Neutral"}]}, {"title": "Fusion Pharmaceuticals Announces Third Quarter 2023 Financial Results and Clinical Program Updates", "url": "https://www.newswire.ca/news-releases/fusion-pharmaceuticals-announces-third-quarter-2023-financial-results-and-clinical-program-updates-807996762.html", "time_published": "20231107T120000", "authors": ["Fusion Pharmaceuticals"], "summary": "Preliminary data for FPI-2265 ( 225Ac-PSMA I&T ) in approximately 20 to 30 patients on track for Q1 2024 Data from Cohort 2 of the FPI-1434 Phase 1 study anticipated around", "banner_image": "https://mma.prnewswire.com/media/1196797/Fusion_Logo.jpg?p=facebook", "source": "Canada Newswire", "category_within_source": "n/a", "source_domain": "www.newswire.ca", "topics": [{"topic": "Earnings", "relevance_score": "0.744043"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.796627"}], "overall_sentiment_score": 0.123039, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.126229", "ticker_sentiment_score": "0.052359", "ticker_sentiment_label": "Neutral"}, {"ticker": "FUSN", "relevance_score": "0.084349", "ticker_sentiment_score": "0.00624", "ticker_sentiment_label": "Neutral"}]}, {"title": "GSK ADR Shows Rising Relative Strength; Still Shy Of Key Threshold", "url": "https://www.investors.com/ibd-data-stories/gsk-adr-shows-rising-relative-strength-still-shy-of-key-threshold/", "time_published": "20231107T080000", "authors": ["INVESTOR'S BUSINESS DAILY", "Investor's Business Daily"], "summary": "GSK ADR Shows Rising Relative Strength. Still Shy Of Key Threshold Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.32635, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.323078", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Cellectis Reports Financial Results for Third Quarter and First Nine Months 2023", "url": "https://www.globenewswire.com/news-release/2023/11/06/2774563/0/en/Cellectis-Reports-Financial-Results-for-Third-Quarter-and-First-Nine-Months-2023.html", "time_published": "20231106T213000", "authors": ["Cellectis Inc."], "summary": "\u2022 Strategic Collaboration and Investment Agreements signed with ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/a84ce25b-a774-4635-9b79-d45241f5decc", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Economy - Fiscal", "relevance_score": "0.310843"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Earnings", "relevance_score": "0.999997"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.682689"}, {"topic": "Blockchain", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.123107, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ALLO", "relevance_score": "0.079597", "ticker_sentiment_score": "0.054169", "ticker_sentiment_label": "Neutral"}, {"ticker": "CLXT", "relevance_score": "0.105992", "ticker_sentiment_score": "0.014568", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.184363", "ticker_sentiment_score": "0.151997", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CLLS", "relevance_score": "0.56296", "ticker_sentiment_score": "0.208701", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "The doctor lowering drug prices for 1 million patients, with help from Mark Cuban, Sam Altman - and Martin Shkreli", "url": "https://www.marketwatch.com/story/the-doctor-lowering-drug-prices-for-1-million-patients-with-help-from-mark-cuban-sam-altman-and-martin-shkreli-5e72d77a", "time_published": "20231106T203200", "authors": ["Eleanor Laise"], "summary": "Kristopher Koeller relies on two daily medications to keep his blood pressure under control. They're both generics that have been on the market for decades-the kind of drugs that should be cheap.", "banner_image": "https://images.mktw.net/im-871045?width=700&height=393", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.066744, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CVS", "relevance_score": "0.055848", "ticker_sentiment_score": "-0.013012", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.027941", "ticker_sentiment_score": "0.088489", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.027941", "ticker_sentiment_score": "0.024774", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.027941", "ticker_sentiment_score": "0.088489", "ticker_sentiment_label": "Neutral"}, {"ticker": "CHRS", "relevance_score": "0.027941", "ticker_sentiment_score": "0.007658", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.041901", "ticker_sentiment_score": "0.007958", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.027941", "ticker_sentiment_score": "0.007658", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.027941", "ticker_sentiment_score": "0.007658", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.027941", "ticker_sentiment_score": "0.024774", "ticker_sentiment_label": "Neutral"}, {"ticker": "UNH", "relevance_score": "0.027941", "ticker_sentiment_score": "-0.042172", "ticker_sentiment_label": "Neutral"}]}, {"title": "AstraZeneca  ( AZN )  to Report Q3 Earnings: What's in the Cards?", "url": "https://www.zacks.com/stock/news/2179516/astrazeneca-azn-to-report-q3-earnings-whats-in-the-cards", "time_published": "20231106T182300", "authors": ["Zacks Equity Research"], "summary": "Higher sales of AstraZeneca's (AZN) key medicines, Lynparza, Tagrisso, Imfinzi and Farxiga, are likely to have driven sales in the third quarter, partially offset by lower sales of legacy drugs.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/e5/1416.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999326"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.134571, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.356225", "ticker_sentiment_score": "0.172171", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BLUE", "relevance_score": "0.137671", "ticker_sentiment_score": "-0.003678", "ticker_sentiment_label": "Neutral"}, {"ticker": "LGND", "relevance_score": "0.137671", "ticker_sentiment_score": "-0.016231", "ticker_sentiment_label": "Neutral"}]}, {"title": "The Drug Discovery Technologies Market Size Is Expected To Reach $97 Billion By 2027 At A CAGR Of More Than 10% As Per The Business Research Company's Drug Discovery Technologies Global Market Report 2023", "url": "https://www.benzinga.com/pressreleases/23/11/g35623916/the-drug-discovery-technologies-market-size-is-expected-to-reach-97-billion-by-2027-at-a-cagr-of-m", "time_published": "20231106T163000", "authors": ["Globe Newswire"], "summary": "LONDON, Nov. 06, 2023 ( GLOBE NEWSWIRE ) -- As per The Business Research Company's Drug Discovery Technologies Global Market Report 2023, the global drug discovery technologies market is on the verge of a significant transformation.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.288853, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GOOG", "relevance_score": "0.052685", "ticker_sentiment_score": "0.172647", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVS", "relevance_score": "0.052685", "ticker_sentiment_score": "0.245776", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.052685", "ticker_sentiment_score": "0.245776", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TMO", "relevance_score": "0.052685", "ticker_sentiment_score": "0.245776", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Price Over Earnings Overview: AstraZeneca - AstraZeneca  ( NASDAQ:AZN ) ", "url": "https://www.benzinga.com/news/23/11/35622426/price-over-earnings-overview-astrazeneca", "time_published": "20231106T153014", "authors": ["Benzinga Insights"], "summary": "In the current market session, AstraZeneca Inc. AZN share price is at $64.33, after a 0.58% increase. Moreover, over the past month, the stock decreased by 5.44%, but in the past year, went up by 4.86%.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.140681, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.461699", "ticker_sentiment_score": "0.356042", "ticker_sentiment_label": "Bullish"}]}, {"title": "Unlocking Q3 Potential of Astrazeneca  ( AZN ) : Exploring Wall Street Estimates for Key Metrics", "url": "https://www.zacks.com/stock/news/2179280/unlocking-q3-potential-of-astrazeneca-azn-exploring-wall-street-estimates-for-key-metrics", "time_published": "20231106T150500", "authors": ["Zacks Equity Research"], "summary": "Besides Wall Street's top -and-bottom-line estimates for Astrazeneca (AZN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2023.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default133.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.947132"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.108566, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.364987", "ticker_sentiment_score": "0.123538", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRYPTO:NXC", "relevance_score": "0.075635", "ticker_sentiment_score": "0.048436", "ticker_sentiment_label": "Neutral"}]}, {"title": "Vaccitech Renames as Barinthus Biotherapeutics to Highlight Strategic Evolution into a T Cell Immunotherapy Company Targeting Chronic Infectious Diseases, Autoimmunity, and Cancer - Vaccitech  ( NASDAQ:VACC ) ", "url": "https://www.benzinga.com/pressreleases/23/11/g35619974/vaccitech-renames-as-barinthus-biotherapeutics-to-highlight-strategic-evolution-into-a-t-cell-immu", "time_published": "20231106T140556", "authors": ["Globe Newswire"], "summary": "New Corporate Brand to be Unveiled at AASLD Liver Meeting\u00ae 2023 with Interim Data", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.650727"}], "overall_sentiment_score": -0.01445, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ABUS", "relevance_score": "0.027164", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.027164", "ticker_sentiment_score": "0.053005", "ticker_sentiment_label": "Neutral"}, {"ticker": "VACC", "relevance_score": "0.054297", "ticker_sentiment_score": "-0.020011", "ticker_sentiment_label": "Neutral"}]}, {"title": "Vaccitech Renames as Barinthus Biotherapeutics to Highlight Strategic Evolution into a T Cell Immunotherapy Company Targeting Chronic Infectious Diseases, Autoimmunity, and Cancer", "url": "https://www.globenewswire.com/news-release/2023/11/06/2774201/0/en/Vaccitech-Renames-as-Barinthus-Biotherapeutics-to-Highlight-Strategic-Evolution-into-a-T-Cell-Immunotherapy-Company-Targeting-Chronic-Infectious-Diseases-Autoimmunity-and-Cancer.html", "time_published": "20231106T140500", "authors": ["Vaccitech UK Limited"], "summary": "OXFORD, United Kingdom, Nov. 06, 2023 ( GLOBE NEWSWIRE ) -- Barinthus Biotherapeutics plc ( NASDAQ: BRNS ) , formerly Vaccitech plc ( NASDAQ: VACC ) , a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/284aac16-bab8-47d0-8077-929f11b0088b", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.495866"}], "overall_sentiment_score": -0.016934, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.030918", "ticker_sentiment_score": "0.053962", "ticker_sentiment_label": "Neutral"}, {"ticker": "VACC", "relevance_score": "0.06179", "ticker_sentiment_score": "-0.022127", "ticker_sentiment_label": "Neutral"}]}, {"title": "Sermonix Pharmaceuticals Announces JCO Precision Oncology Publication of Case Report on a Complete Remission in a Metastatic Breast Cancer Patient Participating in ELAINE-1 Trial - Ligand Pharmaceuticals  ( NASDAQ:LGND ) ", "url": "https://www.benzinga.com/pressreleases/23/11/g35619700/sermonix-pharmaceuticals-announces-jco-precision-oncology-publication-of-case-report-on-a-complete", "time_published": "20231106T140000", "authors": ["Globe Newswire"], "summary": "COLUMBUS, Ohio, Nov. 06, 2023 ( GLOBE NEWSWIRE ) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast cancers harboring ESR1 mutations, today announced that a case report detailing a durable ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.034125, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.031822", "ticker_sentiment_score": "-0.005734", "ticker_sentiment_label": "Neutral"}, {"ticker": "LGND", "relevance_score": "0.063594", "ticker_sentiment_score": "0.088483", "ticker_sentiment_label": "Neutral"}]}, {"title": "Here's how America's economy could begin to weaken | Business", "url": "https://edition.cnn.com/2023/11/05/business/stocks-week-ahead-how-us-economy-weakens/index.html", "time_published": "20231105T123000", "authors": ["Bryan Mena"], "summary": "Here's how America's economy could begin to weaken CNN International ...", "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/gettyimages-1693347660.jpg?c=16x9&q=w_800,c_fill", "source": "CNN", "category_within_source": "Markets", "source_domain": "edition.cnn.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Energy & Transportation", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Finance", "relevance_score": "0.166667"}, {"topic": "Economy - Monetary", "relevance_score": "0.769861"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "0.875462"}, {"topic": "Real Estate & Construction", "relevance_score": "0.166667"}], "overall_sentiment_score": 0.026507, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CG", "relevance_score": "0.030064", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NWSAL", "relevance_score": "0.030064", "ticker_sentiment_score": "0.01712", "ticker_sentiment_label": "Neutral"}, {"ticker": "LYV", "relevance_score": "0.060085", "ticker_sentiment_score": "0.116097", "ticker_sentiment_label": "Neutral"}, {"ticker": "NYT", "relevance_score": "0.030064", "ticker_sentiment_score": "-0.051893", "ticker_sentiment_label": "Neutral"}, {"ticker": "UA", "relevance_score": "0.030064", "ticker_sentiment_score": "-0.051893", "ticker_sentiment_label": "Neutral"}, {"ticker": "DUOL", "relevance_score": "0.030064", "ticker_sentiment_score": "-0.051893", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNEJF", "relevance_score": "0.030064", "ticker_sentiment_score": "0.01712", "ticker_sentiment_label": "Neutral"}, {"ticker": "OXY", "relevance_score": "0.030064", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MGM", "relevance_score": "0.030064", "ticker_sentiment_score": "-0.051893", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.030064", "ticker_sentiment_score": "0.01712", "ticker_sentiment_label": "Neutral"}, {"ticker": "WFC", "relevance_score": "0.030064", "ticker_sentiment_score": "-0.207743", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "WBD", "relevance_score": "0.11983", "ticker_sentiment_score": "-0.059033", "ticker_sentiment_label": "Neutral"}, {"ticker": "UHAL", "relevance_score": "0.030064", "ticker_sentiment_score": "-0.051893", "ticker_sentiment_label": "Neutral"}, {"ticker": "RBLX", "relevance_score": "0.030064", "ticker_sentiment_score": "-0.051893", "ticker_sentiment_label": "Neutral"}, {"ticker": "RL", "relevance_score": "0.030064", "ticker_sentiment_score": "-0.051893", "ticker_sentiment_label": "Neutral"}, {"ticker": "MET", "relevance_score": "0.030064", "ticker_sentiment_score": "-0.037723", "ticker_sentiment_label": "Neutral"}, {"ticker": "RYAOF", "relevance_score": "0.030064", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "UBER", "relevance_score": "0.030064", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.030064", "ticker_sentiment_score": "-0.051893", "ticker_sentiment_label": "Neutral"}]}, {"title": "Here's how America's economy could begin to weaken | Business", "url": "https://www.cnn.com/2023/11/05/business/stocks-week-ahead-how-us-economy-weakens/index.html", "time_published": "20231105T123000", "authors": ["Bryan Mena"], "summary": "Here's how America's economy could begin to weaken ...", "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/gettyimages-1693347660.jpg?c=16x9&q=w_800,c_fill", "source": "CNN", "category_within_source": "Economy", "source_domain": "www.cnn.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Energy & Transportation", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Finance", "relevance_score": "0.166667"}, {"topic": "Economy - Monetary", "relevance_score": "0.769861"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "0.875462"}, {"topic": "Real Estate & Construction", "relevance_score": "0.166667"}], "overall_sentiment_score": 0.026507, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CG", "relevance_score": "0.030064", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NWSAL", "relevance_score": "0.030064", "ticker_sentiment_score": "0.01712", "ticker_sentiment_label": "Neutral"}, {"ticker": "LYV", "relevance_score": "0.060085", "ticker_sentiment_score": "0.116097", "ticker_sentiment_label": "Neutral"}, {"ticker": "NYT", "relevance_score": "0.030064", "ticker_sentiment_score": "-0.051893", "ticker_sentiment_label": "Neutral"}, {"ticker": "UA", "relevance_score": "0.030064", "ticker_sentiment_score": "-0.051893", "ticker_sentiment_label": "Neutral"}, {"ticker": "DUOL", "relevance_score": "0.030064", "ticker_sentiment_score": "-0.051893", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNEJF", "relevance_score": "0.030064", "ticker_sentiment_score": "0.01712", "ticker_sentiment_label": "Neutral"}, {"ticker": "OXY", "relevance_score": "0.030064", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MGM", "relevance_score": "0.030064", "ticker_sentiment_score": "-0.051893", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.030064", "ticker_sentiment_score": "0.01712", "ticker_sentiment_label": "Neutral"}, {"ticker": "WFC", "relevance_score": "0.030064", "ticker_sentiment_score": "-0.207743", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "WBD", "relevance_score": "0.11983", "ticker_sentiment_score": "-0.059033", "ticker_sentiment_label": "Neutral"}, {"ticker": "UHAL", "relevance_score": "0.030064", "ticker_sentiment_score": "-0.051893", "ticker_sentiment_label": "Neutral"}, {"ticker": "RBLX", "relevance_score": "0.030064", "ticker_sentiment_score": "-0.051893", "ticker_sentiment_label": "Neutral"}, {"ticker": "RL", "relevance_score": "0.030064", "ticker_sentiment_score": "-0.051893", "ticker_sentiment_label": "Neutral"}, {"ticker": "MET", "relevance_score": "0.030064", "ticker_sentiment_score": "-0.037723", "ticker_sentiment_label": "Neutral"}, {"ticker": "RYAOF", "relevance_score": "0.030064", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "UBER", "relevance_score": "0.030064", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.030064", "ticker_sentiment_score": "-0.051893", "ticker_sentiment_label": "Neutral"}]}, {"title": "Morimatsu International Adapts to the Changing World by Upholding Technological Innovation in Global Expansion", "url": "https://www.prnewswire.com/news-releases/morimatsu-international-adapts-to-the-changing-world-by-upholding-technological-innovation-in-global-expansion-301977827.html", "time_published": "20231105T065000", "authors": ["Morimatsu"], "summary": "SHANGHAI, Nov. 3, 2023 /PRNewswire/ -- The World Bank recently released its updated \"Global Economic Outlook\" report, projecting a 2.1% global economic growth for 2023.", "banner_image": "https://mma.prnewswire.com/media/2265720/image_5024578_32188180.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}, {"topic": "Earnings", "relevance_score": "0.744043"}], "overall_sentiment_score": 0.326071, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GIC", "relevance_score": "0.022794", "ticker_sentiment_score": "0.057588", "ticker_sentiment_label": "Neutral"}, {"ticker": "WXXWY", "relevance_score": "0.022794", "ticker_sentiment_score": "0.10909", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.022794", "ticker_sentiment_score": "0.10909", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.022794", "ticker_sentiment_score": "0.10909", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.022794", "ticker_sentiment_score": "0.10909", "ticker_sentiment_label": "Neutral"}]}, {"title": "Thinking of Buying Warren Buffett's Favorite Index Fund? Buy This ETF Instead", "url": "https://www.fool.com/investing/2023/11/04/buy-warren-buffetts-favorite-index-fund-sandp-500/", "time_published": "20231104T131000", "authors": ["Jeremy Bowman"], "summary": "Buffett loves the S&P 500, but here's a better option.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F753120%2Fstock-market-chart.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.947132"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.246268, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MSFT", "relevance_score": "0.056808", "ticker_sentiment_score": "0.149963", "ticker_sentiment_label": "Neutral"}, {"ticker": "NFLX", "relevance_score": "0.056808", "ticker_sentiment_score": "0.031159", "ticker_sentiment_label": "Neutral"}, {"ticker": "PYPL", "relevance_score": "0.056808", "ticker_sentiment_score": "0.031159", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.113329", "ticker_sentiment_score": "0.087281", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.056808", "ticker_sentiment_score": "0.149963", "ticker_sentiment_label": "Neutral"}, {"ticker": "COST", "relevance_score": "0.056808", "ticker_sentiment_score": "0.149963", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.113329", "ticker_sentiment_score": "0.158908", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.056808", "ticker_sentiment_score": "0.149963", "ticker_sentiment_label": "Neutral"}, {"ticker": "BRK-A", "relevance_score": "0.056808", "ticker_sentiment_score": "0.038124", "ticker_sentiment_label": "Neutral"}, {"ticker": "PEP", "relevance_score": "0.056808", "ticker_sentiment_score": "0.149963", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.113329", "ticker_sentiment_score": "0.104571", "ticker_sentiment_label": "Neutral"}, {"ticker": "WMT", "relevance_score": "0.056808", "ticker_sentiment_score": "0.031159", "ticker_sentiment_label": "Neutral"}]}, {"title": "Aridis Pharmaceuticals Announces Third Quarter 2023 Financial Results and Business Update", "url": "https://www.globenewswire.com/news-release/2023/11/03/2773449/0/en/Aridis-Pharmaceuticals-Announces-Third-Quarter-2023-Financial-Results-and-Business-Update.html", "time_published": "20231103T201500", "authors": ["Inc.", "Aridis Pharmaceuticals"], "summary": "Received two grant awards from the National Institute of Allergy and Infectious Diseases, a division of the National Institutes of Health ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/1632bb3d-4628-419b-b9ea-dec63e8a038b", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.988915"}, {"topic": "Earnings", "relevance_score": "0.990786"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.077055, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.018454", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ARDS", "relevance_score": "0.092071", "ticker_sentiment_score": "0.088208", "ticker_sentiment_label": "Neutral"}, {"ticker": "SZIHF", "relevance_score": "0.018454", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Ionis  ( IONS )  Q3 Loss Wider Than Expected, Sales Beat Estimates", "url": "https://www.zacks.com/stock/news/2178101/ionis-ions-q3-loss-wider-than-expected-sales-beat-estimates", "time_published": "20231103T134400", "authors": ["Zacks Equity Research"], "summary": "Ionis (IONS) incurs a wider-than-expected third-quarter loss. Sales beat estimates. The company re-affirms its previously issued financial guidance for 2023.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/39/612.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Real Estate & Construction", "relevance_score": "0.5"}], "overall_sentiment_score": 0.054714, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "IONS", "relevance_score": "0.20279", "ticker_sentiment_score": "-0.008397", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALX", "relevance_score": "0.051221", "ticker_sentiment_score": "-0.112424", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.152821", "ticker_sentiment_score": "0.062683", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.300088", "ticker_sentiment_score": "0.116073", "ticker_sentiment_label": "Neutral"}]}, {"title": "Novo Nordisk  ( NVO )  Q3 2023 Earnings Call Transcript", "url": "https://www.fool.com/earnings/call-transcripts/2023/11/02/novo-nordisk-nvo-q3-2023-earnings-call-transcript/", "time_published": "20231102T180024", "authors": ["Motley Fool Transcribing"], "summary": "NVO earnings call for the period ending September 30, 2023.", "banner_image": "https://g.foolcdn.com/misc-assets/fool-transcripts-logo.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.94762"}, {"topic": "Earnings", "relevance_score": "0.838487"}, {"topic": "Finance", "relevance_score": "0.5"}, {"topic": "Economy - Macro", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.271135, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SCGLF", "relevance_score": "0.004883", "ticker_sentiment_score": "0.203146", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BCS", "relevance_score": "0.004883", "ticker_sentiment_score": "0.203146", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "C", "relevance_score": "0.009766", "ticker_sentiment_score": "0.156782", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.004883", "ticker_sentiment_score": "0.023026", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.004883", "ticker_sentiment_score": "0.203146", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVO", "relevance_score": "0.043925", "ticker_sentiment_score": "0.098337", "ticker_sentiment_label": "Neutral"}, {"ticker": "AWON", "relevance_score": "0.009766", "ticker_sentiment_score": "-0.037664", "ticker_sentiment_label": "Neutral"}]}, {"title": "China's mRNA Pioneer Stemirna Faces Post-Covid Reinvention Test - Moderna  ( NASDAQ:MRNA ) , BioNTech  ( NASDAQ:BNTX ) ", "url": "https://www.benzinga.com/markets/asia/23/11/35564074/chinas-mrna-pioneer-stemirna-faces-post-covid-reinvention-test", "time_published": "20231102T134030", "authors": ["The Bamboo Works"], "summary": "Flush with funds from its backers, Stemirna built manufacturing plants that were able to produce up to 400 million vaccine doses a year and put together a sales force for an anticipated surge in Covid demand", "banner_image": "https://cdn.benzinga.com/files/stemirna.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.016895, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GLP", "relevance_score": "0.039614", "ticker_sentiment_score": "0.054922", "ticker_sentiment_label": "Neutral"}, {"ticker": "WUXAY", "relevance_score": "0.039614", "ticker_sentiment_score": "0.063669", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.07913", "ticker_sentiment_score": "0.066947", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.039614", "ticker_sentiment_score": "0.067562", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.07913", "ticker_sentiment_score": "0.066947", "ticker_sentiment_label": "Neutral"}, {"ticker": "CASBF", "relevance_score": "0.039614", "ticker_sentiment_score": "0.067562", "ticker_sentiment_label": "Neutral"}]}, {"title": "These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar", "url": "https://www.zacks.com/stock/news/2177085/these-2-medical-stocks-could-beat-earnings-why-they-should-be-on-your-radar", "time_published": "20231102T125005", "authors": ["Zacks Equity Research"], "summary": "Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default167.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999937"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.355613, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.329112", "ticker_sentiment_score": "0.316067", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABBV", "relevance_score": "0.266101", "ticker_sentiment_score": "0.268975", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Why Roku Shares Are Trading Higher By Around 19%; Here Are 20 Stocks Moving Premarket - Avalon Globocare  ( NASDAQ:ALBT ) , AudioCodes  ( NASDAQ:AUDC ) ", "url": "https://www.benzinga.com/news/23/11/35560461/why-roku-shares-are-trading-higher-by-around-19-here-are-20-stocks-moving-premarket", "time_published": "20231102T120805", "authors": ["Lisa Levin"], "summary": "LumiraDx Limited LMDX shares surged 39.7% to $0.1143 in pre-market trading after falling 17% on Wednesday. LumiraDX recently announced the receipt of the Nasdaq delisting determination. Cellectis S.A. CLLS shares rose 23.8% to $3.27 in pre-market trading.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/11/02/roku_-_logo.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.82617"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.983605"}], "overall_sentiment_score": 0.204323, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PYPL", "relevance_score": "0.170275", "ticker_sentiment_score": "0.434947", "ticker_sentiment_label": "Bullish"}, {"ticker": "ROKU", "relevance_score": "0.170275", "ticker_sentiment_score": "0.380519", "ticker_sentiment_label": "Bullish"}, {"ticker": "ALBT", "relevance_score": "0.170275", "ticker_sentiment_score": "0.152625", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RELY", "relevance_score": "0.170275", "ticker_sentiment_score": "-0.056015", "ticker_sentiment_label": "Neutral"}, {"ticker": "RVLV", "relevance_score": "0.170275", "ticker_sentiment_score": "-0.470382", "ticker_sentiment_label": "Bearish"}, {"ticker": "AUDC", "relevance_score": "0.170275", "ticker_sentiment_score": "0.36472", "ticker_sentiment_label": "Bullish"}, {"ticker": "NVST", "relevance_score": "0.170275", "ticker_sentiment_score": "-0.446416", "ticker_sentiment_label": "Bearish"}, {"ticker": "CLLS", "relevance_score": "0.252987", "ticker_sentiment_score": "0.287304", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SGD", "relevance_score": "0.170275", "ticker_sentiment_score": "-0.277825", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "PCOR", "relevance_score": "0.170275", "ticker_sentiment_score": "0.074825", "ticker_sentiment_label": "Neutral"}, {"ticker": "SEDG", "relevance_score": "0.170275", "ticker_sentiment_score": "-0.049794", "ticker_sentiment_label": "Neutral"}, {"ticker": "LMND", "relevance_score": "0.170275", "ticker_sentiment_score": "0.296555", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.085629", "ticker_sentiment_score": "0.160574", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JAKK", "relevance_score": "0.170275", "ticker_sentiment_score": "0.274884", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "QCOM", "relevance_score": "0.170275", "ticker_sentiment_score": "0.396214", "ticker_sentiment_label": "Bullish"}, {"ticker": "LMDX", "relevance_score": "0.252987", "ticker_sentiment_score": "0.092395", "ticker_sentiment_label": "Neutral"}, {"ticker": "AWRE", "relevance_score": "0.170275", "ticker_sentiment_score": "0.472885", "ticker_sentiment_label": "Bullish"}, {"ticker": "SIEN", "relevance_score": "0.252987", "ticker_sentiment_score": "-0.070272", "ticker_sentiment_label": "Neutral"}, {"ticker": "FSLY", "relevance_score": "0.170275", "ticker_sentiment_score": "0.335504", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HOWL", "relevance_score": "0.170275", "ticker_sentiment_score": "-0.060922", "ticker_sentiment_label": "Neutral"}]}, {"title": "AstraZeneca gets into strategic collaboration and investment agreements with Cellectis", "url": "https://www.financialexpress.com/healthcare/news-healthcare/astrazeneca-gets-into-strategic-collaboration-and-investment-agreements-with-cellectis/3294880/", "time_published": "20231102T071848", "authors": ["Health Desk"], "summary": "AstraZeneca on Wednesday announced a collaboration and investment agreement with Cellectis to accelerate the development of next-generation therapeutics in areas of high unmet need, including oncology, immunology and rare diseases.", "banner_image": "https://www.financialexpress.com/wp-content/uploads/2023/11/vitamins-g81bff71f1_1920.jpg", "source": "The Financial Express", "category_within_source": "n/a", "source_domain": "www.financialexpress.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.623304"}], "overall_sentiment_score": 0.120833, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.762438", "ticker_sentiment_score": "0.233534", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CLLS", "relevance_score": "0.568953", "ticker_sentiment_score": "0.298449", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Ultimovacs Announces Completion of Patient Enrollment in Supplementary Study to INITIUM, UV1 Phase II Trial in Malignant Melanoma", "url": "https://www.globenewswire.com/news-release/2023/11/02/2771871/0/en/Ultimovacs-Announces-Completion-of-Patient-Enrollment-in-Supplementary-Study-to-INITIUM-UV1-Phase-II-Trial-in-Malignant-Melanoma.html", "time_published": "20231102T060000", "authors": ["Ultimovacs ASA"], "summary": "\u2022 The supplementary study to INITIUM is designed to provide in-depth data on the biological activity and mode of action of the vaccine-induced T cells, to support the next stages of development \u2022 Enrollment of 21 patients with unresectable or metastatic malignant melanoma completed \u2022 All ...", "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/23b62627-6dd1-416b-b614-675e9c122324", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.839681"}], "overall_sentiment_score": -0.021716, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.032078", "ticker_sentiment_score": "-0.01357", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.032078", "ticker_sentiment_score": "-0.01357", "ticker_sentiment_label": "Neutral"}]}, {"title": "InnovationRx: The VA's Call For AI Tools", "url": "https://www.forbes.com/sites/alexknapp/2023/11/01/innovationrx-the-vas-call-for-ai-tools/", "time_published": "20231101T214009", "authors": ["Katie Jennings"], "summary": "InnovationRx is your weekly digest of healthcare news. To get it in your inbox, subscribe here. The U.S. Department of Veterans Affairs has issued a call for two different types of health-related artificial intelligence tools on the heels of President Joe Biden's AI executive order issued this ...", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/6542c331da400ef06ef76bfb/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds", "source": "Forbes", "category_within_source": "n/a", "source_domain": "www.forbes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Economy - Fiscal", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.088232, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MSFT", "relevance_score": "0.035189", "ticker_sentiment_score": "0.063943", "ticker_sentiment_label": "Neutral"}, {"ticker": "CVS", "relevance_score": "0.035189", "ticker_sentiment_score": "0.086646", "ticker_sentiment_label": "Neutral"}, {"ticker": "MASI", "relevance_score": "0.07031", "ticker_sentiment_score": "-0.010166", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.07031", "ticker_sentiment_score": "0.038136", "ticker_sentiment_label": "Neutral"}, {"ticker": "SRPT", "relevance_score": "0.035189", "ticker_sentiment_score": "0.032972", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.035189", "ticker_sentiment_score": "-0.080215", "ticker_sentiment_label": "Neutral"}]}, {"title": "Dow Gains Over 100 Points; Fed Leaves Interest Rates Unchanged - Iridex  ( NASDAQ:IRIX ) , Cellectis  ( NASDAQ:CLLS ) ", "url": "https://www.benzinga.com/news/earnings/23/11/35546185/dow-gains-over-100-points-fed-leaves-interest-rates-unchanged", "time_published": "20231101T183323", "authors": ["Lisa Levin"], "summary": "U.S. stocks traded higher toward the end of trading, after the Federal Reserve announced its policy decision. The Dow traded up 0.40% to 33,185.41 while the NASDAQ rose 0.92% to 12,969.54. The S&P 500 also rose, gaining, 0.67% to 4,221.94. Information technology shares jumped by 1.2% on Wednesday.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/11/01/federal_reserve2_-_logo.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.576289"}, {"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.87644"}, {"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.114741, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "TGTX", "relevance_score": "0.124164", "ticker_sentiment_score": "0.360183", "ticker_sentiment_label": "Bullish"}, {"ticker": "PATI", "relevance_score": "0.185306", "ticker_sentiment_score": "0.475838", "ticker_sentiment_label": "Bullish"}, {"ticker": "AZN", "relevance_score": "0.062271", "ticker_sentiment_score": "-0.088669", "ticker_sentiment_label": "Neutral"}, {"ticker": "SPGI", "relevance_score": "0.185306", "ticker_sentiment_score": "-0.118455", "ticker_sentiment_label": "Neutral"}, {"ticker": "IRIX", "relevance_score": "0.185306", "ticker_sentiment_score": "0.218934", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "WEWOW", "relevance_score": "0.062271", "ticker_sentiment_score": "-0.06989", "ticker_sentiment_label": "Neutral"}, {"ticker": "PAYC", "relevance_score": "0.185306", "ticker_sentiment_score": "0.025978", "ticker_sentiment_label": "Neutral"}, {"ticker": "CLLS", "relevance_score": "0.245339", "ticker_sentiment_score": "-0.168776", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "5 Most Active Penny Stocks Today & Why They're Moving Now", "url": "https://pennystocks.com/featured/2023/11/01/5-most-active-penny-stocks-today-why-theyre-moving-now/", "time_published": "20231101T181142", "authors": ["J. Phillip"], "summary": "Penny stocks are the wild west of the stock market. Fast-paced, unpredictable, and laden with potential treasures. And in this vast landscape, one metric stands out: volume. It's like the heartbeat of a stock, echoing its vitality and momentum.", "banner_image": "https://pennystocks.com/wp-content/uploads/2022/08/best-penny-stocks-to-buy-this-week-piggy-bank-coins.jpg", "source": "PennyStocks.com", "category_within_source": "n/a", "source_domain": "pennystocks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.999999"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.234684, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ALDX", "relevance_score": "0.02674", "ticker_sentiment_score": "0.075753", "ticker_sentiment_label": "Neutral"}, {"ticker": "OTLK", "relevance_score": "0.053449", "ticker_sentiment_score": "0.097698", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.106659", "ticker_sentiment_score": "0.043125", "ticker_sentiment_label": "Neutral"}, {"ticker": "BTAI", "relevance_score": "0.080099", "ticker_sentiment_score": "0.073242", "ticker_sentiment_label": "Neutral"}, {"ticker": "BKR", "relevance_score": "0.080099", "ticker_sentiment_score": "0.198922", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABBV", "relevance_score": "0.053449", "ticker_sentiment_score": "0.08271", "ticker_sentiment_label": "Neutral"}, {"ticker": "CLLS", "relevance_score": "0.1331", "ticker_sentiment_score": "0.050938", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why Is Cancer Player Cellectis Stock Trading Over 100% Higher Today? - Cellectis  ( NASDAQ:CLLS ) ", "url": "https://www.benzinga.com/general/biotech/23/11/35538923/why-is-cancer-player-cellectis-stock-trading-over-100-higher-today", "time_published": "20231101T172028", "authors": ["Vandana Singh"], "summary": "Cellectis SA CLLS shares are trading higher after the company announced a research agreement with AstraZeneca Plc AZN AstraZeneca will leverage Cellectis' gene editing technologies and manufacturing capabilities to design cell and gene therapy candidate products.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/11/01/clls.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.309466, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.898236", "ticker_sentiment_score": "0.603279", "ticker_sentiment_label": "Bullish"}, {"ticker": "CLLS", "relevance_score": "0.930964", "ticker_sentiment_score": "0.594837", "ticker_sentiment_label": "Bullish"}]}, {"title": "Nasdaq Surges Over 100 Points Ahead Of Fed Decision; WeWork Shares Plunge - Iridex  ( NASDAQ:IRIX ) , Cellectis  ( NASDAQ:CLLS ) ", "url": "https://www.benzinga.com/news/earnings/23/11/35543219/nasdaq-surges-over-100-points-ahead-of-fed-decision-wework-shares-plunge", "time_published": "20231101T163814", "authors": ["Lisa Levin"], "summary": "U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 100 points on Wednesday. The Dow traded up 0.55% to 33,233.33 while the NASDAQ rose 0.87% to 12,962.92. The S&P 500 also rose, gaining, 0.74% to 4,224.85. Information technology shares jumped by 1.3% on ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/11/01/image26.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.87644"}, {"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.128868, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "TGTX", "relevance_score": "0.139265", "ticker_sentiment_score": "0.379514", "ticker_sentiment_label": "Bullish"}, {"ticker": "PATI", "relevance_score": "0.207571", "ticker_sentiment_score": "0.509835", "ticker_sentiment_label": "Bullish"}, {"ticker": "AZN", "relevance_score": "0.0699", "ticker_sentiment_score": "-0.089639", "ticker_sentiment_label": "Neutral"}, {"ticker": "SPGI", "relevance_score": "0.207571", "ticker_sentiment_score": "-0.129013", "ticker_sentiment_label": "Neutral"}, {"ticker": "IRIX", "relevance_score": "0.207571", "ticker_sentiment_score": "0.237835", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "WEWOW", "relevance_score": "0.0699", "ticker_sentiment_score": "-0.07083", "ticker_sentiment_label": "Neutral"}, {"ticker": "PAYC", "relevance_score": "0.207571", "ticker_sentiment_score": "0.028317", "ticker_sentiment_label": "Neutral"}, {"ticker": "CLLS", "relevance_score": "0.27432", "ticker_sentiment_score": "-0.184091", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "LUNG AMBITION AWARDS: CALL FOR CANADIAN RESEARCH TO IMPROVE LUNG CANCER CARE IS NOW OPEN", "url": "https://www.newswire.ca/news-releases/lung-ambition-awards-call-for-canadian-research-to-improve-lung-cancer-care-is-now-open-829892568.html", "time_published": "20231101T154200", "authors": ["Lung Cancer Canada"], "summary": "$100,000 CAD available in research grants to help address key gaps in lung cancer care TORONTO, Nov. 1, 2023 /CNW/ - To celebrate Lung Cancer Awareness Month, the Lung Ambition Awards - a Canadian-based lung cancer research award program - is back for its second year with $100,000 to be granted ...", "banner_image": "https://mma.prnewswire.com/media/2263767/Lung_Cancer_Canada_LUNG_AMBITION_AWARDS__CALL_FOR_CANADIAN_RESEA.jpg?p=facebook", "source": "Canada Newswire", "category_within_source": "n/a", "source_domain": "www.newswire.ca", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.117652, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.17813", "ticker_sentiment_score": "0.071809", "ticker_sentiment_label": "Neutral"}]}, {"title": "Regulations on AI good as long as we don't hinder innovations: SAP Labs", "url": "https://www.business-standard.com/companies/interviews/regulations-on-ai-are-good-as-long-as-we-don-t-put-brakes-on-innovation-123110100859_1.html", "time_published": "20231101T153000", "authors": ["Ayushman Baruah"], "summary": "Want to eliminate lung cancer as a cause of death: AstraZeneca India MD AI can be as evil as man makes it to be: Keniley-Kumar law firm partner AUM to see 18-20% growth during second half: Shriram Finance's Revankar Never said we are deferring our IPO plans: Pine Labs CEO B Amrish Rau", "banner_image": "https://bsmedia.business-standard.com/_media/bs/img/article/2023-11/01/full/1698838018-6634.jpg?im=FitAndFill=(826,465)", "source": "Business Standard", "category_within_source": "GoogleRSS", "source_domain": "www.business-standard.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "IPO", "relevance_score": "0.158519"}], "overall_sentiment_score": -0.173829, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.192694", "ticker_sentiment_score": "-0.534748", "ticker_sentiment_label": "Bearish"}]}, {"title": "US Stocks Mixed; Private Sector Payrolls Increase Less Than Expected - Iridex  ( NASDAQ:IRIX ) , Cellectis  ( NASDAQ:CLLS ) ", "url": "https://www.benzinga.com/news/earnings/23/11/35537887/us-stocks-mixed-private-sector-payrolls-increase-less-than-expected", "time_published": "20231101T134228", "authors": ["Lisa Levin"], "summary": "U.S. stocks traded mixed this morning, ahead of interest rate decision from the Federal Reserve. Following the market opening Wednesday, the Dow traded down 0.05% to 33,036.63 while the NASDAQ rose 0.32% to 12,892.45. The S&P 500 also rose, gaining, 0.15% to 4,199.94.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/11/01/image41_0.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.796627"}, {"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.152869, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PATI", "relevance_score": "0.217508", "ticker_sentiment_score": "0.524709", "ticker_sentiment_label": "Bullish"}, {"ticker": "AZN", "relevance_score": "0.073321", "ticker_sentiment_score": "-0.090204", "ticker_sentiment_label": "Neutral"}, {"ticker": "MNPR", "relevance_score": "0.146025", "ticker_sentiment_score": "0.255287", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SPGI", "relevance_score": "0.146025", "ticker_sentiment_score": "-0.114049", "ticker_sentiment_label": "Neutral"}, {"ticker": "IRIX", "relevance_score": "0.217508", "ticker_sentiment_score": "0.246361", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "WEWOW", "relevance_score": "0.073321", "ticker_sentiment_score": "-0.071352", "ticker_sentiment_label": "Neutral"}, {"ticker": "PAYC", "relevance_score": "0.217508", "ticker_sentiment_score": "0.029374", "ticker_sentiment_label": "Neutral"}, {"ticker": "CLLS", "relevance_score": "0.2872", "ticker_sentiment_score": "-0.190712", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Why Plus Therapeutics Shares Are Trading Higher By Over 11%; Here Are 20 Stocks Moving Premarket - Brainstorm Cell  ( NASDAQ:BCLI ) , Big 5 Sporting Goods  ( NASDAQ:BGFV ) ", "url": "https://www.benzinga.com/news/23/11/35534128/why-plus-therapeutics-shares-are-trading-higher-by-over-11-here-are-20-stocks-moving-premarket", "time_published": "20231101T120721", "authors": ["Lisa Levin"], "summary": "Cellectis S.A. CLLS shares surged 152% to $2.43 in pre-market trading. Cellectis reported strategic collaboration and investment agreements with AstraZeneca.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/11/01/image21.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Energy & Transportation", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "0.865346"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "0.917436"}, {"topic": "Real Estate & Construction", "relevance_score": "0.166667"}], "overall_sentiment_score": 0.039146, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "PSTV", "relevance_score": "0.130926", "ticker_sentiment_score": "0.204531", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BCLI", "relevance_score": "0.130926", "ticker_sentiment_score": "-0.322912", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "DBVT", "relevance_score": "0.130926", "ticker_sentiment_score": "0.148692", "ticker_sentiment_label": "Neutral"}, {"ticker": "FLJ", "relevance_score": "0.195287", "ticker_sentiment_score": "0.201766", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BHAT", "relevance_score": "0.130926", "ticker_sentiment_score": "0.039519", "ticker_sentiment_label": "Neutral"}, {"ticker": "BGFV", "relevance_score": "0.130926", "ticker_sentiment_score": "-0.042259", "ticker_sentiment_label": "Neutral"}, {"ticker": "SOPA", "relevance_score": "0.130926", "ticker_sentiment_score": "0.231847", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CLLS", "relevance_score": "0.258351", "ticker_sentiment_score": "-0.169443", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "LXRX", "relevance_score": "0.195287", "ticker_sentiment_score": "0.140661", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVX", "relevance_score": "0.258351", "ticker_sentiment_score": "0.518976", "ticker_sentiment_label": "Bullish"}, {"ticker": "AZN", "relevance_score": "0.065685", "ticker_sentiment_score": "-0.08596", "ticker_sentiment_label": "Neutral"}, {"ticker": "TNXP", "relevance_score": "0.130926", "ticker_sentiment_score": "-0.214114", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "RCON", "relevance_score": "0.130926", "ticker_sentiment_score": "-0.133123", "ticker_sentiment_label": "Neutral"}, {"ticker": "SIEN", "relevance_score": "0.195287", "ticker_sentiment_score": "0.159628", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BRSH", "relevance_score": "0.130926", "ticker_sentiment_score": "-0.129702", "ticker_sentiment_label": "Neutral"}, {"ticker": "WEWOW", "relevance_score": "0.130926", "ticker_sentiment_score": "-0.070454", "ticker_sentiment_label": "Neutral"}, {"ticker": "YUMC", "relevance_score": "0.130926", "ticker_sentiment_score": "-0.040909", "ticker_sentiment_label": "Neutral"}, {"ticker": "PAYC", "relevance_score": "0.130926", "ticker_sentiment_score": "0.040702", "ticker_sentiment_label": "Neutral"}, {"ticker": "TMPO", "relevance_score": "0.130926", "ticker_sentiment_score": "-0.055661", "ticker_sentiment_label": "Neutral"}]}, {"title": "Pfizer Layoffs Confirmed As Vaccine Manufacturer Drives For Cost Savings", "url": "https://www.forbes.com/sites/qai/2023/11/01/pfizer-layoffs-confirmed-as-vaccine-manufacturer-drives-for-cost-savings/", "time_published": "20231101T092604", "authors": ["Q.ai - Powering a Personal Wealth Movement"], "summary": "\u2022 Pfizer is laying off an undisclosed amount of employees after confirming it's shutting down its New Jersey facility \u2022 Two other facilities are closing in North Carolina, with other layoffs in Illinois and Colorado \u2022 Pfizer's share price was flat as the company reported a narrower-than-expected ...", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/65421997d4718e624351ab50/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds", "source": "Forbes", "category_within_source": "n/a", "source_domain": "www.forbes.com", "topics": [{"topic": "Earnings", "relevance_score": "0.998663"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.796627"}], "overall_sentiment_score": -0.03368, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SGEN", "relevance_score": "0.044141", "ticker_sentiment_score": "-0.134818", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.044141", "ticker_sentiment_score": "-0.283851", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "AZN", "relevance_score": "0.044141", "ticker_sentiment_score": "-0.283851", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "PFE", "relevance_score": "0.624172", "ticker_sentiment_score": "-0.047063", "ticker_sentiment_label": "Neutral"}]}, {"title": "AstraZeneca signs drug development deal with biotech Cellectis", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/astrazeneca-signs-drug-development-deal-with-biotech-cellectis-2023-11-01/", "time_published": "20231101T071600", "authors": ["Reuters"], "summary": "AstraZeneca signs drug development deal with biotech ...", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/5K4TPWZRQBKTHMJB462BOPACIA.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.101336, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.769861", "ticker_sentiment_score": "0.196191", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CLLS", "relevance_score": "0.451494", "ticker_sentiment_score": "0.240804", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Cellectis Announces Strategic Collaboration and Investment Agreements with AstraZeneca", "url": "https://www.globenewswire.com/news-release/2023/11/01/2770788/0/en/Cellectis-Announces-Strategic-Collaboration-and-Investment-Agreements-with-AstraZeneca.html", "time_published": "20231101T070000", "authors": ["Cellectis Inc."], "summary": "NEW YORK, Nov. 01, 2023 ( GLOBE NEWSWIRE ) -- Cellectis ( Euronext Growth: ALCLS - NASDAQ: CLLS ) today announced it has entered into ( i ) a Joint Research Collaboration Agreement ( the \"Collaboration Agreement\" ) , ( ii ) an investment agreement relating to an initial equity investment of ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/a84ce25b-a774-4635-9b79-d45241f5decc", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Economy - Fiscal", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "1.0"}], "overall_sentiment_score": 0.235485, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.444442", "ticker_sentiment_score": "0.327513", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CLLS", "relevance_score": "0.722447", "ticker_sentiment_score": "0.3877", "ticker_sentiment_label": "Bullish"}]}, {"title": "Cellectis Announces Strategic Collaboration and Investment Agreements with AstraZeneca - AstraZeneca  ( NASDAQ:AZN ) , Cellectis  ( NASDAQ:CLLS ) ", "url": "https://www.benzinga.com/pressreleases/23/11/g35530106/cellectis-announces-strategic-collaboration-and-investment-agreements-with-astrazeneca", "time_published": "20231101T070000", "authors": ["Globe Newswire"], "summary": "Collaboration leverages Cellectis' gene editing technologies and manufacturing capabilities to develop up to 10 novel cell & gene therapy candidate products Cellectis to receive up to $245M in cash ( up to $220M equity investment and $25M upfront payment ) , with potential for additional ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Economy - Fiscal", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "1.0"}], "overall_sentiment_score": 0.219508, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.439987", "ticker_sentiment_score": "0.309542", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CLLS", "relevance_score": "0.688591", "ticker_sentiment_score": "0.363975", "ticker_sentiment_label": "Bullish"}]}, {"title": "Challenge is going to be resource management without doubt: Shankar Raman", "url": "https://www.business-standard.com/companies/interviews/resource-management-is-going-to-be-a-challenge-for-us-l-t-s-shankar-raman-123110101153_1.html", "time_published": "20231101T030300", "authors": ["Amritha Pillay"], "summary": "Want to eliminate lung cancer as a cause of death: AstraZeneca India MD AI can be as evil as man makes it to be: Keniley-Kumar law firm partner AUM to see 18-20% growth during second half: Shriram Finance's Revankar L&T gains 2%, scales to an all-time high on multiple order wins", "banner_image": "https://bsmedia.business-standard.com/_media/bs/img/article/2023-07/26/full/1690376812-0458.jpg?im=FeatureCrop,size=(826,465)", "source": "Business Standard", "category_within_source": "GoogleRSS", "source_domain": "www.business-standard.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.017112, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.218817", "ticker_sentiment_score": "-0.575315", "ticker_sentiment_label": "Bearish"}, {"ticker": "LTOUF", "relevance_score": "0.421485", "ticker_sentiment_score": "0.238094", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Astrazeneca  ( AZN )  Rises But Trails Market: What Investors Should Know", "url": "https://www.zacks.com/stock/news/2175885/astrazeneca-azn-rises-but-trails-market-what-investors-should-know", "time_published": "20231031T215008", "authors": ["Zacks Equity Research"], "summary": "In the most recent trading session, Astrazeneca (AZN) closed at $63.23, indicating a +0.46% shift from the previous trading day.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default233.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.983783"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.10855, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.595343", "ticker_sentiment_score": "0.233973", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Can High Benefits and Expenses Affect Cigna  ( CI )  Q3 Earnings?", "url": "https://www.zacks.com/stock/news/2175752/can-high-benefits-and-expenses-affect-cigna-ci-q3-earnings", "time_published": "20231031T161900", "authors": ["Zacks Equity Research"], "summary": "Cigna's (CI) third-quarter results are likely to reflect growth in medical customers and pharmacy revenues.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/af/2600.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.272345, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "APLS", "relevance_score": "0.153145", "ticker_sentiment_score": "0.088921", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.153145", "ticker_sentiment_score": "0.132386", "ticker_sentiment_label": "Neutral"}, {"ticker": "JAZZ", "relevance_score": "0.153145", "ticker_sentiment_score": "0.147884", "ticker_sentiment_label": "Neutral"}, {"ticker": "CI", "relevance_score": "0.102449", "ticker_sentiment_score": "0.112395", "ticker_sentiment_label": "Neutral"}]}, {"title": "Amgen  ( AMGN )  Beats on Q3 Earnings Beat, Lags Sales, Ups View", "url": "https://www.zacks.com/stock/news/2175771/amgen-amgn-beats-on-q3-earnings-beat-lags-sales-ups-view", "time_published": "20231031T153000", "authors": ["Zacks Equity Research"], "summary": "Amgen (AMGN) beats Q3 estimates for earnings but misses on sales. Following the acquisition of Horizon Therapeutics, it raises earnings and sales guidance for 2023.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f4/2111.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999813"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.796627"}], "overall_sentiment_score": 0.074095, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LGND", "relevance_score": "0.07948", "ticker_sentiment_score": "0.095988", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.053035", "ticker_sentiment_score": "0.062929", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.334529", "ticker_sentiment_score": "0.181836", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.132077", "ticker_sentiment_score": "0.256652", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "ImmPACT Bio Appoints Han Lee, Ph.D., MBA, as President and Chief Financial Officer - PR Newswire", "url": "https://www.prnewswire.com/news-releases/immpact-bio-appoints-han-lee-phd-mba-as-president-and-chief-financial-officer-301971948.html", "time_published": "20231031T114500", "authors": [], "summary": "ImmPACT Bio Appoints Han Lee, Ph.D., MBA, as President and Chief Financial Officer PR ...", "banner_image": null, "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "IPO", "relevance_score": "0.310843"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.251714, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ACLX", "relevance_score": "0.057628", "ticker_sentiment_score": "0.170996", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.114956", "ticker_sentiment_score": "0.191012", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "AMGEN REPORTS THIRD QUARTER FINANCIAL RESULTS", "url": "https://investingnews.com/amgen-reports-third-quarter-financial-results/", "time_published": "20231031T113917", "authors": ["Investing News Network"], "summary": "Amgen ( NASDAQ:AMGN ) today announced financial results for the third quarter of 2023 1 . References in this release to \"non-GAAP\" measures, measures presented \"on a non-GAAP basis\" and \"free cash flow\" ( computed by subtracting capital expenditures from operating cash flow ) refer to ...", "banner_image": "https://mma.prnewswire.com/media/152881/amgen_logo.jpg", "source": "Investing News Network", "category_within_source": "n/a", "source_domain": "investingnews.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.999864"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.161647"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.128468, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GOOG", "relevance_score": "0.01615", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "IDYA", "relevance_score": "0.01615", "ticker_sentiment_score": "0.020913", "ticker_sentiment_label": "Neutral"}, {"ticker": "BGNE", "relevance_score": "0.01615", "ticker_sentiment_score": "0.193788", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.01615", "ticker_sentiment_score": "0.020913", "ticker_sentiment_label": "Neutral"}, {"ticker": "KNBWF", "relevance_score": "0.01615", "ticker_sentiment_score": "0.020913", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.01615", "ticker_sentiment_score": "0.020913", "ticker_sentiment_label": "Neutral"}, {"ticker": "XNCR", "relevance_score": "0.01615", "ticker_sentiment_score": "0.020913", "ticker_sentiment_label": "Neutral"}, {"ticker": "KYKOF", "relevance_score": "0.01615", "ticker_sentiment_score": "0.020913", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.01615", "ticker_sentiment_score": "0.020913", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.01615", "ticker_sentiment_score": "0.020913", "ticker_sentiment_label": "Neutral"}]}, {"title": "Ultimovacs Announces Protocol Amendment in UV1 Phase II Study INITIUM in Malignant Melanoma, Enabling Data Readout in First Half of 2024", "url": "https://www.globenewswire.com/news-release/2023/10/31/2769813/0/en/Ultimovacs-Announces-Protocol-Amendment-in-UV1-Phase-II-Study-INITIUM-in-Malignant-Melanoma-Enabling-Data-Readout-in-First-Half-of-2024.html", "time_published": "20231031T060000", "authors": ["Ultimovacs ASA"], "summary": "Oslo, October 31, 2023: Ultimovacs ASA ( \"Ultimovacs\" ) ( OSE ULTI ) , a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines, today announced that the analysis of the INITIUM data will be initiated in mid-January 2024, following an amendment of the clinical trial ...", "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/23b62627-6dd1-416b-b614-675e9c122324", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.839681"}], "overall_sentiment_score": -0.036295, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.023281", "ticker_sentiment_score": "-0.016788", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.023281", "ticker_sentiment_score": "-0.016788", "ticker_sentiment_label": "Neutral"}]}, {"title": "More 'give' than 'take'? From tariffs to labour norms, the differences are many And someone has to give in", "url": "https://www.financialexpress.com/opinion/more-give-than-take-from-tariffs-to-labour-norms-the-differences-are-many-and-someone-has-to-give-in/3291780/", "time_published": "20231030T223000", "authors": ["Biswajit Dhar"], "summary": "Recent developments indicate that India and the United Kingdom ( UK ) are close to finalising their bilateral free trade agreement ( FTA ) less than two and a half years after prime minister Narendra Modi and then-prime minister Boris Johnson had given their green signal to negotiate such an ...", "banner_image": "https://www.financialexpress.com/wp-content/uploads/2023/09/trade.jpg", "source": "The Financial Express", "category_within_source": "n/a", "source_domain": "www.financialexpress.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Economy - Fiscal", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.154254, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.039483", "ticker_sentiment_score": "0.055302", "ticker_sentiment_label": "Neutral"}]}, {"title": "Infant RSV Antibody Shortage: Here Are The CDC Recommended Alternatives", "url": "https://www.forbes.com/sites/ariannajohnson/2023/10/30/infant-rsv-antibody-shortage-here-are-the-cdc-recommended-alternatives/", "time_published": "20231030T203131", "authors": ["Arianna Johnson"], "summary": "As RSV season approaches, some doses of nirsevimab-the monoclonal antibody RSV immunization for infants-are in a limited supply, so the CDC recommends prioritizing doses for high risk infants and using an expensive, more frequently administered alternative.", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/65400c1f37ebe03c89cb016b/0x0.jpg?format=jpg&crop=4000,2249,x0,y99,safe&height=900&width=1600&fit=bounds", "source": "Forbes", "category_within_source": "n/a", "source_domain": "www.forbes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Manufacturing", "relevance_score": "0.5"}], "overall_sentiment_score": -0.10719, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NYT", "relevance_score": "0.054983", "ticker_sentiment_score": "-0.06", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.054983", "ticker_sentiment_score": "-0.076049", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.109705", "ticker_sentiment_score": "-0.075753", "ticker_sentiment_label": "Neutral"}]}, {"title": "Comparative Study: AstraZeneca And Industry Competitors In Pharmaceuticals Industry - AstraZeneca  ( NASDAQ:AZN ) ", "url": "https://www.benzinga.com/news/23/10/35494533/comparative-study-astrazeneca-and-industry-competitors-in-pharmaceuticals-industry", "time_published": "20231030T160034", "authors": ["Benzinga Insights"], "summary": "In today's rapidly evolving and fiercely competitive business landscape, it is crucial for investors and industry analysts to conduct comprehensive company evaluations. In this article, we will undertake an in-depth industry comparison, assessing AstraZeneca AZN alongside its primary competitors ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.938793"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.692272"}], "overall_sentiment_score": 0.11737, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "PTAIF", "relevance_score": "0.067158", "ticker_sentiment_score": "0.018166", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.551805", "ticker_sentiment_score": "0.198085", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Shriram Finance's Revankar: AUM to see 18-20% growth during second half", "url": "https://www.business-standard.com/companies/interviews/shriram-finance-aum-to-see-18-20-growth-during-second-half-revankar-123102700647_1.html", "time_published": "20231030T134114", "authors": ["Shine Jacob"], "summary": "AUM to see 18-20% growth during second half: Shriram Finance's Revankar Business Standard ...", "banner_image": "https://bsmedia.business-standard.com/_media/bs/img/article/2023-10/27/full/1698401907-4084.jpg?im=FeatureCrop,size=(826,465)", "source": "Business Standard", "category_within_source": "GoogleRSS", "source_domain": "www.business-standard.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}], "overall_sentiment_score": -0.241315, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.327366", "ticker_sentiment_score": "-0.710488", "ticker_sentiment_label": "Bearish"}]}, {"title": "Is Trending Stock AstraZeneca PLC  ( AZN )  a Buy Now?", "url": "https://www.zacks.com/stock/news/2174361/is-trending-stock-astrazeneca-plc-azn-a-buy-now", "time_published": "20231030T130006", "authors": ["Zacks Equity Research"], "summary": "Astrazeneca (AZN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default222.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.5855"}], "overall_sentiment_score": 0.208294, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.491255", "ticker_sentiment_score": "0.120086", "ticker_sentiment_label": "Neutral"}]}, {"title": "Merck KGaA widens work on 'DNA damage' drugs in deal with China's Hengrui", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/merck-kgaa-widens-work-dna-damage-drugs-deal-with-chinas-hengrui-2023-10-30/", "time_published": "20231030T084500", "authors": ["Reuters"], "summary": "Merck KGaA widens work on 'DNA damage' drugs in deal with China's ...", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/VFY7OE67HNPSVOPC6HF23AH7JQ.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.019579, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.19117", "ticker_sentiment_score": "-0.338955", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "India's 5G potential is now unfolding: Ericsson's Nunzio Mirtillo", "url": "https://www.business-standard.com/companies/interviews/with-infra-in-place-potential-of-5g-is-now-unfolding-ericsson-s-mirtillo-123102900691_1.html", "time_published": "20231029T165110", "authors": ["Subhayan Chakraborty"], "summary": "We still anticipate sustained demand for diesel vehicles: Kia India CEO Tally is investing heavily in AI to develop new product experience: Goenka Want to eliminate lung cancer as a cause of death: AstraZeneca India MD AI can be as evil as man makes it to be: Keniley-Kumar law firm partner", "banner_image": "https://bsmedia.business-standard.com/_media/bs/img/article/2023-10/29/full/1698598248-5277.png?im=FitAndFill=(826,465)", "source": "Business Standard", "category_within_source": "GoogleRSS", "source_domain": "www.business-standard.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}], "overall_sentiment_score": -0.199382, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.202366", "ticker_sentiment_score": "-0.550036", "ticker_sentiment_label": "Bearish"}, {"ticker": "VOD", "relevance_score": "0.202366", "ticker_sentiment_score": "0.289835", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "3 No-Brainer Stocks to Buy for Under $100 Right Now", "url": "https://www.fool.com/investing/2023/10/28/3-no-brainer-stocks-to-buy-for-under-100-right-now/", "time_published": "20231028T105000", "authors": ["David Jagielski", "and Prosper Junior Bakiny", "Keith Speights"], "summary": "A couple of these stocks might not be available for under $100 for too much longer.", "banner_image": "https://g.foolcdn.com/editorial/images/752433/happy-stock-investor-holding-smartphone.jpg", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.503496"}, {"topic": "Earnings", "relevance_score": "0.955357"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.221304, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.28008", "ticker_sentiment_score": "0.293012", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.142284", "ticker_sentiment_score": "0.018418", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.367412", "ticker_sentiment_score": "0.002632", "ticker_sentiment_label": "Neutral"}]}, {"title": "Sanofi  ( SNY )  Q3 2023 Earnings Call Transcript", "url": "https://www.fool.com/earnings/call-transcripts/2023/10/27/sanofi-sny-q3-2023-earnings-call-transcript/", "time_published": "20231027T193022", "authors": ["Motley Fool Transcribing"], "summary": "SNY earnings call for the period ending September 30, 2023.", "banner_image": "https://g.foolcdn.com/misc-assets/fool-transcripts-logo.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}, {"topic": "Economy - Fiscal", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.495866"}, {"topic": "Economy - Macro", "relevance_score": "0.576289"}], "overall_sentiment_score": 0.339117, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SCGLF", "relevance_score": "0.003762", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TRMNF", "relevance_score": "0.003762", "ticker_sentiment_score": "0.026075", "ticker_sentiment_label": "Neutral"}, {"ticker": "BCS", "relevance_score": "0.003762", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "C", "relevance_score": "0.007525", "ticker_sentiment_score": "0.069993", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.007525", "ticker_sentiment_score": "0.1364", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.003762", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.060142", "ticker_sentiment_score": "0.207172", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FOREX:USD", "relevance_score": "0.003762", "ticker_sentiment_score": "0.056367", "ticker_sentiment_label": "Neutral"}]}, {"title": "Non-alcoholic Steatohepatitis Market to grow by USD 11.22 billion from 2022 to 2027, North America to account for 51 ... - PR Newswire", "url": "https://www.prnewswire.com/news-releases/non-alcoholic-steatohepatitis-market-to-grow-by-usd-11-22-billion--from-2022-to-2027--north-america-to-account-for-51-of-market-growth--technavio-301969658.html", "time_published": "20231027T183000", "authors": [], "summary": "Non-alcoholic Steatohepatitis Market to grow by USD 11.22 billion from 2022 to 2027, North America to account for 51 ... PR ...", "banner_image": null, "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.239625, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ENZ", "relevance_score": "0.068112", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GNFT", "relevance_score": "0.068112", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.068112", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVA", "relevance_score": "0.068112", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.068112", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDGL", "relevance_score": "0.068112", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.068112", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SEMHF", "relevance_score": "0.068112", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ICPT", "relevance_score": "0.068112", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "FTSE 100 closes 0.9% lower, logs weekly loss as lacklustre results weigh", "url": "https://www.business-standard.com/markets/news/ftse-100-closes-0-9-lower-logs-weekly-loss-as-lacklustre-results-weigh-123102701337_1.html", "time_published": "20231027T171738", "authors": ["Reuters"], "summary": "Britain's FTSE 100 fell on Friday, with the benchmark index posting its second weekly drop after a series of underwhelming earnings updates, with NatWest's gloomy outlook the latest to weigh on banks. The FTSE 100 closed 0.9% lower, with consumer staples like Unilever and Diageo falling more than ...", "banner_image": "https://bsmedia.business-standard.com/_media/bs/img/article/2023-09/18/full/1695058435-1533.jpg?im=FitAndFill=(826,465)", "source": "Business Standard", "category_within_source": "GoogleRSS", "source_domain": "www.business-standard.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": -0.220813, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.145145", "ticker_sentiment_score": "-0.41281", "ticker_sentiment_label": "Bearish"}, {"ticker": "DEO", "relevance_score": "0.145145", "ticker_sentiment_score": "-0.288134", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "NWG", "relevance_score": "0.145145", "ticker_sentiment_score": "-0.078471", "ticker_sentiment_label": "Neutral"}, {"ticker": "UL", "relevance_score": "0.145145", "ticker_sentiment_score": "-0.288134", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Will Lower CenterWell Profit Hurt Humana's  ( HUM )  Q3 Earnings?", "url": "https://www.zacks.com/stock/news/2173885/will-lower-centerwell-profit-hurt-humanas-hum-q3-earnings", "time_published": "20231027T155000", "authors": ["Zacks Equity Research"], "summary": "Humana's (HUM) third-quarter results are likely to reflect higher investment income and premiums.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/6e/54381.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.276101, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "APLS", "relevance_score": "0.139265", "ticker_sentiment_score": "0.084072", "ticker_sentiment_label": "Neutral"}, {"ticker": "HUM", "relevance_score": "0.479954", "ticker_sentiment_score": "0.417934", "ticker_sentiment_label": "Bullish"}, {"ticker": "AZN", "relevance_score": "0.139265", "ticker_sentiment_score": "0.140022", "ticker_sentiment_label": "Neutral"}, {"ticker": "JAZZ", "relevance_score": "0.139265", "ticker_sentiment_score": "0.140022", "ticker_sentiment_label": "Neutral"}]}, {"title": "Sanofi  ( SNY )  Beats on Q3 Earnings, to Spin-Off Consumer Unit", "url": "https://www.zacks.com/stock/news/2173809/sanofi-sny-beats-on-q3-earnings-to-spin-off-consumer-unit", "time_published": "20231027T141800", "authors": ["Zacks Equity Research"], "summary": "Sanofi (SNY) beats third-quarter estimates for earnings but misses the same for sales. It announces plans to separate its Consumer unit into a new public listed company.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f5/284.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Earnings", "relevance_score": "0.999687"}, {"topic": "Economy - Macro", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.133461, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.08146", "ticker_sentiment_score": "0.112646", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.460544", "ticker_sentiment_score": "0.298041", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "No Proven Link Between Weight Loss Drugs And Thyroid Cancer, EU Says", "url": "https://www.forbes.com/sites/tylerroush/2023/10/27/no-proven-link-between-weight-loss-drugs-and-thyroid-cancer-eu-says/", "time_published": "20231027T134701", "authors": ["Ty Roush"], "summary": "There is no evidence to suggest weight loss and diabetes drugs like Ozempic or Wegovy cause thyroid cancer, a European Union agency said Friday, easing fears after a previous study suggested using similar drugs resulted in an increased risk of all thyroid cancers for people with type two diabetes.", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/653bbebc065d2afe7c03484f/0x0.jpg?format=jpg&crop=5190,2921,x3,y111,safe&height=900&width=1600&fit=bounds", "source": "Forbes", "category_within_source": "n/a", "source_domain": "www.forbes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.224727, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.082393", "ticker_sentiment_score": "-0.082582", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.163909", "ticker_sentiment_score": "-0.10737", "ticker_sentiment_label": "Neutral"}]}, {"title": "MRK: Merck & Co.  ( MRK )  Q3 Earnings Assessment: Is the Pharma Stock a Buy or Sell?", "url": "https://stocknews.com/news/mrk-abbv-azn-nvs-dsnky-alpmy-merck-co-mrk-q3-earnings-assessment-is-the-pharma/", "time_published": "20231027T133645", "authors": ["StockNews.com Staff"], "summary": "MRK: Merck & Co. ( MRK ) Q3 Earnings Assessment: Is the Pharma ... ...", "banner_image": "https://stocknews.com/wp-content/uploads/2021/04/wmt-nvs-mrk-scaled.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "stocknews.com", "topics": [{"topic": "Earnings", "relevance_score": "0.997405"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.459462"}], "overall_sentiment_score": 0.262634, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.08183", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALPMF", "relevance_score": "0.040969", "ticker_sentiment_score": "-0.006956", "ticker_sentiment_label": "Neutral"}, {"ticker": "SKXJF", "relevance_score": "0.040969", "ticker_sentiment_score": "0.032441", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVS", "relevance_score": "0.08183", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.08183", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SGEN", "relevance_score": "0.040969", "ticker_sentiment_score": "-0.006956", "ticker_sentiment_label": "Neutral"}, {"ticker": "DSKYF", "relevance_score": "0.040969", "ticker_sentiment_score": "0.032441", "ticker_sentiment_label": "Neutral"}]}, {"title": "On Lok Strengthens Executive Leadership Team with New CFO and CSO", "url": "https://www.prnewswire.com/news-releases/on-lok-strengthens-executive-leadership-team-with-new-cfo-and-cso-301969547.html", "time_published": "20231027T000000", "authors": ["On Lok"], "summary": "SAN FRANCISCO, Oct. 26, 2023 /PRNewswire/ -- On Lok, the San Francisco-based nonprofit organization that empowers older adults to age with dignity and independence, has announced the appointment of Carl Gerlach as Chief Financial Officer ( CFO ) and Min Chang as Chief Strategy Officer ( CSO ) .", "banner_image": "https://mma.prnewswire.com/media/2220610/On_Lok_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.333778, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ACN", "relevance_score": "0.068698", "ticker_sentiment_score": "0.113405", "ticker_sentiment_label": "Neutral"}, {"ticker": "OMC", "relevance_score": "0.068698", "ticker_sentiment_score": "0.113405", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.068698", "ticker_sentiment_score": "0.113405", "ticker_sentiment_label": "Neutral"}]}, {"title": "Want to eliminate lung cancer as a cause of death: AstraZeneca India MD", "url": "https://www.business-standard.com/companies/interviews/want-to-eliminate-lung-cancer-as-a-cause-of-death-astrazeneca-india-md-123102600713_1.html", "time_published": "20231026T160220", "authors": ["Sohini Das"], "summary": "AstraZeneca is working on several cancer projects in India. The British drug major is also developing next-generation vaccines that have the potential to generate potent and long-lasting immune responses.", "banner_image": "https://bsmedia.business-standard.com/_media/bs/img/article/2023-10/26/full/1698336416-1778.jpg?im=FitAndFill=(826,465)", "source": "Business Standard", "category_within_source": "GoogleRSS", "source_domain": "www.business-standard.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.07961, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.817578", "ticker_sentiment_score": "0.122264", "ticker_sentiment_label": "Neutral"}]}, {"title": "JNJ: 3 Pharma Stocks on the Rise - Buy Now", "url": "https://stocknews.com/news/jnj-azn-sny-3-pharma-stocks-on-the-rise-buy-now/", "time_published": "20231026T154843", "authors": ["StockNews.com Staff"], "summary": "The pharmaceutical industry is set to grow in the coming years thanks to an aging population, chronic diseases, and new technologies. In this article, we'll look at the fundamentals of three pharma stocks, Sanofi ( SNY ) , Johnson & Johnson ( JNJ ) and AstraZeneca PLC ( AZN ) , which can boost ...", "banner_image": "https://stocknews.com/wp-content/uploads/2022/03/shutterstock_745024336-scaled.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "stocknews.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999701"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.623304"}], "overall_sentiment_score": 0.303463, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "FWBI", "relevance_score": "0.034136", "ticker_sentiment_score": "0.125736", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.202648", "ticker_sentiment_score": "0.207864", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.068209", "ticker_sentiment_score": "0.068173", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSOI", "relevance_score": "0.034136", "ticker_sentiment_score": "0.08627", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.202648", "ticker_sentiment_score": "0.136799", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.235496", "ticker_sentiment_score": "0.116023", "ticker_sentiment_label": "Neutral"}]}, {"title": "Fatty Liver Treatment Market Is Set To Grow At A CAGR Of 6%, Driven By Rise In Alcohol Consumption As Per The Business Research Company's Fatty Liver Treatment Global Market Report 2023", "url": "https://www.benzinga.com/pressreleases/23/10/g35444012/fatty-liver-treatment-market-is-set-to-grow-at-a-cagr-of-6-driven-by-rise-in-alcohol-consumption-a", "time_published": "20231026T153000", "authors": ["Globe Newswire"], "summary": "LONDON, Oct. 26, 2023 ( GLOBE NEWSWIRE ) -- As per The Business Research Company's Fatty Liver Treatment Global Market Report 2023, the global fatty liver treatment market is gearing up for substantial growth, expected to rise from $20.83 billion in 2022 to $22.17 billion in 2023, with a ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.045999, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AKRO", "relevance_score": "0.05749", "ticker_sentiment_score": "0.060046", "ticker_sentiment_label": "Neutral"}, {"ticker": "KNBWF", "relevance_score": "0.05749", "ticker_sentiment_score": "-0.09449", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.05749", "ticker_sentiment_score": "0.06602", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.05749", "ticker_sentiment_score": "0.06602", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.05749", "ticker_sentiment_score": "0.06602", "ticker_sentiment_label": "Neutral"}]}, {"title": "Merck  ( MRK )  Q3 Earnings Top Estimates, COVID Drug Boosts Sales", "url": "https://www.zacks.com/stock/news/2172963/merck-mrk-q3-earnings-top-estimates-covid-drug-boosts-sales", "time_published": "20231026T151300", "authors": ["Zacks Equity Research"], "summary": "Merck (MRK) beats Q3 estimates for earnings and sales. It raises its 2023 guidance. Stock rises in pre-market.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/20/2483.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.997874"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.658903"}], "overall_sentiment_score": 0.106966, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SKXJF", "relevance_score": "0.132806", "ticker_sentiment_score": "0.034841", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.106423", "ticker_sentiment_score": "0.165144", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DSKYF", "relevance_score": "0.132806", "ticker_sentiment_score": "0.034841", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.106423", "ticker_sentiment_score": "-0.025234", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.079921", "ticker_sentiment_score": "0.050166", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.02668", "ticker_sentiment_score": "-0.001852", "ticker_sentiment_label": "Neutral"}]}, {"title": "Revvity  ( RVTY )  to Report Q3 Earnings: What's in the Cards?", "url": "https://www.zacks.com/stock/news/2172958/revvity-rvty-to-report-q3-earnings-whats-in-the-cards", "time_published": "20231026T140700", "authors": ["Zacks Equity Research"], "summary": "Revvity's (RVTY) third-quarter results are likely to reflect weak performance at the Diagnostics segment, partially offset by strong demand for Life Sciences and Diagnostics franchise.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/e7/2307.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999973"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.060065, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "COO", "relevance_score": "0.118647", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "XRAY", "relevance_score": "0.118647", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AVNS", "relevance_score": "0.17715", "ticker_sentiment_score": "-0.162728", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "AZN", "relevance_score": "0.059488", "ticker_sentiment_score": "0.218048", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RVTY", "relevance_score": "0.449503", "ticker_sentiment_score": "0.318932", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Eli Lilly  ( LLY )  to Report Q3 Earnings: What's in the Cards?", "url": "https://www.zacks.com/stock/news/2172391/eli-lilly-lly-to-report-q3-earnings-whats-in-the-cards", "time_published": "20231026T114000", "authors": ["Zacks Equity Research"], "summary": "On Eli Lilly's (LLY) third-quarter conference call, investor focus is likely to be on the sales of its new diabetes drug, Mounjaro.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ca/2357.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999992"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.796627"}], "overall_sentiment_score": 0.10472, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.417304", "ticker_sentiment_score": "0.022949", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.173958", "ticker_sentiment_score": "0.050098", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.216473", "ticker_sentiment_score": "0.025286", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.216473", "ticker_sentiment_score": "-0.026882", "ticker_sentiment_label": "Neutral"}]}, {"title": "Insmed Reports Third-Quarter 2023 Financial Results and Provides Business Update", "url": "https://www.prnewswire.com/news-releases/insmed-reports-third-quarter-2023-financial-results-and-provides-business-update-301968218.html", "time_published": "20231026T113000", "authors": ["Insmed Incorporated"], "summary": "-ARIKAYCE\u00ae ( amikacin liposome inhalation suspension ) Total Revenue of $79.1 Million for the Third Quarter of 2023 Reflects Highest Quarter of Sales Since Launch and 17% Growth Compared to the Third Quarter of 2022-", "banner_image": "https://mma.prnewswire.com/media/801462/Insmed_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.967645"}, {"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.002436, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.010466", "ticker_sentiment_score": "0.013312", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOOG", "relevance_score": "0.010466", "ticker_sentiment_score": "-0.086354", "ticker_sentiment_label": "Neutral"}, {"ticker": "INSM", "relevance_score": "0.135406", "ticker_sentiment_score": "0.006324", "ticker_sentiment_label": "Neutral"}]}, {"title": "InnovationRx: Ransomware Attacks On U.S. Health Systems Have Cost The Economy Nearly $80 Billion", "url": "https://www.forbes.com/sites/alexknapp/2023/10/25/innovationrx-ransomware-attacks-on-us-health-systems-have-cost-the-economy-nearly-8-billion/", "time_published": "20231026T004247", "authors": ["Alex Knapp"], "summary": "InnovationRx is your weekly digest of healthcare news. To get it in your inbox, subscribe here.", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/6539b5a9b1998d930ede083e/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds", "source": "Forbes", "category_within_source": "n/a", "source_domain": "www.forbes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Real Estate & Construction", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": -0.031463, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GOOG", "relevance_score": "0.106541", "ticker_sentiment_score": "-0.055926", "ticker_sentiment_label": "Neutral"}, {"ticker": "CTXR", "relevance_score": "0.05339", "ticker_sentiment_score": "0.107688", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.05339", "ticker_sentiment_score": "-0.114687", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.05339", "ticker_sentiment_score": "0.059975", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.05339", "ticker_sentiment_score": "-0.292031", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "CNC", "relevance_score": "0.05339", "ticker_sentiment_score": "0.120688", "ticker_sentiment_label": "Neutral"}, {"ticker": "TENK", "relevance_score": "0.05339", "ticker_sentiment_score": "0.107688", "ticker_sentiment_label": "Neutral"}, {"ticker": "INSM", "relevance_score": "0.05339", "ticker_sentiment_score": "-0.068726", "ticker_sentiment_label": "Neutral"}, {"ticker": "BFLY", "relevance_score": "0.05339", "ticker_sentiment_score": "0.059975", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRYPTO:PAY", "relevance_score": "0.05339", "ticker_sentiment_score": "0.107688", "ticker_sentiment_label": "Neutral"}]}, {"title": "Astrazeneca  ( AZN )  Stock Moves -0.56%: What You Should Know", "url": "https://www.zacks.com/stock/news/2172054/astrazeneca-azn-stock-moves--056-what-you-should-know", "time_published": "20231025T215021", "authors": ["Zacks Equity Research"], "summary": "Astrazeneca (AZN) closed at $64.21 in the latest trading session, marking a -0.56% move from the prior day.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default338.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.983783"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.10873, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.576289", "ticker_sentiment_score": "0.236577", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "These 3 healthcare stocks should come to life as boomers live their golden years", "url": "https://www.marketwatch.com/story/these-healthcare-stocks-should-come-to-life-as-boomers-live-their-golden-years-560f5663", "time_published": "20231025T185300", "authors": ["Michael Brush"], "summary": "The baby-boom generation changes every aspect of life it steamrolls through. Now it's doing the same to healthcare.", "banner_image": "https://images.mktw.net/im-377398/social", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.996023"}, {"topic": "Earnings", "relevance_score": "0.684621"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.146886, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ZBH", "relevance_score": "0.166858", "ticker_sentiment_score": "0.128561", "ticker_sentiment_label": "Neutral"}, {"ticker": "MORN", "relevance_score": "0.133841", "ticker_sentiment_score": "-0.008992", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.067158", "ticker_sentiment_score": "-0.113025", "ticker_sentiment_label": "Neutral"}, {"ticker": "STAA", "relevance_score": "0.166858", "ticker_sentiment_score": "-0.046602", "ticker_sentiment_label": "Neutral"}]}, {"title": "Moderna  ( MRNA )  to Report Q3 Earnings: What's in the Cards?", "url": "https://www.zacks.com/stock/news/2171770/moderna-mrna-to-report-q3-earnings-whats-in-the-cards", "time_published": "20231025T131000", "authors": ["Zacks Equity Research"], "summary": "Investors' focus will likely be on updates on Moderna's (MRNA) pipeline, especially its late-stage pipeline candidates, when it reports third-quarter earnings.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/db/3160.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.99998"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.03106, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.593341", "ticker_sentiment_score": "0.07016", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.201523", "ticker_sentiment_score": "0.055846", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.201523", "ticker_sentiment_score": "-0.006354", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.050894", "ticker_sentiment_score": "0.04899", "ticker_sentiment_label": "Neutral"}]}, {"title": "Amgen  ( AMGN )  to Report Q3 Earnings: Will It Beat Estimates?", "url": "https://www.zacks.com/stock/news/2171289/amgen-amgn-to-report-q3-earnings-will-it-beat-estimates", "time_published": "20231025T112600", "authors": ["Zacks Equity Research"], "summary": "Volume growth from Amgen's (AMGN) key drugs like Prolia, Repatha and Evenity, among others, is expected to have been partially offset by biosimilar/generic competition for mature drugs.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/5d/2633.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999989"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.203947, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.219312", "ticker_sentiment_score": "0.114532", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.219312", "ticker_sentiment_score": "0.215777", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.272181", "ticker_sentiment_score": "0.030414", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.272181", "ticker_sentiment_score": "0.036737", "ticker_sentiment_label": "Neutral"}]}, {"title": "GSK ADR Clears Technical Benchmark, Hitting 80-Plus RS Rating", "url": "https://www.investors.com/ibd-data-stories/gsk-adr-clears-technical-benchmark-hitting-80-plus-rs-rating/", "time_published": "20231025T070000", "authors": ["Investor's Business Daily", "INVESTOR'S BUSINESS DAILY"], "summary": "On Wednesday, GSK ADR ( GSK ) cleared a key technical benchmark, with its Relative Strength ( RS ) Rating entering into the 80-plus percentile with an upgrade to 81, a rise from 78 the day before. X When looking for the best stocks to buy and watch, one factor to watch closely is relative ...", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.28354, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.316846", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "A new RSV shot for infants is in short supply", "url": "https://apnews.com/article/rsv-shot-shortage-infants-dc57b7788813cb3c00b081791b4c8ad3", "time_published": "20231024T150600", "authors": ["MIKE STOBBE"], "summary": "NEW YORK ( AP ) - A new shot for infants against RSV is in short supply, and U.S. health officials told doctors they should prioritize giving the drug to babies at the highest risk of severe disease.", "banner_image": "https://dims.apnews.com/dims4/default/0c6cac4/2147483647/strip/true/crop/5137x3422+8+0/resize/599x399!/quality/90/?url=https%3A%2F%2Fassets.apnews.com%2F0e%2F60%2F66c9fcaba483ddb6159f8a401c37%2Fd63bb6bd72794a7d8388305410de4916", "source": "Associated Press", "category_within_source": "Markets", "source_domain": "apnews.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": -0.106683, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.095899", "ticker_sentiment_score": "-0.024326", "ticker_sentiment_label": "Neutral"}, {"ticker": "HHH", "relevance_score": "0.095899", "ticker_sentiment_score": "0.176122", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SNY", "relevance_score": "0.095899", "ticker_sentiment_score": "-0.024326", "ticker_sentiment_label": "Neutral"}]}, {"title": "Dow Surges 250 Points; US Manufacturing PMI Tops Expectations - ReAlpha Tech Corp  ( NASDAQ:AIRE ) , Ascent Solar Technologies  ( NASDAQ:ASTI ) ", "url": "https://www.benzinga.com/news/earnings/23/10/35395378/dow-surges-250-points-us-manufacturing-pmi-tops-expectations", "time_published": "20231024T141423", "authors": ["Lisa Levin"], "summary": "U.S. stocks traded higher this morning, with the Dow Jones index gaining over 250 points on Tuesday. Following the market opening Tuesday, the Dow traded up 0.80% to 33,200.75 while the NASDAQ rose 0.88% to 13,132.62. The S&P 500 also rose, gaining, 0.79% to 4,250.15. Utilities shares rose by ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/10/24/image42.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.796627"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.095386, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.074926", "ticker_sentiment_score": "0.103914", "ticker_sentiment_label": "Neutral"}, {"ticker": "LMDX", "relevance_score": "0.222157", "ticker_sentiment_score": "0.179147", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ASTI", "relevance_score": "0.149192", "ticker_sentiment_score": "0.29633", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FCCO", "relevance_score": "0.074926", "ticker_sentiment_score": "0.103914", "ticker_sentiment_label": "Neutral"}, {"ticker": "INM", "relevance_score": "0.293214", "ticker_sentiment_score": "0.198556", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "LIAN", "relevance_score": "0.149192", "ticker_sentiment_score": "0.332596", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SPGI", "relevance_score": "0.222157", "ticker_sentiment_score": "0.025748", "ticker_sentiment_label": "Neutral"}, {"ticker": "INVO", "relevance_score": "0.149192", "ticker_sentiment_score": "-0.075712", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.074926", "ticker_sentiment_score": "0.266627", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Here's Why You Could Be Giving Yourself-Or Someone Else-A Flu Shot Next Year", "url": "https://www.forbes.com/sites/roberthart/2023/10/24/heres-why-you-could-be-giving-yourself-or-someone-else-a-flu-shot-next-year/", "time_published": "20231024T121726", "authors": ["Robert Hart"], "summary": "The Food and Drug Administration is reviewing a flu vaccine that people could administer themselves at home, British drugmaker AstraZeneca said on Tuesday, potentially the first product of its kind that could boost accessibility, increase uptake and offer an alternative for people scared of ...", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/650acc8e8991d3c92459e63f/0x0.jpg?format=jpg&crop=5025,2826,x8,y481,safe&height=900&width=1600&fit=bounds", "source": "Forbes", "category_within_source": "n/a", "source_domain": "www.forbes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.017121, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "WBD", "relevance_score": "0.121959", "ticker_sentiment_score": "0.012939", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.241085", "ticker_sentiment_score": "0.144021", "ticker_sentiment_label": "Neutral"}]}, {"title": "Pfizer  ( PFE )  to Report Q3 Earnings: Here's What to Expect", "url": "https://www.zacks.com/stock/news/2170681/pfizer-pfe-to-report-q3-earnings-heres-what-to-expect", "time_published": "20231024T113900", "authors": ["Zacks Equity Research"], "summary": "Pfizer (PFE) expects better non-COVID operational revenue growth sequentially in the third quarter, driven by its key products, new launches as well as newly acquired products.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/89/447.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.057075, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.188928", "ticker_sentiment_score": "0.102132", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.234911", "ticker_sentiment_score": "0.026995", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.489057", "ticker_sentiment_score": "0.065703", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.234911", "ticker_sentiment_score": "0.032619", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.047654", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why Logitech International Shares Are Trading Higher By Over 11%; Here Are 20 Stocks Moving Premarket - Argo Blockchain  ( NASDAQ:ARBK ) , Ascent Solar Technologies  ( NASDAQ:ASTI ) ", "url": "https://www.benzinga.com/news/23/10/35390271/why-logitech-international-shares-are-trading-higher-by-over-11-here-are-20-stocks-moving-premarket", "time_published": "20231024T113147", "authors": ["Lisa Levin"], "summary": "AERWINS Technologies Inc. AWIN shares surged 91.2% to $0.2180 in pre-market trading after falling 10% on Monday. Ascent Solar Technologies, Inc.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/10/24/image19.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Finance", "relevance_score": "0.166667"}, {"topic": "Blockchain", "relevance_score": "0.158519"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "0.161647"}, {"topic": "Real Estate & Construction", "relevance_score": "0.166667"}], "overall_sentiment_score": 0.053615, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "WTER", "relevance_score": "0.148731", "ticker_sentiment_score": "-0.060011", "ticker_sentiment_label": "Neutral"}, {"ticker": "ARBK", "relevance_score": "0.148731", "ticker_sentiment_score": "0.161823", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AWIN", "relevance_score": "0.148731", "ticker_sentiment_score": "0.048211", "ticker_sentiment_label": "Neutral"}, {"ticker": "LOGI", "relevance_score": "0.148731", "ticker_sentiment_score": "0.312085", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "LYT", "relevance_score": "0.148731", "ticker_sentiment_score": "0.468291", "ticker_sentiment_label": "Bullish"}, {"ticker": "WISA", "relevance_score": "0.221481", "ticker_sentiment_score": "-0.041922", "ticker_sentiment_label": "Neutral"}, {"ticker": "FCCO", "relevance_score": "0.074692", "ticker_sentiment_score": "0.056485", "ticker_sentiment_label": "Neutral"}, {"ticker": "IONQ", "relevance_score": "0.221481", "ticker_sentiment_score": "-0.312813", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "AZN", "relevance_score": "0.074692", "ticker_sentiment_score": "0.056485", "ticker_sentiment_label": "Neutral"}, {"ticker": "SLNH", "relevance_score": "0.148731", "ticker_sentiment_score": "0.390015", "ticker_sentiment_label": "Bullish"}, {"ticker": "HARP", "relevance_score": "0.221481", "ticker_sentiment_score": "-0.381812", "ticker_sentiment_label": "Bearish"}, {"ticker": "LMDX", "relevance_score": "0.221481", "ticker_sentiment_score": "0.097599", "ticker_sentiment_label": "Neutral"}, {"ticker": "TCRT", "relevance_score": "0.148731", "ticker_sentiment_score": "-0.222706", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "XRTX", "relevance_score": "0.148731", "ticker_sentiment_score": "-0.060011", "ticker_sentiment_label": "Neutral"}, {"ticker": "ASTI", "relevance_score": "0.148731", "ticker_sentiment_score": "0.163093", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ICU", "relevance_score": "0.148731", "ticker_sentiment_score": "-0.255093", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "TCBP", "relevance_score": "0.221481", "ticker_sentiment_score": "0.071495", "ticker_sentiment_label": "Neutral"}, {"ticker": "MKFG", "relevance_score": "0.221481", "ticker_sentiment_score": "-0.119634", "ticker_sentiment_label": "Neutral"}, {"ticker": "INVO", "relevance_score": "0.148731", "ticker_sentiment_score": "-0.032896", "ticker_sentiment_label": "Neutral"}, {"ticker": "ONVO", "relevance_score": "0.148731", "ticker_sentiment_score": "0.247996", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CLSK", "relevance_score": "0.148731", "ticker_sentiment_score": "0.266914", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "LMFA", "relevance_score": "0.148731", "ticker_sentiment_score": "0.048211", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRYPTO:BTC", "relevance_score": "0.074692", "ticker_sentiment_score": "0.213565", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "GSK Gears Up for Q3 Earnings: Will It Surpass Estimates?", "url": "https://www.zacks.com/stock/news/2170671/gsk-gears-up-for-q3-earnings-will-it-surpass-estimates", "time_published": "20231024T112500", "authors": ["Zacks Equity Research"], "summary": "We expect GSK's specialty products like Cabenuva, Juluca, Dovato, Bexsero, Trelegy Ellipta and Shingrix to drive third-quarter sales performance.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.99998"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.131683, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.231773", "ticker_sentiment_score": "0.060659", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.231773", "ticker_sentiment_score": "-0.005316", "ticker_sentiment_label": "Neutral"}, {"ticker": "GSK", "relevance_score": "0.404201", "ticker_sentiment_score": "0.26663", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "What's in the Cards for Encompass Health  ( EHC )  in Q3 Earnings?", "url": "https://www.zacks.com/stock/news/2170634/whats-in-the-cards-for-encompass-health-ehc-in-q3-earnings", "time_published": "20231024T112500", "authors": ["Zacks Equity Research"], "summary": "Encompass Health's (EHC) Q3 results are likely to reflect improved inpatient volumes and bed additions, offset by higher operating expenses.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c0/2563.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999953"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.278993, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "APLS", "relevance_score": "0.175009", "ticker_sentiment_score": "0.097184", "ticker_sentiment_label": "Neutral"}, {"ticker": "EHC", "relevance_score": "0.49292", "ticker_sentiment_score": "0.321684", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.175009", "ticker_sentiment_score": "0.164142", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JAZZ", "relevance_score": "0.175009", "ticker_sentiment_score": "0.138844", "ticker_sentiment_label": "Neutral"}]}, {"title": "Next season, you may be able to take your flu vaccine at home", "url": "https://www.cnn.com/2023/10/24/health/next-season-you-may-be-able-to-take-your-flu-vaccine-at-home/index.html", "time_published": "20231024T060000", "authors": ["Meg Tirrell"], "summary": "How do you know if you are still contagious after an illness? A doctor explains The US Food and Drug Administration is reviewing an application for the nasal spray flu vaccine FluMist to be able to be self-administered at home, drugmaker AstraZeneca said Tuesday.", "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/gettyimages-1337117157.jpg?c=16x9&q=h_144,w_256,c_fill", "source": "CNN", "category_within_source": "Markets", "source_domain": "www.cnn.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.115022, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "WBD", "relevance_score": "0.157827", "ticker_sentiment_score": "0.094135", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.357783", "ticker_sentiment_score": "0.136685", "ticker_sentiment_label": "Neutral"}]}, {"title": "US FDA accepts AstraZeneca's self-administered flu vaccine for review", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-accepts-astrazenecas-self-administered-flu-vaccine-review-2023-10-24/", "time_published": "20231024T001257", "authors": ["Reuters"], "summary": "A general view of the AstraZeneca site in Macclesfield, Britain, May 11, 2021. REUTERS/Phil Noble Acquire Licensing Rights Oct 24 ( Reuters ) - AstraZeneca ( AZN.L ) said on Tuesday the U.S.", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/DA4RWBZNHVORBB76D4SGFRAOE4.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.149159, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.60415", "ticker_sentiment_score": "0.133567", "ticker_sentiment_label": "Neutral"}]}, {"title": "Demand outstrips supply for some doses of new shot that protects babies against RSV", "url": "https://www.cnn.com/2023/10/23/health/demand-outstrips-supply-for-new-shot-that-protects-babies-against-rsv/index.html", "time_published": "20231023T220300", "authors": ["Brenda Goodman"], "summary": "Demand outstrips supply for some doses of new shot that protects babies against ...", "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/230717142758-nirsevimab-rsv-infants.jpg?c=16x9&q=h_144,w_256,c_fill", "source": "CNN", "category_within_source": "Markets", "source_domain": "www.cnn.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.0, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.042647", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.127456", "ticker_sentiment_score": "0.03975", "ticker_sentiment_label": "Neutral"}]}, {"title": "Crude Oil Falls Sharply; Apollomics Shares Plunge - Akumin  ( NASDAQ:AKU ) , Apollomics  ( NASDAQ:APLM ) ", "url": "https://www.benzinga.com/news/earnings/23/10/35381019/crude-oil-falls-sharply-apollomics-shares-plunge", "time_published": "20231023T183929", "authors": ["Lisa Levin"], "summary": "U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite gaining over 100 points on Monday. The Dow traded down 0.19% to 33,062.85 while the NASDAQ rose 0.80% to 13,088.09. The S&P 500 also rose, gaining, 0.28% to 4,236.12. Communication services shares rose by 1.3% on Monday.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/10/23/crude_oil_4-_logo.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.164499, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LICY", "relevance_score": "0.192694", "ticker_sentiment_score": "0.250384", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.097062", "ticker_sentiment_score": "0.07146", "ticker_sentiment_label": "Neutral"}, {"ticker": "LMDX", "relevance_score": "0.192694", "ticker_sentiment_score": "0.104831", "ticker_sentiment_label": "Neutral"}, {"ticker": "FCCO", "relevance_score": "0.097062", "ticker_sentiment_score": "0.07146", "ticker_sentiment_label": "Neutral"}, {"ticker": "AKU", "relevance_score": "0.192694", "ticker_sentiment_score": "0.4885", "ticker_sentiment_label": "Bullish"}, {"ticker": "INVO", "relevance_score": "0.192694", "ticker_sentiment_score": "0.383528", "ticker_sentiment_label": "Bullish"}, {"ticker": "RVMD", "relevance_score": "0.192694", "ticker_sentiment_score": "0.250384", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "APLM", "relevance_score": "0.192694", "ticker_sentiment_score": "0.060694", "ticker_sentiment_label": "Neutral"}]}, {"title": "Nasdaq Turns Higher; Akumin Shares Jump - Akumin  ( NASDAQ:AKU ) , Apollomics  ( NASDAQ:APLM ) ", "url": "https://www.benzinga.com/news/earnings/23/10/35378014/nasdaq-turns-higher-akumin-shares-jump", "time_published": "20231023T160610", "authors": ["Lisa Levin"], "summary": "U.S. stocks pared losses midway through trading, with the Nasdaq Composite gaining over 60 points on Monday. The Dow traded down 0.01% to 33,126.50 while the NASDAQ rose 0.54% to 13,054.00. The S&P 500 also rose, gaining, 0.29% to 4,236.55. Communication services shares rose by 0.9% on Monday.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/10/23/image17_0.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.137072, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LICY", "relevance_score": "0.194242", "ticker_sentiment_score": "0.251827", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.097854", "ticker_sentiment_score": "0.071651", "ticker_sentiment_label": "Neutral"}, {"ticker": "LMDX", "relevance_score": "0.194242", "ticker_sentiment_score": "0.10546", "ticker_sentiment_label": "Neutral"}, {"ticker": "FCCO", "relevance_score": "0.097854", "ticker_sentiment_score": "0.071651", "ticker_sentiment_label": "Neutral"}, {"ticker": "AKU", "relevance_score": "0.194242", "ticker_sentiment_score": "0.490875", "ticker_sentiment_label": "Bullish"}, {"ticker": "INVO", "relevance_score": "0.194242", "ticker_sentiment_score": "0.385575", "ticker_sentiment_label": "Bullish"}, {"ticker": "RVMD", "relevance_score": "0.194242", "ticker_sentiment_score": "0.251827", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "APLM", "relevance_score": "0.194242", "ticker_sentiment_score": "0.061061", "ticker_sentiment_label": "Neutral"}]}, {"title": "Dow Falls Over 100 Points; Chicago Fed National Activity Index Increases In September - Akumin  ( NASDAQ:AKU ) , INVO Bioscience  ( NASDAQ:INVO ) ", "url": "https://www.benzinga.com/news/earnings/23/10/35374157/dow-falls-over-100-points-chicago-fed-national-activity-index-increases-in-september", "time_published": "20231023T134301", "authors": ["Lisa Levin"], "summary": "U.S. stocks traded lower this morning, with the Dow Jones index falling over 100 points on Monday. Following the market opening Monday, The Dow traded down 0.41% to 32,991.58 while the NASDAQ fell 0.33% to 12,940.56. The S&P 500 also fell, dropping, 0.33% to 4,210.14.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/10/23/image19.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.014732, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LICY", "relevance_score": "0.194242", "ticker_sentiment_score": "0.251827", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.097854", "ticker_sentiment_score": "0.071651", "ticker_sentiment_label": "Neutral"}, {"ticker": "LMDX", "relevance_score": "0.194242", "ticker_sentiment_score": "0.10546", "ticker_sentiment_label": "Neutral"}, {"ticker": "XRTX", "relevance_score": "0.194242", "ticker_sentiment_score": "-0.155739", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "FCCO", "relevance_score": "0.097854", "ticker_sentiment_score": "0.071651", "ticker_sentiment_label": "Neutral"}, {"ticker": "AKU", "relevance_score": "0.194242", "ticker_sentiment_score": "0.490875", "ticker_sentiment_label": "Bullish"}, {"ticker": "INVO", "relevance_score": "0.194242", "ticker_sentiment_score": "0.385575", "ticker_sentiment_label": "Bullish"}, {"ticker": "RVMD", "relevance_score": "0.194242", "ticker_sentiment_score": "0.251827", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "What's in the Cards for Universal Health  ( UHS )  in Q3 Earnings?", "url": "https://www.zacks.com/stock/news/2170192/whats-in-the-cards-for-universal-health-uhs-in-q3-earnings", "time_published": "20231023T132800", "authors": ["Zacks Equity Research"], "summary": "Universal Health's (UHS) Q3 results are likely to benefit from higher patient volumes at its acute care hospitals and behavioral health facilities, partly offset by increased physician expenses.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c0/2563.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999953"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.29094, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "APLS", "relevance_score": "0.164656", "ticker_sentiment_score": "0.093193", "ticker_sentiment_label": "Neutral"}, {"ticker": "UHS", "relevance_score": "0.270973", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.164656", "ticker_sentiment_score": "0.157531", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JAZZ", "relevance_score": "0.164656", "ticker_sentiment_score": "0.133221", "ticker_sentiment_label": "Neutral"}]}, {"title": "What's in Store for Bristol-Myers  ( BMY )  in Q3 Earnings?", "url": "https://www.zacks.com/stock/news/2170140/whats-in-store-for-bristol-myers-bmy-in-q3-earnings", "time_published": "20231023T124700", "authors": ["Zacks Equity Research"], "summary": "Investors are likely to focus on Opdivo's demand along with an incremental contribution from newer drugs when Bristol-Myers (BMY) reports Q3 results.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/b7/2106.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999974"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.235812, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.11324", "ticker_sentiment_score": "0.060688", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRTX", "relevance_score": "0.075635", "ticker_sentiment_score": "0.17719", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.150592", "ticker_sentiment_score": "0.046863", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.22421", "ticker_sentiment_score": "0.260342", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Why Troika Media Group Shares Are Trading Lower By Over 20%; Here Are 20 Stocks Moving Premarket - Akumin  ( NASDAQ:AKU ) , Bit Brother  ( NASDAQ:BETS ) ", "url": "https://www.benzinga.com/news/23/10/35370062/why-troika-media-group-shares-are-trading-lower-by-over-20-here-are-20-stocks-moving-premarket", "time_published": "20231023T113232", "authors": ["Lisa Levin"], "summary": "LumiraDx Limited LMDX shares surged 151.7% to $0.2190 in pre-market trading after the company reported a strategic collaboration with AstraZeneca and Everton in the Community to set up England's first community-based heart and lung screening hub. Akumin Inc.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/10/23/image18.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.846708"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.082798, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "WTER", "relevance_score": "0.163354", "ticker_sentiment_score": "0.051253", "ticker_sentiment_label": "Neutral"}, {"ticker": "GLG", "relevance_score": "0.163354", "ticker_sentiment_score": "-0.063821", "ticker_sentiment_label": "Neutral"}, {"ticker": "GSUN", "relevance_score": "0.163354", "ticker_sentiment_score": "-0.364637", "ticker_sentiment_label": "Bearish"}, {"ticker": "MOTS", "relevance_score": "0.163354", "ticker_sentiment_score": "0.326997", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FAZE", "relevance_score": "0.24289", "ticker_sentiment_score": "0.019531", "ticker_sentiment_label": "Neutral"}, {"ticker": "FCCO", "relevance_score": "0.082111", "ticker_sentiment_score": "0.065021", "ticker_sentiment_label": "Neutral"}, {"ticker": "WLGS", "relevance_score": "0.163354", "ticker_sentiment_score": "-0.017805", "ticker_sentiment_label": "Neutral"}, {"ticker": "AKU", "relevance_score": "0.163354", "ticker_sentiment_score": "0.338745", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ROIV", "relevance_score": "0.163354", "ticker_sentiment_score": "0.187592", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TRKA", "relevance_score": "0.163354", "ticker_sentiment_score": "-0.046832", "ticker_sentiment_label": "Neutral"}, {"ticker": "INBS", "relevance_score": "0.163354", "ticker_sentiment_score": "-0.017805", "ticker_sentiment_label": "Neutral"}, {"ticker": "TGH", "relevance_score": "0.163354", "ticker_sentiment_score": "0.252184", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.082111", "ticker_sentiment_score": "0.065021", "ticker_sentiment_label": "Neutral"}, {"ticker": "CFRX", "relevance_score": "0.163354", "ticker_sentiment_score": "-0.142145", "ticker_sentiment_label": "Neutral"}, {"ticker": "HARP", "relevance_score": "0.163354", "ticker_sentiment_score": "0.158059", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "LMDX", "relevance_score": "0.163354", "ticker_sentiment_score": "0.088535", "ticker_sentiment_label": "Neutral"}, {"ticker": "XRTX", "relevance_score": "0.163354", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TGL", "relevance_score": "0.163354", "ticker_sentiment_score": "0.148362", "ticker_sentiment_label": "Neutral"}, {"ticker": "CBIO", "relevance_score": "0.163354", "ticker_sentiment_score": "-0.23576", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "BETS", "relevance_score": "0.163354", "ticker_sentiment_score": "0.033871", "ticker_sentiment_label": "Neutral"}, {"ticker": "LMFA", "relevance_score": "0.163354", "ticker_sentiment_score": "0.182226", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Merck  ( MRK )  to Report Q3 Earnings: What's in the Cards?", "url": "https://www.zacks.com/stock/news/2170134/merck-mrk-to-report-q3-earnings-whats-in-the-cards", "time_published": "20231023T112500", "authors": ["Zacks Equity Research"], "summary": "Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, when the company reports Q3 earnings.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/52/873.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.99989"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.153023, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.206245", "ticker_sentiment_score": "-0.024239", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.305058", "ticker_sentiment_score": "0.100231", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.052112", "ticker_sentiment_score": "0.171568", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.256179", "ticker_sentiment_score": "-0.02884", "ticker_sentiment_label": "Neutral"}]}, {"title": "European Markets Extending Recent Losses", "url": "https://markets.businessinsider.com/news/stocks/european-markets-extending-recent-losses-1032728373", "time_published": "20231023T112107", "authors": ["markets.businessinsider.com"], "summary": "( RTTNews ) - European stocks are down in negative territory a little past noon on Monday as lingering concerns about the outlook for economic growth, interest rates, and geopolitical situation continue to hurt investor sentiment, prompting them to lighten commitments.", "banner_image": "https://markets.businessinsider.com/Images/FacebookIcon.jpg", "source": "Business Insider", "category_within_source": "GoogleRSS", "source_domain": "markets.businessinsider.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Energy & Transportation", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.0, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "FNLPF", "relevance_score": "0.152499", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CPYYF", "relevance_score": "0.152499", "ticker_sentiment_score": "-0.081968", "ticker_sentiment_label": "Neutral"}, {"ticker": "STM", "relevance_score": "0.152499", "ticker_sentiment_score": "-0.12107", "ticker_sentiment_label": "Neutral"}, {"ticker": "SEGXF", "relevance_score": "0.152499", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "WWLNF", "relevance_score": "0.152499", "ticker_sentiment_score": "-0.12107", "ticker_sentiment_label": "Neutral"}, {"ticker": "TLPFF", "relevance_score": "0.152499", "ticker_sentiment_score": "-0.12107", "ticker_sentiment_label": "Neutral"}, {"ticker": "PDYPF", "relevance_score": "0.152499", "ticker_sentiment_score": "0.331654", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NWG", "relevance_score": "0.152499", "ticker_sentiment_score": "-0.081968", "ticker_sentiment_label": "Neutral"}, {"ticker": "ANFGF", "relevance_score": "0.152499", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ENGQF", "relevance_score": "0.152499", "ticker_sentiment_score": "-0.12107", "ticker_sentiment_label": "Neutral"}, {"ticker": "AOMFF", "relevance_score": "0.152499", "ticker_sentiment_score": "-0.12107", "ticker_sentiment_label": "Neutral"}, {"ticker": "VNNVF", "relevance_score": "0.152499", "ticker_sentiment_score": "0.002781", "ticker_sentiment_label": "Neutral"}, {"ticker": "ZLNDY", "relevance_score": "0.152499", "ticker_sentiment_score": "0.002781", "ticker_sentiment_label": "Neutral"}, {"ticker": "NGG", "relevance_score": "0.152499", "ticker_sentiment_score": "-0.081968", "ticker_sentiment_label": "Neutral"}, {"ticker": "PPRUF", "relevance_score": "0.152499", "ticker_sentiment_score": "-0.12107", "ticker_sentiment_label": "Neutral"}, {"ticker": "RNSDF", "relevance_score": "0.152499", "ticker_sentiment_score": "-0.12107", "ticker_sentiment_label": "Neutral"}, {"ticker": "BOUYF", "relevance_score": "0.152499", "ticker_sentiment_score": "0.282256", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FSNUF", "relevance_score": "0.152499", "ticker_sentiment_score": "0.002781", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.152499", "ticker_sentiment_score": "-0.081968", "ticker_sentiment_label": "Neutral"}, {"ticker": "RKLIF", "relevance_score": "0.152499", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "THLEF", "relevance_score": "0.152499", "ticker_sentiment_score": "0.282256", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GLCNF", "relevance_score": "0.152499", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "LRLCF", "relevance_score": "0.152499", "ticker_sentiment_score": "0.282256", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ROYMF", "relevance_score": "0.152499", "ticker_sentiment_score": "0.331654", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ERFSF", "relevance_score": "0.152499", "ticker_sentiment_score": "0.282256", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Asthma Biologics Market Predicted to Reach USD 19.2 billion by 2031, Growing at a 12.5% CAGR | Exclusive Report by Transparency Market Research", "url": "https://www.prnewswire.com/news-releases/asthma-biologics-market-predicted-to-reach-usd-19-2-billion-by-2031--growing-at-a-12-5-cagr--exclusive-report-by-transparency-market-research-301964281.html", "time_published": "20231023T091400", "authors": ["Transparency Market Research"], "summary": "Asthma Biologics Market Predicted to Reach USD 19.2 billion by 2031, Growing at a 12.5% CAGR | Exclusive Report ... PR ...", "banner_image": "https://mma.prnewswire.com/media/1682871/TMR_Logo_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.405759, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.046273", "ticker_sentiment_score": "0.278548", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.09239", "ticker_sentiment_score": "0.274714", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "AbbVie  ( ABBV )  to Report Q3 Earnings: What's in the Cards?", "url": "https://www.zacks.com/stock/news/2170056/abbvie-abbv-to-report-q3-earnings-whats-in-the-cards", "time_published": "20231023T083200", "authors": ["Zacks Equity Research"], "summary": "AbbVie's (ABBV) Q3 performance will likely reflect its newer immunotherapy drugs trying to compensate for declining Humira sales following the loss of U.S. exclusivity.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/36/1919.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999992"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.202745, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SSNLF", "relevance_score": "0.043264", "ticker_sentiment_score": "0.029734", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.412523", "ticker_sentiment_score": "0.324419", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.2138", "ticker_sentiment_score": "0.05686", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.2138", "ticker_sentiment_score": "-0.004984", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.043264", "ticker_sentiment_score": "0.115711", "ticker_sentiment_label": "Neutral"}]}, {"title": "Ultimovacs Provides Complete Phase II NIPU Results Presented at ESMO 2023: Significant and Clinically Meaningful Improvement in Overall Survival for Patients with Malignant Mesothelioma Receiving UV1 Cancer Vaccine", "url": "https://www.globenewswire.com/news-release/2023/10/23/2764362/0/en/Ultimovacs-Provides-Complete-Phase-II-NIPU-Results-Presented-at-ESMO-2023-Significant-and-Clinically-Meaningful-Improvement-in-Overall-Survival-for-Patients-with-Malignant-Mesothel.html", "time_published": "20231023T050000", "authors": ["Ultimovacs ASA"], "summary": "Oslo, October 23, 2023: Ultimovacs ASA ( \"Ultimovacs\" ) ( OSE ULTI ) , a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines, today announced the full dataset from the NIPU clinical trial ( NCT04300244 ) presented at the ESMO Congress 2023 in Madrid.", "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/23b62627-6dd1-416b-b614-675e9c122324", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.839681"}], "overall_sentiment_score": -0.060518, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.016975", "ticker_sentiment_score": "-0.04316", "ticker_sentiment_label": "Neutral"}, {"ticker": "AWON", "relevance_score": "0.033942", "ticker_sentiment_score": "0.096999", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.067823", "ticker_sentiment_score": "-0.028368", "ticker_sentiment_label": "Neutral"}]}, {"title": "LumiraDx Partners with AstraZeneca & Everton in the Community to Set Up England's First Heart & Lung Screening Hub", "url": "https://markets.businessinsider.com/news/stocks/lumiradx-partners-with-astrazeneca-everton-in-the-community-to-set-up-england-s-first-heart-lung-screening-hub-1032725484", "time_published": "20231020T223448", "authors": ["markets.businessinsider.com"], "summary": "\u2022 Made possible thanks to unrestricted grant funding from AstraZeneca and run by the official charity of Everton Football Club - Everton in the Community - the Liverpool-based hub will provide significant support for individuals suffering from chronic breathlessness and other heart and ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/bc5a952d-8c66-4795-a9c7-4ef64deb20c0", "source": "Business Insider", "category_within_source": "RSS", "source_domain": "markets.businessinsider.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.447639, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "FCCO", "relevance_score": "0.040484", "ticker_sentiment_score": "0.113111", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDT", "relevance_score": "0.040484", "ticker_sentiment_score": "0.089288", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.239305", "ticker_sentiment_score": "0.367411", "ticker_sentiment_label": "Bullish"}, {"ticker": "LMDX", "relevance_score": "0.457566", "ticker_sentiment_score": "0.541557", "ticker_sentiment_label": "Bullish"}]}, {"title": "LumiraDx Partners with AstraZeneca & Everton in the Community to Set Up England's First Heart & Lung Screening Hub", "url": "https://www.globenewswire.com/news-release/2023/10/20/2764275/0/en/LumiraDx-Partners-with-AstraZeneca-Everton-in-the-Community-to-Set-Up-England-s-First-Heart-Lung-Screening-Hub.html", "time_published": "20231020T223400", "authors": ["LumiraDx Inc"], "summary": "LONDON, Oct. 20, 2023 ( GLOBE NEWSWIRE ) -- LumiraDx Limited ( Nasdaq: LMDX ) , a next-generation point of care diagnostics company, is pleased to announce a strategic collaboration with AstraZeneca and Everton in the Community to set up England's first community-based heart and lung screening ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/bc5a952d-8c66-4795-a9c7-4ef64deb20c0", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.310843"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.378523, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "FCCO", "relevance_score": "0.032916", "ticker_sentiment_score": "0.111238", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDT", "relevance_score": "0.032916", "ticker_sentiment_score": "0.086775", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.195551", "ticker_sentiment_score": "0.318209", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "LMDX", "relevance_score": "0.490905", "ticker_sentiment_score": "0.421566", "ticker_sentiment_label": "Bullish"}]}, {"title": "Sanofi seeing 'unprecedented' demand for RSV therapy", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/sanofi-seeing-unprecedented-demand-rsv-therapy-2023-10-20/", "time_published": "20231020T184300", "authors": ["Reuters"], "summary": "The logo of French drugmaker Sanofi is seen a the Sanofi Genzyme Polyclonals in Lyon, France, September 30, 2023. REUTERS/Gonzalo Fuentes/File Photo Acquire Licensing Rights", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/WRF25P62ZFJITPPAPS2ZD2I67A.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.195672, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.250386", "ticker_sentiment_score": "0.346632", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SNY", "relevance_score": "0.798255", "ticker_sentiment_score": "0.140874", "ticker_sentiment_label": "Neutral"}]}, {"title": "ABBV: 3 High-Performing Pharma Stocks to Boost Your Portfolio", "url": "https://stocknews.com/news/abbv-azn-taro-pfe-3-high-performing-pharma-stocks-to-boost-your-portfolio/", "time_published": "20231020T163940", "authors": ["StockNews.com Staff"], "summary": "The pharmaceutical industry is set to grow in the coming years, thanks to an aging population, heightened toll of chronic diseases, and new technologies.", "banner_image": "https://stocknews.com/wp-content/uploads/2022/07/shutterstock_1110645284.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "stocknews.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.54554"}, {"topic": "Earnings", "relevance_score": "0.999981"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.264607, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ABBV", "relevance_score": "0.366961", "ticker_sentiment_score": "0.24808", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GS", "relevance_score": "0.031738", "ticker_sentiment_score": "0.090137", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.219383", "ticker_sentiment_score": "0.188134", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TARO", "relevance_score": "0.12645", "ticker_sentiment_score": "0.044321", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.063425", "ticker_sentiment_score": "0.068026", "ticker_sentiment_label": "Neutral"}]}, {"title": "Stocks Struggle As Yields Soar; Tesla Tumbles: Weekly Review", "url": "https://www.investors.com/news/stock-market-struggles-as-treasury-yields-soar-tesla-nvidia-among-notable-losers/", "time_published": "20231020T154900", "authors": ["IBD STAFF", "Investor's Business Daily"], "summary": "Stock Market Struggles As Treasury Yields Soar. Tesla, Nvidia ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2019/02/Stock-UpDownArrows-04-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Energy & Transportation", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "1.0"}], "overall_sentiment_score": -0.154552, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "ENPH", "relevance_score": "0.044469", "ticker_sentiment_score": "-0.304019", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "UAL", "relevance_score": "0.044469", "ticker_sentiment_score": "-0.263305", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "VMW", "relevance_score": "0.088799", "ticker_sentiment_score": "-0.101013", "ticker_sentiment_label": "Neutral"}, {"ticker": "AVGO", "relevance_score": "0.044469", "ticker_sentiment_score": "-0.09585", "ticker_sentiment_label": "Neutral"}, {"ticker": "TEX", "relevance_score": "0.11087", "ticker_sentiment_score": "-0.277675", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "JNJ", "relevance_score": "0.044469", "ticker_sentiment_score": "-0.064247", "ticker_sentiment_label": "Neutral"}, {"ticker": "SLB", "relevance_score": "0.044469", "ticker_sentiment_score": "0.163964", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SKXJF", "relevance_score": "0.022243", "ticker_sentiment_score": "-0.342954", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "DSKYF", "relevance_score": "0.022243", "ticker_sentiment_score": "-0.342954", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "STT", "relevance_score": "0.044469", "ticker_sentiment_score": "-0.079928", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABT", "relevance_score": "0.044469", "ticker_sentiment_score": "-0.064247", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.132855", "ticker_sentiment_score": "-0.15922", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "UNP", "relevance_score": "0.06666", "ticker_sentiment_score": "-0.28162", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "LRCX", "relevance_score": "0.044469", "ticker_sentiment_score": "-0.048687", "ticker_sentiment_label": "Neutral"}, {"ticker": "NFLX", "relevance_score": "0.088799", "ticker_sentiment_score": "0.032981", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.044469", "ticker_sentiment_score": "0.069336", "ticker_sentiment_label": "Neutral"}, {"ticker": "IBKR", "relevance_score": "0.044469", "ticker_sentiment_score": "-0.068991", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.088799", "ticker_sentiment_score": "-0.160615", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "TSM", "relevance_score": "0.044469", "ticker_sentiment_score": "-0.048687", "ticker_sentiment_label": "Neutral"}, {"ticker": "FSLR", "relevance_score": "0.044469", "ticker_sentiment_score": "-0.304019", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "LMT", "relevance_score": "0.06666", "ticker_sentiment_score": "-0.106722", "ticker_sentiment_label": "Neutral"}, {"ticker": "SEDG", "relevance_score": "0.06666", "ticker_sentiment_score": "-0.310714", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "AZN", "relevance_score": "0.044469", "ticker_sentiment_score": "-0.359384", "ticker_sentiment_label": "Bearish"}, {"ticker": "CAT", "relevance_score": "0.044469", "ticker_sentiment_score": "-0.219468", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "PG", "relevance_score": "0.06666", "ticker_sentiment_score": "0.117914", "ticker_sentiment_label": "Neutral"}, {"ticker": "AXP", "relevance_score": "0.044469", "ticker_sentiment_score": "0.347311", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SCHW", "relevance_score": "0.06666", "ticker_sentiment_score": "-0.070334", "ticker_sentiment_label": "Neutral"}, {"ticker": "ISRG", "relevance_score": "0.044469", "ticker_sentiment_score": "-0.263305", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Merck Signs Multi-Billion Deal With Japan's Daiichi Sankyo For Cancer Therapy Drug Development - AstraZeneca  ( NASDAQ:AZN ) , Merck & Co  ( NYSE:MRK ) , Daiichi Sankyo Co  ( OTC:DSKYF ) ", "url": "https://www.benzinga.com/general/biotech/23/10/35349800/merck-signs-multi-billion-deal-with-japans-daiichi-sankyo-for-cancer-therapy-drug-development", "time_published": "20231020T145918", "authors": ["Nabaparna Bhattacharya"], "summary": "Merck & Company, Inc. MRK and Japan's Daiichi Sankyo Co. Ltd. DSKYF entered into a global development and commercialization agreement. The companies are developing three of Daiichi Sankyo's DXd antibody-drug conjugate ( ADC ) candidates for patients across multiple types of cancer.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/10/20/bz_briefs_0.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.161647"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.019086, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "DSKYF", "relevance_score": "0.769861", "ticker_sentiment_score": "0.083422", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.268294", "ticker_sentiment_score": "-0.338336", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "SKXJF", "relevance_score": "0.696319", "ticker_sentiment_score": "0.079944", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:JPY", "relevance_score": "0.136113", "ticker_sentiment_score": "0.068308", "ticker_sentiment_label": "Neutral"}]}, {"title": "Novartis  ( NVS )  to Report Q3 Earnings: What's in the Offing?", "url": "https://www.zacks.com/stock/news/2169736/novartis-nvs-to-report-q3-earnings-whats-in-the-offing", "time_published": "20231020T142000", "authors": ["Zacks Equity Research"], "summary": "Investor focus is likely to be on the top and bottom-line numbers, and updates on guidance post-Sandoz spin-off when Novartis (NVS) reports its third-quarter results.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default89.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999999"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.237467, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "NVS", "relevance_score": "0.257895", "ticker_sentiment_score": "0.260712", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.130689", "ticker_sentiment_score": "0.066913", "ticker_sentiment_label": "Neutral"}, {"ticker": "GSK", "relevance_score": "0.130689", "ticker_sentiment_score": "0.064556", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.130689", "ticker_sentiment_score": "0.0516", "ticker_sentiment_label": "Neutral"}, {"ticker": "KDNY", "relevance_score": "0.043738", "ticker_sentiment_score": "0.06155", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why Astrazeneca  ( AZN )  is a Top Value Stock for the Long-Term", "url": "https://www.zacks.com/stock/news/2169594/why-astrazeneca-azn-is-a-top-value-stock-for-the-long-term", "time_published": "20231020T134008", "authors": ["Zacks Equity Research"], "summary": "The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default205.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.890401"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.374923, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "PTAIF", "relevance_score": "0.069697", "ticker_sentiment_score": "-0.052174", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.338119", "ticker_sentiment_score": "0.079525", "ticker_sentiment_label": "Neutral"}]}, {"title": "Pharma Stock Roundup: JNJ Posts Upbeat Q3 Earnings, PFE, NVO Revise 2023 View", "url": "https://www.zacks.com/stock/news/2169495/pharma-stock-roundup-jnj-posts-upbeat-q3-earnings-pfe-nvo-revise-2023-view", "time_published": "20231020T130200", "authors": ["Kinjel Shah"], "summary": "J&J (JNJ) reports strong third-quarter results. Merck's (MRK) new deal with Japan's Daiichi Sankyo to jointly develop the latter's three DXd ADC candidates.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f5/952.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.994953"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.102884, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.064362", "ticker_sentiment_score": "-0.153214", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "SKXJF", "relevance_score": "0.128306", "ticker_sentiment_score": "-0.016733", "ticker_sentiment_label": "Neutral"}, {"ticker": "DSKYF", "relevance_score": "0.128306", "ticker_sentiment_score": "-0.016733", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.032207", "ticker_sentiment_score": "-0.277037", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "NVO", "relevance_score": "0.222546", "ticker_sentiment_score": "0.12752", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.253316", "ticker_sentiment_score": "-0.128908", "ticker_sentiment_label": "Neutral"}]}, {"title": "Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings", "url": "https://www.zacks.com/stock/news/2169463/want-better-returns-dont-ignore-these-2-medical-stocks-set-to-beat-earnings", "time_published": "20231020T125007", "authors": ["Zacks Equity Research"], "summary": "The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default145.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999326"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.367248, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.263942", "ticker_sentiment_score": "0.280227", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AWON", "relevance_score": "0.067158", "ticker_sentiment_score": "0.18767", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Striving Together For A Thriving Industry, International Biopharma Industry Week Shanghai 2023 Opens", "url": "https://www.prnewswire.com/apac/news-releases/striving-together-for-a-thriving-industry-international-biopharma-industry-week-shanghai-2023-opens-301962953.html", "time_published": "20231020T072900", "authors": ["Shanghai Biomedical Industry Promotion Center"], "summary": "SHANGHAI, Oct. 20, 2023 /PRNewswire/ -- On October 16th, the inaugural ceremony of the 2023 International Biopharma Industry Week Shanghai ( IBIWS 2023 ) unfolded at the Zhangjiang Science Hall in Shanghai.", "banner_image": "https://mma.prnewswire.com/media/2251946/1.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Blockchain", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.384066, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "GAHC", "relevance_score": "0.019364", "ticker_sentiment_score": "0.031713", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDT", "relevance_score": "0.019364", "ticker_sentiment_score": "0.190474", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.019364", "ticker_sentiment_score": "0.190474", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BSX", "relevance_score": "0.019364", "ticker_sentiment_score": "0.190474", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.019364", "ticker_sentiment_score": "0.190474", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SNY", "relevance_score": "0.019364", "ticker_sentiment_score": "0.190474", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Press release Biocartis Group NV: Four Abstracts Showing Excellent Data for Idylla\u2122 Presented at European Society of Molecular Oncology Congress  ( ESMO ) ", "url": "https://www.globenewswire.com/news-release/2023/10/20/2763794/0/en/Press-release-Biocartis-Group-NV-Four-Abstracts-Showing-Excellent-Data-for-Idylla-Presented-at-European-Society-of-Molecular-Oncology-Congress-ESMO.html", "time_published": "20231020T050000", "authors": ["Biocartis NV"], "summary": "PRESS RELEASE 20 October 2023, 07:00 CEST ...", "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/c576d4bd-cacb-49bc-a12a-5c3607f3b067", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.05745, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.028592", "ticker_sentiment_score": "0.001904", "ticker_sentiment_label": "Neutral"}]}, {"title": "Astrazeneca  ( AZN )  Falls More Steeply Than Broader Market: What Investors Need to Know", "url": "https://www.zacks.com/stock/news/2169225/astrazeneca-azn-falls-more-steeply-than-broader-market-what-investors-need-to-know", "time_published": "20231019T215019", "authors": ["Zacks Equity Research"], "summary": "The latest trading day saw Astrazeneca (AZN) settling at $64.42, representing a -1.26% change from its previous close.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default44.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}, {"topic": "Earnings", "relevance_score": "0.972476"}], "overall_sentiment_score": 0.085339, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.537213", "ticker_sentiment_score": "0.113074", "ticker_sentiment_label": "Neutral"}]}, {"title": "Will Rising Costs Hurt HCA Healthcare's  ( HCA )  Q3 Earnings?", "url": "https://www.zacks.com/stock/news/2169139/will-rising-costs-hurt-hca-healthcares-hca-q3-earnings", "time_published": "20231019T171600", "authors": ["Zacks Equity Research"], "summary": "HCA Healthcare's (HCA) third-quarter results are likely to reflect an increased occupancy rate and a lower average length of stay.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/5d/41051.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.227395, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "APLS", "relevance_score": "0.13873", "ticker_sentiment_score": "0.083893", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.13873", "ticker_sentiment_score": "0.142176", "ticker_sentiment_label": "Neutral"}, {"ticker": "JAZZ", "relevance_score": "0.13873", "ticker_sentiment_score": "0.120188", "ticker_sentiment_label": "Neutral"}, {"ticker": "HCA", "relevance_score": "0.439786", "ticker_sentiment_score": "0.257397", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Granules India gets USFDA nod for generic drug used to treat heartburn", "url": "https://www.business-standard.com/india-news/granules-india-gets-usfda-nod-for-generic-drug-used-to-treat-heartburn-123101900462_1.html", "time_published": "20231019T090517", "authors": ["Press Trust of India"], "summary": "Granules India Ltd on Thursday said it has received approval from the US health regulator for its generic Esomeprazole Magnesium delayed-release capsules indicated for short-term treatment of heartburn and other symptoms associated with gastroesophageal reflux disease.", "banner_image": "https://bsmedia.business-standard.com/_media/bs/img/article/2022-11/25/full/1669400288-0753.jpg?im=FeatureCrop,size=(826,465)", "source": "Business Standard", "category_within_source": "GoogleRSS", "source_domain": "www.business-standard.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.01184, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.21686", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRYPTO:NXC", "relevance_score": "0.21686", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Granules India gets USFDA nod for generic drug used for short-term treatment of heartburn", "url": "https://www.moneycontrol.com/news/business/granules-india-gets-usfda-nod-for-generic-drug-used-for-short-term-treatment-of-heartburn-11563181.html", "time_published": "20231019T083648", "authors": [], "summary": "The approval by the US Food Drug Administration ( USFDA ) is for the abbreviated new drug application ( ANDA ) for Esomeprazole Magnesium delayed-release capsules of strengths 20 mg and 40 mg, Granules India said in a regulatory filing.", "banner_image": "https://images.moneycontrol.com/static-mcnews/2021/02/Pharma.shutterstock-1-770x433.jpg", "source": "Money Control", "category_within_source": "Business", "source_domain": "www.moneycontrol.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.01184, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.21686", "ticker_sentiment_score": "-0.154629", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "CRYPTO:NXC", "relevance_score": "0.21686", "ticker_sentiment_score": "-0.154629", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Can Growing Visits Aid Teladoc's  ( TDOC )  Earnings in Q3?", "url": "https://www.zacks.com/stock/news/2168290/can-growing-visits-aid-teladocs-tdoc-earnings-in-q3", "time_published": "20231018T162300", "authors": ["Zacks Equity Research"], "summary": "Teladoc's (TDOC) third-quarter results are likely to reflect growth in BetterHelp paying users.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/6c/1876.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.265246, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "APLS", "relevance_score": "0.147516", "ticker_sentiment_score": "0.08691", "ticker_sentiment_label": "Neutral"}, {"ticker": "TDOC", "relevance_score": "0.243376", "ticker_sentiment_score": "0.176569", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.147516", "ticker_sentiment_score": "0.147147", "ticker_sentiment_label": "Neutral"}, {"ticker": "JAZZ", "relevance_score": "0.147516", "ticker_sentiment_score": "0.124403", "ticker_sentiment_label": "Neutral"}, {"ticker": "HCSG", "relevance_score": "0.049424", "ticker_sentiment_score": "0.215061", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Why Is AstraZeneca Stock Trading Lower Today? - AstraZeneca  ( NASDAQ:AZN ) ", "url": "https://www.benzinga.com/general/biotech/23/10/35312418/why-is-astrazeneca-stock-trading-lower-today", "time_published": "20231018T155746", "authors": ["Vandana Singh"], "summary": "AstraZeneca Plc AZN shares are trading lower after a data abstract on its experimental drug, datopotamab deruxtecan, for lung cancer patients in a late-stage trial disappointed some analysts. The abstract was published before the European Society for Medical Oncology's ( ESMO ) congress.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/10/18/azn.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}], "overall_sentiment_score": -0.084411, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.373378", "ticker_sentiment_score": "-0.277278", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Why AstraZeneca's Lung Cancer Update Also Tripped Gilead Stock", "url": "https://www.investors.com/news/technology/astrazeneca-stock-dives-pulling-gilead-with-it-on-a-disappointing-update-in-lung-cancer-treatment/", "time_published": "20231018T153500", "authors": ["Investor's Business Daily", "ALLISON GATLIN"], "summary": "AstraZeneca Stock Dives, Pulling Gilead With It, On A Disappointing ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2021/03/Stock-astrazenecavac-01-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.989041"}], "overall_sentiment_score": 0.017385, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SKXJF", "relevance_score": "0.119532", "ticker_sentiment_score": "-0.093561", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.119532", "ticker_sentiment_score": "0.008141", "ticker_sentiment_label": "Neutral"}, {"ticker": "DSKYF", "relevance_score": "0.119532", "ticker_sentiment_score": "-0.093561", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.633079", "ticker_sentiment_score": "-0.111714", "ticker_sentiment_label": "Neutral"}]}, {"title": "People of African ancestry are poorly represented in genetic studies. A new effort would change that", "url": "https://apnews.com/article/genetics-african-ancestry-black-americans-hbcu-2b19d22d04392ff31871c008e7133e4f", "time_published": "20231018T145200", "authors": ["LAURA UNGAR"], "summary": "Scientists are setting out to collect genetic material from 500,000 people of African ancestry to create what they believe will be the world's largest database of genomic information from the population.", "banner_image": "https://dims.apnews.com/dims4/default/acf2e7b/2147483647/strip/true/crop/5204x3466+0+1/resize/599x399!/quality/90/?url=https%3A%2F%2Fassets.apnews.com%2F5e%2F2a%2F125ae6a43bc9adfbdafe96a51f2f%2F8c70064dccd342b08ed8358c698746df", "source": "Associated Press", "category_within_source": "Markets", "source_domain": "apnews.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.147593, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "HESG", "relevance_score": "0.071784", "ticker_sentiment_score": "0.084481", "ticker_sentiment_label": "Neutral"}, {"ticker": "HHH", "relevance_score": "0.071784", "ticker_sentiment_score": "0.168255", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.071784", "ticker_sentiment_score": "0.074409", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.071784", "ticker_sentiment_score": "0.074409", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biotech Stumbles As It Aims For A First-Ever In CRISPR Gene Editing", "url": "https://www.investors.com/news/technology/ntla-stock-stumbles-as-intellia-aims-for-a-first-ever-in-crispr-gene-editing/", "time_published": "20231018T143800", "authors": ["ALLISON GATLIN", "Investor's Business Daily"], "summary": "The Food and Drug Administration gave Intellia Therapeutics ( NTLA ) the go-ahead to begin a pivotal study of its gene-editing treatment for a deadly heart disease, but NTLA stock reversed lower at the open.", "banner_image": "https://www.investors.com/wp-content/uploads/2022/01/Stock-intelliatherapeutics-01-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.989041"}], "overall_sentiment_score": 0.054805, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ALNY", "relevance_score": "0.192694", "ticker_sentiment_score": "0.359459", "ticker_sentiment_label": "Bullish"}, {"ticker": "VRTX", "relevance_score": "0.192694", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.192694", "ticker_sentiment_score": "-0.034344", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.192694", "ticker_sentiment_score": "0.359459", "ticker_sentiment_label": "Bullish"}, {"ticker": "PFE", "relevance_score": "0.192694", "ticker_sentiment_score": "0.359459", "ticker_sentiment_label": "Bullish"}, {"ticker": "NTLA", "relevance_score": "0.606706", "ticker_sentiment_score": "-0.145803", "ticker_sentiment_label": "Neutral"}]}, {"title": "AstraZeneca PLC  ( AZN )  is Attracting Investor Attention: Here is What You Should Know", "url": "https://www.zacks.com/stock/news/2167863/astrazeneca-plc-azn-is-attracting-investor-attention-here-is-what-you-should-know", "time_published": "20231018T130005", "authors": ["Zacks Equity Research"], "summary": "Zacks.com users have recently been watching Astrazeneca (AZN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default137.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999999"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.5855"}], "overall_sentiment_score": 0.254711, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.485711", "ticker_sentiment_score": "0.170111", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "AstraZeneca shares fall as abstract for lung cancer trial data disappoints", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/astrazeneca-shares-fall-abstract-lung-cancer-trial-data-disappoints-2023-10-18/", "time_published": "20231018T122600", "authors": ["Reuters"], "summary": "A company logo is seen at the AstraZeneca site in Macclesfield, Britain, May 11, 2021. REUTERS/Phil Noble/File Photo Acquire Licensing Rights", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/QBKENUA4NBKF7OENKFKMX6MUYM.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.06483, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.859898", "ticker_sentiment_score": "-0.137384", "ticker_sentiment_label": "Neutral"}]}, {"title": "Futures Fall Ahead Of Housing Data", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-fall-ahead-of-housing-data-netflix-tesla-earnings-next/", "time_published": "20231018T121600", "authors": ["SCOTT LEHTONEN", "Investor's Business Daily"], "summary": "Dow Jones futures dropped Wednesday, along with S&P 500 futures and Nasdaq futures, ahead of key housing data. Up next, Netflix ( NFLX ) and Tesla ( TSLA ) will report their quarterly earnings results after the close. The Commerce Department's housing starts and building permits report is due ...", "banner_image": "https://www.investors.com/wp-content/uploads/2017/08/WallStreetFinance2-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Energy & Transportation", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.769861"}], "overall_sentiment_score": 0.078847, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NFLX", "relevance_score": "0.062679", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.093897", "ticker_sentiment_score": "0.139343", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.186498", "ticker_sentiment_score": "0.040902", "ticker_sentiment_label": "Neutral"}, {"ticker": "UAL", "relevance_score": "0.062679", "ticker_sentiment_score": "-0.106297", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.155853", "ticker_sentiment_score": "0.080598", "ticker_sentiment_label": "Neutral"}, {"ticker": "ANET", "relevance_score": "0.093897", "ticker_sentiment_score": "0.061784", "ticker_sentiment_label": "Neutral"}, {"ticker": "IBKR", "relevance_score": "0.093897", "ticker_sentiment_score": "-0.112508", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.124971", "ticker_sentiment_score": "0.077569", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.093897", "ticker_sentiment_score": "-0.112508", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.031364", "ticker_sentiment_score": "0.00873", "ticker_sentiment_label": "Neutral"}, {"ticker": "ASML", "relevance_score": "0.124971", "ticker_sentiment_score": "0.012177", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.093897", "ticker_sentiment_score": "0.063902", "ticker_sentiment_label": "Neutral"}, {"ticker": "LULU", "relevance_score": "0.093897", "ticker_sentiment_score": "0.139343", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.21686", "ticker_sentiment_score": "0.088343", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.062679", "ticker_sentiment_score": "0.162858", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PG", "relevance_score": "0.093897", "ticker_sentiment_score": "-0.112508", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.093897", "ticker_sentiment_score": "0.062208", "ticker_sentiment_label": "Neutral"}]}, {"title": "SOPHiA GENETICS Enters New Collaboration with Memorial Sloan Kettering Cancer Center and AstraZeneca to Address Global Inequalities in Comprehensive Cancer Care", "url": "https://www.newswire.ca/news-releases/sophia-genetics-enters-new-collaboration-with-memorial-sloan-kettering-cancer-center-and-astrazeneca-to-address-global-inequalities-in-comprehensive-cancer-care-874450887.html", "time_published": "20231018T120000", "authors": ["SOPHiA GENETICS"], "summary": "SOPHiA GENETICS Enters New Collaboration with Memorial Sloan Kettering Cancer Center and AstraZeneca to ... Canada ...", "banner_image": "https://mma.prnewswire.com/media/1673202/SOPHiA_GENETICS_Logo.jpg?p=facebook", "source": "Canada Newswire", "category_within_source": "n/a", "source_domain": "www.newswire.ca", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": 0.063414, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.201523", "ticker_sentiment_score": "-0.003407", "ticker_sentiment_label": "Neutral"}, {"ticker": "SOPH", "relevance_score": "0.47672", "ticker_sentiment_score": "0.047454", "ticker_sentiment_label": "Neutral"}]}, {"title": "United Airlines, Interactive Brokers And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - AstraZeneca  ( NASDAQ:AZN ) , BGC Group  ( NASDAQ:BGC ) ", "url": "https://www.benzinga.com/news/23/10/35303853/united-airlines-interactive-brokers-and-other-big-stocks-moving-lower-in-wednesdays-pre-market-sessi", "time_published": "20231018T100523", "authors": ["Lisa Levin"], "summary": "U.S. stock futures traded lower this morning on Wednesday. Here are some big stocks recording losses in today's pre-market trading session. BGC Group, Inc. BGC shares fell 6.2% to $ 5.60 in pre-market trading after gaining over 1% on Tuesday. Genmab A/S GMAB declined 5.6% to $30.13 in pre-market ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/10/18/united_airlines_-_logo.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.503496"}, {"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Energy & Transportation", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": -0.106982, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "UAL", "relevance_score": "0.268294", "ticker_sentiment_score": "-0.214092", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "IBKR", "relevance_score": "0.268294", "ticker_sentiment_score": "-0.380062", "ticker_sentiment_label": "Bearish"}, {"ticker": "AZN", "relevance_score": "0.268294", "ticker_sentiment_score": "0.142223", "ticker_sentiment_label": "Neutral"}, {"ticker": "BGC", "relevance_score": "0.268294", "ticker_sentiment_score": "0.193177", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIDU", "relevance_score": "0.392948", "ticker_sentiment_score": "0.374199", "ticker_sentiment_label": "Bullish"}, {"ticker": "LAC", "relevance_score": "0.392948", "ticker_sentiment_score": "-0.203647", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Glenmark Pharma launches triple-combination drug for Type 2 Diabetes", "url": "https://www.business-standard.com/companies/news/glenmark-pharma-launches-triple-combination-drug-for-type-2-diabetes-123101800383_1.html", "time_published": "20231018T070250", "authors": ["BS Reporter"], "summary": "The company said it is the first drug of its kind in India to which combines three medications to improve glycemic control - maintenance of blood glucose levels within a desirable range - in diabetes patients. This medication will be sold under the brand name Zita DM.", "banner_image": "https://bsmedia.business-standard.com/_media/bs/img/article/2018-10/26/full/1540545645-3313.jpg?im=FeatureCrop,size=(826,465)", "source": "Business Standard", "category_within_source": "GoogleRSS", "source_domain": "www.business-standard.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.064445, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.271274", "ticker_sentiment_score": "-0.17049", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Can Centene's  ( CNC )  Q3 Earnings Beat on Membership Growth?", "url": "https://www.zacks.com/stock/news/2167399/can-centenes-cnc-q3-earnings-beat-on-membership-growth", "time_published": "20231017T160300", "authors": ["Zacks Equity Research"], "summary": "Centene's (CNC) third-quarter results are likely to reflect higher premiums and lower cost of services.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/6e/2354.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.262854, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "APLS", "relevance_score": "0.155451", "ticker_sentiment_score": "0.089761", "ticker_sentiment_label": "Neutral"}, {"ticker": "CNC", "relevance_score": "0.398939", "ticker_sentiment_score": "0.281598", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.155451", "ticker_sentiment_score": "0.149248", "ticker_sentiment_label": "Neutral"}, {"ticker": "JAZZ", "relevance_score": "0.104002", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Ultimovacs Announces NIPU Results Presented at ESMO 2023: Significant and Clinically Meaningful Improvement in Overall Survival for Patients Receiving UV1 Cancer Vaccine in Phase II NIPU Trial in Malignant Mesothelioma", "url": "https://www.globenewswire.com/news-release/2023/10/17/2761776/0/en/Ultimovacs-Announces-NIPU-Results-Presented-at-ESMO-2023-Significant-and-Clinically-Meaningful-Improvement-in-Overall-Survival-for-Patients-Receiving-UV1-Cancer-Vaccine-in-Phase-II.html", "time_published": "20231017T160100", "authors": ["Ultimovacs ASA"], "summary": "\u2022 UV1, in combination with the checkpoint inhibitors ipilimumab and nivolumab from Bristol-Myers Squibb, demonstrated a clinically meaningful overall survival benefit with no added toxicities, compared to ipilimumab and nivolumab alone, in the second-line treatment of patients with malignant ...", "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/23b62627-6dd1-416b-b614-675e9c122324", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.839681"}], "overall_sentiment_score": -0.043833, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.015851", "ticker_sentiment_score": "-0.042849", "ticker_sentiment_label": "Neutral"}, {"ticker": "AWON", "relevance_score": "0.015851", "ticker_sentiment_score": "0.052239", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.063341", "ticker_sentiment_score": "-0.041314", "ticker_sentiment_label": "Neutral"}]}, {"title": "AstraZeneca's  ( AZN )  Tagrisso Combo Gets FDA's Priority Review", "url": "https://www.zacks.com/stock/news/2167361/astrazenecas-azn-tagrisso-combo-gets-fdas-priority-review", "time_published": "20231017T153000", "authors": ["Zacks Equity Research"], "summary": "The FDA accepts and grants priority review to AstraZeneca's (AZN) sNDA, seeking approval of Tagrisso combined with chemotherapy as a first-line treatment for EGFR-mutated advanced NSCLC. A decision is due in first-quarter 2024.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/49/1007.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.99237"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.153163, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MEIP", "relevance_score": "0.31482", "ticker_sentiment_score": "0.165059", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.373378", "ticker_sentiment_score": "0.287504", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SRPT", "relevance_score": "0.31482", "ticker_sentiment_score": "0.02113", "ticker_sentiment_label": "Neutral"}, {"ticker": "NBIX", "relevance_score": "0.373378", "ticker_sentiment_score": "0.068178", "ticker_sentiment_label": "Neutral"}]}, {"title": "FDA Approves Merck's Top Selling Drug, Keytruda For Expanded Use In Lung Cancer Indication - Merck & Co  ( NYSE:MRK ) ", "url": "https://www.benzinga.com/general/biotech/23/10/35282353/fda-approves-mercks-top-selling-drug-keytruda-for-expanded-use-in-lung-cancer-indication", "time_published": "20231017T112825", "authors": ["Vandana Singh"], "summary": "The FDA approved Merck & Co Inc's MRK Keytruda for resectable ( tumors \u22654 centimeters [cm] or node-positive ) non-small cell lung cancer ( NSCLC ) in combination with platinum-containing chemotherapy as neoadjuvant treatment and then continued as a single agent as adjuvant treatment after ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/10/17/mrk.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.233292, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.272788", "ticker_sentiment_score": "-0.171685", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "MORN", "relevance_score": "0.138464", "ticker_sentiment_score": "-0.105216", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.272788", "ticker_sentiment_score": "-0.171685", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Large Granular Lymphocyte Leukemia Market is Projected to Grow During the Study Period  ( 2019-2032 ) , Assesses DelveInsight | Key Companies - Bristol Myers Squibb, Innate Pharma, Kymera Therapeutics, EUSA Pharma, Abcuro, Dren Bio, Novotech", "url": "https://www.prnewswire.com/news-releases/large-granular-lymphocyte-leukemia-market-is-projected-to-grow-during-the-study-period-20192032-assesses-delveinsight--key-companies---bristol-myers-squibb-innate-pharma-kymera-therapeutics-eusa-pharma-abcuro-dren-bio-n-301957023.html", "time_published": "20231016T210100", "authors": ["LLP", "DelveInsight Business Research"], "summary": "Large Granular Lymphocyte Leukemia Market is Projected to Grow During the Study Period ( 2019-2032 ) , Assesses ... PR ...", "banner_image": "https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.069381, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "IPHA", "relevance_score": "0.025845", "ticker_sentiment_score": "0.095897", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.025845", "ticker_sentiment_score": "-0.032245", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.051663", "ticker_sentiment_score": "-0.028928", "ticker_sentiment_label": "Neutral"}, {"ticker": "LVTX", "relevance_score": "0.025845", "ticker_sentiment_score": "-0.026539", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.025845", "ticker_sentiment_score": "-0.026539", "ticker_sentiment_label": "Neutral"}, {"ticker": "KYMR", "relevance_score": "0.025845", "ticker_sentiment_score": "0.095897", "ticker_sentiment_label": "Neutral"}, {"ticker": "TGTX", "relevance_score": "0.025845", "ticker_sentiment_score": "-0.026539", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.077426", "ticker_sentiment_score": "-0.029504", "ticker_sentiment_label": "Neutral"}, {"ticker": "ONCT", "relevance_score": "0.025845", "ticker_sentiment_score": "-0.026539", "ticker_sentiment_label": "Neutral"}, {"ticker": "APVO", "relevance_score": "0.025845", "ticker_sentiment_score": "-0.023726", "ticker_sentiment_label": "Neutral"}, {"ticker": "NRIX", "relevance_score": "0.025845", "ticker_sentiment_score": "-0.026539", "ticker_sentiment_label": "Neutral"}, {"ticker": "INCY", "relevance_score": "0.025845", "ticker_sentiment_score": "-0.026539", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.051663", "ticker_sentiment_score": "-0.028928", "ticker_sentiment_label": "Neutral"}, {"ticker": "APRE", "relevance_score": "0.025845", "ticker_sentiment_score": "-0.026539", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.025845", "ticker_sentiment_score": "-0.023726", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.025845", "ticker_sentiment_score": "-0.023726", "ticker_sentiment_label": "Neutral"}]}, {"title": "Pfizer, Sanofi's Respiratory Syncytial Virus Products Faces Insurance And Logistical Hurdles To Protect Infants - Pfizer  ( NYSE:PFE ) , Sanofi  ( NASDAQ:SNY ) ", "url": "https://www.benzinga.com/general/biotech/23/10/35269447/pfizer-sanofis-respiratory-syncytial-virus-products-faces-insurance-and-logistical-hurdles-to-pro", "time_published": "20231016T161655", "authors": ["Vandana Singh"], "summary": "As the respiratory virus season kicks off, healthcare providers are racing against time to offer Pfizer Inc's PFE vaccine, Abrysvo, to pregnant patients and Sanofi SA's SNY monoclonal antibody, Beyfortus, to protect against respiratory syncytial virus ( RSV ) complications in infants.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/10/16/pfe.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": 0.036575, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.25168", "ticker_sentiment_score": "0.050999", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.478939", "ticker_sentiment_score": "0.216145", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SNY", "relevance_score": "0.577527", "ticker_sentiment_score": "-0.070082", "ticker_sentiment_label": "Neutral"}]}, {"title": "Understanding AstraZeneca's Position In Pharmaceuticals Industry Compared To Competitors - AstraZeneca  ( NASDAQ:AZN ) ", "url": "https://www.benzinga.com/news/23/10/35270979/understanding-astrazenecas-position-in-pharmaceuticals-industry-compared-to-competitors", "time_published": "20231016T160035", "authors": ["Benzinga Insights"], "summary": "In the dynamic and cutthroat world of business, conducting thorough company analysis is essential for investors and industry experts. In this article, we will undertake a comprehensive industry comparison, evaluating AstraZeneca AZN and its primary competitors in the Pharmaceuticals industry.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.938793"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.658903"}], "overall_sentiment_score": 0.141042, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "PTAIF", "relevance_score": "0.067919", "ticker_sentiment_score": "0.018184", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.605937", "ticker_sentiment_score": "0.218457", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Top Stories Monday, Oct 16: Bitcoin's ETF Approval Rumor, Pfizer Slashes Annual Outlook, Activist Shareholder Shakes Up News Corp's Status Quo", "url": "https://www.benzinga.com/markets/cryptocurrency/23/10/35268834/bitcoins-etf-approval-rumor-pfizer-slashes-annual-outlook-activist-shareholder-shakes-up-n", "time_published": "20231016T143510", "authors": ["Vandana Singh"], "summary": "Bitcoin ( BTC/USD ) , the ace cryptocurrency, spiked on unverified reports of the approval of an iShares Bitcoin ETF. BlackRock said the information is false, according to Fox Business journalist Eleanor Terrett. The company's Bitcoin ETF application is still under review, BlackRock, which ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/10/16/bitcoin-3024279_1920.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "Blockchain", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.650727"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.360215"}], "overall_sentiment_score": 0.105307, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BLK", "relevance_score": "0.080188", "ticker_sentiment_score": "-0.07011", "ticker_sentiment_label": "Neutral"}, {"ticker": "CVS", "relevance_score": "0.159569", "ticker_sentiment_score": "-0.128103", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.19871", "ticker_sentiment_score": "0.170354", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HON", "relevance_score": "0.080188", "ticker_sentiment_score": "0.126314", "ticker_sentiment_label": "Neutral"}, {"ticker": "NWSAL", "relevance_score": "0.040145", "ticker_sentiment_score": "0.113712", "ticker_sentiment_label": "Neutral"}, {"ticker": "GS", "relevance_score": "0.080188", "ticker_sentiment_score": "0.088453", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.12003", "ticker_sentiment_score": "-0.181602", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "BNTX", "relevance_score": "0.080188", "ticker_sentiment_score": "-0.260631", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "RAD", "relevance_score": "0.159569", "ticker_sentiment_score": "0.069039", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.080188", "ticker_sentiment_score": "0.08422", "ticker_sentiment_label": "Neutral"}, {"ticker": "RPGRF", "relevance_score": "0.040145", "ticker_sentiment_score": "0.144351", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALB", "relevance_score": "0.159569", "ticker_sentiment_score": "0.174221", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "WBA", "relevance_score": "0.080188", "ticker_sentiment_score": "-0.183791", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "MANU", "relevance_score": "0.080188", "ticker_sentiment_score": "-0.024758", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVAX", "relevance_score": "0.080188", "ticker_sentiment_score": "-0.17741", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "WEWOW", "relevance_score": "0.080188", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRYPTO:BTC", "relevance_score": "0.159569", "ticker_sentiment_score": "0.113322", "ticker_sentiment_label": "Neutral"}]}, {"title": "AstraZeneca's Tagrisso-Chemo Combo Under FDA Priority Review For Most Common Form Of Lung Cancer - AstraZeneca  ( NASDAQ:AZN ) ", "url": "https://www.benzinga.com/general/biotech/23/10/35266622/astrazenecas-tagrisso-chemo-combo-under-fda-priority-review-for-most-common-form-of-lung-cancer", "time_published": "20231016T142023", "authors": ["Vandana Singh"], "summary": "AstraZeneca Plc's AZN supplemental New Drug Application for Tagrisso ( osimertinib ) in combination with chemotherapy has been accepted and granted Priority Review in the U.S. for locally advanced or metastatic epidermal growth factor receptor-mutated ( EGFRm ) non-small cell lung cancer ( NSCLC ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/10/16/azn.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.060776, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.388879", "ticker_sentiment_score": "0.256105", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Fortress Biotech Subsidiary Helocyte Announces Option Agreement with City of Hope for Exclusive Worldwide Rights to use a Novel Bispecific CMV/HIV CAR T Cell Therapy  ( optionally in combination with Triplex )  for the Treatment of Adults Living with HIV-1 - Fortress Biotech  ( NASDAQ:FBIO ) ", "url": "https://www.benzinga.com/pressreleases/23/10/g35266464/fortress-biotech-subsidiary-helocyte-announces-option-agreement-with-city-of-hope-for-exclusive-wo", "time_published": "20231016T130022", "authors": ["Globe Newswire"], "summary": "Recent $11.3 million grant from the California Institute for Regenerative Medicine ( CIRM ) intended to fund the Phase 1 clinical trial at City of Hope; the Investigational New Drug application for which has now been accepted by the Food and Drug Administration", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.146347, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.023673", "ticker_sentiment_score": "0.152267", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FBIO", "relevance_score": "0.047324", "ticker_sentiment_score": "0.048873", "ticker_sentiment_label": "Neutral"}]}, {"title": "Fortress Biotech Subsidiary Helocyte Announces Option Agreement with City of Hope for Exclusive Worldwide Rights to use a Novel Bispecific CMV/HIV CAR T Cell Therapy  ( optionally in combination with Triplex )  for the Treatment of Adults Living with HIV-1", "url": "https://www.globenewswire.com/news-release/2023/10/16/2760729/28889/en/Fortress-Biotech-Subsidiary-Helocyte-Announces-Option-Agreement-with-City-of-Hope-for-Exclusive-Worldwide-Rights-to-use-a-Novel-Bispecific-CMV-HIV-CAR-T-Cell-Therapy-optionally-in-.html", "time_published": "20231016T130000", "authors": ["Inc.", "Fortress Biotech"], "summary": "Recent $11.3 million grant from the California Institute for Regenerative Medicine ( CIRM ) intended to fund the Phase 1 clinical trial at City of Hope. the Investigational New Drug application for which has now been accepted by the Food and Drug Administration ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/d82bf2ce-81b7-4989-9e6b-08e6bb6e1f95", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.614606"}], "overall_sentiment_score": 0.165567, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.019286", "ticker_sentiment_score": "0.153713", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FBIO", "relevance_score": "0.057814", "ticker_sentiment_score": "0.130081", "ticker_sentiment_label": "Neutral"}]}, {"title": "Fusion Pharmaceuticals Appoints Life Science Industry Leaders Jeremy Bender, Teresa Bitetti and David Meek to its Board of Directors", "url": "https://www.prnewswire.com/news-releases/fusion-pharmaceuticals-appoints-life-science-industry-leaders-jeremy-bender-teresa-bitetti-and-david-meek-to-its-board-of-directors-301957344.html", "time_published": "20231016T115000", "authors": ["Fusion Pharmaceuticals"], "summary": "Fusion Pharmaceuticals Appoints Life Science Industry Leaders Jeremy Bender, Teresa Bitetti and David Meek to its ... PR ...", "banner_image": "https://mma.prnewswire.com/media/1196797/Fusion_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.092194, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "QURE", "relevance_score": "0.044386", "ticker_sentiment_score": "-0.02047", "ticker_sentiment_label": "Neutral"}, {"ticker": "INVA", "relevance_score": "0.044386", "ticker_sentiment_score": "-0.02047", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.044386", "ticker_sentiment_score": "0.041683", "ticker_sentiment_label": "Neutral"}, {"ticker": "STRO", "relevance_score": "0.044386", "ticker_sentiment_score": "-0.061069", "ticker_sentiment_label": "Neutral"}, {"ticker": "DAWN", "relevance_score": "0.044386", "ticker_sentiment_score": "-0.061069", "ticker_sentiment_label": "Neutral"}, {"ticker": "FUSN", "relevance_score": "0.132611", "ticker_sentiment_score": "0.06807", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.044386", "ticker_sentiment_score": "-0.061069", "ticker_sentiment_label": "Neutral"}, {"ticker": "MREO", "relevance_score": "0.044386", "ticker_sentiment_score": "-0.061069", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRTX", "relevance_score": "0.044386", "ticker_sentiment_score": "-0.02047", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.044386", "ticker_sentiment_score": "-0.047896", "ticker_sentiment_label": "Neutral"}]}, {"title": "Fusion Pharmaceuticals Appoints Life Science Industry Leaders Jeremy Bender, Teresa Bitetti and David Meek to its Board of Directors", "url": "https://www.newswire.ca/news-releases/fusion-pharmaceuticals-appoints-life-science-industry-leaders-jeremy-bender-teresa-bitetti-and-david-meek-to-its-board-of-directors-816998848.html", "time_published": "20231016T115000", "authors": ["Fusion Pharmaceuticals"], "summary": "Fusion Pharmaceuticals Appoints Life Science Industry Leaders Jeremy Bender, Teresa Bitetti and David Meek to its ... Canada ...", "banner_image": "https://mma.prnewswire.com/media/1196797/Fusion_Logo.jpg?p=facebook", "source": "Canada Newswire", "category_within_source": "n/a", "source_domain": "www.newswire.ca", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.092194, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "QURE", "relevance_score": "0.044386", "ticker_sentiment_score": "-0.02047", "ticker_sentiment_label": "Neutral"}, {"ticker": "INVA", "relevance_score": "0.044386", "ticker_sentiment_score": "-0.02047", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.044386", "ticker_sentiment_score": "0.041683", "ticker_sentiment_label": "Neutral"}, {"ticker": "STRO", "relevance_score": "0.044386", "ticker_sentiment_score": "-0.061069", "ticker_sentiment_label": "Neutral"}, {"ticker": "DAWN", "relevance_score": "0.044386", "ticker_sentiment_score": "-0.061069", "ticker_sentiment_label": "Neutral"}, {"ticker": "FUSN", "relevance_score": "0.132611", "ticker_sentiment_score": "0.06807", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.044386", "ticker_sentiment_score": "-0.061069", "ticker_sentiment_label": "Neutral"}, {"ticker": "MREO", "relevance_score": "0.044386", "ticker_sentiment_score": "-0.061069", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRTX", "relevance_score": "0.044386", "ticker_sentiment_score": "-0.02047", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.044386", "ticker_sentiment_score": "-0.047896", "ticker_sentiment_label": "Neutral"}]}, {"title": "AstraZeneca's Tagrisso-chemo combo given priority review in US", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/astrazenecas-tagrisso-chemo-combo-given-priority-review-us-2023-10-16/", "time_published": "20231016T060047", "authors": ["Reuters"], "summary": "FILE PHOTO-People pose with syringe with needle in front of displayed AstraZeneca logo in this illustration taken, December 11, 2021. REUTERS/Dado Ruvic/Illustration/File Photo Acquire Licensing Rights", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/5TME6QWY4BOT7GL6MUYE2PHJ5U.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.169519, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.398148", "ticker_sentiment_score": "-0.027894", "ticker_sentiment_label": "Neutral"}]}, {"title": "Ascentage, AstraZeneca Collaborate On Phase III Study Of Lisaftoclax Combination In CLL/SLL", "url": "https://markets.businessinsider.com/news/stocks/ascentage-astrazeneca-collaborate-on-phase-iii-study-of-lisaftoclax-combination-in-cll-sll-1032706166", "time_published": "20231016T032513", "authors": ["markets.businessinsider.com"], "summary": "Ascentage, AstraZeneca Collaborate On Phase III Study Of Lisaftoclax Combination In ...", "banner_image": "https://markets.businessinsider.com/Images/FacebookIcon.jpg", "source": "Business Insider", "category_within_source": "RSS", "source_domain": "markets.businessinsider.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.016444, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.252987", "ticker_sentiment_score": "-0.150708", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "ASPHF", "relevance_score": "0.252987", "ticker_sentiment_score": "-0.150708", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Ascentage Pharma and AstraZeneca Enter into Clinical Collaboration on the Registrational Phase III Study of Bcl-2 Inhibitor Lisaftoclax in Combination with BTK Inhibitor Acalabrutinib in Treatment-Na\u00efve Patients with First-Line CLL/SLL", "url": "https://www.prnewswire.com/news-releases/ascentage-pharma-and-astrazeneca-enter-into-clinical-collaboration-on-the-registrational-phase-iii-study-of-bcl-2-inhibitor-lisaftoclax-in-combination-with-btk-inhibitor-acalabrutinib-in-treatment-naive-patients-with-first-line-cl-301956934.html", "time_published": "20231016T012300", "authors": ["Ascentage Pharma"], "summary": "Ascentage Pharma and AstraZeneca Enter into Clinical Collaboration on the Registrational Phase III Study of Bcl-2 ... PR ...", "banner_image": "https://mma.prnewswire.com/media/891219/Ascentage_Pharma_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.684621"}], "overall_sentiment_score": 0.133232, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.167488", "ticker_sentiment_score": "0.095422", "ticker_sentiment_label": "Neutral"}, {"ticker": "ASPHF", "relevance_score": "0.327676", "ticker_sentiment_score": "0.090362", "ticker_sentiment_label": "Neutral"}, {"ticker": "UBX", "relevance_score": "0.024102", "ticker_sentiment_score": "0.077791", "ticker_sentiment_label": "Neutral"}]}, {"title": "A big climate change stress test is coming for Amazon sellers and suppliers", "url": "https://www.cnbc.com/2023/10/14/a-climate-change-stress-test-is-coming-to-amazon-sellers-and-suppliers.html", "time_published": "20231014T141809", "authors": ["Laura Petrecca"], "summary": "As Amazon and other big companies reduce their carbon footprint, they're putting pressure on suppliers to do the same, or risk losing business.", "banner_image": "https://image.cnbcfm.com/api/v1/image/107303775-16952252081695225205-31274491622-1080pnbcnews.jpg?v=1695227040&w=750&h=422&vtcrop=y", "source": "CNBC", "category_within_source": "Top News", "source_domain": "www.cnbc.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}], "overall_sentiment_score": 0.124985, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MSFT", "relevance_score": "0.033052", "ticker_sentiment_score": "0.169417", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NYT", "relevance_score": "0.033052", "ticker_sentiment_score": "-0.043031", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.033052", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "WMT", "relevance_score": "0.033052", "ticker_sentiment_score": "0.169417", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Growing Geriatric Population Fuels Ankylosing Spondylitis Market: Management of Pain and Mobility Gains Importance in Aging Demographics", "url": "https://www.prnewswire.com/news-releases/growing-geriatric-population-fuels-ankylosing-spondylitis-market-management-of-pain-and-mobility-gains-importance-in-aging-demographics-301956060.html", "time_published": "20231013T154500", "authors": ["Research and Markets"], "summary": "Growing Geriatric Population Fuels Ankylosing Spondylitis Market: Management of Pain and Mobility Gains Importance ... PR ...", "banner_image": "https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.144187, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.036643", "ticker_sentiment_score": "0.067285", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.036643", "ticker_sentiment_score": "0.067285", "ticker_sentiment_label": "Neutral"}, {"ticker": "VTRS", "relevance_score": "0.036643", "ticker_sentiment_score": "0.067285", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALPMF", "relevance_score": "0.036643", "ticker_sentiment_score": "0.067285", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVS", "relevance_score": "0.036643", "ticker_sentiment_score": "0.067285", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.036643", "ticker_sentiment_score": "0.067285", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.036643", "ticker_sentiment_score": "0.067285", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.036643", "ticker_sentiment_score": "0.067285", "ticker_sentiment_label": "Neutral"}, {"ticker": "RXDX", "relevance_score": "0.073209", "ticker_sentiment_score": "0.139168", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.036643", "ticker_sentiment_score": "0.067285", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.073209", "ticker_sentiment_score": "0.08925", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.036643", "ticker_sentiment_score": "0.067285", "ticker_sentiment_label": "Neutral"}]}, {"title": "UnitedHealth Group  ( UNH )  Q3 Earnings Beat, Boosts '23 EPS View", "url": "https://www.zacks.com/stock/news/2165676/unitedhealth-group-unh-q3-earnings-beat-boosts-23-eps-view", "time_published": "20231013T151900", "authors": ["Zacks Equity Research"], "summary": "UnitedHealth Group's (UNH) management presently forecasts adjusted net EPS between $24.85 and $25.00 for 2023.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/49/44858.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.858979"}, {"topic": "Earnings", "relevance_score": "0.999892"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.188232, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "APLS", "relevance_score": "0.120834", "ticker_sentiment_score": "0.111749", "ticker_sentiment_label": "Neutral"}, {"ticker": "CNC", "relevance_score": "0.080728", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.120834", "ticker_sentiment_score": "0.13073", "ticker_sentiment_label": "Neutral"}, {"ticker": "UNH", "relevance_score": "0.456884", "ticker_sentiment_score": "0.290584", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "J&J  ( JNJ )  to Report Q3 Earnings, Its First After Unit Spin-Off", "url": "https://www.zacks.com/stock/news/2165582/jj-jnj-to-report-q3-earnings-its-first-after-unit-spin-off", "time_published": "20231013T134900", "authors": ["Zacks Equity Research"], "summary": "J&J's (JNJ) third-quarter results are the first quarterly update for the new company after the Consumer Health spin-off.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ff/1612.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.99393"}, {"topic": "Earnings", "relevance_score": "0.999992"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.149943, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "KVUE", "relevance_score": "0.130453", "ticker_sentiment_score": "0.063321", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.173333", "ticker_sentiment_score": "-0.063835", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.257442", "ticker_sentiment_score": "0.135924", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.215702", "ticker_sentiment_score": "0.094996", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.173333", "ticker_sentiment_score": "0.080645", "ticker_sentiment_label": "Neutral"}]}, {"title": "MORE PATIENT EDUCATION NEEDED ON THE USE OF ANTICOAGULANTS AND TREATING SERIOUS BLEEDS", "url": "https://www.newswire.ca/news-releases/more-patient-education-needed-on-the-use-of-anticoagulants-and-treating-serious-bleeds-870738962.html", "time_published": "20231013T111500", "authors": ["Thrombosis Canada"], "summary": "New research about patient attitudes and knowledge about use of anticoagulants is the focus of awareness campaign during Thrombosis Month in Canada TORONTO, Oct. 13, 2023 /CNW/ - Sahar Monzavi-Bacon remembers the exact moment her life changed in 2019.", "banner_image": "https://mma.prnewswire.com/media/2245143/Thrombosis_Canada_MORE_PATIENT_EDUCATION_NEEDED_ON_THE_USE_OF_AN.pdf?p=pdfthumbnail", "source": "Canada Newswire", "category_within_source": "n/a", "source_domain": "www.newswire.ca", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.01708, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.0378", "ticker_sentiment_score": "0.191871", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Why the Market Dipped But  ( AZN )  Gained Today", "url": "https://www.zacks.com/stock/news/2165193/why-the-market-dipped-but-azn-gained-today", "time_published": "20231012T215021", "authors": ["Zacks Equity Research"], "summary": "Astrazeneca (AZN) concluded the recent trading session at $68.11, signifying a +0.15% move from its prior day's close.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default145.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}, {"topic": "Earnings", "relevance_score": "0.986564"}], "overall_sentiment_score": 0.121544, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.469457", "ticker_sentiment_score": "0.162769", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Can Elevance's  ( ELV )  Q3 Earnings Beat on Carelon Strength?", "url": "https://www.zacks.com/stock/news/2165137/can-elevances-elv-q3-earnings-beat-on-carelon-strength", "time_published": "20231012T172100", "authors": ["Zacks Equity Research"], "summary": "The third-quarter results of Elevance (ELV) are likely to reflect strong rate adjustments and membership growth in the Health Benefits business.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/45/26891.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.309865, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "APLS", "relevance_score": "0.14573", "ticker_sentiment_score": "0.104554", "ticker_sentiment_label": "Neutral"}, {"ticker": "CNC", "relevance_score": "0.097457", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIOS", "relevance_score": "0.04882", "ticker_sentiment_score": "0.137981", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.14573", "ticker_sentiment_score": "0.143605", "ticker_sentiment_label": "Neutral"}, {"ticker": "ELV", "relevance_score": "0.375722", "ticker_sentiment_score": "0.263747", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "The Zacks Analyst Blog UnitedHealth, Chevron, AstraZeneca, Adobe and Pfizer", "url": "https://www.zacks.com/stock/news/2164828/the-zacks-analyst-blog-unitedhealth-chevron-astrazeneca-adobe-and-pfizer", "time_published": "20231012T123100", "authors": ["Zacks Equity Research"], "summary": "UnitedHealth, Chevron, AstraZeneca, Adobe and Pfizer are part of the Zacks Analyst Blog.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/89/447.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.684621"}, {"topic": "Earnings", "relevance_score": "0.538269"}, {"topic": "Energy & Transportation", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.260501, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ADBE", "relevance_score": "0.152983", "ticker_sentiment_score": "0.040903", "ticker_sentiment_label": "Neutral"}, {"ticker": "CVX", "relevance_score": "0.370418", "ticker_sentiment_score": "0.305548", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.370418", "ticker_sentiment_score": "0.224836", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.152983", "ticker_sentiment_score": "0.040903", "ticker_sentiment_label": "Neutral"}, {"ticker": "UNH", "relevance_score": "0.227716", "ticker_sentiment_score": "0.054664", "ticker_sentiment_label": "Neutral"}]}, {"title": "Fusion Pharmaceuticals Announces Presentation of Preclinical Data Supporting FPI-2068, a Novel Targeted Alpha Therapy for EGFR-cMET Expressing Cancers", "url": "https://www.newswire.ca/news-releases/fusion-pharmaceuticals-announces-presentation-of-preclinical-data-supporting-fpi-2068-a-novel-targeted-alpha-therapy-for-egfr-cmet-expressing-cancers-887089321.html", "time_published": "20231012T114500", "authors": ["Fusion Pharmaceuticals"], "summary": "Fusion Pharmaceuticals Announces Presentation of Preclinical Data Supporting FPI-2068, a Novel Targeted Alpha ... Canada ...", "banner_image": "https://mma.prnewswire.com/media/1196797/Fusion_Logo.jpg?p=facebook", "source": "Canada Newswire", "category_within_source": "n/a", "source_domain": "www.newswire.ca", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}], "overall_sentiment_score": -0.028948, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.131823", "ticker_sentiment_score": "0.055811", "ticker_sentiment_label": "Neutral"}, {"ticker": "FUSN", "relevance_score": "0.164356", "ticker_sentiment_score": "0.014007", "ticker_sentiment_label": "Neutral"}]}, {"title": "Attention Medicare Recipients: You Could See Lower Costs for These 10 Drugs in the Not-Too-Distant Future", "url": "https://www.fool.com/retirement/2023/10/12/medicare-recipients-could-see-lower-costs-for-thes/", "time_published": "20231012T091500", "authors": ["Keith Speights"], "summary": "Medicare will soon begin negotiations with drugmakers for the first time ever.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F750108%2Folder-couple-pill-bottle.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.127947, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.08687", "ticker_sentiment_score": "-0.129312", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.08687", "ticker_sentiment_score": "-0.129312", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.08687", "ticker_sentiment_score": "-0.129312", "ticker_sentiment_label": "Neutral"}]}, {"title": "Startup Cerebras stands out in the high-risk AI chip arena: 'No one has built a chip this big'", "url": "https://www.marketwatch.com/story/startup-cerebras-stands-out-in-the-high-risk-ai-chip-arena-no-one-has-built-a-chip-this-big-baee73ff", "time_published": "20231011T234400", "authors": ["Therese Poletti"], "summary": "While most computer-chip makers over the past decades have touted the benefits of an ever-shrinking product, a well-funded Silicon Valley company has built what it says is the largest and fastest-ever computer chip, dedicated to AI.", "banner_image": "https://images.mktw.net/im-866186?width=700&height=526", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "IPO", "relevance_score": "0.310843"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.138026, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMD", "relevance_score": "0.103035", "ticker_sentiment_score": "0.007619", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.068797", "ticker_sentiment_score": "0.075229", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.237469", "ticker_sentiment_score": "0.129374", "ticker_sentiment_label": "Neutral"}]}, {"title": "Top Analyst Reports for UnitedHealth, Chevron & AstraZeneca", "url": "https://www.zacks.com/research-daily/2164179/top-analyst-reports-for-unitedhealth-chevron-astrazeneca", "time_published": "20231011T190500", "authors": ["Sheraz Mian"], "summary": "Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth Group Incorporated (UNH), Chevron Corporation (CVX) and AstraZeneca PLC (AZN).", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default193.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}, {"topic": "Earnings", "relevance_score": "0.538269"}, {"topic": "Energy & Transportation", "relevance_score": "0.5"}], "overall_sentiment_score": 0.321777, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CVX", "relevance_score": "0.218817", "ticker_sentiment_score": "0.370877", "ticker_sentiment_label": "Bullish"}, {"ticker": "AZN", "relevance_score": "0.218817", "ticker_sentiment_score": "0.328975", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "The RNA Targeting Small Molecules Therapeutics Market Size Is Expected To Reach A Value Of $3.6 Billion By 2027 As Per The Business Research Company's RNA Targeting Small Molecules Therapeutics Global Market Report 2023", "url": "https://www.benzinga.com/pressreleases/23/10/g35196902/the-rna-targeting-small-molecules-therapeutics-market-size-is-expected-to-reach-a-value-of-3-6-bil", "time_published": "20231011T153000", "authors": ["Globe Newswire"], "summary": "LONDON, Oct. 11, 2023 ( GLOBE NEWSWIRE ) -- As per The Business Research Company's RNA Targeting Small Molecules Therapeutics Global Market Report 2023, the RNA Targeting Small Molecules Therapeutics market is witnessing a spectacular surge in 2023, backed by critical factors and trends.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.158701, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.055751", "ticker_sentiment_score": "0.096877", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAYZF", "relevance_score": "0.055751", "ticker_sentiment_score": "0.096877", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.055751", "ticker_sentiment_score": "0.096877", "ticker_sentiment_label": "Neutral"}]}, {"title": "Lexicon's  ( LXRX )  Inpefa Gets Preferred Status at Express Scripts", "url": "https://www.zacks.com/stock/news/2164477/lexicons-lxrx-inpefa-gets-preferred-status-at-express-scripts", "time_published": "20231011T151300", "authors": ["Zacks Equity Research"], "summary": "A pharmacy benefit manager decides to place Lexicon's (LXRX) heart failure drug as a preferred product on Medicare national formularies on Nov. 1. The stock jumped 12% post this announcement.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.118925, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.419733", "ticker_sentiment_score": "0.103863", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.419733", "ticker_sentiment_score": "0.103863", "ticker_sentiment_label": "Neutral"}, {"ticker": "LXRX", "relevance_score": "0.510588", "ticker_sentiment_score": "0.299286", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Will UnitedHealth's  ( UNH )  UnitedHealthcare Unit Aid Q3 Earnings?", "url": "https://www.zacks.com/stock/news/2164387/will-unitedhealths-unh-unitedhealthcare-unit-aid-q3-earnings", "time_published": "20231011T141000", "authors": ["Zacks Equity Research"], "summary": "UnitedHealth's (UNH) third-quarter results are expected to benefit from an increase in UnitedHealthcare's Community & State revenues as well as the number of people it served.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/16/2258.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999756"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.241153, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "APLS", "relevance_score": "0.142284", "ticker_sentiment_score": "0.085095", "ticker_sentiment_label": "Neutral"}, {"ticker": "CNC", "relevance_score": "0.095138", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.142284", "ticker_sentiment_score": "0.141677", "ticker_sentiment_label": "Neutral"}, {"ticker": "UNH", "relevance_score": "0.4499", "ticker_sentiment_score": "0.236845", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Conduit Pharmaceuticals Partners with ClinConnect on Cocrystal Development Program for AZD1656", "url": "https://www.globenewswire.com/news-release/2023/10/11/2758351/0/en/Conduit-Pharmaceuticals-Partners-with-ClinConnect-on-Cocrystal-Development-Program-for-AZD1656.html", "time_published": "20231011T123000", "authors": ["Conduit Pharmaceuticals"], "summary": "Collaboration underscores Conduit's mission to advance promising treatments by developing assets that have already completed Phase I trials Collaboration underscores Conduit's mission to advance promising treatments by developing assets that have already completed Phase I trials ...", "banner_image": "", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}, {"topic": "Real Estate & Construction", "relevance_score": "0.5"}], "overall_sentiment_score": 0.278423, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.03786", "ticker_sentiment_score": "0.308998", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CDT", "relevance_score": "0.150592", "ticker_sentiment_score": "0.123375", "ticker_sentiment_label": "Neutral"}]}, {"title": "Bexion Pharmaceuticals, Inc. Appoints Dr. Catherine Pearce, DHSc, MBA, to Board of Directors - PR Newswire", "url": "https://www.prnewswire.com/news-releases/bexion-pharmaceuticals-inc-appoints-dr-catherine-pearce-dhsc-mba-to-board-of-directors-301952712.html", "time_published": "20231010T185100", "authors": [], "summary": "Bexion Pharmaceuticals, Inc. Appoints Dr. Catherine Pearce, DHSc, MBA, to Board of Directors PR ...", "banner_image": null, "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.26221, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "HESG", "relevance_score": "0.087503", "ticker_sentiment_score": "0.057968", "ticker_sentiment_label": "Neutral"}, {"ticker": "MEDP", "relevance_score": "0.087503", "ticker_sentiment_score": "0.057968", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.087503", "ticker_sentiment_score": "0.057968", "ticker_sentiment_label": "Neutral"}]}, {"title": "Can High Medical Costs Affect UnitedHealth  ( UNH )  Q3 Earnings?", "url": "https://www.zacks.com/stock/news/2163630/can-high-medical-costs-affect-unitedhealth-unh-q3-earnings", "time_published": "20231010T155000", "authors": ["Zacks Equity Research"], "summary": "UnitedHealth's (UNH) third-quarter results are likely to reflect growth in memberships and premium levels.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/16/2258.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.248159, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "APLS", "relevance_score": "0.138198", "ticker_sentiment_score": "0.083716", "ticker_sentiment_label": "Neutral"}, {"ticker": "CNC", "relevance_score": "0.09239", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.138198", "ticker_sentiment_score": "0.141884", "ticker_sentiment_label": "Neutral"}, {"ticker": "UNH", "relevance_score": "0.357507", "ticker_sentiment_score": "0.160221", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Why Astrazeneca  ( AZN )  is a Top Momentum Stock for the Long-Term", "url": "https://www.zacks.com/stock/news/2163439/why-astrazeneca-azn-is-a-top-momentum-stock-for-the-long-term", "time_published": "20231010T135007", "authors": ["Zacks Equity Research"], "summary": "The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default71.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.576289"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.918141"}], "overall_sentiment_score": 0.328322, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PTAIF", "relevance_score": "0.126119", "ticker_sentiment_score": "-0.059995", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.659096", "ticker_sentiment_score": "0.099084", "ticker_sentiment_label": "Neutral"}]}, {"title": "Medicenna Therapeutics Appoints Humphrey Gardner, M.D., as Chief Medical Officer - Medicenna Therapeutics  ( NASDAQ:MDNA ) ", "url": "https://www.benzinga.com/pressreleases/23/10/g35158239/medicenna-therapeutics-appoints-humphrey-gardner-m-d-as-chief-medical-officer", "time_published": "20231010T110753", "authors": ["Globe Newswire"], "summary": "TORONTO and HOUSTON, Oct. 10, 2023 ( GLOBE NEWSWIRE ) -- Medicenna Therapeutics Corp. ( \"Medicenna\" or the \"Company\" ) MDNAMDNA, a clinical-stage immunotherapy company focused on the development of novel Superkines, today announced the appointment of Humphrey Gardner, M.D., as Chief Medical ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.171183, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "EVLO", "relevance_score": "0.051111", "ticker_sentiment_score": "0.00497", "ticker_sentiment_label": "Neutral"}, {"ticker": "ROIV", "relevance_score": "0.051111", "ticker_sentiment_score": "0.00497", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.051111", "ticker_sentiment_score": "0.00497", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDNA", "relevance_score": "0.102013", "ticker_sentiment_score": "0.123332", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.051111", "ticker_sentiment_score": "0.00497", "ticker_sentiment_label": "Neutral"}]}, {"title": "Medicenna Therapeutics Appoints Humphrey Gardner, M.D., as Chief Medical Officer", "url": "https://www.globenewswire.com/news-release/2023/10/10/2757337/0/en/Medicenna-Therapeutics-Appoints-Humphrey-Gardner-M-D-as-Chief-Medical-Officer.html", "time_published": "20231010T110700", "authors": ["Medicenna Therapeutics Corp."], "summary": "Dr. Gardner brings over 30 years of experience leading clinical development to support innovative oncology programs and translational research at global biopharmaceutical companies and major academic institutions Dr. Gardner brings over 30 years of experience leading clinical development to ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/1644a38b-bed9-4a76-96fa-d57dd028e650", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.175941, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "EVLO", "relevance_score": "0.051774", "ticker_sentiment_score": "0.004975", "ticker_sentiment_label": "Neutral"}, {"ticker": "ROIV", "relevance_score": "0.051774", "ticker_sentiment_score": "0.004975", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.051774", "ticker_sentiment_score": "0.004975", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDNA", "relevance_score": "0.204936", "ticker_sentiment_score": "0.190836", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.051774", "ticker_sentiment_score": "0.004975", "ticker_sentiment_label": "Neutral"}]}, {"title": "Fortress Biotech Announces Reverse Stock Split", "url": "https://www.globenewswire.com/news-release/2023/10/09/2756959/28889/en/Fortress-Biotech-Announces-Reverse-Stock-Split.html", "time_published": "20231009T165000", "authors": ["Fortress Biotech", "Inc."], "summary": "MIAMI, Oct. 09, 2023 ( GLOBE NEWSWIRE ) -- Fortress Biotech, Inc. ( Nasdaq: FBIO ) ( \"Fortress\" or the \"Company\" ) , an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/d82bf2ce-81b7-4989-9e6b-08e6bb6e1f95", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "1.0"}], "overall_sentiment_score": 0.230396, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.039353", "ticker_sentiment_score": "0.191886", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FBIO", "relevance_score": "0.156461", "ticker_sentiment_score": "0.169326", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Antibody Drug Conjugates Market Revenue to Hit $29.6 Billion, Globally, by 2030 - Exclusive Study by The Insight Partners", "url": "https://www.benzinga.com/pressreleases/23/10/g35143608/antibody-drug-conjugates-market-revenue-to-hit-29-6-billion-globally-by-2030-exclusive-study-by-th", "time_published": "20231009T120410", "authors": ["Globe Newswire"], "summary": "Pune, India, Oct. 09, 2023 ( GLOBE NEWSWIRE ) -- Antibody drug conjugates ( ADC ) are one of the fastest growing anticancer drugs. It is typically composed of a monoclonal antibody ( mAbs ) covalently attached to a cytotoxic drug via a chemical linker.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.138172, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ASAN", "relevance_score": "0.04406", "ticker_sentiment_score": "0.047239", "ticker_sentiment_label": "Neutral"}, {"ticker": "SRNEQ", "relevance_score": "0.04406", "ticker_sentiment_score": "0.047239", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALPMF", "relevance_score": "0.04406", "ticker_sentiment_score": "0.092172", "ticker_sentiment_label": "Neutral"}, {"ticker": "IMGN", "relevance_score": "0.174903", "ticker_sentiment_score": "0.089155", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADCT", "relevance_score": "0.301052", "ticker_sentiment_score": "0.09182", "ticker_sentiment_label": "Neutral"}, {"ticker": "PKBO", "relevance_score": "0.04406", "ticker_sentiment_score": "0.047239", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.04406", "ticker_sentiment_score": "0.092172", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGMF", "relevance_score": "0.04406", "ticker_sentiment_score": "0.092172", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.04406", "ticker_sentiment_score": "0.092172", "ticker_sentiment_label": "Neutral"}, {"ticker": "STRO", "relevance_score": "0.04406", "ticker_sentiment_score": "0.047239", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.087985", "ticker_sentiment_score": "0.057624", "ticker_sentiment_label": "Neutral"}, {"ticker": "SGEN", "relevance_score": "0.04406", "ticker_sentiment_score": "0.047239", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.04406", "ticker_sentiment_score": "0.047239", "ticker_sentiment_label": "Neutral"}, {"ticker": "GSK", "relevance_score": "0.04406", "ticker_sentiment_score": "0.092172", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.04406", "ticker_sentiment_score": "0.047239", "ticker_sentiment_label": "Neutral"}, {"ticker": "TAK", "relevance_score": "0.04406", "ticker_sentiment_score": "0.092172", "ticker_sentiment_label": "Neutral"}]}, {"title": "Page 42167 of", "url": "https://www.financialexpress.com/about-news/page/42167/", "time_published": "20231009T061240", "authors": [], "summary": "Rafting may fall overboard in rapids of dam projects Business worth Rs 60 crore, at least 4,000 jobs and the priceless thrill of white-water rafting are at stake with\u2026 A day after chief election commissioner N Gopalaswami informed the Supreme Court that the CEC has the power to initiate\u2026", "banner_image": "https://www.financialexpress.com/wp-content/uploads/2021/11/fe-og.png", "source": "The Financial Express", "category_within_source": "n/a", "source_domain": "www.financialexpress.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.165268, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.113062", "ticker_sentiment_score": "-0.177318", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Ultimovacs Receives FDA Orphan Drug Designation for the UV1 Cancer Vaccine for Treatment of Mesothelioma", "url": "https://www.globenewswire.com/news-release/2023/10/09/2756420/0/en/Ultimovacs-Receives-FDA-Orphan-Drug-Designation-for-the-UV1-Cancer-Vaccine-for-Treatment-of-Mesothelioma.html", "time_published": "20231009T050000", "authors": ["Ultimovacs ASA"], "summary": "\u2022 The orphan drug designation was granted based on data from the randomized Phase II clinical trial NIPU \u2022 The results from the NIPU study will be presented at the ESMO Congress being held October 20-24, 2023 in Madrid \u2022 UV1 also received FDA orphan drug designation for treatment of patients ...", "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/23b62627-6dd1-416b-b614-675e9c122324", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.650727"}], "overall_sentiment_score": -0.164163, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.022536", "ticker_sentiment_score": "-0.044573", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.067536", "ticker_sentiment_score": "-0.03938", "ticker_sentiment_label": "Neutral"}]}, {"title": "Here's Why Astrazeneca  ( AZN )  Gained But Lagged the Market Today", "url": "https://www.zacks.com/stock/news/2161863/heres-why-astrazeneca-azn-gained-but-lagged-the-market-today", "time_published": "20231006T215021", "authors": ["Zacks Equity Research"], "summary": "Astrazeneca (AZN) concluded the recent trading session at $67.42, signifying a +0.81% move from its prior day's close.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default218.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.976913"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.168141, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.540358", "ticker_sentiment_score": "0.301811", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Pharma Stock Roundup: LLY Offers to Buy POINT Biopharma & Other Updates", "url": "https://www.zacks.com/stock/news/2161488/pharma-stock-roundup-lly-offers-to-buy-point-biopharma-other-updates", "time_published": "20231006T133000", "authors": ["Kinjel Shah"], "summary": "Eli Lilly (LLY) offers to buy POINT Biopharma for approximately $1.4 billion. Sanofi (SNY) partners with Teva for co-developing immunology candidate.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/cc/389.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.108891, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.220522", "ticker_sentiment_score": "0.077117", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.158519", "ticker_sentiment_score": "0.095413", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.158519", "ticker_sentiment_score": "-0.036263", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.063763", "ticker_sentiment_score": "-0.122104", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.251032", "ticker_sentiment_score": "0.060059", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRYPTO:NXC", "relevance_score": "0.127119", "ticker_sentiment_score": "-0.03195", "ticker_sentiment_label": "Neutral"}]}, {"title": "2 Nasdaq 100 Stocks That Are Surefire Buys in October, and 1 to Avoid Like the Plague", "url": "https://www.fool.com/investing/2023/10/06/2-nasdaq-100-stocks-buy-and-1-to-avoid-like-plague/", "time_published": "20231006T092100", "authors": ["Sean Williams"], "summary": "Two Nasdaq 100 components stand out as plain-as-day values, while another widely owned Nasdaq 100 stock may find it impossible to meet investors' lofty growth expectations.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F749471%2Fstock-chart-crash-correction-plunge-bounce-bear-market-bar-trend-invest-crypto-getty.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.503496"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.614606"}], "overall_sentiment_score": 0.138799, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NVDA", "relevance_score": "0.286528", "ticker_sentiment_score": "0.015214", "ticker_sentiment_label": "Neutral"}, {"ticker": "SBUX", "relevance_score": "0.313726", "ticker_sentiment_score": "0.233114", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.116772", "ticker_sentiment_score": "0.064897", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMD", "relevance_score": "0.029292", "ticker_sentiment_score": "-0.035711", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.029292", "ticker_sentiment_score": "0.133784", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.029292", "ticker_sentiment_score": "0.133784", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.029292", "ticker_sentiment_score": "0.133784", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSM", "relevance_score": "0.029292", "ticker_sentiment_score": "0.007708", "ticker_sentiment_label": "Neutral"}]}, {"title": "GSK raises $1.1 billion from Haleon stake sale", "url": "https://www.reuters.com/markets/deals/gsk-raises-886-mln-pounds-haleon-stake-sale-2023-10-06/", "time_published": "20231006T080442", "authors": ["Reuters"], "summary": "GSK ( GlaxoSmithKline ) logo is seen in this illustration, August 10, 2022. REUTERS/Dado Ruvic/Illustration Acquire Licensing Rights", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/ZKS7OXUCFZOGZI3ROI3QUVLBQU.jpg", "source": "Reuters", "category_within_source": "Markets", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}, {"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.014234, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "HLN", "relevance_score": "0.741116", "ticker_sentiment_score": "0.169227", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "LDNXF", "relevance_score": "0.128135", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.128135", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.252987", "ticker_sentiment_score": "0.06669", "ticker_sentiment_label": "Neutral"}]}, {"title": "Landmark studies utilizing Olink\u00ae Explore technology signal a new era for population-scale proteogenomics", "url": "https://www.globenewswire.com/news-release/2023/10/05/2755799/0/en/Landmark-studies-utilizing-Olink-Explore-technology-signal-a-new-era-for-population-scale-proteogenomics.html", "time_published": "20231005T202500", "authors": ["Olink Proteomics AB"], "summary": "Three landmark studies published in Nature demonstrate the power of Olink technology for understanding human biology.", "banner_image": "https://ml.globenewswire.com/Resource/Download/a14adc55-e7e7-441a-9810-60092c9a6a01", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.17812, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.032164", "ticker_sentiment_score": "0.050377", "ticker_sentiment_label": "Neutral"}, {"ticker": "OLK", "relevance_score": "0.128135", "ticker_sentiment_score": "0.108411", "ticker_sentiment_label": "Neutral"}]}, {"title": "Landmark studies utilizing Olink\u00ae Explore technology signal a new era for population-scale proteogenomics - Olink Holding  ( NASDAQ:OLK ) ", "url": "https://www.benzinga.com/pressreleases/23/10/g35116954/landmark-studies-utilizing-olink-explore-technology-signal-a-new-era-for-population-scale-proteoge", "time_published": "20231005T202500", "authors": ["Globe Newswire"], "summary": "UPPSALA, Sweden, Oct. 05, 2023 ( GLOBE NEWSWIRE ) -- Olink Holding AB ( publ ) OLK today reported the publication of three articles in the prestigious scientific journal, Nature, that demonstrate the power of the Olink Explore platform for driving impactful proteogenomic studies at the ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.495866"}], "overall_sentiment_score": 0.166582, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.030998", "ticker_sentiment_score": "0.050081", "ticker_sentiment_label": "Neutral"}, {"ticker": "OLK", "relevance_score": "0.092807", "ticker_sentiment_score": "0.091758", "ticker_sentiment_label": "Neutral"}]}, {"title": "Sanofi  ( SNY )  Stock Outperforms Industry YTD: What's Next?", "url": "https://www.zacks.com/stock/news/2160817/sanofi-sny-stock-outperforms-industry-ytd-whats-next", "time_published": "20231005T135400", "authors": ["Zacks Equity Research"], "summary": "Continued strong sales of Dupixent, contributions from new product launches and positive pipeline progress are likely to keep Sanofi's (SNY) stock afloat.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/52/873.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.231695, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.122581", "ticker_sentiment_score": "0.12576", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALPN", "relevance_score": "0.242285", "ticker_sentiment_score": "0.253978", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SNY", "relevance_score": "0.559416", "ticker_sentiment_score": "0.384973", "ticker_sentiment_label": "Bullish"}]}, {"title": "Fortress Biotech to Present at ROTH MKM 2023 Healthcare Opportunities Conference", "url": "https://www.globenewswire.com/news-release/2023/10/05/2755404/28889/en/Fortress-Biotech-to-Present-at-ROTH-MKM-2023-Healthcare-Opportunities-Conference.html", "time_published": "20231005T123000", "authors": ["Inc.", "Fortress Biotech"], "summary": "Fortress Biotech will present at the ROTH MKM 2023 Healthcare Opportunities Conference in New York City on Thursday, October 12, 2023, at 11:00 a.m. ET.", "banner_image": "https://ml.globenewswire.com/Resource/Download/d82bf2ce-81b7-4989-9e6b-08e6bb6e1f95", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.426661, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.143415", "ticker_sentiment_score": "0.247601", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FBIO", "relevance_score": "0.412298", "ticker_sentiment_score": "0.491118", "ticker_sentiment_label": "Bullish"}]}, {"title": "Medicare Price Talks to Include All 10 Drugmakers", "url": "https://www.kiplinger.com/retirement/medicare/medicare-price-talks-to-include-all-10-drugmakers", "time_published": "20231004T231326", "authors": ["Esther D&rsquo;Amico", "Joey Solitro"], "summary": "The 10 pharmaceutical companies whose drugs will be part of the first cycle of the upcoming Medicare Drug Price Negotiation Program have agreed to participate in the talks, the White House announced on October 3. The drugmakers slated to take part in the discussions with Medicare are: AstraZeneca ...", "banner_image": "https://cdn.mos.cms.futurecdn.net/SF4pYAF773BsTCSCwCrkMe-415-80.jpg", "source": "Kiplinger", "category_within_source": "n/a", "source_domain": "www.kiplinger.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.05959, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.090134", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.090134", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.090134", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Astrazeneca  ( AZN )  Advances But Underperforms Market: Key Facts", "url": "https://www.zacks.com/stock/news/2160363/astrazeneca-azn-advances-but-underperforms-market-key-facts", "time_published": "20231004T220020", "authors": ["Zacks Equity Research"], "summary": "Astrazeneca (AZN) concluded the recent trading session at $66.62, signifying a +0.54% move from its prior day's close.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default267.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.972476"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.168133, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.543535", "ticker_sentiment_score": "0.29435", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Small-Cell Lung Cancer Market to Accelerate Substantially During the Study Period  ( 2019-2032 ) , Assesses DelveInsight | Leading Companies - Amgen, Novartis, AbbVie, BMS, Clovis Oncology, Cardiff Oncology, Roche, Daiichi Sankyo", "url": "https://www.prnewswire.com/news-releases/small-cell-lung-cancer-market-to-accelerate-substantially-during-the-study-period-20192032-assesses-delveinsight--leading-companies----amgen-novartis-abbvie-bms-clovis-oncology-cardiff-oncology-roche-daiichi-sankyo-301946615.html", "time_published": "20231004T210100", "authors": ["LLP", "DelveInsight Business Research"], "summary": "Small-Cell Lung Cancer Market to Accelerate Substantially During the Study Period ( 2019-2032 ) , Assesses ... PR ...", "banner_image": "https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.128467, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SYRS", "relevance_score": "0.021778", "ticker_sentiment_score": "-0.020221", "ticker_sentiment_label": "Neutral"}, {"ticker": "GLTO", "relevance_score": "0.021778", "ticker_sentiment_score": "-0.092267", "ticker_sentiment_label": "Neutral"}, {"ticker": "IPHA", "relevance_score": "0.021778", "ticker_sentiment_score": "-0.02031", "ticker_sentiment_label": "Neutral"}, {"ticker": "LEGN", "relevance_score": "0.021778", "ticker_sentiment_score": "-0.020221", "ticker_sentiment_label": "Neutral"}, {"ticker": "SKXJF", "relevance_score": "0.065268", "ticker_sentiment_score": "-0.0392", "ticker_sentiment_label": "Neutral"}, {"ticker": "DSKYF", "relevance_score": "0.065268", "ticker_sentiment_score": "-0.0392", "ticker_sentiment_label": "Neutral"}, {"ticker": "XNCR", "relevance_score": "0.021778", "ticker_sentiment_score": "-0.066559", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRTX", "relevance_score": "0.043539", "ticker_sentiment_score": "-0.058975", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.021778", "ticker_sentiment_score": "-0.092267", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.043539", "ticker_sentiment_score": "-0.042655", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVBXF", "relevance_score": "0.021778", "ticker_sentiment_score": "-0.092267", "ticker_sentiment_label": "Neutral"}, {"ticker": "CGEM", "relevance_score": "0.021778", "ticker_sentiment_score": "-0.02031", "ticker_sentiment_label": "Neutral"}, {"ticker": "HARP", "relevance_score": "0.021778", "ticker_sentiment_score": "-0.020221", "ticker_sentiment_label": "Neutral"}, {"ticker": "INBX", "relevance_score": "0.021778", "ticker_sentiment_score": "-0.092267", "ticker_sentiment_label": "Neutral"}, {"ticker": "GTHX", "relevance_score": "0.021778", "ticker_sentiment_score": "-0.066559", "ticker_sentiment_label": "Neutral"}, {"ticker": "JBPHF", "relevance_score": "0.021778", "ticker_sentiment_score": "-0.020221", "ticker_sentiment_label": "Neutral"}, {"ticker": "ASPHF", "relevance_score": "0.021778", "ticker_sentiment_score": "-0.066559", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.086948", "ticker_sentiment_score": "-0.051258", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLCM", "relevance_score": "0.021778", "ticker_sentiment_score": "-0.020221", "ticker_sentiment_label": "Neutral"}, {"ticker": "APLM", "relevance_score": "0.021778", "ticker_sentiment_score": "-0.092267", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRDF", "relevance_score": "0.021778", "ticker_sentiment_score": "-0.020221", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.086948", "ticker_sentiment_score": "-0.040696", "ticker_sentiment_label": "Neutral"}, {"ticker": "SURF", "relevance_score": "0.021778", "ticker_sentiment_score": "-0.092267", "ticker_sentiment_label": "Neutral"}, {"ticker": "BYSI", "relevance_score": "0.021778", "ticker_sentiment_score": "-0.02031", "ticker_sentiment_label": "Neutral"}, {"ticker": "RAIN", "relevance_score": "0.021778", "ticker_sentiment_score": "-0.02031", "ticker_sentiment_label": "Neutral"}, {"ticker": "IOVA", "relevance_score": "0.043539", "ticker_sentiment_score": "-0.058975", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.065268", "ticker_sentiment_score": "-0.046141", "ticker_sentiment_label": "Neutral"}, {"ticker": "TIL", "relevance_score": "0.021778", "ticker_sentiment_score": "-0.02031", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALRN", "relevance_score": "0.021778", "ticker_sentiment_score": "-0.066559", "ticker_sentiment_label": "Neutral"}, {"ticker": "BBIO", "relevance_score": "0.043539", "ticker_sentiment_score": "-0.10057", "ticker_sentiment_label": "Neutral"}, {"ticker": "LYPHF", "relevance_score": "0.021778", "ticker_sentiment_score": "-0.066559", "ticker_sentiment_label": "Neutral"}, {"ticker": "SZIHF", "relevance_score": "0.021778", "ticker_sentiment_score": "-0.092267", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.021778", "ticker_sentiment_score": "-0.02031", "ticker_sentiment_label": "Neutral"}, {"ticker": "RVMD", "relevance_score": "0.043539", "ticker_sentiment_score": "-0.058975", "ticker_sentiment_label": "Neutral"}, {"ticker": "CLVSQ", "relevance_score": "0.021778", "ticker_sentiment_score": "-0.020221", "ticker_sentiment_label": "Neutral"}, {"ticker": "IUGNF", "relevance_score": "0.021778", "ticker_sentiment_score": "-0.092267", "ticker_sentiment_label": "Neutral"}, {"ticker": "OPHLF", "relevance_score": "0.021778", "ticker_sentiment_score": "-0.092267", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why Shares of Conduit Pharmaceuticals Are Jumping Wednesday", "url": "https://www.fool.com/investing/2023/10/04/why-shares-of-conduit-pharmaceuticals-are-jumping/", "time_published": "20231004T160730", "authors": ["Jim Halley"], "summary": "The stock had a brief big rebound from a huge drop on Tuesday.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Real Estate & Construction", "relevance_score": "0.5"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.100382, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.275867", "ticker_sentiment_score": "0.142049", "ticker_sentiment_label": "Neutral"}, {"ticker": "CDT", "relevance_score": "0.275867", "ticker_sentiment_score": "0.106008", "ticker_sentiment_label": "Neutral"}]}, {"title": "Principal Investigator of Artelo's CAReS Trial to Participate in Medical Expert Webinar Hosted by H.C. Wainwright to Discuss Current Development Strategies for Cancer-Related Anorexia and Cachexia", "url": "https://www.globenewswire.com/news-release/2023/10/04/2754579/0/en/Principal-Investigator-of-Artelo-s-CAReS-Trial-to-Participate-in-Medical-Expert-Webinar-Hosted-by-H-C-Wainwright-to-Discuss-Current-Development-Strategies-for-Cancer-Related-Anorex.html", "time_published": "20231004T123000", "authors": ["Artelo Biosciences"], "summary": "SOLANA BEACH, Calif., Oct. 04, 2023 ( GLOBE NEWSWIRE ) -- Artelo Biosciences, Inc. ( Nasdaq: ARTL ) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/460502d7-b0d3-43d8-a15a-5b2bb963bbbb", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.576289"}], "overall_sentiment_score": -0.039551, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.038345", "ticker_sentiment_score": "0.032698", "ticker_sentiment_label": "Neutral"}, {"ticker": "QEBR", "relevance_score": "0.038345", "ticker_sentiment_score": "-0.025771", "ticker_sentiment_label": "Neutral"}, {"ticker": "ARTL", "relevance_score": "0.114682", "ticker_sentiment_score": "-0.002368", "ticker_sentiment_label": "Neutral"}]}, {"title": "AstraZeneca  ( AZN )  Settles Heartburn Drugs Lawsuits for $425M", "url": "https://www.zacks.com/stock/news/2159856/astrazeneca-azn-settles-heartburn-drugs-lawsuits-for-425m", "time_published": "20231004T121700", "authors": ["Zacks Equity Research"], "summary": "AstraZeneca (AZN) agrees to pay $425 million to settle lawsuits related to heartburn drugs, Nexium and Prilosec.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c4/390.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.028961, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.500477", "ticker_sentiment_score": "0.093379", "ticker_sentiment_label": "Neutral"}, {"ticker": "AUPH", "relevance_score": "0.370418", "ticker_sentiment_score": "0.19997", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ALPN", "relevance_score": "0.300394", "ticker_sentiment_score": "0.24724", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CRYPTO:NXC", "relevance_score": "0.227716", "ticker_sentiment_score": "0.084651", "ticker_sentiment_label": "Neutral"}]}, {"title": "PM360 Announces 2023 Trailblazer Award Winners", "url": "https://www.prnewswire.com/news-releases/pm360-announces-2023-trailblazer-award-winners-301943290.html", "time_published": "20231004T120000", "authors": ["PM360"], "summary": "Top Companies, Marketers, CEOs, Products, and Initiatives Were Honored During Gala on October 3rd NEW YORK, Oct. 4, 2023 /PRNewswire/ -- Last night at a gala event held at Gotham Hall in New York City, PM360 announced the winners of its 15th annual Trailblazer Awards.", "banner_image": "https://mma.prnewswire.com/media/545940/PM360_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.316548, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "TVTX", "relevance_score": "0.020615", "ticker_sentiment_score": "0.337018", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "OPRX", "relevance_score": "0.020615", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MAYNF", "relevance_score": "0.020615", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.082322", "ticker_sentiment_score": "0.061158", "ticker_sentiment_label": "Neutral"}, {"ticker": "NBIX", "relevance_score": "0.020615", "ticker_sentiment_score": "0.257102", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SYNH", "relevance_score": "0.020615", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DVAX", "relevance_score": "0.020615", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TARS", "relevance_score": "0.020615", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CDNA", "relevance_score": "0.020615", "ticker_sentiment_score": "-0.068139", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRTX", "relevance_score": "0.020615", "ticker_sentiment_score": "-0.253155", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "PFE", "relevance_score": "0.020615", "ticker_sentiment_score": "0.305846", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BMY", "relevance_score": "0.020615", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.041216", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "HZNP", "relevance_score": "0.020615", "ticker_sentiment_score": "-0.292847", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "SSUMF", "relevance_score": "0.020615", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CHRS", "relevance_score": "0.041216", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ARGX", "relevance_score": "0.06179", "ticker_sentiment_score": "0.097016", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.020615", "ticker_sentiment_score": "0.20635", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SNY", "relevance_score": "0.020615", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Breast Cancer Therapeutics Market to Hit $63.96 Billion, Globally, by 2030 - Exclusive Report by The Insight Partners", "url": "https://www.benzinga.com/pressreleases/23/10/g35082720/breast-cancer-therapeutics-market-to-hit-63-96-billion-globally-by-2030-exclusive-report-by-the-in", "time_published": "20231004T095703", "authors": ["Globe Newswire"], "summary": "Pune, India, Oct. 04, 2023 ( GLOBE NEWSWIRE ) -- Breast cancer is one of the most common types of cancer and has a sizable market for therapies. According to the Centers for Disease Control and Prevention, in 2020, in the US, 239,612 new cases of breast cancer were reported among women, of which ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.334725, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "NVS", "relevance_score": "0.036643", "ticker_sentiment_score": "-0.119027", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.036643", "ticker_sentiment_score": "-0.119027", "ticker_sentiment_label": "Neutral"}, {"ticker": "TEVA", "relevance_score": "0.036643", "ticker_sentiment_score": "-0.119027", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.036643", "ticker_sentiment_score": "-0.119027", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.073209", "ticker_sentiment_score": "-0.060171", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.036643", "ticker_sentiment_score": "-0.119027", "ticker_sentiment_label": "Neutral"}]}, {"title": "Global South should learn from Big Pharma's bullying of South Africa", "url": "https://www.aljazeera.com/opinions/2023/10/4/global-south-should-learn-from-big-pharmas-bullying-of-south-africa", "time_published": "20231004T084241", "authors": ["Ray Mwareya"], "summary": "The extortionate vaccine contracts Pretoria signed during the pandemic demonstrate why achieving pharmaceutical sovereignty should be a priority for all developing nations.", "banner_image": "https://www.aljazeera.com/wp-content/uploads/2021/12/2021-12-16T185808Z_56729251_RC2UFR99D011_RTRMADP_3_TRADE-WTO.jpg?resize=770%2C513&quality=80", "source": "Al Jareeza", "category_within_source": "n/a", "source_domain": "www.aljazeera.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": 0.058231, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.03798", "ticker_sentiment_score": "-0.007817", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.075874", "ticker_sentiment_score": "-0.004109", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.03798", "ticker_sentiment_score": "-0.007817", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.03798", "ticker_sentiment_score": "0.000994", "ticker_sentiment_label": "Neutral"}]}, {"title": "Fusion Inhibitors Market Revenue to Cross USD 7.2 billion by 2031, Exhibiting a 14.2% CAGR: TMR Report", "url": "https://www.benzinga.com/pressreleases/23/10/g35081060/fusion-inhibitors-market-revenue-to-cross-usd-7-2-billion-by-2031-exhibiting-a-14-2-cagr-tmr-repor", "time_published": "20231004T075211", "authors": ["Globe Newswire"], "summary": "Wilmington, Delaware, United States, Oct. 04, 2023 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - The fusion inhibitors market attained US$ 295.3 million in 2021. The market is likely to gain US$ 7.2 billion by 2031 securing a CAGR of 14.2% between 2022 and 2031.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.210913, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.037271", "ticker_sentiment_score": "0.170772", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BMY", "relevance_score": "0.07446", "ticker_sentiment_score": "-0.085926", "ticker_sentiment_label": "Neutral"}]}, {"title": "Drugmakers Agree To Participate For Medicare Drug Price Negotiation With Biden Administration - Novo Nordisk  ( NYSE:NVO ) ", "url": "https://www.benzinga.com/general/biotech/23/10/35068559/drugmakers-agree-to-participate-for-medicare-drug-price-negotiation-with-biden-administration", "time_published": "20231003T173519", "authors": ["Vandana Singh"], "summary": "All ten manufacturers of the first drugs selected for Medicare price negotiations will be participating, the White House said, even though many of them are suing the administration to halt the process.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/10/03/pills-image_by_steve_buissinne_from_pixabay.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.08438, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.262522", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.262522", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.262522", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.262522", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVS", "relevance_score": "0.262522", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.262522", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.262522", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Drugmakers Agree To US Govt Price Talks Amid Pushback", "url": "https://www.barrons.com/news/drugmakers-agree-to-us-govt-price-talks-amid-pushback-c7eb4567", "time_published": "20231003T154800", "authors": ["Beiyi SEOW"], "summary": "Drugmakers Agree To US Govt Price Talks Amid ...", "banner_image": "https://www.barrons.com/asset/external-media/afp/AFP2007430630409481451714611589397832456678---1.jpg", "source": "Barrons", "category_within_source": "n/a", "source_domain": "www.barrons.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.048405, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.070725", "ticker_sentiment_score": "0.148076", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.070725", "ticker_sentiment_score": "-0.235822", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "JNJ", "relevance_score": "0.070725", "ticker_sentiment_score": "-0.029698", "ticker_sentiment_label": "Neutral"}]}, {"title": "Top Stories Tuesday, Oct 3: 'Airbnb Has Foundational Cracks', Disney+ Follows Netflix On Subscription Sharing Crackdown, Microsoft's Nadella Criticizes Google's Exclusive Content Deals - Apple  ( NASDAQ:AAPL ) , ALX Oncology Holdings  ( NASDAQ:ALXO ) ", "url": "https://www.benzinga.com/news/23/10/35064552/airbnb-has-foundational-cracks-disney-follows-netflix-on-subscription-sharing-crackdown-microsofts-n", "time_published": "20231003T141120", "authors": ["Vandana Singh"], "summary": "In a significant development, Microsoft Corp's MSFT CEO, Satya Nadella, has voiced concerns over the competitive landscape of content acquisition essential for training artificial intelligence ( AI ) .", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/10/03/airbnbtoronto5.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Energy & Transportation", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "0.538269"}, {"topic": "Real Estate & Construction", "relevance_score": "0.166667"}], "overall_sentiment_score": 0.058194, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "TGT", "relevance_score": "0.076236", "ticker_sentiment_score": "0.263048", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GOOG", "relevance_score": "0.189076", "ticker_sentiment_score": "0.273786", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AAPL", "relevance_score": "0.038162", "ticker_sentiment_score": "0.139139", "ticker_sentiment_label": "Neutral"}, {"ticker": "SPOT", "relevance_score": "0.076236", "ticker_sentiment_score": "0.144617", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.076236", "ticker_sentiment_score": "0.21709", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.076236", "ticker_sentiment_score": "-0.067693", "ticker_sentiment_label": "Neutral"}, {"ticker": "MU", "relevance_score": "0.076236", "ticker_sentiment_score": "0.143767", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABNB", "relevance_score": "0.114137", "ticker_sentiment_score": "-0.017859", "ticker_sentiment_label": "Neutral"}, {"ticker": "DAL", "relevance_score": "0.076236", "ticker_sentiment_score": "-0.098084", "ticker_sentiment_label": "Neutral"}, {"ticker": "ASML", "relevance_score": "0.076236", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.076236", "ticker_sentiment_score": "0.14478", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.076236", "ticker_sentiment_score": "-0.038103", "ticker_sentiment_label": "Neutral"}, {"ticker": "PNT", "relevance_score": "0.076236", "ticker_sentiment_score": "0.179376", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VTRS", "relevance_score": "0.076236", "ticker_sentiment_score": "0.067102", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.076236", "ticker_sentiment_score": "0.179376", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ALXO", "relevance_score": "0.076236", "ticker_sentiment_score": "-0.146817", "ticker_sentiment_label": "Neutral"}, {"ticker": "GME", "relevance_score": "0.114137", "ticker_sentiment_score": "-0.130984", "ticker_sentiment_label": "Neutral"}, {"ticker": "BA", "relevance_score": "0.076236", "ticker_sentiment_score": "0.021659", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.114137", "ticker_sentiment_score": "-0.064201", "ticker_sentiment_label": "Neutral"}, {"ticker": "TAK", "relevance_score": "0.076236", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRYPTO:NXC", "relevance_score": "0.038162", "ticker_sentiment_score": "-0.036553", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why Cancer-Focused ALX Oncology Stock Gained Over 100% Today?", "url": "https://markets.businessinsider.com/news/stocks/why-cancer-focused-alx-oncology-stock-gained-over-100-today-1032674452", "time_published": "20231003T131055", "authors": ["Vandana Singh"], "summary": "ALX Oncology Holdings Inc ( NASDAQ:ALXO ) released prespecified interim Phase 2 data from its ASPEN-06 trial of evorpacept plus trastuzumab, Cyramza ( ramucirumab ) and paclitaxel for HER2-positive gastric/gastroesophageal junction cancer. Cyramza ( ramucirumab ) is owned by Eli Lilly And Co ...", "banner_image": "https://cdn.benzinga.com/files/imagecache/1024x768xUP/images/story/2023/10/03/alxo.png", "source": "Business Insider", "category_within_source": "GoogleRSS", "source_domain": "markets.businessinsider.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.03816, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ALXO", "relevance_score": "0.290607", "ticker_sentiment_score": "-0.107462", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.147818", "ticker_sentiment_score": "-0.093296", "ticker_sentiment_label": "Neutral"}]}, {"title": "AstraZeneca Settles Lawsuits Alleging Heartburn Drugs Caused Kidney Disease For $425 Million", "url": "https://www.forbes.com/sites/maryroeloffs/2023/10/03/astrazeneca-settles-lawsuits-alleging-heartburn-drugs-caused-kidney-disease-for-425-million/", "time_published": "20231003T131038", "authors": ["Mary Whitfill Roeloffs"], "summary": "The payout will settle the claims of 11,000 people who said they weren't property warned Nexium and Prilosec could cause chronic kidney disease.", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/651c1205bf81147cb8240fde/0x0.jpg?format=jpg&crop=3000,1688,x0,y245,safe&width=1200", "source": "Forbes", "category_within_source": "Business", "source_domain": "www.forbes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.137374, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.309539", "ticker_sentiment_score": "-0.055704", "ticker_sentiment_label": "Neutral"}, {"ticker": "GSK", "relevance_score": "0.209365", "ticker_sentiment_score": "-0.026128", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRYPTO:NXC", "relevance_score": "0.209365", "ticker_sentiment_score": "-0.176724", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Why Cancer-Focused ALX Oncology Stock Gained Over 100% Today? - ALX Oncology Holdings  ( NASDAQ:ALXO ) ", "url": "https://www.benzinga.com/general/biotech/23/10/35057455/why-cancer-focused-alx-oncology-stock-gained-over-100-today", "time_published": "20231003T125830", "authors": ["Vandana Singh"], "summary": "ALX Oncology Holdings Inc ALXO released prespecified interim Phase 2 data from its ASPEN-06 trial of evorpacept plus trastuzumab, Cyramza ( ramucirumab ) and paclitaxel for HER2-positive gastric/gastroesophageal junction cancer. Cyramza ( ramucirumab ) is owned by Eli Lilly And Co LLY.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/10/03/alxo.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.033284, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ALXO", "relevance_score": "0.40348", "ticker_sentiment_score": "-0.126347", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.275867", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.275867", "ticker_sentiment_score": "-0.139155", "ticker_sentiment_label": "Neutral"}]}, {"title": "AstraZeneca Settles Heartburn Treatment Lawsuit For One Of Biggest Selling Drug - AstraZeneca  ( NASDAQ:AZN ) ", "url": "https://www.benzinga.com/general/biotech/23/10/35052662/astrazeneca-settles-heartburn-treatment-lawsuit-for-one-of-biggest-selling-drug", "time_published": "20231003T121854", "authors": ["Vandana Singh"], "summary": "AstraZeneca Plc AZN has agreed to pay $425 million to settle U.S. lawsuits related to heartburn and stomach acid treatments Nexium and Prilosec. The heartburn treatments have been under litigation, as some users said they caused kidney damage.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/10/03/azn.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.108044, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.595343", "ticker_sentiment_score": "-0.266856", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "GSK", "relevance_score": "0.323078", "ticker_sentiment_score": "-0.126928", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.323078", "ticker_sentiment_score": "-0.126928", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.323078", "ticker_sentiment_score": "-0.126928", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRYPTO:NXC", "relevance_score": "0.468029", "ticker_sentiment_score": "-0.270222", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Drugmakers agree to negotiate prices in Medicare even as they sue to stop the program | Politics", "url": "https://www.cnn.com/2023/10/03/politics/drugmakers-medicare-price-negotiations/index.html", "time_published": "20231003T121200", "authors": ["Tami Luhby"], "summary": "Drugmakers agree to negotiate prices in Medicare even as they sue to stop the program ...", "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/230929184725-medicare-drug-price-negotiations-092923.jpg?c=16x9&q=w_800,c_fill", "source": "CNN", "category_within_source": "Markets", "source_domain": "www.cnn.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.081676, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.064623", "ticker_sentiment_score": "0.056036", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.128822", "ticker_sentiment_score": "0.087547", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.128822", "ticker_sentiment_score": "-0.014444", "ticker_sentiment_label": "Neutral"}]}, {"title": "Ocean Biomedical Announces Newly Published Findings Demonstrating Ability to Restore Treatment Sensitivity to AstraZeneca's Leading Lung Cancer Drug After Resistance Has Formed, and Enhanced Tumor Suppression in EGFR-Mutation Lung Cancers", "url": "https://www.globenewswire.com/news-release/2023/10/03/2753594/0/en/Ocean-Biomedical-Announces-Newly-Published-Findings-Demonstrating-Ability-to-Restore-Treatment-Sensitivity-to-AstraZeneca-s-Leading-Lung-Cancer-Drug-After-Resistance-Has-Formed-and.html", "time_published": "20231003T120100", "authors": ["Inc.", "Ocean Biomedical"], "summary": "Company to Host Cancer R&D Update on October 19, 2023 to Share Latest Details of Multipronged Cancer Program Based on Pioneering Anti-CHI3L1 Discoveries ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/b15ee8f3-2fb5-43e9-b824-f61a6b4e651e", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Earnings", "relevance_score": "0.108179"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}], "overall_sentiment_score": -0.019454, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "OCEA", "relevance_score": "0.251562", "ticker_sentiment_score": "0.073276", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.023259", "ticker_sentiment_score": "-0.019939", "ticker_sentiment_label": "Neutral"}]}, {"title": "Marksans Pharma gets USFDA approval for Esomeprazole Magnesium Capsules", "url": "https://www.business-standard.com/companies/news/marksans-pharma-gets-usfda-approval-for-esomeprazole-magnesium-capsules-123100300706_1.html", "time_published": "20231003T101648", "authors": ["BS Reporter"], "summary": "Mumbai-headquartered pharma company Marksans Pharma announced on Tuesday that it has received final approval from the US Food and Drug Administration ( USFDA ) for its Abbreviated New Drug Application ( ANDA ) for Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg ( OTC ) .", "banner_image": "https://bsmedia.business-standard.com/_media/bs/img/article/2023-06/18/full/1687106818-6297.jpg?im=FeatureCrop,size=(826,465)", "source": "Business Standard", "category_within_source": "GoogleRSS", "source_domain": "www.business-standard.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.310843"}], "overall_sentiment_score": -0.088153, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.199037", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRYPTO:NXC", "relevance_score": "0.199037", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "AstraZeneca to pay $425 million to settle Nexium, Prilosec litigation in US", "url": "https://www.financialexpress.com/healthcare/pharma-healthcare/astrazeneca-to-pay-425-million-to-settle-nexium-prilosec-litigation-in-us/3261312/", "time_published": "20231003T070013", "authors": ["Health Desk"], "summary": "Pharma major AstraZeneca on Tuesday said it will pay $425 million to settle product liability litigations against prescription-only acid-reflux medicine Nexium and heartburn drug Prilosec in the United States.", "banner_image": "https://www.financialexpress.com/wp-content/uploads/2023/05/AstraZeneca-covid-19-drug.jpg", "source": "The Financial Express", "category_within_source": "n/a", "source_domain": "www.financialexpress.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.080414, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.666827", "ticker_sentiment_score": "-0.029815", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRYPTO:NXC", "relevance_score": "0.371523", "ticker_sentiment_score": "-0.03447", "ticker_sentiment_label": "Neutral"}]}, {"title": "AstraZeneca ADR Earns Relative Strength Rating Upgrade", "url": "https://www.investors.com/ibd-data-stories/astrazeneca-adr-earns-relative-strength-rating-upgrade/", "time_published": "20231003T070000", "authors": ["INVESTOR'S BUSINESS DAILY", "Investor's Business Daily"], "summary": "AstraZeneca ADR ( AZN ) saw a welcome improvement to its Relative Strength ( RS ) Rating on Tuesday, rising from 63 to 74. When looking for the best stocks to buy and watch, be sure to pay attention to relative price strength.", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.108179"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.353869, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.760593", "ticker_sentiment_score": "0.40918", "ticker_sentiment_label": "Bullish"}]}, {"title": "Ex-UK PM Liz Truss renews calls for Reagan-style tax cuts one year after mini-budget blowup", "url": "https://www.cnbc.com/2023/10/03/ex-uk-pm-liz-truss-renews-calls-for-reagan-style-tax-cuts.html", "time_published": "20231003T051506", "authors": ["Karen Gilchrist"], "summary": "Liz Truss, the Reaganomics enthusiast who lasted just 44 days as U.K. prime minister, staged a comeback on Monday, drawing fans from breakaway Conservative factions as she renewed calls for business tax cuts.", "banner_image": "https://image.cnbcfm.com/api/v1/image/107140316-GettyImages-1435082544.jpg?v=1666711554&w=750&h=422&vtcrop=y", "source": "CNBC", "category_within_source": "Top News", "source_domain": "www.cnbc.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Economy - Fiscal", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.151454, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.086245", "ticker_sentiment_score": "-0.089417", "ticker_sentiment_label": "Neutral"}]}, {"title": "AstraZeneca India falls 0.6% despite a new CFO and nod to drug imports", "url": "https://www.moneycontrol.com/news/business/markets/astrazeneca-india-falls-0-6-despite-a-new-cfo-and-nod-to-drug-imports-11467431.html", "time_published": "20231003T045339", "authors": [], "summary": "AstraZeneca Pharma India shares slipped 0.6% in trade on October 3. The firm appointed a new CFO and received approval from the CDSCO to import a new drug.", "banner_image": "https://images.moneycontrol.com/static-mcnews/2023/01/IndusInd-Bank.jpg?impolicy=website&width=168&height=118", "source": "Money Control", "category_within_source": "Buzzing Stocks", "source_domain": "www.moneycontrol.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": -0.019031, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.592095", "ticker_sentiment_score": "-0.161313", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Drugmakers opt in to Medicare drug price negotiations - here's what happens next", "url": "https://www.cnbc.com/2023/10/02/drugmakers-agree-to-medicare-price-negotiations-whats-next.html", "time_published": "20231002T193402", "authors": ["Annika Kim Constantino"], "summary": "The lengthy negotiation process with Medicare won't end until August 2024, with reduced prices going into effect in January 2026.", "banner_image": "https://image.cnbcfm.com/api/v1/image/106330644-1578667127386rts2xt0x.jpg?v=1696275242&w=1920&h=1080", "source": "CNBC", "category_within_source": "Business", "source_domain": "www.cnbc.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Economy - Fiscal", "relevance_score": "0.158519"}, {"topic": "Earnings", "relevance_score": "0.684621"}], "overall_sentiment_score": 0.014398, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ABBV", "relevance_score": "0.051221", "ticker_sentiment_score": "0.183448", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.051221", "ticker_sentiment_score": "0.2125", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVO", "relevance_score": "0.051221", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.102231", "ticker_sentiment_score": "-0.114146", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.051221", "ticker_sentiment_score": "-0.057993", "ticker_sentiment_label": "Neutral"}]}, {"title": "Medicare Drug Price Negotiation - What Court's Decision Means for Americans - AstraZeneca  ( NASDAQ:AZN ) , Bristol-Myers Squibb  ( NYSE:BMY ) ", "url": "https://www.benzinga.com/general/biotech/23/10/35030476/medicare-drug-price-negotiation-what-courts-decision-means-for-americans", "time_published": "20231002T145414", "authors": ["Vandana Singh"], "summary": "A U.S. District Judge has upheld a pivotal initiative of President Joe Biden, giving the green light for Medicare to commence negotiations on prescription drug prices. U.S.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/10/02/pills-image_by_steve_buissinne_from_pixabay.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.243086, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.265378", "ticker_sentiment_score": "0.264687", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BMY", "relevance_score": "0.265378", "ticker_sentiment_score": "0.264687", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "J&J's  ( JNJ )  Rybrevant Combo Meets Primary Goal in NSCLC Study", "url": "https://www.zacks.com/stock/news/2158753/jjs-jnj-rybrevant-combo-meets-primary-goal-in-nsclc-study", "time_published": "20231002T144500", "authors": ["Zacks Equity Research"], "summary": "J&J (JNJ) meets the primary goal in the late-stage study of the combination therapy of Rybrevant and lazertinib against Tagrisso for EGFR-mutated first-line NSCLC.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ff/1612.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.194358, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.153961", "ticker_sentiment_score": "0.043345", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.302243", "ticker_sentiment_score": "-0.022095", "ticker_sentiment_label": "Neutral"}]}, {"title": "AstraZeneca  ( AZN )  Key Drugs to Aid Growth, Pipeline Strong", "url": "https://www.zacks.com/stock/news/2158718/astrazeneca-azn-key-drugs-to-aid-growth-pipeline-strong", "time_published": "20231002T140000", "authors": ["Zacks Equity Research"], "summary": "AstraZeneca's (AZN) key drugs like Lynparza, Tagrisso, Fasenra and Farxiga should keep driving revenues. Its pipeline is strong, with several phase III data readouts lined up.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/e5/1416.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.614606"}, {"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.10017, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.666827", "ticker_sentiment_score": "0.188219", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SNY", "relevance_score": "0.118354", "ticker_sentiment_score": "0.223857", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Multi-Billion Dollar Treatment Market For Lung Infection That Causes Over 200,000 Hospitalizations Annually With Elderly, Young At Most Risk Has Game-Changing New Entrant - AstraZeneca  ( NASDAQ:AZN ) , GSK  ( NYSE:GSK ) ", "url": "https://www.benzinga.com/general/biotech/23/10/35030457/multi-billion-dollar-treatment-market-for-lung-infection-that-causes-over-200-000-hospitalization", "time_published": "20231002T125010", "authors": ["David Willey"], "summary": "The CDC recently issued a warning that Respiratory Syncytial Virus ( RSV ) , a common and highly contagious lung infection that can cause bronchitis and pneumonia, is on the rise in the Southeastern United States - and the very young and the elderly are the most at risk of developing severe ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/10/02/screenshot_2023-10-02_at_6.16.49_pm.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": -0.125257, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "PSTV", "relevance_score": "0.055492", "ticker_sentiment_score": "0.155013", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.110717", "ticker_sentiment_score": "0.085099", "ticker_sentiment_label": "Neutral"}, {"ticker": "GSK", "relevance_score": "0.110717", "ticker_sentiment_score": "-0.049793", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.110717", "ticker_sentiment_score": "-0.049793", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.110717", "ticker_sentiment_score": "0.085099", "ticker_sentiment_label": "Neutral"}]}, {"title": "The Zacks Analyst Blog Highlights AbbVie, Lilly, Sanofi, Merck and J&J", "url": "https://www.zacks.com/stock/news/2158561/the-zacks-analyst-blog-highlights-abbvie-lilly-sanofi-merck-and-jj", "time_published": "20231002T103100", "authors": ["Zacks Investment Research"], "summary": "AbbVie, Lilly, Sanofi, Merck and J&J are included in this Analyst Blog.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/7d/1177.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.210323, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.149192", "ticker_sentiment_score": "0.022956", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.074926", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.037504", "ticker_sentiment_score": "-0.12063", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.074926", "ticker_sentiment_score": "0.113572", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.037504", "ticker_sentiment_score": "-0.11573", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.074926", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "AstraZeneca gets CDSCO approval for preventive therapy for respiratory syncytial virus", "url": "https://www.financialexpress.com/healthcare/pharma-healthcare/astrazeneca-gets-cdsco-approval-for-preventive-therapy-for-respiratory-syncytial-virus/3259590/", "time_published": "20230930T160022", "authors": ["PTI"], "summary": "AstraZeneca Pharma India on Saturday said it has received an approval from the Central Drugs Standard Control Organisation ( CDSCO ) to import and market a medication to prevent Respiratory Syncytial virus.", "banner_image": "https://www.financialexpress.com/wp-content/uploads/2023/09/AstraZeneca.jpg", "source": "The Financial Express", "category_within_source": "n/a", "source_domain": "www.financialexpress.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.029174, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.272788", "ticker_sentiment_score": "0.073316", "ticker_sentiment_label": "Neutral"}]}, {"title": "From AI to Slide-Free Imaging: The 2023 Next-Gen Digital Pathology Conference Sheds Light on Medicine's Future  ( Boston, United States - October 19-20th, 2023 ) ", "url": "https://www.prnewswire.com/news-releases/from-ai-to-slide-free-imaging-the-2023-next-gen-digital-pathology-conference-sheds-light-on-medicines-future-boston-united-states---october-19-20th-2023-301943194.html", "time_published": "20230929T223000", "authors": ["Research and Markets"], "summary": "From AI to Slide-Free Imaging: The 2023 Next-Gen Digital Pathology Conference Sheds Light on Medicine's Future ... PR ...", "banner_image": "https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.311649, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.081276", "ticker_sentiment_score": "0.128767", "ticker_sentiment_label": "Neutral"}, {"ticker": "GEN", "relevance_score": "0.081276", "ticker_sentiment_score": "0.112124", "ticker_sentiment_label": "Neutral"}]}, {"title": "Federal judge declines to block Medicare price negotiations", "url": "https://www.cnbc.com/2023/09/29/medicare-price-negotiations-federal-judge-denies-injunction-request.html", "time_published": "20230929T213958", "authors": ["Annika Kim Constantino"], "summary": "Judge Michael Newman of the Southern District of Ohio issued a ruling denying a preliminary injunction sought by the Chamber of Commerce.", "banner_image": "https://image.cnbcfm.com/api/v1/image/106330644-1578667127386rts2xt0x.jpg?v=1696023598&w=1920&h=1080", "source": "CNBC", "category_within_source": "Business", "source_domain": "www.cnbc.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Economy - Fiscal", "relevance_score": "0.158519"}, {"topic": "Earnings", "relevance_score": "0.360215"}], "overall_sentiment_score": -0.024126, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ABBV", "relevance_score": "0.057907", "ticker_sentiment_score": "-0.117981", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.057907", "ticker_sentiment_score": "-0.117981", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.057907", "ticker_sentiment_score": "-0.117981", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.057907", "ticker_sentiment_score": "-0.102975", "ticker_sentiment_label": "Neutral"}]}, {"title": "As Merck, AstraZeneca and other drugmakers sign on, Medicare price negotiations face critical moment", "url": "https://www.marketwatch.com/story/as-merck-astrazeneca-and-other-drugmakers-sign-on-medicare-price-negotiations-face-critical-moment-9d85879f", "time_published": "20230929T142000", "authors": ["Eleanor Laise"], "summary": "A deadline looms to sign drug-price negotiation agreements as industry watches for legal reprieve.", "banner_image": "https://images.mktw.net/im-860220/social", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.004787, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ABBV", "relevance_score": "0.100099", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.100099", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.149656", "ticker_sentiment_score": "0.138204", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.100099", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.100099", "ticker_sentiment_score": "-0.006512", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.100099", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Pharma Stock Roundup: FDA and EMA Regulatory Updates for ABBV, LLY, SNY & MRK's Drugs", "url": "https://www.zacks.com/stock/news/2157714/pharma-stock-roundup-fda-and-ema-regulatory-updates-for-abbv-lly-sny-mrks-drugs", "time_published": "20230929T132800", "authors": ["Kinjel Shah"], "summary": "The European Commission approves AbbVie's (ABBV) Tepkinly (epcoritamab) for DLBCL. FDA approves Lilly's (LLY) Jardiance for chronic kidney disease.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f5/952.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.215184, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.116536", "ticker_sentiment_score": "0.100453", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.038969", "ticker_sentiment_score": "-0.121201", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.077845", "ticker_sentiment_score": "0.114096", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.038969", "ticker_sentiment_score": "-0.116285", "ticker_sentiment_label": "Neutral"}]}, {"title": "MCL1 Inhibitors Drugs Clinical Trial Insight", "url": "https://www.benzinga.com/pressreleases/23/09/g34993218/mcl1-inhibitors-drugs-clinical-trial-insight", "time_published": "20230929T070713", "authors": ["Globe Newswire"], "summary": "Delhi, Sept. 29, 2023 ( GLOBE NEWSWIRE ) -- MCL1 Inhibitor Drug Clinical Trials & Commercialization Opportunity Insights 2023 Report Highlights: ML1 Inhibitor Drug In Clinical Trials: > 12 Drugs Commercially Approved MCL1 Inhibitor Drug: 1 ( Synribo )", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": 0.115387, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.043658", "ticker_sentiment_score": "0.107818", "ticker_sentiment_label": "Neutral"}]}, {"title": "Is it Time to Buy Pfizer, Moderna, or AstraZeneca's Stock?", "url": "https://www.zacks.com/stock/news/2157418/is-it-time-to-buy-pfizer-moderna-or-astrazenecas-stock", "time_published": "20230929T021300", "authors": ["Shaun Pruitt"], "summary": "Despite slowing COVID-19 vaccine sales these healthcare titans are trading at more reasonable valuations with a lot of the risk-to-reward being priced into their stocks considering their earnings potential.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default8.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.995921"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.990999"}], "overall_sentiment_score": 0.150959, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.369163", "ticker_sentiment_score": "0.149301", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.268589", "ticker_sentiment_score": "0.205987", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.268589", "ticker_sentiment_score": "0.024587", "ticker_sentiment_label": "Neutral"}]}, {"title": "Astrazeneca  ( AZN )  Stock Sinks As Market Gains: What You Should Know", "url": "https://www.zacks.com/stock/news/2157345/astrazeneca-azn-stock-sinks-as-market-gains-what-you-should-know", "time_published": "20230928T215019", "authors": ["Zacks Equity Research"], "summary": "In the latest trading session, Astrazeneca (AZN) closed at $67.42, marking a -0.77% move from the previous day.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default293.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.95493"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.143675, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.682689", "ticker_sentiment_score": "0.30533", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "What to know as fall vaccinations against COVID, flu and RSV get underway", "url": "https://apnews.com/article/vaccines-flu-covid19-rsv-viruses-fall-8ffa6bf0c2c0da1a8842db524aad5006", "time_published": "20230928T210200", "authors": ["LAURAN NEERGAARD"], "summary": "WASHINGTON ( AP ) - Updated may be getting a little easier for adults to find but they're still frustratingly scarce for young children. Health officials said Thursday the kid shots have started shipping - and reminded most everyone to get a fall flu shot too.", "banner_image": "https://dims.apnews.com/dims4/default/5e15441/2147483647/strip/true/crop/4171x2778+0+1/resize/599x399!/quality/90/?url=https%3A%2F%2Fassets.apnews.com%2F93%2F1f%2F012c38962005406e5ddb72505b60%2F96701a07a16d4b69bc8f9db397fbde09", "source": "Associated Press", "category_within_source": "Markets", "source_domain": "apnews.com", "topics": [{"topic": "Real Estate & Construction", "relevance_score": "0.333333"}, {"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}], "overall_sentiment_score": -0.070067, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CVS", "relevance_score": "0.036365", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "HHC", "relevance_score": "0.036365", "ticker_sentiment_score": "0.161419", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.036365", "ticker_sentiment_score": "-0.05016", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.036365", "ticker_sentiment_score": "0.047182", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.072655", "ticker_sentiment_score": "-0.002031", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.036365", "ticker_sentiment_score": "0.047182", "ticker_sentiment_label": "Neutral"}]}, {"title": "Dianthus' Monoclonal Antibody On Promising Pathway To Gaining The Upper Hand - Analyst - Dianthus Therapeutics  ( NASDAQ:DNTH ) ", "url": "https://www.benzinga.com/general/biotech/23/09/34984163/dianthus-monoclonal-antibody-on-promising-pathway-to-gaining-the-upper-hand-analyst", "time_published": "20230928T193357", "authors": ["Vandana Singh"], "summary": "Raymond James initiated coverage on Dianthus Therapeutics Inc DNTH, a recent reverse merger with the old Magenta Therapeutics. The analysts initiate with an Outperform rating and a price target of $24.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/09/28/dnth.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.355865, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "MGTA", "relevance_score": "0.115787", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.439786", "ticker_sentiment_score": "0.485844", "ticker_sentiment_label": "Bullish"}, {"ticker": "UCBJF", "relevance_score": "0.439786", "ticker_sentiment_score": "0.485844", "ticker_sentiment_label": "Bullish"}, {"ticker": "SNY", "relevance_score": "0.229149", "ticker_sentiment_score": "0.020673", "ticker_sentiment_label": "Neutral"}]}, {"title": "Eplontersen Phase 3 results published in JAMA show consistent and sustained benefit", "url": "https://markets.businessinsider.com/news/stocks/eplontersen-phase-3-results-published-in-jama-show-consistent-and-sustained-benefit-1032664035", "time_published": "20230928T160200", "authors": ["markets.businessinsider.com"], "summary": "\u2022 Publication of NEURO-TTRansform study in patients with hereditary transthyretin-mediated amyloid polyneuropathy ( ATTRv-PN ) showed eplontersen halted disease progression and continuously improved quality of life at 35-, 66- and 85-week analyses \u2022 Data demonstrates consistent and sustained ...", "banner_image": "https://mma.prnewswire.com/media/882077/Ionis_Logo.jpg", "source": "Business Insider", "category_within_source": "RSS", "source_domain": "markets.businessinsider.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.167612, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.084324", "ticker_sentiment_score": "0.115228", "ticker_sentiment_label": "Neutral"}, {"ticker": "IONS", "relevance_score": "0.112269", "ticker_sentiment_score": "0.053874", "ticker_sentiment_label": "Neutral"}]}, {"title": "NHS preparing to roll out coronavirus vaccine next month if jab gets approved", "url": "https://theweek.com/108321/leaked-nhs-documents-reveal-plan-for-coronavirus-vaccinations-to-begin-november", "time_published": "20230928T154910", "authors": ["Aaron Drapkin"], "summary": "A free daily digest of the biggest news stories of the day - and the best features from our website Thank you for signing up to TheWeek. You will receive a verification email shortly. There was a problem. Please refresh the page and try again.", "banner_image": "https://cdn.mos.cms.futurecdn.net/HHUAY3hUagfhw7quY3PRvg-415-80.jpg", "source": "The Week News", "category_within_source": "n/a", "source_domain": "theweek.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}], "overall_sentiment_score": 0.123405, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.044634", "ticker_sentiment_score": "0.043433", "ticker_sentiment_label": "Neutral"}, {"ticker": "FRNWF", "relevance_score": "0.044634", "ticker_sentiment_score": "0.057763", "ticker_sentiment_label": "Neutral"}]}, {"title": "NVO: 3 A-Rated Pharma Buys for October", "url": "https://stocknews.com/news/nvo-azn-nbix-3-a-rated-pharma-buys-for-october/", "time_published": "20230928T152729", "authors": ["StockNews.com Staff"], "summary": "The pharma industry is fueled by the introduction of generic medicines and a growing focus on the development of personalized medicines. Given the industry's steady growth prospects, investors could consider quality pharma stocks Neurocrine Biosciences, Inc. ( NBIX ) , Novo Nordisk A/S ( NVO ) , ...", "banner_image": "https://stocknews.com/wp-content/uploads/2022/03/shutterstock_745024336-scaled.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "stocknews.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999696"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.658903"}], "overall_sentiment_score": 0.282619, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.264658", "ticker_sentiment_score": "0.20527", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVO", "relevance_score": "0.357917", "ticker_sentiment_score": "0.248698", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NBIX", "relevance_score": "0.232598", "ticker_sentiment_score": "0.215165", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Pharma Giants Shift Stance, Embrace Medicare Negotiations Amid Rising Drug Costs - AstraZeneca  ( NASDAQ:AZN ) ", "url": "https://www.benzinga.com/general/biotech/23/09/34977352/pharma-giants-shift-stance-embrace-medicare-negotiations-amid-rising-drug-costs", "time_published": "20230928T141956", "authors": ["Vandana Singh"], "summary": "AstraZeneca Plc AZN, Bristol Myers Squibb & Co BMY, and Boehringer Ingelheim are willing to participate in the initial round of Medicare drug price negotiations despite having previously sued to halt the process.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/09/28/pills-image_by_steve_buissinne_from_pixabay.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.169527, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.56415", "ticker_sentiment_score": "0.325881", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BMY", "relevance_score": "0.303175", "ticker_sentiment_score": "0.293044", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.303175", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "AstraZeneca Unusual Options Activity For September 28 - AstraZeneca  ( NASDAQ:AZN ) ", "url": "https://www.benzinga.com/markets/options/23/09/34977757/astrazeneca-unusual-options-activity-for-september-28", "time_published": "20230928T141643", "authors": ["Benzinga Insights"], "summary": "A whale with a lot of money to spend has taken a noticeably bearish stance on AstraZeneca. Looking at options history for AstraZeneca AZN we detected 11 strange trades. If we consider the specifics of each trade, it is accurate to state that 45% of the investors opened trades with bullish ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.160781, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.721785", "ticker_sentiment_score": "0.057729", "ticker_sentiment_label": "Neutral"}]}, {"title": "Ionis  ( IONS )  Inks New Deal With Roche to Develop Novel RNA Drugs", "url": "https://www.zacks.com/stock/news/2157174/ionis-ions-inks-new-deal-with-roche-to-develop-novel-rna-drugs", "time_published": "20230928T140600", "authors": ["Zacks Equity Research"], "summary": "Per the agreement, Ionis (IONS) will grant exclusive global rights to Roche to develop and market two novel RNA-therapeutics for Alzheimer's and Huntington's diseases.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/5a/2110.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.128688, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.27838", "ticker_sentiment_score": "0.130759", "ticker_sentiment_label": "Neutral"}, {"ticker": "IONS", "relevance_score": "0.27838", "ticker_sentiment_score": "0.150773", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.382088", "ticker_sentiment_score": "0.203331", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Karolinska Development's portfolio company PharmNovo reports promising preclinical results on abuse potential and withdrawal symptom relief for its candidate drug PN6047", "url": "https://www.globenewswire.com/news-release/2023/09/28/2751090/0/en/Karolinska-Development-s-portfolio-company-PharmNovo-reports-promising-preclinical-results-on-abuse-potential-and-withdrawal-symptom-relief-for-its-candidate-drug-PN6047.html", "time_published": "20230928T112700", "authors": ["Karolinska Development AB (publ)"], "summary": "STOCKHOLM, SWEDEN, September 28, 2023. Karolinska Development AB ( Nasdaq Stockholm: KDEV ) announces that its portfolio company PharmNovo has reported promising results in a preclinical study of the company's drug candidate PN6047.", "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/3626524f-14a1-4bc4-9461-b2613ec9035e", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.299618, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.077593", "ticker_sentiment_score": "-0.0691", "ticker_sentiment_label": "Neutral"}]}, {"title": "4 Mutual Funds to Buy Amid Ongoing Market Volatility", "url": "https://www.zacks.com/stock/news/2156862/4-mutual-funds-to-buy-amid-ongoing-market-volatility", "time_published": "20230928T095500", "authors": ["Zacks Equity Research"], "summary": "During times of market volatility, selecting stable mutual funds like FSUTX, FRUAX, JNGLX and PRHSX is a prudent decision. These funds offer a combination of stability and growth potential.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/8b/1160.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.98396"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.142911, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "HESG", "relevance_score": "0.052112", "ticker_sentiment_score": "0.136539", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.052112", "ticker_sentiment_score": "0.04869", "ticker_sentiment_label": "Neutral"}, {"ticker": "EIX", "relevance_score": "0.052112", "ticker_sentiment_score": "0.049686", "ticker_sentiment_label": "Neutral"}, {"ticker": "TMO", "relevance_score": "0.052112", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "JHG", "relevance_score": "0.052112", "ticker_sentiment_score": "0.148545", "ticker_sentiment_label": "Neutral"}, {"ticker": "SO", "relevance_score": "0.104002", "ticker_sentiment_score": "0.052519", "ticker_sentiment_label": "Neutral"}, {"ticker": "UNH", "relevance_score": "0.104002", "ticker_sentiment_score": "0.025951", "ticker_sentiment_label": "Neutral"}, {"ticker": "NEE", "relevance_score": "0.104002", "ticker_sentiment_score": "0.052519", "ticker_sentiment_label": "Neutral"}]}, {"title": "What does China 'de-risking' actually mean?", "url": "https://www.ft.com/content/02e743fe-22d2-4789-a860-e29acdfcfd2a", "time_published": "20230928T040017", "authors": [], "summary": "This is an audio transcript of the FT News Briefing podcast episode: 'What does China \"de-risking\" actually mean?' Good morning from the Financial Times. Today is Thursday, September 28th, and this is your FT News Briefing. Western companies are trying to protect their interests from China.", "banner_image": "https://www.ft.com/__origami/service/image/v2/images/raw/https%3A%2F%2Fd1e00ek4ebabms.cloudfront.net%2Fproduction%2F2854e38c-8215-4de4-84be-f50a68442c34.jpg?source=next-article&fit=scale-down&quality=highest&width=700&dpr=1", "source": "Financial Times", "category_within_source": "GoogleRSS", "source_domain": "www.ft.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.413559"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.158837, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ATVI", "relevance_score": "0.026213", "ticker_sentiment_score": "0.087909", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.026213", "ticker_sentiment_score": "0.087909", "ticker_sentiment_label": "Neutral"}, {"ticker": "WRK", "relevance_score": "0.026213", "ticker_sentiment_score": "0.087909", "ticker_sentiment_label": "Neutral"}, {"ticker": "SPLK", "relevance_score": "0.026213", "ticker_sentiment_score": "0.087909", "ticker_sentiment_label": "Neutral"}, {"ticker": "SMFTF", "relevance_score": "0.026213", "ticker_sentiment_score": "0.087909", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.026213", "ticker_sentiment_score": "-0.036883", "ticker_sentiment_label": "Neutral"}]}, {"title": "Astrazeneca  ( AZN )  Stock Sinks As Market Gains: What You Should Know", "url": "https://www.zacks.com/stock/news/2156617/astrazeneca-azn-stock-sinks-as-market-gains-what-you-should-know", "time_published": "20230927T220020", "authors": ["Zacks Equity Research"], "summary": "Astrazeneca (AZN) closed at $67.94 in the latest trading session, marking a -0.41% move from the prior day.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default188.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.983783"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.138708, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.620664", "ticker_sentiment_score": "0.22905", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "AstraZeneca, Boehringer Ingelheim to participate in Medicare drug price negotiations", "url": "https://www.cnbc.com/2023/09/27/diabetes-medicare-drug-price-negotiations.html", "time_published": "20230927T195522", "authors": ["Annika Kim Constantino"], "summary": "AstraZeneca, Boehringer Ingelheim and other drugmakers have filed at least eight lawsuits seeking to declare the Medicare price talks unconstitutional.", "banner_image": "https://image.cnbcfm.com/api/v1/image/107294456-1693489275735-gettyimages-1647279478-030a1107_yizu3aax.jpeg?v=1695844522&w=1920&h=1080", "source": "CNBC", "category_within_source": "Business", "source_domain": "www.cnbc.com", "topics": [{"topic": "Earnings", "relevance_score": "0.538269"}, {"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.069057, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.262052", "ticker_sentiment_score": "-0.065977", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.088799", "ticker_sentiment_score": "-0.182524", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "JNJ", "relevance_score": "0.088799", "ticker_sentiment_score": "-0.182524", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Ionis-Roche Join Forces To Compete In Neurodegenerative Disease Space, Analyst Sees Short-Term Challenges - Roche Holding  ( OTC:RHHBF ) , Roche Holding  ( OTC:RHHVF ) , Roche Holding  ( OTC:RHHBY ) ", "url": "https://www.benzinga.com/general/biotech/23/09/34954649/ionis-roche-join-forces-to-compete-in-neurodegenerative-disease-space-analyst-sees-short-term-cha", "time_published": "20230927T171257", "authors": ["Vandana Singh"], "summary": "Ionis Pharmaceuticals Inc IONS entered an agreement with Roche Holdings AG RHHBY for two undisclosed early-stage programs for RNA-targeting investigational medicines for the treatment of Alzheimer's disease ( AD ) and Huntington's disease ( HD ) .", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/09/27/ions.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.33483, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ALNY", "relevance_score": "0.234684", "ticker_sentiment_score": "0.199301", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.234684", "ticker_sentiment_score": "0.579588", "ticker_sentiment_label": "Bullish"}, {"ticker": "IONS", "relevance_score": "0.449503", "ticker_sentiment_score": "0.242909", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Ionis  ( IONS )  Meets Rare Disease Drug Study Goal, Stock Up 8.5%", "url": "https://www.zacks.com/stock/news/2156308/ionis-ions-meets-rare-disease-drug-study-goal-stock-up-85", "time_published": "20230927T135800", "authors": ["Zacks Equity Research"], "summary": "Ionis (IONS) reports positive phase III study results, supporting the benefits of olezarsen to treat familial chylomicronemia syndrome (FCS), a rare genetic disorder.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/07/905.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.028602, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.276491", "ticker_sentiment_score": "0.132036", "ticker_sentiment_label": "Neutral"}, {"ticker": "IONS", "relevance_score": "0.168099", "ticker_sentiment_score": "0.124396", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.3796", "ticker_sentiment_score": "0.222398", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Top Stories Wednesday, Sep 27: Apple Defends Its $19B Google Search Deal, Hollywood's Writers Secure Credit For AI Training, China's Ambitious Chip Fund Faces Headwinds - Alibaba Gr Holding  ( NYSE:BABA ) ", "url": "https://www.benzinga.com/news/23/09/34949379/apple-defends-its-19b-google-search-deal-hollywoods-writers-secure-credit-for-ai-training-chinas-amb", "time_published": "20230927T134747", "authors": ["Vandana Singh"], "summary": "Alibaba Group Holding Limited BABA stock is trading higher Wednesday as the company's logistics arm Cainiao Smart Logistics Network Ltd filed for its Hong Kong initial public offering on Tuesday. The first-time share sale could fetch a minimum of $1 billion.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/09/27/google_search_iphone.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.148277, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BABA", "relevance_score": "0.111144", "ticker_sentiment_score": "0.095986", "ticker_sentiment_label": "Neutral"}, {"ticker": "NFLX", "relevance_score": "0.07423", "ticker_sentiment_score": "0.159668", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TGT", "relevance_score": "0.07423", "ticker_sentiment_score": "0.077628", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOOG", "relevance_score": "0.184176", "ticker_sentiment_score": "0.084378", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.111144", "ticker_sentiment_score": "0.025411", "ticker_sentiment_label": "Neutral"}, {"ticker": "PARA", "relevance_score": "0.07423", "ticker_sentiment_score": "0.159668", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JPM", "relevance_score": "0.07423", "ticker_sentiment_score": "0.07364", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.07423", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TRI", "relevance_score": "0.111144", "ticker_sentiment_score": "0.053298", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.07423", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSM", "relevance_score": "0.07423", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SSNLF", "relevance_score": "0.07423", "ticker_sentiment_score": "-0.051384", "ticker_sentiment_label": "Neutral"}, {"ticker": "WMG", "relevance_score": "0.07423", "ticker_sentiment_score": "0.273503", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.07423", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PAYX", "relevance_score": "0.111144", "ticker_sentiment_score": "0.070338", "ticker_sentiment_label": "Neutral"}, {"ticker": "QCOM", "relevance_score": "0.147818", "ticker_sentiment_score": "-0.038811", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.147818", "ticker_sentiment_score": "0.067619", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.07423", "ticker_sentiment_score": "0.083661", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.07423", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "CytoSorbents Highlights Upcoming Presentations at EACTS 2023: Focus on Antithrombotic Removal including the 2nd Analysis of the International STAR Registry - CytoSorbents  ( NASDAQ:CTSO ) ", "url": "https://www.benzinga.com/pressreleases/23/09/g34942966/cytosorbents-highlights-upcoming-presentations-at-eacts-2023-focus-on-antithrombotic-removal-inclu", "time_published": "20230927T110000", "authors": ["Globe Newswire"], "summary": "PRINCETON, N.J., Sept. 27, 2023 ( GLOBE NEWSWIRE ) -- CytoSorbents Corporation CTSO, a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announced the upcoming original ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": 0.007233, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "META", "relevance_score": "0.018995", "ticker_sentiment_score": "0.060729", "ticker_sentiment_label": "Neutral"}, {"ticker": "CTSO", "relevance_score": "0.132368", "ticker_sentiment_score": "0.029897", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.018995", "ticker_sentiment_score": "0.043822", "ticker_sentiment_label": "Neutral"}, {"ticker": "ILST", "relevance_score": "0.056943", "ticker_sentiment_score": "0.011011", "ticker_sentiment_label": "Neutral"}, {"ticker": "SKXJF", "relevance_score": "0.03798", "ticker_sentiment_score": "0.048799", "ticker_sentiment_label": "Neutral"}, {"ticker": "DSKYF", "relevance_score": "0.03798", "ticker_sentiment_score": "0.048799", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.018995", "ticker_sentiment_score": "0.043822", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.018995", "ticker_sentiment_score": "0.043822", "ticker_sentiment_label": "Neutral"}]}, {"title": "EU regulator to discuss anaesthesia risk for weight-loss drugs", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/eu-regulator-discuss-anaesthesia-risk-weight-loss-drugs-2023-09-26/", "time_published": "20230926T164400", "authors": ["Ludwig Burger"], "summary": "The exterior of EMA, European Medicines Agency is seen in Amsterdam, Netherlands December 18, 2020. REUTERS/Piroschka van de Wouw/File Photo Acquire Licensing Rights", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/LPZOZ52XOBMCDLMFHQZI5YJIKI.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.007199, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.074001", "ticker_sentiment_score": "0.063476", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.074001", "ticker_sentiment_score": "0.026147", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.074001", "ticker_sentiment_score": "0.063476", "ticker_sentiment_label": "Neutral"}]}, {"title": "Ionis Climbs On Late-Stage Trial Results For Body Fat Disorder", "url": "https://www.investors.com/news/technology/ionis-stock-ionis-stock-gains-olezarsen-body-fat/", "time_published": "20230926T155400", "authors": ["Investor's Business Daily", "REINHARDT KRAUSE"], "summary": "Ionis Pharmaceuticals ( IONS ) on Tuesday said Olezarsen, an experimental drug in late-stage patient trials, succeeded in reducing abnormally high levels of body fat in patients with a rare genetic disorder. Ionis stock broke out on the news.", "banner_image": "https://www.investors.com/wp-content/uploads/2019/05/Stock-IonisHQ-01-company.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.161647"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.962106"}], "overall_sentiment_score": 0.021939, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.265378", "ticker_sentiment_score": "-0.129658", "ticker_sentiment_label": "Neutral"}, {"ticker": "IONS", "relevance_score": "0.502207", "ticker_sentiment_score": "0.185605", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.388879", "ticker_sentiment_score": "-0.17433", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "AstraZeneca PLC  ( AZN )  Is a Trending Stock: Facts to Know Before Betting on It", "url": "https://www.zacks.com/stock/news/2155361/astrazeneca-plc-azn-is-a-trending-stock-facts-to-know-before-betting-on-it", "time_published": "20230926T130005", "authors": ["Zacks Equity Research"], "summary": "Astrazeneca (AZN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default136.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.54554"}], "overall_sentiment_score": 0.217696, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.490323", "ticker_sentiment_score": "0.10797", "ticker_sentiment_label": "Neutral"}]}, {"title": "Multi-Billion Dollar Treatment Market For Lung Infection That Causes Over 200,000 Hospitalizations Annually With Elderly, Young At Most Risk Has Game-Changing New Entrant - AstraZeneca  ( NASDAQ:AZN ) , GSK  ( NYSE:GSK ) ", "url": "https://www.benzinga.com/general/biotech/23/09/34905240/multi-billion-dollar-treatment-market-for-lung-infection-that-causes-over-200-000-hospitalization", "time_published": "20230926T124512", "authors": ["David Willey"], "summary": "The CDC recently issued a warning that Respiratory Syncytial Virus ( RSV ) , a common and highly contagious lung infection that can cause bronchitis and pneumonia, is on the rise in the Southeastern United States - and the very young and the elderly are the most at risk of developing severe ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/09/26/screenshot_2023-09-26_at_6.11.54_pm.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": -0.125257, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "PSTV", "relevance_score": "0.055492", "ticker_sentiment_score": "0.155013", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.110717", "ticker_sentiment_score": "0.085099", "ticker_sentiment_label": "Neutral"}, {"ticker": "GSK", "relevance_score": "0.110717", "ticker_sentiment_score": "-0.049793", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.110717", "ticker_sentiment_score": "-0.049793", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.110717", "ticker_sentiment_score": "0.085099", "ticker_sentiment_label": "Neutral"}]}, {"title": "AstraZeneca Looks To China For Growth - But CEO Says Spinoff Not Happening", "url": "https://www.forbes.com/sites/qai/2023/09/26/astrazeneca-looks-to-china-for-growthbut-ceo-says-spinoff-not-happening/", "time_published": "20230926T120001", "authors": ["Q.ai - Powering a Personal Wealth Movement"], "summary": "AstraZeneca is the largest foreign owned pharmaceutical company in China based on revenue, and they're continuing to increase investment in the country ...", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/65129aaa608edb877ad8d8d2/0x0.jpg?format=jpg&width=1200", "source": "Forbes", "category_within_source": "Markets", "source_domain": "www.forbes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.684621"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.007296, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.658693", "ticker_sentiment_score": "0.129905", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.039944", "ticker_sentiment_score": "-0.08666", "ticker_sentiment_label": "Neutral"}]}, {"title": "FDA Expands Lilly  ( LLY )  Jardiance Label in Chronic Kidney Disease", "url": "https://www.zacks.com/stock/news/2155039/fda-expands-lilly-lly-jardiance-label-in-chronic-kidney-disease", "time_published": "20230925T160400", "authors": ["Zacks Equity Research"], "summary": "Following the latest approval, Lilly's (LLY) Jardiance can access a target market that affects more than 35 million adults in the United States.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ff/2922.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.96136"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.147868, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ANVS", "relevance_score": "0.186738", "ticker_sentiment_score": "0.043115", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.568953", "ticker_sentiment_score": "0.173008", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.306198", "ticker_sentiment_score": "0.071326", "ticker_sentiment_label": "Neutral"}]}, {"title": "AstraZeneca's  ( AZN )  Dato-DXd Meets Goal in Breast Cancer Study", "url": "https://www.zacks.com/stock/news/2154945/astrazenecas-azn-dato-dxd-meets-goal-in-breast-cancer-study", "time_published": "20230925T150500", "authors": ["Zacks Equity Research"], "summary": "AstraZeneca (AZN) announces positive results from the late-stage study evaluating its antibody-drug conjugate, Dato-DXd, in pre-treated patients with HR+/HER2- metastatic breast cancer.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/e5/1416.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.928139"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.063404, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CORT", "relevance_score": "0.158173", "ticker_sentiment_score": "0.12322", "ticker_sentiment_label": "Neutral"}, {"ticker": "DVAX", "relevance_score": "0.158173", "ticker_sentiment_score": "0.092984", "ticker_sentiment_label": "Neutral"}, {"ticker": "SKXJF", "relevance_score": "0.158173", "ticker_sentiment_score": "-0.140101", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.105836", "ticker_sentiment_score": "0.217231", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DSKYF", "relevance_score": "0.158173", "ticker_sentiment_score": "-0.140101", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.49407", "ticker_sentiment_score": "-0.181821", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Stock Market Slow To Start New Week; Amazon Stock Lifts On AI News", "url": "https://www.investors.com/market-trend/stock-market-today/stock-market-amazon-stock-slow-to-start-new-week-amazon-climbs-on-ai-news/", "time_published": "20230925T144900", "authors": ["KIMBERLEY KOENIG", "Investor's Business Daily"], "summary": "Stock Market Slow To Start New Week. Amazon Stock Lifts On AI News Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2022/05/Stock-amazonwebservices-01-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Economy - Fiscal", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}], "overall_sentiment_score": -0.009726, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MORF", "relevance_score": "0.149656", "ticker_sentiment_score": "-0.139176", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.222838", "ticker_sentiment_score": "-0.322225", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "AZN", "relevance_score": "0.149656", "ticker_sentiment_score": "0.117856", "ticker_sentiment_label": "Neutral"}, {"ticker": "NIO", "relevance_score": "0.294093", "ticker_sentiment_score": "-0.157539", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "KMX", "relevance_score": "0.149656", "ticker_sentiment_score": "0.19553", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "LI", "relevance_score": "0.149656", "ticker_sentiment_score": "-0.246346", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "URBN", "relevance_score": "0.149656", "ticker_sentiment_score": "-0.153389", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "CDC Recommends Pfizer's  ( PFE )  RSV Jab to Protect Newborns", "url": "https://www.zacks.com/stock/news/2154937/cdc-recommends-pfizers-pfe-rsv-jab-to-protect-newborns", "time_published": "20230925T133800", "authors": ["Zacks Equity Research"], "summary": "Pfizer's (PFE) Abrysvo has been recommended by the CDC for preventing RSV in infants by immunizing pregnant women, during weeks 32-36 of pregnancy.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/89/447.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.206657, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.303175", "ticker_sentiment_score": "0.305217", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.373751", "ticker_sentiment_score": "0.073507", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.229872", "ticker_sentiment_score": "0.246892", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "The Zacks Analyst Blog Highlights Pfizer, Merck and AstraZeneca", "url": "https://www.zacks.com/stock/news/2154894/the-zacks-analyst-blog-highlights-pfizer-merck-and-astrazeneca", "time_published": "20230925T125500", "authors": ["Zacks Equity Research"], "summary": "Pfizer, Merck and AstraZeneca are part of the Zacks top Analyst Blog.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/20/2483.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.215522, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.104683", "ticker_sentiment_score": "0.091488", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.257805", "ticker_sentiment_score": "0.044915", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.052455", "ticker_sentiment_score": "-0.124581", "ticker_sentiment_label": "Neutral"}]}, {"title": "Baidu To Rally Over 29%? Here Are 10 Other Analyst Forecasts For Monday - AcelRx Pharmaceuticals  ( NASDAQ:ACRX ) , Allegiant Travel  ( NASDAQ:ALGT ) ", "url": "https://www.benzinga.com/news/23/09/34861974/baidu-to-rally-over-29-here-are-10-other-analyst-forecasts-for-monday", "time_published": "20230925T123931", "authors": ["Lisa Levin"], "summary": "Goldman Sachs increased the price target for Constellation Brands, Inc. STZ from $275 to $305. Goldman Sachs analyst Bonnie Herzog maintained a Buy rating. Constellation shares fell 0.8% to $254.00 in pre-market trading. Wedbush raised CarMax, Inc. KMX price target from $85 to $90.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/09/25/baidu_-_logo.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Energy & Transportation", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Finance", "relevance_score": "0.166667"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "0.999967"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}], "overall_sentiment_score": 0.068478, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VACC", "relevance_score": "0.192694", "ticker_sentiment_score": "-0.222112", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "ALGT", "relevance_score": "0.285526", "ticker_sentiment_score": "0.01776", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.192694", "ticker_sentiment_score": "-0.222112", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "BIDU", "relevance_score": "0.285526", "ticker_sentiment_score": "0.297204", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NKE", "relevance_score": "0.192694", "ticker_sentiment_score": "-0.133567", "ticker_sentiment_label": "Neutral"}, {"ticker": "GS", "relevance_score": "0.192694", "ticker_sentiment_score": "0.062307", "ticker_sentiment_label": "Neutral"}, {"ticker": "URBN", "relevance_score": "0.285526", "ticker_sentiment_score": "-0.147512", "ticker_sentiment_label": "Neutral"}, {"ticker": "MA", "relevance_score": "0.192694", "ticker_sentiment_score": "0.165962", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.285526", "ticker_sentiment_score": "0.42094", "ticker_sentiment_label": "Bullish"}, {"ticker": "ACRX", "relevance_score": "0.285526", "ticker_sentiment_score": "-0.123356", "ticker_sentiment_label": "Neutral"}, {"ticker": "KMX", "relevance_score": "0.285526", "ticker_sentiment_score": "0.28926", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "STZ", "relevance_score": "0.192694", "ticker_sentiment_score": "0.062307", "ticker_sentiment_label": "Neutral"}, {"ticker": "DELL", "relevance_score": "0.192694", "ticker_sentiment_score": "0.076401", "ticker_sentiment_label": "Neutral"}]}, {"title": "Stocks making the biggest moves in premarket trading: AstraZeneca, Paramount, Nike and more", "url": "https://www.cnbc.com/2023/09/25/stocks-making-the-biggest-moves-in-premarket-trading-azn-para-nke-and-more.html", "time_published": "20230925T121904", "authors": ["Hakyung Kim"], "summary": "These are the stocks posting the largest moves in early trading.", "banner_image": "https://image.cnbcfm.com/api/v1/image/107302604-1695071250324-gettyimages-1689146179-mt_26500_tqzunxvm.jpeg?v=1695644344&w=1920&h=1080", "source": "CNBC", "category_within_source": "Top News", "source_domain": "www.cnbc.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}, {"topic": "Real Estate & Construction", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.102098, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "PDD", "relevance_score": "0.097457", "ticker_sentiment_score": "0.032409", "ticker_sentiment_label": "Neutral"}, {"ticker": "SEE", "relevance_score": "0.097457", "ticker_sentiment_score": "0.181115", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "C", "relevance_score": "0.28664", "ticker_sentiment_score": "0.097694", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.097457", "ticker_sentiment_score": "0.100934", "ticker_sentiment_label": "Neutral"}, {"ticker": "FL", "relevance_score": "0.193465", "ticker_sentiment_score": "-0.032844", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.097457", "ticker_sentiment_score": "0.090379", "ticker_sentiment_label": "Neutral"}, {"ticker": "BRK-A", "relevance_score": "0.097457", "ticker_sentiment_score": "0.058631", "ticker_sentiment_label": "Neutral"}, {"ticker": "SKXJF", "relevance_score": "0.097457", "ticker_sentiment_score": "0.100934", "ticker_sentiment_label": "Neutral"}, {"ticker": "DSKYF", "relevance_score": "0.097457", "ticker_sentiment_score": "0.100934", "ticker_sentiment_label": "Neutral"}, {"ticker": "URBN", "relevance_score": "0.193465", "ticker_sentiment_score": "-0.032844", "ticker_sentiment_label": "Neutral"}, {"ticker": "OPEN", "relevance_score": "0.097457", "ticker_sentiment_score": "-0.018694", "ticker_sentiment_label": "Neutral"}]}, {"title": "Ageing bodies need to get rid of decrepit cells", "url": "https://www.economist.com/technology-quarterly/2023/09/25/ageing-bodies-need-to-get-rid-of-decrepit-cells", "time_published": "20230925T104856", "authors": ["The Economist"], "summary": "I , then at the Wistar Institute in Philadelphia, now retired, made one of the most famous observations in the science of longevity: in laboratories, non-cancerous mammalian cells can reproduce themselves for only a fixed number of times before cell division ceases and they enter a state called ...", "banner_image": "https://www.economist.com/img/b/1280/720/90/media-assets/image/20230930_TQD003.jpg", "source": "The Economist", "category_within_source": "BusinessGoogleRSS", "source_domain": "www.economist.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "IPO", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.023968, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.019634", "ticker_sentiment_score": "0.014666", "ticker_sentiment_label": "Neutral"}, {"ticker": "UBX", "relevance_score": "0.019634", "ticker_sentiment_score": "-0.040972", "ticker_sentiment_label": "Neutral"}]}, {"title": "Paramount Global and Netflix stock boosted by possible end to writer's strike as Nike shares slip on downgrade", "url": "https://www.marketwatch.com/story/paramount-global-and-netflix-stock-boosted-by-possible-end-to-writers-strike-as-nike-shares-slip-on-downgrade-a44ea4ba", "time_published": "20230925T090700", "authors": ["MarketWatch"], "summary": "Paramount Global, Netflix, Foot Locker and Nike were stocks in the spotlight.", "banner_image": "https://images.mktw.net/im-857259/social", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.077644, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NFLX", "relevance_score": "0.421485", "ticker_sentiment_score": "0.008729", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.595343", "ticker_sentiment_score": "0.490681", "ticker_sentiment_label": "Bullish"}, {"ticker": "PARA", "relevance_score": "0.421485", "ticker_sentiment_score": "0.008729", "ticker_sentiment_label": "Neutral"}, {"ticker": "FL", "relevance_score": "0.421485", "ticker_sentiment_score": "-0.222524", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "MS", "relevance_score": "0.218817", "ticker_sentiment_score": "0.257192", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVO", "relevance_score": "0.421485", "ticker_sentiment_score": "0.409693", "ticker_sentiment_label": "Bullish"}, {"ticker": "NKE", "relevance_score": "0.421485", "ticker_sentiment_score": "-0.008893", "ticker_sentiment_label": "Neutral"}, {"ticker": "URBN", "relevance_score": "0.421485", "ticker_sentiment_score": "-0.222524", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "European shares weaken at start of quarter's last week", "url": "https://www.reuters.com/markets/europe/european-shares-weaken-start-quarters-last-week-2023-09-25/", "time_published": "20230925T072300", "authors": ["Reuters"], "summary": "The German share price index DAX graph is pictured at the stock exchange in Frankfurt, Germany, September 21, 2023. REUTERS/Staff/File photo Acquire Licensing Rights", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/TRSREPZUFVKNHINHZXNZGQ6HYI.jpg", "source": "Reuters", "category_within_source": "Markets", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": 0.036635, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.165031", "ticker_sentiment_score": "0.239987", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GMVHF", "relevance_score": "0.165031", "ticker_sentiment_score": "-0.225215", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "PPRUF", "relevance_score": "0.165031", "ticker_sentiment_score": "0.281362", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "ASTRAZENECA AND INSTITUT KANSER NEGARA PARTNER TO INTRODUCE AI TECHNOLOGY FOR LUNG SCREENING", "url": "https://www.prnewswire.com/apac/news-releases/astrazeneca-and-institut-kanser-negara-partner-to-introduce-ai-technology-for-lung-screening-301936092.html", "time_published": "20230925T010000", "authors": ["AstraZeneca Malaysia"], "summary": "ASTRAZENECA AND INSTITUT KANSER NEGARA PARTNER TO INTRODUCE AI TECHNOLOGY FOR LUNG ... PR ...", "banner_image": "https://mma.prnewswire.com/media/2218514/Photo_1_Vinod_Narayanan___Country_President__AstraZeneca_Malaysia__together_with_Dr__Puteri_Norliza.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.115451, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.288515", "ticker_sentiment_score": "0.079462", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 Magnificent Growth Stocks to Buy Right Now", "url": "https://www.fool.com/investing/2023/09/24/3-magnificent-growth-stocks-to-buy-right-now/", "time_published": "20230924T105000", "authors": ["David Jagielski", "and Prosper Junior Bakiny", "Keith Speights"], "summary": "If you're looking for growth, these stocks could be just the ticket.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.744043"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.459462"}], "overall_sentiment_score": 0.352979, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.166743", "ticker_sentiment_score": "0.245837", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.12546", "ticker_sentiment_score": "0.201716", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.287441", "ticker_sentiment_score": "0.437472", "ticker_sentiment_label": "Bullish"}]}, {"title": "Innovative Gelatin Capsules Transforming Pharmaceutical Industry: A Look into the Future", "url": "https://www.prnewswire.com/news-releases/innovative-gelatin-capsules-transforming-pharmaceutical-industry-a-look-into-the-future-301936082.html", "time_published": "20230922T214500", "authors": ["Research and Markets"], "summary": "DUBLIN, Sept. 22, 2023 /PRNewswire/ -- The \"Pharmaceutical Gelatin Market Share, Size, Trends, Industry Analysis Report, By Source, By Function, By End Use, By Regions, Segment Forecast, 2023-2032\" report has been added to ResearchAndMarkets.com's offering.", "banner_image": "https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.269668, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.060236", "ticker_sentiment_score": "-0.055999", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.060236", "ticker_sentiment_score": "-0.055999", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVS", "relevance_score": "0.060236", "ticker_sentiment_score": "-0.055999", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.060236", "ticker_sentiment_score": "-0.055999", "ticker_sentiment_label": "Neutral"}, {"ticker": "BHC", "relevance_score": "0.060236", "ticker_sentiment_score": "-0.055999", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.060236", "ticker_sentiment_score": "-0.055999", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.060236", "ticker_sentiment_score": "-0.055999", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.060236", "ticker_sentiment_score": "-0.055999", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.060236", "ticker_sentiment_score": "-0.055999", "ticker_sentiment_label": "Neutral"}]}, {"title": "Global Dermatology Drugs Market Set to Skyrocket, Anticipated Valuation of $50.47 Billion by 2032", "url": "https://www.prnewswire.com/news-releases/global-dermatology-drugs-market-set-to-skyrocket-anticipated-valuation-of-50-47-billion-by-2032--301936081.html", "time_published": "20230922T213000", "authors": ["Research and Markets"], "summary": "DUBLIN, Sept. 22, 2023 /PRNewswire/ -- The \"Dermatology Drugs Market Share, Size, Trends, Industry Analysis Report, By Therapeutic Area, By Drug Class, By Route of Administration, By Distribution Channel, By Region, Segment Forecast, 2023-2032\" report has been added to ResearchAndMarkets.com's ...", "banner_image": "https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.263166, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.060541", "ticker_sentiment_score": "-0.056", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.060541", "ticker_sentiment_score": "-0.056", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVS", "relevance_score": "0.060541", "ticker_sentiment_score": "-0.056", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.060541", "ticker_sentiment_score": "-0.056", "ticker_sentiment_label": "Neutral"}, {"ticker": "BHC", "relevance_score": "0.060541", "ticker_sentiment_score": "-0.056", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.060541", "ticker_sentiment_score": "-0.056", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.060541", "ticker_sentiment_score": "-0.056", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.060541", "ticker_sentiment_score": "-0.056", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.060541", "ticker_sentiment_score": "-0.056", "ticker_sentiment_label": "Neutral"}]}, {"title": "Precision Medicine Takes Center Stage: Innovative Report Explores the Role of Companion Diagnostics in Transforming Healthcare", "url": "https://www.prnewswire.com/news-releases/precision-medicine-takes-center-stage-innovative-report-explores-the-role-of-companion-diagnostics-in-transforming-healthcare-301936080.html", "time_published": "20230922T211500", "authors": ["Research and Markets"], "summary": "Precision Medicine Takes Center Stage: Innovative Report Explores the Role of Companion Diagnostics in ... PR ...", "banner_image": "https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.201401, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GH", "relevance_score": "0.146618", "ticker_sentiment_score": "0.108862", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALBT", "relevance_score": "0.04912", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.098054", "ticker_sentiment_score": "-0.406244", "ticker_sentiment_label": "Bearish"}, {"ticker": "OCX", "relevance_score": "0.04912", "ticker_sentiment_score": "-0.327454", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "TMO", "relevance_score": "0.04912", "ticker_sentiment_score": "0.277279", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CSPHF", "relevance_score": "0.04912", "ticker_sentiment_score": "-0.299355", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "NEO", "relevance_score": "0.04912", "ticker_sentiment_score": "0.230136", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "QGEN", "relevance_score": "0.194632", "ticker_sentiment_score": "0.262602", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Breakthrough Properties ontwikkelt nieuw Europees hoofdkantoor voor Neogene Therapeutics", "url": "https://www.prnewswire.com/news-releases/breakthrough-properties-ontwikkelt-nieuw-europees-hoofdkantoor-voor-neogene-therapeutics-301936640.html", "time_published": "20230922T211300", "authors": ["Breakthrough Properties"], "summary": "Neogene Therapeutics ( Neogene ) , een volledige dochteronderneming van de wereldwijde biofarmaceut AstraZeneca, is een biotechnologiebedrijf in de klinische fase dat pioniert in het ontdekken, ontwikkelen en produceren van geavanceerde T-celreceptor ( TCR ) -therapie\u00ebn die zich richten op een ...", "banner_image": "https://mma.prnewswire.com/media/2217822/Breakthrough_Properties_Kavel_F_Final_1.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.049449, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.031907", "ticker_sentiment_score": "-0.085425", "ticker_sentiment_label": "Neutral"}, {"ticker": "BDX", "relevance_score": "0.031907", "ticker_sentiment_score": "0.067894", "ticker_sentiment_label": "Neutral"}]}, {"title": "Pfizer maternal RSV vaccine recommended by CDC advisers", "url": "https://www.marketwatch.com/story/pfizer-maternal-rsv-vaccine-recommended-by-cdc-advisors-25d7e6ad", "time_published": "20230922T200200", "authors": ["Eleanor Laise"], "summary": "New shot aims to protect babies from a leading cause of hospitalization.", "banner_image": "https://images.mktw.net/im-589512/social", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.126124, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.244109", "ticker_sentiment_score": "0.112142", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.465901", "ticker_sentiment_score": "0.365773", "ticker_sentiment_label": "Bullish"}, {"ticker": "SNY", "relevance_score": "0.244109", "ticker_sentiment_score": "0.112142", "ticker_sentiment_label": "Neutral"}]}, {"title": "CDC advisors recommend Pfizer maternal RSV vaccine to protect infants", "url": "https://www.cnbc.com/2023/09/22/rsv-vaccine-cdc-advisors-recommend-pfizer-maternal-shot-for-infants-.html", "time_published": "20230922T185701", "authors": ["Annika Kim Constantino"], "summary": "CDC Director Mandy Cohen still needs to sign off on that recommendation before mothers can receive Pfizer's shot to protect their infants from RSV.", "banner_image": "https://image.cnbcfm.com/api/v1/image/107290038-1692711312864-gettyimages-1236760215-20090101211124-99-118562.jpeg?v=1695409021&w=1920&h=1080", "source": "CNBC", "category_within_source": "Top News", "source_domain": "www.cnbc.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.040913, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.041181", "ticker_sentiment_score": "0.062051", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.203729", "ticker_sentiment_score": "0.022611", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.041181", "ticker_sentiment_score": "0.062051", "ticker_sentiment_label": "Neutral"}]}, {"title": "European shares clock weekly decline as higher-for-longer rates loom", "url": "https://www.reuters.com/markets/europe/european-shares-clock-weekly-decline-higher-for-longer-rates-loom-2023-09-22/", "time_published": "20230922T162500", "authors": ["Bansari Kamdar", "Shashwat Chauhan"], "summary": "Sept 22 ( Reuters ) - European shares closed lower on Friday, logging sharp weekly losses as investors grappled with the prospects of global interest rates remaining elevated for longer.", "banner_image": "https://s3.amazonaws.com/arc-authors/reuters/36cd72fb-82f8-4f2c-848e-6faa6950a36e.png", "source": "Reuters", "category_within_source": "Markets", "source_domain": "www.reuters.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.576289"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": -0.078268, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.097854", "ticker_sentiment_score": "-0.130313", "ticker_sentiment_label": "Neutral"}, {"ticker": "EBAY", "relevance_score": "0.097854", "ticker_sentiment_score": "0.142904", "ticker_sentiment_label": "Neutral"}, {"ticker": "BX", "relevance_score": "0.097854", "ticker_sentiment_score": "0.142904", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:EUR", "relevance_score": "0.194242", "ticker_sentiment_score": "0.004777", "ticker_sentiment_label": "Neutral"}]}, {"title": "We Can Finally Do Something About the Third 'Tripledemic' Virus", "url": "https://www.theatlantic.com/health/archive/2023/09/tripledemic-virus-rsv-vaccine/675417/", "time_published": "20230922T161108", "authors": ["Sarah Zhang"], "summary": "Every fall, when the air turns chilly and the leaves red, pediatric ICUs begin preparing for the onslaught of the virus known as RSV. Not flu, not COVID, but RSV, or respiratory syncytial virus, is the No. 1 reason babies are hospitalized, year after year.", "banner_image": "https://cdn.theatlantic.com/thumbor/lCKp76bDRrGXOlASeHqK9j7F2nc=/0x0:4800x2700/960x540/media/img/mt/2023/09/vax_copy2/original.jpg", "source": "The Atlantic", "category_within_source": "n/a", "source_domain": "www.theatlantic.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.0, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.056474", "ticker_sentiment_score": "-0.031015", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.028254", "ticker_sentiment_score": "0.11233", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.084622", "ticker_sentiment_score": "0.027121", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.028254", "ticker_sentiment_score": "0.11233", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biopharma Co. Adds CTO to Team", "url": "https://www.investorideas.com/news/2023/biotech/09221DiaMedica-Therapeutics.asp", "time_published": "20230922T154858", "authors": [], "summary": "September 22, 2023 ( Investorideas.com Newswire ) This newest member brings with him extensive experience in protein development and manufacturing, noted an Oppenheimer report.", "banner_image": "https://www.streetwisereports.com/images/111.png", "source": "Investor Ideas", "category_within_source": "n/a", "source_domain": "www.investorideas.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.181243, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DMAC", "relevance_score": "0.102449", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.102449", "ticker_sentiment_score": "0.140431", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.102449", "ticker_sentiment_score": "0.140431", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.102449", "ticker_sentiment_score": "0.140431", "ticker_sentiment_label": "Neutral"}]}, {"title": "CCMB moves 83 terabytes of genomics data to AWS cloud to boost research", "url": "https://www.business-standard.com/companies/news/ccmb-moves-83-terabytes-of-genomics-data-to-aws-cloud-to-boost-research-123092201230_1.html", "time_published": "20230922T150030", "authors": ["Ashutosh Mishra"], "summary": "Amazon Web Services ( AWS ) on Friday announced that the Centre for Cellular and Molecular Biology ( CCMB ) -- India's premier research organisation for modern molecular biology and genomics -- has selected AWS as its preferred cloud provider to accelerate its genomics research projects.", "banner_image": "https://bsmedia.business-standard.com/_media/bs/img/article/2023-07/26/full/1690395058-7423.jpg?im=FitAndFill=(826,465)", "source": "Business Standard", "category_within_source": "GoogleRSS", "source_domain": "www.business-standard.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.035579, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.074926", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ILMN", "relevance_score": "0.074926", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Trump's Niece Urges Media To Call Out Ex-President's Lies, Google Roasts Apple With New Mocking 'iPager - Top Headlines Today While US Was Sleeping", "url": "https://www.benzinga.com/news/23/09/34822623/trumps-niece-urges-media-to-call-out-ex-presidents-lies-google-roasts-apple-with-new-mocking-ipager", "time_published": "20230922T143306", "authors": ["Akanksha Bakshi"], "summary": "Zoom Video, eBay And 2 Other Stocks Insiders Are Selling Wall Street's Most Accurate Analysts Say Hold These 3 Risk Off Stocks Delivering High-Dividend Yields Bruised Stocks Set For Rebound After 3 Days Of Losses Despite Lofty Bond Yields: Why This Analyst Says 'Don't Lose Faith Just Yet'", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/09/22/newspaper-photo_by_gino_crescoli_from_pixabay.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": -0.235738, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "BABA", "relevance_score": "0.050679", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOOG", "relevance_score": "0.101154", "ticker_sentiment_score": "-0.188365", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "TSLA", "relevance_score": "0.297061", "ticker_sentiment_score": "-0.016005", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.050679", "ticker_sentiment_score": "-0.250037", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "EBAY", "relevance_score": "0.050679", "ticker_sentiment_score": "-0.181352", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "STAA", "relevance_score": "0.050679", "ticker_sentiment_score": "0.142323", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIVN", "relevance_score": "0.050679", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SKXJF", "relevance_score": "0.050679", "ticker_sentiment_score": "-0.250037", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "DSKYF", "relevance_score": "0.050679", "ticker_sentiment_score": "-0.250037", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "COIN", "relevance_score": "0.050679", "ticker_sentiment_score": "0.023082", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRYPTO:BTC", "relevance_score": "0.151222", "ticker_sentiment_score": "-0.303892", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "CRYPTO:ETH", "relevance_score": "0.101154", "ticker_sentiment_score": "-0.214259", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "CRYPTO:SHIB", "relevance_score": "0.050679", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRYPTO:DOGE", "relevance_score": "0.050679", "ticker_sentiment_score": "-0.282587", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "AstraZeneca Surges After Breast Cancer Drug Tops Chemo", "url": "https://www.investors.com/news/technology/azn-stock-surges-after-breast-cancer-drug-tops-chemo/", "time_published": "20230922T134900", "authors": ["Investor's Business Daily", "ALLISON GATLIN"], "summary": "AZN Stock Surges After Breast Cancer Drug Tops Chemo Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2017/11/Stock-AstraZenecaFlags-01-shutter.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.929393"}], "overall_sentiment_score": -0.154543, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "SKXJF", "relevance_score": "0.40348", "ticker_sentiment_score": "-0.155649", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "TVTX", "relevance_score": "0.140076", "ticker_sentiment_score": "-0.375818", "ticker_sentiment_label": "Bearish"}, {"ticker": "DSKYF", "relevance_score": "0.40348", "ticker_sentiment_score": "-0.155649", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "AZN", "relevance_score": "0.622414", "ticker_sentiment_score": "-0.201114", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "NVO", "relevance_score": "0.140076", "ticker_sentiment_score": "-0.238699", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Pharma Stock Roundup: EU Nod to PFE's Litfulo, FDA Priority Tag to MRK Applications", "url": "https://www.zacks.com/stock/news/2154134/pharma-stock-roundup-eu-nod-to-pfes-litfulo-fda-priority-tag-to-mrk-applications", "time_published": "20230922T132100", "authors": ["Kinjel Shah"], "summary": "The European Commission approves Pfizer's (PFE) Litfulo for severe alopecia areata. FDA gives priority tag to Merck's (MRK) supplemental applications for Welireg and Keytruda.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/66/1019.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.22278, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.108958", "ticker_sentiment_score": "0.124765", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.162802", "ticker_sentiment_score": "0.043157", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.054607", "ticker_sentiment_score": "-0.124806", "ticker_sentiment_label": "Neutral"}]}, {"title": "Stocks making the biggest moves premarket: AstraZeneca, Wayfair, Alibaba and more", "url": "https://www.cnbc.com/2023/09/22/stocks-making-the-biggest-moves-premarket-astrazeneca-wayfair-alibaba-and-more.html", "time_published": "20230922T120527", "authors": ["Hakyung Kim"], "summary": "These are the stocks posting the largest moves before the bell.", "banner_image": "https://image.cnbcfm.com/api/v1/image/106921772-1628084601228-gettyimages-1234445243-AFP_9JW2F6.jpeg?v=1695384327&w=1920&h=1080", "source": "CNBC", "category_within_source": "Market Insider", "source_domain": "www.cnbc.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.459462"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.614606"}], "overall_sentiment_score": 0.259664, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BABA", "relevance_score": "0.103331", "ticker_sentiment_score": "0.111614", "ticker_sentiment_label": "Neutral"}, {"ticker": "PDD", "relevance_score": "0.103331", "ticker_sentiment_score": "0.111614", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.103331", "ticker_sentiment_score": "0.103471", "ticker_sentiment_label": "Neutral"}, {"ticker": "WFC", "relevance_score": "0.103331", "ticker_sentiment_score": "0.231175", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "W", "relevance_score": "0.103331", "ticker_sentiment_score": "0.430315", "ticker_sentiment_label": "Bullish"}, {"ticker": "RL", "relevance_score": "0.103331", "ticker_sentiment_score": "-0.02588", "ticker_sentiment_label": "Neutral"}, {"ticker": "SGEN", "relevance_score": "0.103331", "ticker_sentiment_score": "0.162626", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CCORF", "relevance_score": "0.103331", "ticker_sentiment_score": "-0.006872", "ticker_sentiment_label": "Neutral"}, {"ticker": "CHTR", "relevance_score": "0.204936", "ticker_sentiment_score": "0.338303", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Better Than Chemotherapy - AstraZeneca/Daiichi Sankyo Partnered Cancer Drug Meets Primary Goal In Breast Cancer Setting - AstraZeneca  ( NASDAQ:AZN ) ", "url": "https://www.benzinga.com/general/biotech/23/09/34818340/better-than-chemotherapy-astrazenecadaiichi-sankyo-partnered-cancer-drug-meets-primary-goal-in-br", "time_published": "20230922T114644", "authors": ["Vandana Singh"], "summary": "AstraZeneca Plc AZN and Daiichi Sankyo DSKYF DSNKY released topline data from the TROPION-Breast01 phase 3 trial of datopotamab deruxtecan ( Dato-DXd ) in previously treated patients with inoperable or metastatic hormone receptor ( HR ) positive, HER2 low or negative breast cancer.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/09/22/azn.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.189689, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "DSKYF", "relevance_score": "0.263942", "ticker_sentiment_score": "-0.330273", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "AZN", "relevance_score": "0.600602", "ticker_sentiment_score": "-0.291594", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "SKXJF", "relevance_score": "0.133841", "ticker_sentiment_score": "-0.208124", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Buy These 3 Defensive Funds to Beat Market Volatility", "url": "https://www.zacks.com/stock/news/2154030/buy-these-3-defensive-funds-to-beat-market-volatility", "time_published": "20230922T095400", "authors": ["Zacks Equity Research"], "summary": "Invest in recession-proof industries like FSUTX, VGHCX and FDIGX to preserve your capital and earn positive returns during volatile market conditions.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/6e/50121.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.890401"}, {"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.858979"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Energy & Transportation", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.109219, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MDLZ", "relevance_score": "0.045482", "ticker_sentiment_score": "0.051977", "ticker_sentiment_label": "Neutral"}, {"ticker": "KO", "relevance_score": "0.045482", "ticker_sentiment_score": "0.051977", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.045482", "ticker_sentiment_score": "0.048038", "ticker_sentiment_label": "Neutral"}, {"ticker": "UNH", "relevance_score": "0.045482", "ticker_sentiment_score": "0.048038", "ticker_sentiment_label": "Neutral"}, {"ticker": "NEE", "relevance_score": "0.045482", "ticker_sentiment_score": "0.049023", "ticker_sentiment_label": "Neutral"}, {"ticker": "PG", "relevance_score": "0.045482", "ticker_sentiment_score": "0.051977", "ticker_sentiment_label": "Neutral"}]}, {"title": "Scholastic stock tumbles on loss, Activision share rises on Microsoft deal news and more moving stocks", "url": "https://www.marketwatch.com/story/scholastic-stock-tumbles-on-loss-activision-share-rises-on-microsoft-deal-news-and-more-moving-stocks-2d2aaf43", "time_published": "20230922T093000", "authors": ["MarketWatch"], "summary": "Activision Blizzard, AstraZeneca, Scholastic, Faraday Futures, Alibaba and NIO were the most active stocks ahead of Friday's market open.", "banner_image": "https://images.mktw.net/im-856309/social", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Real Estate & Construction", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}], "overall_sentiment_score": 0.03876, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BABA", "relevance_score": "0.297661", "ticker_sentiment_score": "-0.287256", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "MSFT", "relevance_score": "0.297661", "ticker_sentiment_score": "0.161953", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SCHL", "relevance_score": "0.297661", "ticker_sentiment_score": "-0.121014", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.297661", "ticker_sentiment_score": "0.122234", "ticker_sentiment_label": "Neutral"}, {"ticker": "NIO", "relevance_score": "0.297661", "ticker_sentiment_score": "-0.287256", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "ATVI", "relevance_score": "0.55533", "ticker_sentiment_score": "0.247342", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SKXJF", "relevance_score": "0.151539", "ticker_sentiment_score": "0.073929", "ticker_sentiment_label": "Neutral"}, {"ticker": "UBSFF", "relevance_score": "0.151539", "ticker_sentiment_score": "0.097501", "ticker_sentiment_label": "Neutral"}, {"ticker": "DSKYF", "relevance_score": "0.151539", "ticker_sentiment_score": "0.073929", "ticker_sentiment_label": "Neutral"}, {"ticker": "FFIE", "relevance_score": "0.297661", "ticker_sentiment_score": "0.403736", "ticker_sentiment_label": "Bullish"}, {"ticker": "CGCO", "relevance_score": "0.151539", "ticker_sentiment_score": "-0.175604", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "JPMorgan says there may be many oil crises this decade as it lifts rating on energy stocks", "url": "https://www.marketwatch.com/story/jpmorgan-says-there-may-be-many-oil-crises-this-decade-as-it-lifts-rating-on-energy-stocks-52cb2406", "time_published": "20230922T085200", "authors": ["Steve Goldstein"], "summary": "JPMorgan on Friday pounded the table for energy stocks, as higher-for-longer interest rates further squeezes the flow of capital into new supply.", "banner_image": "https://images.mktw.net/im-856303?width=700&height=625", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Energy & Transportation", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}, {"topic": "Manufacturing", "relevance_score": "0.2"}], "overall_sentiment_score": 0.126604, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "TTE", "relevance_score": "0.204647", "ticker_sentiment_score": "0.143941", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.137278", "ticker_sentiment_score": "0.150495", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BKR", "relevance_score": "0.137278", "ticker_sentiment_score": "0.08798", "ticker_sentiment_label": "Neutral"}, {"ticker": "SKXJF", "relevance_score": "0.068896", "ticker_sentiment_score": "0.095074", "ticker_sentiment_label": "Neutral"}, {"ticker": "UBSFF", "relevance_score": "0.068896", "ticker_sentiment_score": "0.118431", "ticker_sentiment_label": "Neutral"}, {"ticker": "DSKYF", "relevance_score": "0.068896", "ticker_sentiment_score": "0.095074", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.068896", "ticker_sentiment_score": "0.118431", "ticker_sentiment_label": "Neutral"}, {"ticker": "NTOIF", "relevance_score": "0.137278", "ticker_sentiment_score": "0.121566", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.137278", "ticker_sentiment_score": "0.117492", "ticker_sentiment_label": "Neutral"}, {"ticker": "XOM", "relevance_score": "0.137278", "ticker_sentiment_score": "0.08798", "ticker_sentiment_label": "Neutral"}, {"ticker": "ATVI", "relevance_score": "0.204647", "ticker_sentiment_score": "0.191236", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CTXAF", "relevance_score": "0.068896", "ticker_sentiment_score": "0.073226", "ticker_sentiment_label": "Neutral"}, {"ticker": "PCCYF", "relevance_score": "0.068896", "ticker_sentiment_score": "0.073226", "ticker_sentiment_label": "Neutral"}, {"ticker": "BEPTF", "relevance_score": "0.068896", "ticker_sentiment_score": "0.073226", "ticker_sentiment_label": "Neutral"}, {"ticker": "TS", "relevance_score": "0.137278", "ticker_sentiment_score": "0.08798", "ticker_sentiment_label": "Neutral"}]}, {"title": "European shares set for weekly drop as higher-for-longer rates loom", "url": "https://www.reuters.com/markets/europe/european-shares-set-weekly-drop-higher-for-longer-rates-loom-2023-09-22/", "time_published": "20230922T072700", "authors": ["Bansari Kamdar"], "summary": "Sept 22 ( Reuters ) - European shares slipped on Friday and were on track to close a week, packed with central banks' decisions, sharply lower as investors assessed the prospects that borrowing costs will remain high for some time.", "banner_image": "https://s3.amazonaws.com/arc-authors/reuters/36cd72fb-82f8-4f2c-848e-6faa6950a36e.png", "source": "Reuters", "category_within_source": "Markets", "source_domain": "www.reuters.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.769861"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": -0.014536, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.093289", "ticker_sentiment_score": "-0.142004", "ticker_sentiment_label": "Neutral"}, {"ticker": "EBAY", "relevance_score": "0.093289", "ticker_sentiment_score": "0.14124", "ticker_sentiment_label": "Neutral"}, {"ticker": "BX", "relevance_score": "0.093289", "ticker_sentiment_score": "0.14124", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:EUR", "relevance_score": "0.093289", "ticker_sentiment_score": "0.10288", "ticker_sentiment_label": "Neutral"}]}, {"title": "China relaxes capital controls to entice badly needed foreign investment | Business", "url": "https://www.cnn.com/2023/09/22/economy/china-loosens-capital-controls-intl-hnk/index.html", "time_published": "20230922T065811", "authors": ["Laura He"], "summary": "China relaxes capital controls to entice badly needed foreign investment ...", "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/230922124730-china-economy-yuan-notes.jpg?c=16x9&q=h_720,w_1280,c_fill", "source": "CNN", "category_within_source": "Markets", "source_domain": "www.cnn.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Economy - Fiscal", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.990999"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.126544, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BLK", "relevance_score": "0.055364", "ticker_sentiment_score": "0.099853", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.110462", "ticker_sentiment_score": "0.118497", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.055364", "ticker_sentiment_score": "0.099853", "ticker_sentiment_label": "Neutral"}, {"ticker": "BACHY", "relevance_score": "0.055364", "ticker_sentiment_score": "0.143879", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.110462", "ticker_sentiment_score": "0.118497", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:USD", "relevance_score": "0.055364", "ticker_sentiment_score": "-0.055214", "ticker_sentiment_label": "Neutral"}]}, {"title": "China relaxes capital controls to entice badly needed foreign investment | Business", "url": "https://edition.cnn.com/2023/09/22/economy/china-loosens-capital-controls-intl-hnk/index.html", "time_published": "20230922T065800", "authors": ["Laura He"], "summary": "China relaxes capital controls to entice badly needed foreign investment CNN International ...", "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/230922124730-china-economy-yuan-notes.jpg?c=16x9&q=h_720,w_1280,c_fill", "source": "CNN", "category_within_source": "Economy", "source_domain": "edition.cnn.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Economy - Fiscal", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.990999"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.126544, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BLK", "relevance_score": "0.055364", "ticker_sentiment_score": "0.099853", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.110462", "ticker_sentiment_score": "0.118497", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.055364", "ticker_sentiment_score": "0.099853", "ticker_sentiment_label": "Neutral"}, {"ticker": "BACHY", "relevance_score": "0.055364", "ticker_sentiment_score": "0.143879", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.110462", "ticker_sentiment_score": "0.118497", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:USD", "relevance_score": "0.055364", "ticker_sentiment_score": "-0.055214", "ticker_sentiment_label": "Neutral"}]}, {"title": "AstraZeneca and Daiichi's breast cancer drug meets goal in study", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/astrazeneca-daiichis-breast-cancer-drug-meets-goal-study-2023-09-22/", "time_published": "20230922T065222", "authors": ["Reuters"], "summary": "FILE PHOTO-Test tubes are seen in front of a displayed AstraZeneca logo in this illustration taken, May 21, 2021. REUTERS/Dado Ruvic/Illustration/File Photo Acquire Licensing Rights", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/3HEU7DNXOFILXPOSFV27GKHQPI.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.054109, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.7887", "ticker_sentiment_score": "-0.103372", "ticker_sentiment_label": "Neutral"}]}, {"title": "Astrazeneca  ( AZN )  Stock Moves -1.38%: What You Should Know", "url": "https://www.zacks.com/stock/news/2153923/astrazeneca-azn-stock-moves--138-what-you-should-know", "time_published": "20230921T215020", "authors": ["Zacks Equity Research"], "summary": "Astrazeneca (AZN) closed at $67.02 in the latest trading session, marking a -1.38% move from the prior day.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default176.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.986564"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.089785, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.615462", "ticker_sentiment_score": "0.127919", "ticker_sentiment_label": "Neutral"}]}, {"title": "What is the cost of cheaper drugs?", "url": "https://www.economist.com/podcasts/2023/09/21/what-is-the-cost-of-cheaper-drugs", "time_published": "20230921T170320", "authors": ["The Economist"], "summary": "Sign up for Economist Podcasts+ now and get 50% off your subscription with our limited time offer* O many aims of President Joe Biden's signature legislation, the Inflation Reduction Act, is to cut the cost of drugs prescribed by Medicare, a government health insurance programme for Americans 65 ...", "banner_image": "https://www.economist.com/img/b/1280/720/90/media-assets/image/20230923_PDP507.jpg", "source": "The Economist", "category_within_source": "BusinessGoogleRSS", "source_domain": "www.economist.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.049157, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.252987", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "What is the cost of cheaper drugs?", "url": "https://www.economist.com/news/2023/09/21/what-is-the-cost-of-cheaper-drugs", "time_published": "20230921T170320", "authors": ["The Economist"], "summary": "Sign up for Economist Podcasts+ now and get 50% off your subscription with our limited time offer* O many aims of President Joe Biden's signature legislation, the Inflation Reduction Act, is to cut the cost of drugs prescribed by Medicare, a government health insurance programme for Americans 65 ...", "banner_image": "https://www.economist.com/img/b/1280/720/90/media-assets/image/20230923_PDP507.jpg", "source": "The Economist", "category_within_source": "MarketsGoogleRSS", "source_domain": "www.economist.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.049157, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.252987", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Big pharma can't get enough of one class of cancer drugs", "url": "https://www.economist.com/business/2023/09/21/big-pharma-cant-get-enough-of-one-class-of-cancer-drugs", "time_published": "20230921T125146", "authors": ["The Economist"], "summary": "A spate of dealmaking suggests high expectations for antibody-drug conjugates ...", "banner_image": "https://www.economist.com/cdn-cgi/image/width=1424,quality=80,format=auto/content-assets/images/20230923_WBC663.png", "source": "The Economist", "category_within_source": "Business", "source_domain": "www.economist.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.048564, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.27432", "ticker_sentiment_score": "0.06449", "ticker_sentiment_label": "Neutral"}, {"ticker": "NRIX", "relevance_score": "0.0699", "ticker_sentiment_score": "-0.026247", "ticker_sentiment_label": "Neutral"}, {"ticker": "SKXJF", "relevance_score": "0.0699", "ticker_sentiment_score": "0.034814", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.0699", "ticker_sentiment_score": "0.157028", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SGEN", "relevance_score": "0.0699", "ticker_sentiment_score": "-0.026247", "ticker_sentiment_label": "Neutral"}, {"ticker": "DSKYF", "relevance_score": "0.0699", "ticker_sentiment_score": "0.034814", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.0699", "ticker_sentiment_score": "-0.026247", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.0699", "ticker_sentiment_score": "0.099427", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.0699", "ticker_sentiment_score": "0.099427", "ticker_sentiment_label": "Neutral"}]}, {"title": "SHAREHOLDER ALERT: Morris Kandinov Investigating EBS, JRVR, EGIO, and HAFC; Shareholders are Encouraged to Contact the Firm", "url": "https://www.benzinga.com/pressreleases/23/09/g34771758/shareholder-alert-morris-kandinov-investigating-ebs-jrvr-egio-and-hafc-shareholders-are-encouraged", "time_published": "20230920T190955", "authors": ["Globe Newswire"], "summary": "SAN DIEGO, Sept. 20, 2023 ( GLOBE NEWSWIRE ) -- National law firm Morris Kandinov is investigating the actions of the officers and board of directors of Emergent BioSolutions Inc., James River Group Holdings, Ltd., Edgio, Inc., and Hanmi Financial Corporation.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.684621"}], "overall_sentiment_score": -0.036585, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "EGIO", "relevance_score": "0.187827", "ticker_sentiment_score": "-0.034709", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.047371", "ticker_sentiment_score": "-0.066999", "ticker_sentiment_label": "Neutral"}, {"ticker": "JRVR", "relevance_score": "0.233556", "ticker_sentiment_score": "-0.046772", "ticker_sentiment_label": "Neutral"}, {"ticker": "EBS", "relevance_score": "0.322474", "ticker_sentiment_score": "-0.11929", "ticker_sentiment_label": "Neutral"}, {"ticker": "HAFC", "relevance_score": "0.094576", "ticker_sentiment_score": "0.056029", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.094576", "ticker_sentiment_score": "-0.072926", "ticker_sentiment_label": "Neutral"}]}, {"title": "Lupus Foundation of America Launches Mobile App for Lupus Self-Management Program", "url": "https://www.benzinga.com/pressreleases/23/09/n34763800/lupus-foundation-of-america-launches-mobile-app-for-lupus-self-management-program", "time_published": "20230920T140000", "authors": ["PRNewswire"], "summary": "WASHINGTON, Sept. 20, 2023 /PRNewswire/ -- The Lupus Foundation of America ( LFA ) announces the launch of a mobile app for its Strategies to Embrace Living with Lupus Fearlessly ( SELF ) program.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.257283, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.079656", "ticker_sentiment_score": "0.224424", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GOOG", "relevance_score": "0.079656", "ticker_sentiment_score": "0.224424", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Oxford Biomedica Plc - INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2023", "url": "https://www.globenewswire.com/news-release/2023/09/20/2746360/0/en/Oxford-Biomedica-Plc-INTERIM-RESULTS-FOR-THE-SIX-MONTHS-ENDED-30-JUNE-2023.html", "time_published": "20230920T114100", "authors": ["Oxford BioMedica plc"], "summary": "The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Market Abuse Regulation ( EU ) No. 596/2014 ( as it forms part of domestic law by virtue of the European Union ( Withdrawal ) Act 2018 ) .", "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/28eea7f8-0d39-4be0-8eae-0934a202f8ed", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.999696"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.503496"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.175864, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GOOG", "relevance_score": "0.002888", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CABA", "relevance_score": "0.014441", "ticker_sentiment_score": "0.061973", "ticker_sentiment_label": "Neutral"}, {"ticker": "ORTX", "relevance_score": "0.005777", "ticker_sentiment_score": "0.005521", "ticker_sentiment_label": "Neutral"}, {"ticker": "FIXX", "relevance_score": "0.025991", "ticker_sentiment_score": "0.074513", "ticker_sentiment_label": "Neutral"}, {"ticker": "CHYL", "relevance_score": "0.002888", "ticker_sentiment_score": "0.162994", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AWON", "relevance_score": "0.002888", "ticker_sentiment_score": "0.151432", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "LDNXF", "relevance_score": "0.002888", "ticker_sentiment_score": "-0.055109", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.002888", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ACLX", "relevance_score": "0.005777", "ticker_sentiment_score": "0.081562", "ticker_sentiment_label": "Neutral"}, {"ticker": "BEAM", "relevance_score": "0.008665", "ticker_sentiment_score": "0.056551", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.014441", "ticker_sentiment_score": "0.023365", "ticker_sentiment_label": "Neutral"}, {"ticker": "OXBDF", "relevance_score": "0.241698", "ticker_sentiment_score": "0.147305", "ticker_sentiment_label": "Neutral"}, {"ticker": "NHPEF", "relevance_score": "0.002888", "ticker_sentiment_score": "-0.005305", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.002888", "ticker_sentiment_score": "0.050395", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:GBP", "relevance_score": "0.002888", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 Best Janus Mutual Funds to Invest In", "url": "https://www.zacks.com/stock/news/2152914/3-best-janus-mutual-funds-to-invest-in", "time_published": "20230920T105200", "authors": ["Zacks Equity Research"], "summary": "Invest in Janus mutual funds such as JANEX, JNGLX and JDPAX, which have demonstrated a track record of delivering impressive returns.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/09/344.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.977154"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Energy & Transportation", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.288345, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CNSWF", "relevance_score": "0.065506", "ticker_sentiment_score": "0.067072", "ticker_sentiment_label": "Neutral"}, {"ticker": "LNT", "relevance_score": "0.065506", "ticker_sentiment_score": "-0.046219", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.065506", "ticker_sentiment_score": "0.047042", "ticker_sentiment_label": "Neutral"}, {"ticker": "BSX", "relevance_score": "0.065506", "ticker_sentiment_score": "0.067072", "ticker_sentiment_label": "Neutral"}, {"ticker": "HIG", "relevance_score": "0.065506", "ticker_sentiment_score": "-0.046219", "ticker_sentiment_label": "Neutral"}, {"ticker": "JHG", "relevance_score": "0.194763", "ticker_sentiment_score": "0.195302", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "UNH", "relevance_score": "0.065506", "ticker_sentiment_score": "0.047042", "ticker_sentiment_label": "Neutral"}, {"ticker": "ON", "relevance_score": "0.065506", "ticker_sentiment_score": "0.067072", "ticker_sentiment_label": "Neutral"}]}, {"title": "New Kidney Health Alliance Elevates Chronic Kidney Disease on Global Health Agenda", "url": "https://www.prnewswire.com/apac/news-releases/new-kidney-health-alliance-elevates-chronic-kidney-disease-on-global-health-agenda-301931429.html", "time_published": "20230919T160000", "authors": ["Global Patient Alliance for Kidney Health"], "summary": "WASHINGTON, Sept. 20, 2023 /PRNewswire/ -- Seventeen patient advocacy organizations from North and South America, Europe, Asia and the Middle East have formed the Global Patient Alliance for Kidney Health.", "banner_image": "https://mma.prnewswire.com/media/2213545/Global_Patient_Alliance_for_Kidney_Health_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.102888, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.073546", "ticker_sentiment_score": "0.216292", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "New Kidney Health Alliance Elevates Chronic Kidney Disease on Global Health Agenda", "url": "https://www.newswire.ca/news-releases/new-kidney-health-alliance-elevates-chronic-kidney-disease-on-global-health-agenda-812734554.html", "time_published": "20230919T160000", "authors": ["Global Patient Alliance for Kidney Health"], "summary": "WASHINGTON, Sept. 19, 2023 /CNW/ -- Seventeen patient advocacy organizations from North and South America, Europe, Asia and the Middle East have formed the Global Patient Alliance for Kidney Health.", "banner_image": "https://mma.prnewswire.com/media/2213545/Global_Patient_Alliance_for_Kidney_Health_Logo.jpg?p=facebook", "source": "Canada Newswire", "category_within_source": "n/a", "source_domain": "www.newswire.ca", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.102888, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.073546", "ticker_sentiment_score": "0.216292", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "COMPASS Pathways appoints Daphne Karydas to its Board of Directors", "url": "https://investingnews.com/compass-pathways-appoints-daphne-karydas-to-its-board-of-directors/", "time_published": "20230918T212536", "authors": ["Investing News Network"], "summary": "COMPASS Pathways plc ( Nasdaq: CMPS ) ( \"COMPASS\" ) , a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the appointment of Daphne Karydas to its Board of Directors, effective September 18, 2023.", "banner_image": "https://investingnews.com/media-library/eyJhbGciOiJIUzI1NiIsInR5cCI6IkpXVCJ9.eyJpbWFnZSI6Imh0dHBzOi8vYXNzZXRzLnJibC5tcy8yNTg1ODg1NS9vcmlnaW4ucG5nIiwiZXhwaXJlc19hdCI6MTcwODY4MTIxOX0.Phin9ClvosnPNpkGRdBWHz_VFepTco5fqEYZcXCsZIQ/image.png?width=210", "source": "Investing News Network", "category_within_source": "n/a", "source_domain": "investingnews.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.495866"}], "overall_sentiment_score": 0.031534, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CMPS", "relevance_score": "0.237138", "ticker_sentiment_score": "0.149263", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.034381", "ticker_sentiment_score": "-0.042562", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.034381", "ticker_sentiment_score": "-0.004831", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNDX", "relevance_score": "0.034381", "ticker_sentiment_score": "-0.004831", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.034381", "ticker_sentiment_score": "-0.004831", "ticker_sentiment_label": "Neutral"}, {"ticker": "GS", "relevance_score": "0.068698", "ticker_sentiment_score": "-0.005049", "ticker_sentiment_label": "Neutral"}, {"ticker": "MLYS", "relevance_score": "0.034381", "ticker_sentiment_score": "-0.042562", "ticker_sentiment_label": "Neutral"}]}, {"title": "Head and Neck Squamous Cell Carcinoma Market to Witness Upsurge in Growth by 2032, Assesses DelveInsight | Key Companies in the Market - Pfizer, Merck, Eisai, AstraZeneca, Innate, Roche, GlaxoSmithKline, BeiGene, IO Biotech, Incyte", "url": "https://www.prnewswire.com/news-releases/head-and-neck-squamous-cell-carcinoma-market-to-witness-upsurge-in-growth-by-2032-assesses-delveinsight--key-companies-in-the-market---pfizer-merck-eisai-astrazeneca-innate-roche-glaxosmithkline-beigene-io-biotech-incyt-301930322.html", "time_published": "20230918T210100", "authors": ["DelveInsight Business Research", "LLP"], "summary": "Head and Neck Squamous Cell Carcinoma Market to Witness Upsurge in Growth by 2032, Assesses DelveInsight | Key ... PR ...", "banner_image": "https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.109459, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GLTO", "relevance_score": "0.023146", "ticker_sentiment_score": "0.04357", "ticker_sentiment_label": "Neutral"}, {"ticker": "IPHA", "relevance_score": "0.023146", "ticker_sentiment_score": "0.04357", "ticker_sentiment_label": "Neutral"}, {"ticker": "BGNE", "relevance_score": "0.069361", "ticker_sentiment_score": "0.052186", "ticker_sentiment_label": "Neutral"}, {"ticker": "IMMP", "relevance_score": "0.069361", "ticker_sentiment_score": "0.052186", "ticker_sentiment_label": "Neutral"}, {"ticker": "REPL", "relevance_score": "0.023146", "ticker_sentiment_score": "0.04357", "ticker_sentiment_label": "Neutral"}, {"ticker": "FUSN", "relevance_score": "0.023146", "ticker_sentiment_score": "0.04357", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.023146", "ticker_sentiment_score": "0.04357", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.023146", "ticker_sentiment_score": "0.04357", "ticker_sentiment_label": "Neutral"}, {"ticker": "SURF", "relevance_score": "0.023146", "ticker_sentiment_score": "0.04357", "ticker_sentiment_label": "Neutral"}, {"ticker": "RKUNF", "relevance_score": "0.046273", "ticker_sentiment_score": "0.04824", "ticker_sentiment_label": "Neutral"}, {"ticker": "IOVA", "relevance_score": "0.069361", "ticker_sentiment_score": "0.052186", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.023146", "ticker_sentiment_score": "0.04357", "ticker_sentiment_label": "Neutral"}, {"ticker": "AKESF", "relevance_score": "0.046273", "ticker_sentiment_score": "0.058004", "ticker_sentiment_label": "Neutral"}, {"ticker": "CALT", "relevance_score": "0.023146", "ticker_sentiment_score": "0.04357", "ticker_sentiment_label": "Neutral"}, {"ticker": "INCY", "relevance_score": "0.023146", "ticker_sentiment_score": "0.04357", "ticker_sentiment_label": "Neutral"}, {"ticker": "EXEL", "relevance_score": "0.046273", "ticker_sentiment_score": "0.058004", "ticker_sentiment_label": "Neutral"}, {"ticker": "IOBT", "relevance_score": "0.023146", "ticker_sentiment_score": "0.04357", "ticker_sentiment_label": "Neutral"}, {"ticker": "KURA", "relevance_score": "0.069361", "ticker_sentiment_score": "0.052186", "ticker_sentiment_label": "Neutral"}, {"ticker": "SGEN", "relevance_score": "0.023146", "ticker_sentiment_score": "0.04357", "ticker_sentiment_label": "Neutral"}, {"ticker": "NBTX", "relevance_score": "0.023146", "ticker_sentiment_score": "0.04357", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.023146", "ticker_sentiment_score": "0.04357", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.023146", "ticker_sentiment_score": "0.04357", "ticker_sentiment_label": "Neutral"}, {"ticker": "VCNX", "relevance_score": "0.023146", "ticker_sentiment_score": "0.04357", "ticker_sentiment_label": "Neutral"}]}, {"title": "COMPASS Pathways appoints Daphne Karydas to its Board of Directors", "url": "https://www.globenewswire.com/news-release/2023/09/18/2745209/0/en/COMPASS-Pathways-appoints-Daphne-Karydas-to-its-Board-of-Directors.html", "time_published": "20230918T203100", "authors": ["COMPASS Pathways"], "summary": "LONDON, Sept. 18, 2023 ( GLOBE NEWSWIRE ) -- COMPASS Pathways plc ( Nasdaq: CMPS ) ( \"COMPASS\" ) , a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the appointment of Daphne Karydas to its Board of Directors, ...", "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/e61ab9b9-87f6-4418-b0d9-2fd1a7f5f90c", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.495866"}], "overall_sentiment_score": 0.026764, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CMPS", "relevance_score": "0.193207", "ticker_sentiment_score": "0.101252", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.032513", "ticker_sentiment_score": "-0.042274", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.032513", "ticker_sentiment_score": "-0.004796", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNDX", "relevance_score": "0.032513", "ticker_sentiment_score": "-0.004796", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.032513", "ticker_sentiment_score": "-0.004796", "ticker_sentiment_label": "Neutral"}, {"ticker": "GS", "relevance_score": "0.064973", "ticker_sentiment_score": "-0.005028", "ticker_sentiment_label": "Neutral"}, {"ticker": "MLYS", "relevance_score": "0.032513", "ticker_sentiment_score": "-0.042274", "ticker_sentiment_label": "Neutral"}]}, {"title": "COMPASS Pathways appoints Daphne Karydas to its Board of Directors - Compass Pathways  ( NASDAQ:CMPS ) ", "url": "https://www.benzinga.com/pressreleases/23/09/g34702085/compass-pathways-appoints-daphne-karydas-to-its-board-of-directors", "time_published": "20230918T203100", "authors": ["Globe Newswire"], "summary": "LONDON, Sept. 18, 2023 ( GLOBE NEWSWIRE ) -- COMPASS Pathways plc CMPS ( \"COMPASS\" ) , a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the appointment of Daphne Karydas to its Board of Directors, effective September ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.650727"}], "overall_sentiment_score": 0.026707, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CMPS", "relevance_score": "0.158103", "ticker_sentiment_score": "0.083464", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.031822", "ticker_sentiment_score": "-0.04216", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.031822", "ticker_sentiment_score": "-0.004783", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNDX", "relevance_score": "0.031822", "ticker_sentiment_score": "-0.004783", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.031822", "ticker_sentiment_score": "-0.004783", "ticker_sentiment_label": "Neutral"}, {"ticker": "GS", "relevance_score": "0.063594", "ticker_sentiment_score": "-0.005022", "ticker_sentiment_label": "Neutral"}, {"ticker": "MLYS", "relevance_score": "0.031822", "ticker_sentiment_score": "-0.04216", "ticker_sentiment_label": "Neutral"}]}, {"title": "CHMP Endorses AstraZeneca's  ( AZN )  Enhertu in Lung Cancer", "url": "https://www.zacks.com/stock/news/2152040/chmp-endorses-astrazenecas-azn-enhertu-in-lung-cancer", "time_published": "20230918T153900", "authors": ["Zacks Equity Research"], "summary": "Data from a mid-stage study shows that treatment with AstraZeneca's (AZN) Enhertu achieved strong and durable tumor responses in certain non-small cell lung cancer patients.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/e5/1416.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.972193"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.1598, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SKXJF", "relevance_score": "0.12645", "ticker_sentiment_score": "0.168451", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DTIL", "relevance_score": "0.366961", "ticker_sentiment_score": "0.077624", "ticker_sentiment_label": "Neutral"}, {"ticker": "ANVS", "relevance_score": "0.188683", "ticker_sentiment_score": "0.040394", "ticker_sentiment_label": "Neutral"}, {"ticker": "DSKYF", "relevance_score": "0.12645", "ticker_sentiment_score": "0.168451", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.366961", "ticker_sentiment_score": "0.131853", "ticker_sentiment_label": "Neutral"}, {"ticker": "SELB", "relevance_score": "0.30928", "ticker_sentiment_score": "0.092676", "ticker_sentiment_label": "Neutral"}]}, {"title": "Breast Cancer Monoclonal Antibodies Market to grow by USD 15 billion from 2022 to 2027, North America to account ... - PR Newswire", "url": "https://www.prnewswire.com/news-releases/breast-cancer-monoclonal-antibodies-market-to-grow-by-usd-15-billion-from-2022-to-2027-north-america-to-account-for-42-of-market-growth---technavio-301929309.html", "time_published": "20230918T091500", "authors": [], "summary": "Breast Cancer Monoclonal Antibodies Market to grow by USD 15 billion from 2022 to 2027, North America to account ... PR ...", "banner_image": null, "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.019617, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MGNX", "relevance_score": "0.043108", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CLDX", "relevance_score": "0.043108", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.043108", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PBYI", "relevance_score": "0.043108", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SKXJF", "relevance_score": "0.043108", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVS", "relevance_score": "0.043108", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DSKYF", "relevance_score": "0.043108", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.08609", "ticker_sentiment_score": "-0.093515", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.043108", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.043108", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.043108", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "VTRS", "relevance_score": "0.043108", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.043108", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SGEN", "relevance_score": "0.043108", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TEVA", "relevance_score": "0.043108", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.043108", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.043108", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "International Business School Suzhou at XJTLU celebrates 10 years with alumni event", "url": "https://www.prnewswire.com/in/news-releases/international-business-school-suzhou-at-xjtlu-celebrates-10-years-with-alumni-event-301930222.html", "time_published": "20230918T083700", "authors": ["Xi'an Jiaotong-Liverpool University"], "summary": "SUZHOU, China, Sept. 18, 2023 /PRNewswire/ -- International Business School Suzhou ( IBSS ) at Xi'an Jiaotong-Liverpool University kicked off its 10th anniversary year with an alumni reunion on 9 September.", "banner_image": "https://mma.prnewswire.com/media/2212699/Alumni_reunion_9_2023.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": 0.303843, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.102888", "ticker_sentiment_score": "0.246808", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Large Molecule Injectable Drugs Market to grow by USD 191.45 billion from 2022-2027 | North America to account for ... - PR Newswire", "url": "https://www.prnewswire.com/news-releases/large-molecule-injectable-drugs-market-to-grow-by-usd-191-45-billion-from-2022-2027--north-america-to-account-for-45-of-market-growth---technavio-301929312.html", "time_published": "20230918T083500", "authors": [], "summary": "Large Molecule Injectable Drugs Market to grow by USD 191.45 billion from 2022-2027 | North America to account for ... PR ...", "banner_image": null, "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.157274, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "NVO", "relevance_score": "0.052685", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.052685", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVS", "relevance_score": "0.052685", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.052685", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.052685", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.052685", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.052685", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.052685", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAX", "relevance_score": "0.052685", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.052685", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDT", "relevance_score": "0.052685", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.052685", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.052685", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TAK", "relevance_score": "0.052685", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "International Business School Suzhou at XJTLU celebrates 10 years with alumni event", "url": "https://www.prnewswire.com/apac/news-releases/international-business-school-suzhou-at-xjtlu-celebrates-10-years-with-alumni-event-301930108.html", "time_published": "20230918T062400", "authors": ["Xi'an Jiaotong-Liverpool University"], "summary": "SUZHOU, China, Sept. 18, 2023 /PRNewswire/ -- International Business School Suzhou ( IBSS ) at Xi'an Jiaotong-Liverpool University kicked off its 10th anniversary year with an alumni reunion on 9 September.", "banner_image": "https://mma.prnewswire.com/media/2213279/Alumni_reunion_9_2023.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": 0.303843, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.102888", "ticker_sentiment_score": "0.246808", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "How Covid death demographics have changed", "url": "https://theweek.com/news/science-health/953923/how-covid-death-demographics-have-changed", "time_published": "20230916T064233", "authors": ["The Week Staff"], "summary": "A free daily digest of the biggest news stories of the day - and the best features from our website Thank you for signing up to TheWeek. You will receive a verification email shortly. There was a problem. Please refresh the page and try again.", "banner_image": "https://cdn.mos.cms.futurecdn.net/mjHtHyq4yTNZonwgx6JJ8a-415-80.jpg", "source": "The Week News", "category_within_source": "n/a", "source_domain": "theweek.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.038221, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "FRNWF", "relevance_score": "0.04111", "ticker_sentiment_score": "0.057157", "ticker_sentiment_label": "Neutral"}, {"ticker": "WLDS", "relevance_score": "0.04111", "ticker_sentiment_score": "-0.055743", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.04111", "ticker_sentiment_score": "-0.007977", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.082111", "ticker_sentiment_score": "-0.01154", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.04111", "ticker_sentiment_score": "-0.007977", "ticker_sentiment_label": "Neutral"}]}, {"title": "Astrazeneca  ( AZN )  Gains As Market Dips: What You Should Know", "url": "https://www.zacks.com/stock/news/2149828/astrazeneca-azn-gains-as-market-dips-what-you-should-know", "time_published": "20230915T215018", "authors": ["Zacks Equity Research"], "summary": "Astrazeneca (AZN) closed at $68.27 in the latest trading session, marking a +0.72% move from the prior day.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default184.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.95493"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.118139, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.612033", "ticker_sentiment_score": "0.166826", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "EU recommends approval of AstraZeneca and Daiichi's drug for a type of lung cancer", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/eu-recommends-approval-astrazeneca-daiichis-drug-type-lung-cancer-2023-09-15/", "time_published": "20230915T141740", "authors": ["Reuters"], "summary": "AstraZeneca's cancer medicine Enhertu, a drug developed jointly with Japan's Daiichi Sankyo, is pictured in an undated handout image obtained by Reuters on June 27, 2022. AstraZeneca/Handout via REUTERS/File photo Acquire Licensing Rights", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/LGMSH5CKNNO3TENSD3QSN6FNOQ.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.033843, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "DSKYF", "relevance_score": "0.377142", "ticker_sentiment_score": "-0.309996", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "AZN", "relevance_score": "0.674691", "ticker_sentiment_score": "-0.060797", "ticker_sentiment_label": "Neutral"}, {"ticker": "SKXJF", "relevance_score": "0.377142", "ticker_sentiment_score": "-0.309996", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Pharma Stock Roundup: FDA Nod to Updated PFE, MRNA COVID Jabs, & More", "url": "https://www.zacks.com/stock/news/2149445/pharma-stock-roundup-fda-nod-to-updated-pfe-mrna-covid-jabs-more", "time_published": "20230915T133300", "authors": ["Kinjel Shah"], "summary": "The FDA authorizes Pfizer (PFE) and Moderna's (MRNA) updated mRNA-based COVID-19 vaccines. Novo Nordisk (NVO) conducts a two-for-one split of its shares and ADRs.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/66/1019.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.413559"}], "overall_sentiment_score": 0.059775, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ABBV", "relevance_score": "0.107736", "ticker_sentiment_score": "0.031869", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.315493", "ticker_sentiment_score": "0.13387", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.107736", "ticker_sentiment_score": "0.031869", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.265089", "ticker_sentiment_score": "0.093183", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.364529", "ticker_sentiment_score": "0.081749", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.107736", "ticker_sentiment_score": "0.036452", "ticker_sentiment_label": "Neutral"}]}, {"title": "Investors Heavily Search AstraZeneca PLC  ( AZN ) : Here is What You Need to Know", "url": "https://www.zacks.com/stock/news/2149405/investors-heavily-search-astrazeneca-plc-azn-here-is-what-you-need-to-know", "time_published": "20230915T130006", "authors": ["Zacks Equity Research"], "summary": "Zacks.com users have recently been watching Astrazeneca (AZN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default273.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999999"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.54554"}], "overall_sentiment_score": 0.22206, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.495015", "ticker_sentiment_score": "0.124102", "ticker_sentiment_label": "Neutral"}]}, {"title": "Asthma Market is Predicted to Exhibit Remarkable Growth by 2032, Predicts DelveInsight | Key Companies to Look Out - GlaxoSmithKline, AstraZeneca, Sanofi, Roche, Amgen, Regeneron, Incyte, Areteia, Suzhou Connect, Cumberland, Pulmatrix", "url": "https://www.prnewswire.com/news-releases/asthma-market-is-predicted-to-exhibit-remarkable-growth-by-2032-predicts-delveinsight--key-companies-to-look-out---glaxosmithkline-astrazeneca-sanofi-roche-amgen-regeneron-incyte-areteia-suzhou-connect-cumberland-pulma-301927336.html", "time_published": "20230914T210100", "authors": ["DelveInsight Business Research", "LLP"], "summary": "Asthma Market is Predicted to Exhibit Remarkable Growth by 2032, Predicts DelveInsight | Key Companies to Look Out ... PR ...", "banner_image": "https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.116778, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ALDX", "relevance_score": "0.025929", "ticker_sentiment_score": "0.029052", "ticker_sentiment_label": "Neutral"}, {"ticker": "SPRY", "relevance_score": "0.025929", "ticker_sentiment_score": "0.084714", "ticker_sentiment_label": "Neutral"}, {"ticker": "CPIX", "relevance_score": "0.077677", "ticker_sentiment_score": "0.077029", "ticker_sentiment_label": "Neutral"}, {"ticker": "PULM", "relevance_score": "0.025929", "ticker_sentiment_score": "0.084714", "ticker_sentiment_label": "Neutral"}, {"ticker": "KNBWY", "relevance_score": "0.025929", "ticker_sentiment_score": "0.003692", "ticker_sentiment_label": "Neutral"}, {"ticker": "AVTX", "relevance_score": "0.05183", "ticker_sentiment_score": "0.092531", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRNA", "relevance_score": "0.025929", "ticker_sentiment_score": "0.029052", "ticker_sentiment_label": "Neutral"}, {"ticker": "MNOV", "relevance_score": "0.025929", "ticker_sentiment_score": "0.029052", "ticker_sentiment_label": "Neutral"}, {"ticker": "AKTX", "relevance_score": "0.025929", "ticker_sentiment_score": "0.029052", "ticker_sentiment_label": "Neutral"}, {"ticker": "EVLO", "relevance_score": "0.025929", "ticker_sentiment_score": "0.029052", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.17998", "ticker_sentiment_score": "0.064093", "ticker_sentiment_label": "Neutral"}, {"ticker": "RAPT", "relevance_score": "0.025929", "ticker_sentiment_score": "0.084714", "ticker_sentiment_label": "Neutral"}, {"ticker": "INCY", "relevance_score": "0.025929", "ticker_sentiment_score": "0.084714", "ticker_sentiment_label": "Neutral"}, {"ticker": "TEVA", "relevance_score": "0.025929", "ticker_sentiment_score": "0.029052", "ticker_sentiment_label": "Neutral"}, {"ticker": "TFFP", "relevance_score": "0.025929", "ticker_sentiment_score": "0.029052", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.025929", "ticker_sentiment_score": "0.084714", "ticker_sentiment_label": "Neutral"}, {"ticker": "KYKOF", "relevance_score": "0.025929", "ticker_sentiment_score": "0.003692", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.129099", "ticker_sentiment_score": "0.052198", "ticker_sentiment_label": "Neutral"}]}, {"title": "Notification of managers' transactions", "url": "https://www.globenewswire.com/news-release/2023/09/14/2743487/0/en/Notification-of-managers-transactions.html", "time_published": "20230914T152000", "authors": ["Chemometec A/S"], "summary": "ANNOUNCEMENT NO. ...", "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/dda6d08e-1d43-433e-bc7b-b1e84b4963be", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.119699, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.282234", "ticker_sentiment_score": "0.124107", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.282234", "ticker_sentiment_score": "0.124107", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.282234", "ticker_sentiment_score": "0.124107", "ticker_sentiment_label": "Neutral"}]}, {"title": "Next month: Enterprises discuss use of XR / spatial computing / metaverse and try out the latest AR/VR hardware/software for work", "url": "https://www.prnewswire.com/news-releases/next-month-enterprises-discuss-use-of-xr--spatial-computing--metaverse-and-try-out-the-latest-arvr-hardwaresoftware-for-work-301926895.html", "time_published": "20230914T140000", "authors": ["BrainXchange / Augmented Enterprise Summit"], "summary": "Next month: Enterprises discuss use of XR / spatial computing / metaverse and try out the latest AR/VR hardware ... PR ...", "banner_image": "https://i.ytimg.com/vi/ONSbx7e5c7k/hqdefault.jpg", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Energy & Transportation", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}], "overall_sentiment_score": 0.259901, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LNVGF", "relevance_score": "0.101154", "ticker_sentiment_score": "0.065968", "ticker_sentiment_label": "Neutral"}, {"ticker": "MTTR", "relevance_score": "0.101154", "ticker_sentiment_score": "0.065968", "ticker_sentiment_label": "Neutral"}, {"ticker": "PCAR", "relevance_score": "0.101154", "ticker_sentiment_score": "0.135612", "ticker_sentiment_label": "Neutral"}, {"ticker": "VMW", "relevance_score": "0.101154", "ticker_sentiment_score": "0.065968", "ticker_sentiment_label": "Neutral"}, {"ticker": "KO", "relevance_score": "0.101154", "ticker_sentiment_score": "0.184052", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VUZI", "relevance_score": "0.101154", "ticker_sentiment_score": "0.065968", "ticker_sentiment_label": "Neutral"}, {"ticker": "CL", "relevance_score": "0.101154", "ticker_sentiment_score": "0.135612", "ticker_sentiment_label": "Neutral"}, {"ticker": "DAL", "relevance_score": "0.101154", "ticker_sentiment_score": "0.184052", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.101154", "ticker_sentiment_score": "0.135612", "ticker_sentiment_label": "Neutral"}, {"ticker": "HSY", "relevance_score": "0.101154", "ticker_sentiment_score": "0.135612", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.101154", "ticker_sentiment_score": "0.184052", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PEP", "relevance_score": "0.101154", "ticker_sentiment_score": "0.135612", "ticker_sentiment_label": "Neutral"}, {"ticker": "FDX", "relevance_score": "0.101154", "ticker_sentiment_score": "0.184052", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BA", "relevance_score": "0.101154", "ticker_sentiment_score": "0.184052", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "WMT", "relevance_score": "0.101154", "ticker_sentiment_score": "0.184052", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Five Things To Know About British Chip Champion Arm", "url": "https://www.barrons.com/news/five-things-to-know-about-british-chip-champion-arm-77f7ec50", "time_published": "20230914T125100", "authors": ["AFP - Agence France Presse"], "summary": "Here are five things to know about British chip designing giant Arm, which will launch a blockbuster listing on Wall Street on Thursday. The company, owned by Japan's SoftBank, is targeting a valuation of more than $52 billion on the Nasdaq stock exchange for its initial public offering ( IPO ) , ...", "banner_image": "https://asset.barrons.com/barrons/images/afp-metadata-default.jpg", "source": "Barrons", "category_within_source": "n/a", "source_domain": "www.barrons.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "IPO", "relevance_score": "0.451494"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.114601, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NVDA", "relevance_score": "0.062271", "ticker_sentiment_score": "0.144808", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.062271", "ticker_sentiment_score": "0.228264", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "QCOM", "relevance_score": "0.062271", "ticker_sentiment_score": "0.065962", "ticker_sentiment_label": "Neutral"}, {"ticker": "SFTBF", "relevance_score": "0.185306", "ticker_sentiment_score": "-0.057917", "ticker_sentiment_label": "Neutral"}]}, {"title": "Acute Lymphocytic Leukemia Market to Accelerate Substantially by 2032, Assesses DelveInsight | Key Companies in the Market - Beam, Pfizer, Genentech, AbbVie, Fate, Roche, Ascentage, Janssen, Jazz, ADC, Kymera, Syndax, ImmunoGen", "url": "https://www.prnewswire.com/news-releases/acute-lymphocytic-leukemia-market-to-accelerate-substantially-by-2032-assesses-delveinsight--key-companies-in-the-market---beam-pfizer-genentech-abbvie-fate-roche-ascentage-janssen-jazz-adc-kymera-syndax-immunogen-301925772.html", "time_published": "20230913T210100", "authors": ["LLP", "DelveInsight Business Research"], "summary": "Acute Lymphocytic Leukemia Market to Accelerate Substantially by 2032, Assesses DelveInsight | Key Companies in ... PR ...", "banner_image": "https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.180785, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MEDP", "relevance_score": "0.021897", "ticker_sentiment_score": "0.047845", "ticker_sentiment_label": "Neutral"}, {"ticker": "CABA", "relevance_score": "0.021897", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "LEGN", "relevance_score": "0.021897", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SKXJF", "relevance_score": "0.021897", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNDX", "relevance_score": "0.043778", "ticker_sentiment_score": "0.034443", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADCT", "relevance_score": "0.043778", "ticker_sentiment_score": "0.052326", "ticker_sentiment_label": "Neutral"}, {"ticker": "DSKYF", "relevance_score": "0.021897", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "FATE", "relevance_score": "0.043778", "ticker_sentiment_score": "0.034443", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.021897", "ticker_sentiment_score": "0.047845", "ticker_sentiment_label": "Neutral"}, {"ticker": "ATNXQ", "relevance_score": "0.043778", "ticker_sentiment_score": "0.034443", "ticker_sentiment_label": "Neutral"}, {"ticker": "DTIL", "relevance_score": "0.021897", "ticker_sentiment_score": "0.047845", "ticker_sentiment_label": "Neutral"}, {"ticker": "JAZZ", "relevance_score": "0.043778", "ticker_sentiment_score": "0.034443", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.043778", "ticker_sentiment_score": "0.034443", "ticker_sentiment_label": "Neutral"}, {"ticker": "ERYP", "relevance_score": "0.021897", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "INAB", "relevance_score": "0.021897", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NKTX", "relevance_score": "0.043778", "ticker_sentiment_score": "0.034443", "ticker_sentiment_label": "Neutral"}, {"ticker": "ASPHF", "relevance_score": "0.021897", "ticker_sentiment_score": "0.047845", "ticker_sentiment_label": "Neutral"}, {"ticker": "IMGN", "relevance_score": "0.021897", "ticker_sentiment_score": "0.047845", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.043778", "ticker_sentiment_score": "0.034443", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLCM", "relevance_score": "0.021897", "ticker_sentiment_score": "0.047845", "ticker_sentiment_label": "Neutral"}, {"ticker": "LVTX", "relevance_score": "0.021897", "ticker_sentiment_score": "0.047845", "ticker_sentiment_label": "Neutral"}, {"ticker": "CLLS", "relevance_score": "0.021897", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BEAM", "relevance_score": "0.043778", "ticker_sentiment_score": "0.052326", "ticker_sentiment_label": "Neutral"}, {"ticker": "KYMR", "relevance_score": "0.043778", "ticker_sentiment_score": "0.034443", "ticker_sentiment_label": "Neutral"}, {"ticker": "JWCTF", "relevance_score": "0.021897", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.021897", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DNPUF", "relevance_score": "0.021897", "ticker_sentiment_score": "0.047845", "ticker_sentiment_label": "Neutral"}, {"ticker": "SSUMF", "relevance_score": "0.021897", "ticker_sentiment_score": "0.047845", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMEA", "relevance_score": "0.043778", "ticker_sentiment_score": "0.034443", "ticker_sentiment_label": "Neutral"}, {"ticker": "INCY", "relevance_score": "0.021897", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "KPTI", "relevance_score": "0.021897", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Annual Report 2022/23 - Continued solid earnings, but weaker growth amid challenging market conditions", "url": "https://www.globenewswire.com/news-release/2023/09/13/2742833/0/en/Annual-Report-2022-23-Continued-solid-earnings-but-weaker-growth-amid-challenging-market-conditions.html", "time_published": "20230913T175000", "authors": ["Chemometec A/S"], "summary": "ANNOUNCEMENT NO. ...", "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/dda6d08e-1d43-433e-bc7b-b1e84b4963be", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Earnings", "relevance_score": "0.796627"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.233703, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.065685", "ticker_sentiment_score": "0.061067", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.065685", "ticker_sentiment_score": "0.061067", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.065685", "ticker_sentiment_score": "0.061067", "ticker_sentiment_label": "Neutral"}]}, {"title": "Guidance for the 2023/24 financial year", "url": "https://www.globenewswire.com/news-release/2023/09/13/2742832/0/en/Guidance-for-the-2023-24-financial-year.html", "time_published": "20230913T174500", "authors": ["Chemometec A/S"], "summary": "ANNOUNCEMENT NO. ...", "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/dda6d08e-1d43-433e-bc7b-b1e84b4963be", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.140299, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.299478", "ticker_sentiment_score": "0.130157", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.299478", "ticker_sentiment_score": "0.130157", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.299478", "ticker_sentiment_score": "0.130157", "ticker_sentiment_label": "Neutral"}]}, {"title": "As countries around the world accelerate their genome-based testing readiness, Canada's health systems can't afford to fall behind", "url": "https://www.newswire.ca/news-releases/as-countries-around-the-world-accelerate-their-genome-based-testing-readiness-canada-s-health-systems-can-t-afford-to-fall-behind-854748920.html", "time_published": "20230913T110000", "authors": ["Access to Genomic Testing"], "summary": "As countries around the world accelerate their genome-based testing readiness, Canada's health systems can't afford ... Canada ...", "banner_image": "https://mma.prnewswire.com/media/2209242/Access_to_Genomic_Testing_As_countries_around_the_world_accelera.jpg?p=facebook", "source": "Canada Newswire", "category_within_source": "n/a", "source_domain": "www.newswire.ca", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.333998, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.021718", "ticker_sentiment_score": "0.333267", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Daiichi to file for US approval of new lung cancer drug by March", "url": "https://www.financialexpress.com/healthcare/pharma-healthcare/daiichi-to-file-for-us-approval-of-new-lung-cancer-drug-by-march/3241343/", "time_published": "20230913T023000", "authors": ["Bloomberg"], "summary": "Daiichi Sankyo Co. plans to file for US approval of its novel lung cancer drug by the end of March after the medicine showed a benefit in patients with advanced disease. Patritumab deruxtecan was given to non-small cell lung cancer patients who had seen their cancer progress despite extensive ...", "banner_image": "https://www.financialexpress.com/wp-content/uploads/2023/09/lung.jpg", "source": "The Financial Express", "category_within_source": "n/a", "source_domain": "www.financialexpress.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.012494, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "DSKYF", "relevance_score": "0.244109", "ticker_sentiment_score": "0.215012", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.123526", "ticker_sentiment_score": "0.189129", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SKXJF", "relevance_score": "0.244109", "ticker_sentiment_score": "0.215012", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "AstraZeneca  ( AZN )  Posts Upbeat Data on Lung Cancer Drug Combo", "url": "https://www.zacks.com/stock/news/2147960/astrazeneca-azn-posts-upbeat-data-on-lung-cancer-drug-combo", "time_published": "20230912T154900", "authors": ["Zacks Equity Research"], "summary": "Data from a late-stage study shows that AstraZeneca's (AZN) Tagrisso combined with chemotherapy cut the risk of disease progression or death by 38% in certain lung cancer patients.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/e5/1416.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.576289"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.128415, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ANVS", "relevance_score": "0.249744", "ticker_sentiment_score": "0.072946", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.573826", "ticker_sentiment_score": "0.183949", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.12645", "ticker_sentiment_score": "-0.05543", "ticker_sentiment_label": "Neutral"}]}, {"title": "Back to work: the UK's plan for life after coronavirus", "url": "https://theweek.com/coronavirus/106917/back-to-work-the-uk-s-plan-for-life-after-coronavirus", "time_published": "20230912T133852", "authors": ["The Week Staff"], "summary": "A free daily digest of the biggest news stories of the day - and the best features from our website Thank you for signing up to TheWeek. You will receive a verification email shortly. There was a problem. Please refresh the page and try again.", "banner_image": "https://cdn.mos.cms.futurecdn.net/HoqZccRoFe6YWxd5dAM4jm-415-80.jpg", "source": "The Week News", "category_within_source": "n/a", "source_domain": "theweek.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.067547, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.026098", "ticker_sentiment_score": "0.309782", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FRNWF", "relevance_score": "0.026098", "ticker_sentiment_score": "0.053307", "ticker_sentiment_label": "Neutral"}, {"ticker": "VALN", "relevance_score": "0.026098", "ticker_sentiment_score": "0.309782", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Covid testing: the 'great new game of holiday roulette'", "url": "https://theweek.com/news/science-health/953802/covid-pcr-testing-holiday-roulette", "time_published": "20230912T132242", "authors": ["The Week Staff"], "summary": "The questions Sajid Javid is facing over 'rip-off' holiday PCR testing A free daily digest of the biggest news stories of the day - and the best features from our website Thank you for signing up to TheWeek. You will receive a verification email shortly. There was a problem.", "banner_image": "https://cdn.mos.cms.futurecdn.net/QXXBKrZD4UB9X8JQPxjVrC-415-80.jpg", "source": "The Week News", "category_within_source": "n/a", "source_domain": "theweek.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.048521, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "WLDS", "relevance_score": "0.044469", "ticker_sentiment_score": "-0.055925", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.044469", "ticker_sentiment_score": "-0.005", "ticker_sentiment_label": "Neutral"}, {"ticker": "FRNWF", "relevance_score": "0.044469", "ticker_sentiment_score": "0.057737", "ticker_sentiment_label": "Neutral"}]}, {"title": "BC Platforms Appoints Mikaela Bruhammar as Chief Operating Officer, Markets", "url": "https://www.benzinga.com/pressreleases/23/09/g34477878/bc-platforms-appoints-mikaela-bruhammar-as-chief-operating-officer-markets", "time_published": "20230912T100000", "authors": ["Globe Newswire"], "summary": "ZURICH, Switzerland, Sept. 12, 2023 ( GLOBE NEWSWIRE ) -- BC Platforms ( BCP ) , a global leader in healthcare data management and analytics, today announces the appointment of Mikaela Bruhammar, an experienced life sciences executive, as the company's Chief Operating Officer, Markets ( COO ) .", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.283349, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.052801", "ticker_sentiment_score": "0.018985", "ticker_sentiment_label": "Neutral"}]}, {"title": "HUTCHMED Highlights Presentation of Results from the Phase IIIb Trial of Savolitinib at the 2023 World Conference of Lung Cancer", "url": "https://www.globenewswire.com/news-release/2023/09/12/2741334/0/en/HUTCHMED-Highlights-Presentation-of-Results-from-the-Phase-IIIb-Trial-of-Savolitinib-at-the-2023-World-Conference-of-Lung-Cancer.html", "time_published": "20230912T083000", "authors": ["HUTCHMED (China) Limited"], "summary": "HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Sept. 12, 2023 ( GLOBE NEWSWIRE ) -- HUTCHMED ( China ) Limited ( \"HUTCHMED\" ) ( Nasdaq/AIM: HCM, HKEX: 13 ) today announces that results from the confirmatory Phase IIIb clinical trial of savolitinib in patients with mesenchymal epithelial ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/085957ad-3bec-49ee-b13e-39961b83c7be", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.614606"}], "overall_sentiment_score": 0.016822, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.19393", "ticker_sentiment_score": "0.173866", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HCM", "relevance_score": "0.341437", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "HUTCHMED Highlights Presentation of Results from the Phase IIIb Trial of Savolitinib at the 2023 World Conference of Lung Cancer - HUTCHMED  ( China )   ( NASDAQ:HCM ) ", "url": "https://www.benzinga.com/pressreleases/23/09/g34475083/hutchmed-highlights-presentation-of-results-from-the-phase-iiib-trial-of-savolitinib-at-the-2023-w", "time_published": "20230912T083000", "authors": ["Globe Newswire"], "summary": "HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Sept. 12, 2023 ( GLOBE NEWSWIRE ) -- HUTCHMED ( China ) Limited ( \"HUTCHMED\" ) ( Nasdaq/AIM: HCM, HKEX: 13 ) today announces that results from the confirmatory Phase IIIb clinical trial of savolitinib in patients with mesenchymal epithelial ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.744043"}], "overall_sentiment_score": 0.014384, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.19117", "ticker_sentiment_score": "0.172039", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HCM", "relevance_score": "0.336789", "ticker_sentiment_score": "-0.002458", "ticker_sentiment_label": "Neutral"}]}, {"title": "AstraZeneca's Tagrisso-Chemo Combo Data In Lung Cancer Sets High Bar For Johnson & Johnson's Cancer Drug: Analyst - AstraZeneca  ( NASDAQ:AZN ) ", "url": "https://www.benzinga.com/analyst-ratings/analyst-color/23/09/34451156/astrazenecas-tagrisso-chemo-combo-data-in-lung-cancer-sets-high-bar-for-johnson-joh", "time_published": "20230911T183109", "authors": ["Vandana Singh"], "summary": "On Sunday night, AstraZeneca Plc AZN presented the Phase 3 FLAURA2 results evaluating Tagrisso plus chemotherapy versus Tagrisso monotherapy as first-line treatment for patients with EGFR mutant lung cancer.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/09/11/azn_1.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.241517, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.463792", "ticker_sentiment_score": "0.309664", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "The Prostate Cancer Drugs Market Is Expected To Reach A Value Of $23 Billion By 2027 At A CAGR Of More Than 5 % As Per The Business Research Company's Prostate Cancer Drugs Global Market Report 2023", "url": "https://www.benzinga.com/pressreleases/23/09/g34446203/the-prostate-cancer-drugs-market-is-expected-to-reach-a-value-of-23-billion-by-2027-at-a-cagr-of-m", "time_published": "20230911T153000", "authors": ["Globe Newswire"], "summary": "LONDON, Sept. 11, 2023 ( GLOBE NEWSWIRE ) -- As per The Business Research Company's Prostate Cancer Drugs Global Market Report 2023, the global prostate cancer drugs market is making strides worth noting.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": -0.098411, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.059341", "ticker_sentiment_score": "0.012045", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAYZF", "relevance_score": "0.059341", "ticker_sentiment_score": "0.012045", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.059341", "ticker_sentiment_score": "0.012045", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.059341", "ticker_sentiment_score": "0.012045", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.059341", "ticker_sentiment_score": "0.012045", "ticker_sentiment_label": "Neutral"}]}, {"title": "Top Stories Monday, Sep. 11: Qualcomm-Apple Chip Supply Agreement, Report On AstraZeneca CEO's Alleged Intention To Step Down, Apple & Google Face Off in Antitrust Showdown - AstraZeneca  ( NASDAQ:AZN ) , Boeing  ( NYSE:BA ) ", "url": "https://www.benzinga.com/news/23/09/34444460/qualcomm-apples-chip-supply-agreement-alleged-report-about-astrazeneca-ceo-sir-pascal-soriots-intent", "time_published": "20230911T145131", "authors": ["Vandana Singh"], "summary": "Qualcomm Inc QCOM stock is trading higher Monday after the chip designer forged a deal with Apple Inc APPL. Under the deal, Qualcomm will supply Snapdragon 5G Modem\u2011RF Systems for the iPhone maker's smartphone launch in 2024, 2025, and 2026.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/09/11/qualcomm_5g_1.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "IPO", "relevance_score": "0.682689"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Real Estate & Construction", "relevance_score": "0.2"}], "overall_sentiment_score": 0.121882, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BABA", "relevance_score": "0.162255", "ticker_sentiment_score": "-0.018112", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOOG", "relevance_score": "0.162255", "ticker_sentiment_score": "0.04428", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.081552", "ticker_sentiment_score": "-0.051616", "ticker_sentiment_label": "Neutral"}, {"ticker": "F", "relevance_score": "0.081552", "ticker_sentiment_score": "-0.197371", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "GM", "relevance_score": "0.081552", "ticker_sentiment_score": "-0.197371", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "WELL", "relevance_score": "0.122062", "ticker_sentiment_score": "0.246435", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "UBS", "relevance_score": "0.081552", "ticker_sentiment_score": "-0.249919", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "NVS", "relevance_score": "0.081552", "ticker_sentiment_score": "0.147022", "ticker_sentiment_label": "Neutral"}, {"ticker": "SSNLF", "relevance_score": "0.040829", "ticker_sentiment_score": "0.140655", "ticker_sentiment_label": "Neutral"}, {"ticker": "EADSF", "relevance_score": "0.081552", "ticker_sentiment_score": "0.05496", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.081552", "ticker_sentiment_score": "0.096829", "ticker_sentiment_label": "Neutral"}, {"ticker": "QCOM", "relevance_score": "0.122062", "ticker_sentiment_score": "-0.085417", "ticker_sentiment_label": "Neutral"}, {"ticker": "SFTBF", "relevance_score": "0.081552", "ticker_sentiment_score": "0.094784", "ticker_sentiment_label": "Neutral"}, {"ticker": "BA", "relevance_score": "0.162255", "ticker_sentiment_score": "0.212128", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Why AstraZeneca  ( AZN )  Shares Are Trading Lower Today? - AstraZeneca  ( NASDAQ:AZN ) ", "url": "https://www.benzinga.com/general/biotech/23/09/34443397/whats-going-on-with-astrazeneca-stock-today", "time_published": "20230911T143558", "authors": ["Vandana Singh"], "summary": "Shares in European pharmaceutical giant AstraZeneca Plc AZN are down amid speculations swirling around the potential departure of AstraZeneca's Chief Executive, Pascal Soriot.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/09/11/azn_0.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.150344, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.824067", "ticker_sentiment_score": "0.444953", "ticker_sentiment_label": "Bullish"}]}, {"title": "Why AstraZeneca  ( AZN )  Shares Are Trading Lower Today? - AstraZeneca  ( NASDAQ:AZN ) ", "url": "https://www.benzinga.com/general/biotech/23/09/34438541/astrazenecas-reinforces-hold-in-lung-cancer-settings-touts-promising-data-from-three-trials", "time_published": "20230911T135927", "authors": ["Vandana Singh"], "summary": "Daiichi Sankyo DSKYF DSNKY and AstraZeneca plc AZN released initial results from the TROPION-Lung04 phase 1b trial.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/09/11/azn.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.026516, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "DSKYF", "relevance_score": "0.16849", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.329551", "ticker_sentiment_score": "-0.129198", "ticker_sentiment_label": "Neutral"}, {"ticker": "SKXJF", "relevance_score": "0.084722", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "AstraZeneca shares fall 3.6% to 7-1/2 week low", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/astrazeneca-shares-fall-36-7-12-week-low-2023-09-11/", "time_published": "20230911T122657", "authors": ["Reuters"], "summary": "The company logo for pharmaceutical company AstraZeneca is displayed on a screen on the floor at the New York Stock Exchange, U.S., April 8, 2019. REUTERS/Brendan McDermid/File Photo Acquire Licensing Rights", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/UN2TWTU3SFINLMPBDRR2F2HDEE.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": -0.125302, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.82082", "ticker_sentiment_score": "-0.435746", "ticker_sentiment_label": "Bearish"}]}, {"title": "AstraZeneca's Tagrisso-chemo combo results raise bar for J&J cancer drug-analysts", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/astrazenecas-tagrisso-chemo-combo-results-raise-bar-jj-cancer-drug-analysts-2023-09-11/", "time_published": "20230911T121500", "authors": ["Maggie Fick"], "summary": "AstraZeneca's Tagrisso-chemo combo results raise bar for J&J cancer ...", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/Z7C3LXVLABIWJCVMO4JCQLWQGY.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.081894, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.366061", "ticker_sentiment_score": "-0.013231", "ticker_sentiment_label": "Neutral"}, {"ticker": "BCS", "relevance_score": "0.188193", "ticker_sentiment_score": "0.208424", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.094762", "ticker_sentiment_score": "0.079645", "ticker_sentiment_label": "Neutral"}]}, {"title": "Major shareholder announcement - BlackRock, Inc.", "url": "https://www.globenewswire.com/news-release/2023/09/11/2740670/0/en/Major-shareholder-announcement-BlackRock-Inc.html", "time_published": "20230911T111500", "authors": ["Chemometec A/S"], "summary": "ANNOUNCEMENT NO. ...", "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/dda6d08e-1d43-433e-bc7b-b1e84b4963be", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.142316, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BLK", "relevance_score": "0.666827", "ticker_sentiment_score": "0.299741", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.252987", "ticker_sentiment_score": "0.076328", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.252987", "ticker_sentiment_score": "0.076328", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.252987", "ticker_sentiment_score": "0.076328", "ticker_sentiment_label": "Neutral"}]}, {"title": "The Zacks Analyst Blog Highlights Chevron, AstraZeneca, Netflix, Medtronic and Marvell Technology", "url": "https://www.zacks.com/stock/news/2146982/the-zacks-analyst-blog-highlights-chevron-astrazeneca-netflix-medtronic-and-marvell-technology", "time_published": "20230911T085000", "authors": ["Zacks Investment Research"], "summary": "Chevron, AstraZeneca, Netflix, Medtronic and Marvell Technology are included in this Analyst Blog.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/83/93.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.77141"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.303486, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "NFLX", "relevance_score": "0.276648", "ticker_sentiment_score": "0.217135", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "WBD", "relevance_score": "0.070517", "ticker_sentiment_score": "0.062323", "ticker_sentiment_label": "Neutral"}, {"ticker": "CVX", "relevance_score": "0.341857", "ticker_sentiment_score": "0.282304", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MDT", "relevance_score": "0.140485", "ticker_sentiment_score": "0.040143", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.276648", "ticker_sentiment_score": "0.187477", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRVL", "relevance_score": "0.140485", "ticker_sentiment_score": "0.040143", "ticker_sentiment_label": "Neutral"}]}, {"title": "Updated Covid-19 shots are coming soon, to be part of trio of vaccines", "url": "https://www.business-standard.com/india-news/updated-covid-19-shots-are-coming-soon-to-be-part-of-trio-of-vaccines-123090900529_1.html", "time_published": "20230909T100851", "authors": ["AP"], "summary": "Updated COVID-19 vaccines are coming soon, just in time to pair them with flu shots. And this fall, the first vaccines for another scary virus called RSV are rolling out to older adults and pregnant women.", "banner_image": "https://bsmedia.business-standard.com/_media/bs/img/article/2023-01/19/full/1674097211-0177.jpg?im=FeatureCrop,size=(826,465)", "source": "Business Standard", "category_within_source": "GoogleRSS", "source_domain": "www.business-standard.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.014692, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NVAX", "relevance_score": "0.045655", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.045655", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.045655", "ticker_sentiment_score": "0.159168", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.091162", "ticker_sentiment_score": "0.072647", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.045655", "ticker_sentiment_score": "0.159168", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "4 Top-Tier Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip", "url": "https://www.fool.com/investing/2023/09/09/nasdaq-bear-market-4-growth-stocks-regret-not-buy/", "time_published": "20230909T090600", "authors": ["Sean Williams"], "summary": "Deals can still be found with the Nasdaq Composite roughly 14% below its record-closing high.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F746858%2Fbear-market-stocks-plunge-crash-invest-correction-getty.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.413559"}, {"topic": "Earnings", "relevance_score": "0.744043"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.143765, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SBUX", "relevance_score": "0.25714", "ticker_sentiment_score": "0.082406", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.173126", "ticker_sentiment_score": "0.095934", "ticker_sentiment_label": "Neutral"}, {"ticker": "PUBM", "relevance_score": "0.25714", "ticker_sentiment_score": "0.312315", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMZN", "relevance_score": "0.25714", "ticker_sentiment_score": "-0.011981", "ticker_sentiment_label": "Neutral"}]}, {"title": "Updated COVID shots are coming. They're part of a trio of vaccines to block fall viruses", "url": "https://apnews.com/article/covid-flu-rsv-vaccines-tripledemic-2a55728638c1c0879ce58deeeb0196bf", "time_published": "20230909T042900", "authors": ["LAURAN NEERGAARD"], "summary": "WASHINGTON ( AP ) - Updated COVID-19 are coming soon, just in time to pair them with flu shots. And this fall, the first vaccines for another scary virus called RSV are rolling out to and .", "banner_image": "https://dims.apnews.com/dims4/default/2d6c9d5/2147483647/strip/true/crop/5184x3453+0+1/resize/599x399!/quality/90/?url=https%3A%2F%2Fassets.apnews.com%2F9a%2F49%2F3c605305504dfd887c1d87622bc8%2Fdec49713a1d44ba8a82f79c577d7d6f1", "source": "Associated Press", "category_within_source": "Markets", "source_domain": "apnews.com", "topics": [{"topic": "Real Estate & Construction", "relevance_score": "0.5"}, {"topic": "Life Sciences", "relevance_score": "0.5"}], "overall_sentiment_score": 0.022031, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "HHC", "relevance_score": "0.04531", "ticker_sentiment_score": "0.165054", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVAX", "relevance_score": "0.04531", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.04531", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.04531", "ticker_sentiment_score": "0.159067", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.090474", "ticker_sentiment_score": "0.072535", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.04531", "ticker_sentiment_score": "0.159067", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Pharma Stock Roundup: J&J to End Hypertension Study & Other Regulatory Updates", "url": "https://www.zacks.com/stock/news/2146892/pharma-stock-roundup-jj-to-end-hypertension-study-other-regulatory-updates", "time_published": "20230908T225400", "authors": ["Kinjel Shah"], "summary": "J&J (JNJ) to end a late-stage study on macitentan for CTEPH. Merck's (MRK) Ebola vaccine gets approval in Europe for use in kids.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/49/1007.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.066878, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "KVUE", "relevance_score": "0.059636", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.177584", "ticker_sentiment_score": "0.072099", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.11894", "ticker_sentiment_score": "-0.135549", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why Is Ionis Pharmaceuticals  ( IONS )  Up 1.4% Since Last Earnings Report?", "url": "https://www.zacks.com/stock/news/2146705/why-is-ionis-pharmaceuticals-ions-up-14-since-last-earnings-report", "time_published": "20230908T153027", "authors": ["Zacks Equity Research"], "summary": "Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default246.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.938238"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.459462"}], "overall_sentiment_score": 0.117935, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CORT", "relevance_score": "0.049526", "ticker_sentiment_score": "0.061385", "ticker_sentiment_label": "Neutral"}, {"ticker": "IONS", "relevance_score": "0.243864", "ticker_sentiment_score": "0.167708", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.049526", "ticker_sentiment_score": "0.125135", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.147818", "ticker_sentiment_score": "0.021972", "ticker_sentiment_label": "Neutral"}]}, {"title": "Verge Genomics Announces Artificial Intelligence-Enabled Drug Discovery Collaboration with Alexion for Rare Neurodegenerative and Neuromuscular Diseases", "url": "https://www.benzinga.com/pressreleases/23/09/g34357361/verge-genomics-announces-artificial-intelligence-enabled-drug-discovery-collaboration-with-alexion", "time_published": "20230908T110020", "authors": ["Globe Newswire"], "summary": "Verge to receive up to $42M in upfront and near-term payments, with future cumulative milestones worth up to $840M The collaboration is the second with a leading global pharmaceutical company and shows the unique scalability of the CONVERGE\u2122 platform for technology-enabled drug discovery", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.335584, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.130926", "ticker_sentiment_score": "0.200967", "ticker_sentiment_label": "Somewhat-Bullish"}]}]}